

2019 ESC/EAS Guidelines for the management of dyslipidaemias: *lipid modification to reduce cardiovascular risk*

The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)

Authors/Task Force Members: François Mach* (Chairperson) (Switzerland), Colin Baigent* (Chairperson) (United Kingdom), Alberico L. Catapano¹* (Chairperson) (Italy), Konstantinos C. Koskinas (Switzerland), Manuela Casula¹ (Italy), Lina Badimon (Spain), M. John Chapman¹ (France), Guy G. De Backer (Belgium), Victoria Delgado (Netherlands), Brian A. Ference (United Kingdom), Ian M. Graham (Ireland), Alison Halliday (United Kingdom), Ulf Landmesser (Germany), Borislava Mihaylova (United Kingdom), Terje R. Pedersen (Norway), Gabriele Riccardi¹ (Italy), Dimitrios J. Richter (Greece), Marc S. Sabatine (United States of America), Marja-Riitta Taskinen¹ (Finland), Lale Tokgozoglul¹ (Turkey), Olov Wiklund¹ (Sweden)

The three chairpersons contributed equally to the document.

*Corresponding authors: François Mach, Cardiology Department, Geneva University Hospital, 4 Gabrielle-Perret-Gentil, 1211 Geneva, Switzerland. Tel: +41 223 727 192, Fax: +41 223 727 229, Email: francois.mach@hcuge.ch. Colin Baigent, Nuffield Department of Population Health, University of Oxford, Richard Doll Building, Roosevelt Drive, Oxford OX3 7LF, United Kingdom. Tel: +44 1865 743 741, Fax: +44 1865 743 985, Email: colin.baigent@ndph.ox.ac.uk. Alberico L. Catapano, Department of Pharmacological and Biomolecular Sciences, University of Milan, Via Balzaretti, 9, 20133 Milan, and Multimedica IRCCS, Milan, Italy. Tel: +39 02 5031 8401, Fax: +39 02 5031 8386, Email: alberico.catapano@unimi.it.

ESC Committee for Practice Guidelines (CPG), National Cardiac Societies document reviewers and Author/Task Force Member affiliations: listed in the Appendix.

¹Representing the EAS.

ESC entities having participated in the development of this document:

Associations: Acute Cardiovascular Care Association (ACCA), Association of Cardiovascular Nursing & Allied Professions (ACNAP), European Association of Cardiovascular Imaging (EACVI), European Association of Preventive Cardiology (EAPC), European Association of Percutaneous Cardiovascular Interventions (EAPCI).

Councils: Council for Cardiology Practice, Council on Hypertension, Council on Stroke.

Working Groups: Aorta and Peripheral Vascular Diseases, Atherosclerosis and Vascular Biology, Cardiovascular Pharmacotherapy, e-Cardiology, Thrombosis.

The content of these European Society of Cardiology (ESC) Guidelines has been published for personal and educational use only. No commercial use is authorized. No part of the ESC Guidelines may be translated or reproduced in any form without written permission from the ESC. Permission can be obtained upon submission of a written request to Oxford University Press, the publisher of the *European Heart Journal* and the party authorized to handle such permissions on behalf of the ESC (journals.permissions@oxfordjournals.org).

Disclaimer. The ESC/EAS Guidelines represent the views of the ESC and EAS, and were produced after careful consideration of the scientific and medical knowledge, and the evidence available at the time of their publication. The ESC and EAS is not responsible in the event of any contradiction, discrepancy, and/or ambiguity between the ESC/EAS Guidelines and any other official recommendations or guidelines issued by the relevant public health authorities, in particular in relation to good use of healthcare or therapeutic strategies. Health professionals are encouraged to take the ESC/EAS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic, or therapeutic medical strategies; however, the ESC/EAS Guidelines do not override, in any way whatsoever, the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient and, where appropriate and/or necessary, the patient's caregiver. Nor do the ESC/EAS Guidelines exempt health professionals from taking into full and careful consideration the relevant official updated recommendations or guidelines issued by the competent public health authorities, in order to manage each patient's case in light of the scientifically accepted data pursuant to their respective ethical and professional obligations. It is also the health professional's responsibility to verify the applicable rules and regulations relating to drugs and medical devices at the time of prescription.

Document Reviewers: Christian Mueller (ESC Review Coordinator) (Switzerland), Heinz Drexel (EAS Review Coordinator) (Austria), Victor Aboyans (France), Alberto Corsini¹ (Italy), Wolfram Doehner (Germany), Michel Farnier (France), Bruna Gigante (Sweden), Meral Kayikcioglu¹ (Turkey), Goran Krstacic (Croatia), Ekaterini Lambrinou (Cyprus), Basil S. Lewis (Israel), Josep Masip (Spain), Philippe Moulin¹ (France), Steffen Petersen (United Kingdom), Anna Sonia Petronio (Italy), Massimo Francesco Piepoli (Italy), Xavier Pintó¹ (Spain), Lorenz R ber (Switzerland), Kausik K. Ray¹ (United Kingdom),  eljko Reiner¹ (Croatia), Walter F. Riesen (Switzerland), Marco Roffi (Switzerland), Jean-Paul Schmid (Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Erik Stroes¹ (Netherlands), Isabella Sudano (Switzerland), Alexandros D. Tselepis¹ (Greece), Margus Viigimaa¹ (Estonia), Cecile Vindis (France), Alexander Vonbank (Austria), Michal Vrablik¹ (Czech Republic), Mislav Vrsalovic (Croatia), Jos  Luis Zamorano Gomez (Spain), Jean-Philippe Collet (ESC CPG Supervisor) (France)

The disclosure forms of all experts involved in the development of these Guidelines are available on the ESC website www.escardio.org/guidelines

SD For the Supplementary Data which include background information and detailed discussion of the data that have provided the basis for the Guidelines see <https://academic.oup.com/eurheartj/article-lookup/doi/10.1093/eurheartj/ehz455#supplementary-data>

Online publish-ahead-of-print 31 August 2019

Keywords

Guidelines • dyslipidaemias • cholesterol • triglycerides • low-density lipoproteins • high-density lipoproteins • apolipoprotein B • lipoprotein(a) • lipoprotein remnants • total cardiovascular risk • treatment (lifestyle) • treatment (drugs) • treatment (adherence) • very low-density lipoproteins • familial hypercholesterolaemia

Table of contents

Abbreviations and acronyms	114	5.3.4 Lipoprotein(a) and risk of atherosclerosis	129
1 Preamble	116	5.4 Laboratory measurement of lipids and lipoproteins	129
2 Introduction	118	5.4.1 Lipoprotein measurement	129
2.1 What is new in the 2019 Guidelines?	118	5.4.2 Lipid measurements	20
3 What is cardiovascular disease prevention?	118	5.4.3 Fasting or non-fasting?	130
3.1 Definition and rationale	118	5.5 Recommendations for measuring lipids and lipoproteins to estimate risk of atherosclerotic cardiovascular disease	130
3.2 Development of the Joint Task Force Guidelines for the management of dyslipidaemias	118	6 Treatment targets and goals	131
4 Total cardiovascular risk	118	7 Lifestyle modifications to improve the plasma lipid profile	132
4.1 Total cardiovascular risk estimation	118	7.1 Influence of lifestyle on total cholesterol and low-density lipoprotein cholesterol levels	134
4.1.1 Rationale for assessing total cardiovascular disease risk ...	121	7.2 Influence of lifestyle on triglyceride levels	134
4.1.2 How to use the risk estimation charts	124	7.3 Influence of lifestyle on high-density lipoprotein cholesterol levels	135
4.2 Risk levels	125	7.4 Lifestyle recommendations to improve the plasma lipid profile	135
4.2.1 Role of non-invasive cardiovascular imaging techniques in the assessment of total cardiovascular disease risk	126	7.4.1 Body weight and physical activity	135
4.2.2 Risk-based intervention strategies	127	7.4.2 Dietary fat	135
5 Lipids and lipoproteins	127	7.4.3 Dietary carbohydrate and fibre	136
5.1 Biological role of lipids and lipoproteins	127	7.4.4 Alcohol	136
5.2 Role of lipids and lipoproteins in the pathophysiology of atherosclerosis	127	7.4.5 Smoking	136
5.3 Evidence for the causal effects of lipids and lipoproteins on the risk of atherosclerotic cardiovascular disease	128	7.5 Dietary supplements and functional foods for the treatment of dyslipidaemias	136
5.3.1 Low-density lipoprotein cholesterol and risk of atherosclerosis	128	7.5.1 Phytosterols	136
5.3.2 Triglyceride-rich lipoproteins and risk of atherosclerosis ..	128	7.5.2 Monoclin and red yeast rice	136
5.3.3 High-density lipoprotein cholesterol and risk of atherosclerosis	129	7.5.3 Dietary fibre	137
		7.5.4 Soy	137
		7.5.5 Policosanol and berberine	27
		7.5.6 n-3 unsaturated fatty acids	137

8 Drugs for treatment of dyslipidaemias	137	8.12 Strategies to control plasma cholesterol	145
8.1 Statins	137	8.13 Strategies to control plasma triglycerides	145
8.1.1 Mechanism of action	137	9 Management of dyslipidaemias in different clinical settings	148
8.1.2 Effects on lipids	137	9.1 Familial dyslipidaemias	148
8.1.2.1 Low-density lipoprotein cholesterol	137	9.1.1 Familial combined hyperlipidaemia	148
8.1.2.2 Triglycerides	137	9.1.2 Familial hypercholesterolaemia	148
8.1.2.3 High-density lipoprotein cholesterol	137	9.1.2.1 Heterozygous familial hypercholesterolaemia	148
8.1.2.4 Lipoprotein(a)	137	9.1.2.2 Homozygous familial hypercholesterolaemia	151
8.1.3 Other effects of statins	138	9.1.2.3 Familial hypercholesterolaemia in children	151
8.1.3.1 Effect on cardiovascular morbidity and mortality	138	9.1.3 Familial dysbetalipoproteinaemia	151
8.1.4 Adverse effects and interactions of statins	138	9.1.4 Genetic causes of hypertriglyceridaemia	151
8.1.4.1 Adverse effects on muscle	138	9.1.4.1 Action to prevent acute pancreatitis in severe	
8.1.4.2 Adverse effects on the liver	139	hypertriglyceridaemia	151
8.1.4.3 Increased risk of new-onset diabetes mellitus	139	9.1.5 Other genetic disorders of lipoprotein metabolism	152
8.1.4.4 Increased risk of haemorrhagic stroke	139	9.2 Women	152
8.1.4.5 Adverse effects on kidney function	139	9.2.1 Effects of statins in primary and secondary prevention	152
8.1.4.6 Interactions	139	9.2.2 Non-statin lipid-lowering drugs	152
8.2 Cholesterol absorption inhibitors	140	9.2.3 Hormone therapy	152
8.2.1 Mechanism of action	140	9.3 Older people	152
8.2.2 Effects on lipids	140	9.3.1 Effects of statins in primary and secondary prevention	153
8.2.3 Effect on cardiovascular morbidity and mortality	140	9.3.2 Adverse effects, interactions, and adherence	153
8.2.4 Adverse effects and interactions	140	9.4 Diabetes and metabolic syndrome	153
8.3 Bile acid sequestrants	140	9.4.1 Specific features of dyslipidaemia in insulin resistance	
8.3.1 Mechanism of action	140	and type 2 diabetes	153
8.3.2 Effects on lipids	140	9.4.2 Evidence for lipid-lowering therapy	154
8.3.3 Effect on cardiovascular morbidity and mortality	140	9.4.2.1 Low-density lipoprotein cholesterol	154
8.3.4 Adverse effects and interactions	141	9.4.2.2 Triglycerides and high-density lipoprotein cholesterol	154
8.4 Proprotein convertase subtilisin/kexin type 9 inhibitors	141	9.4.3 Type 1 diabetes	155
8.4.1 Mechanism of action	141	9.4.4 Management of dyslipidaemia for pregnant women	
8.4.2 Effects on lipids	141	with diabetes	155
8.4.2.1 Low-density lipoprotein cholesterol	141	9.5 Patients with acute coronary syndromes and patients	
8.4.2.2 Triglycerides and high-density lipoprotein cholesterol	141	undergoing percutaneous coronary intervention	156
8.4.2.3 Lipoprotein(a)	141	9.5.1 Lipid-lowering therapy in patients with acute	
8.4.3 Effect on cardiovascular morbidity and mortality	141	coronary syndromes	156
8.4.4 Adverse effects and interactions	142	9.5.1.1 Statins	156
8.5 Lomitapide	142	9.5.1.2 Ezetimibe	156
8.6 Mipomersen	142	9.5.1.3 Proprotein convertase subtilisin/kexin type 9 inhibitors	156
8.7 Fibrates	142	9.5.1.4 n-3 polyunsaturated fatty acids	157
8.7.1 Mechanism of action	142	9.5.1.5 Cholesteryl ester transfer protein inhibitors	157
8.7.2 Effects on lipids	142	9.5.2 Lipid-lowering therapy in patients undergoing	
8.7.3 Effect on cardiovascular morbidity and mortality	143	percutaneous coronary intervention	157
8.7.4 Adverse effects and interactions	143	9.6 Stroke	158
8.8 n-3 fatty acids	143	9.7 Heart failure and valvular diseases	158
8.8.1 Mechanism of action	143	9.7.1 Prevention of incident heart failure in coronary artery	
8.8.2 Effects on lipids	143	disease patients	158
8.8.3 Effect on cardiovascular morbidity and mortality	143	9.7.2 Chronic heart failure	158
8.8.4 Safety and interactions	144	9.7.3 Valvular heart diseases	158
8.9 Nicotinic acid	144	9.8 Chronic kidney disease	159
8.10 Cholesteryl ester transfer protein inhibitors	144	9.8.1 Lipoprotein profile in chronic kidney disease	159
8.11 Future perspectives	144	9.8.2 Evidence for risk reduction through statin-based	
8.11.1 New approaches to reduce low-density lipoprotein		therapy in patients with chronic kidney disease	159
cholesterol	144	9.8.3 Safety of lipid management in patients with chronic	
8.11.2 New approaches to reduce triglyceride-rich		kidney disease	159
lipoproteins and their remnants	144	9.9 Transplantation	160
8.11.3 New approaches to increase high-density lipoprotein		9.10 Peripheral arterial disease	160
cholesterol	145	9.10.1 Lower extremity arterial disease	160
8.11.4 New approaches to reduce lipoprotein(a) levels	145	9.10.2 Carotid artery disease	161

9.10.3 Retinal vascular disease	161
9.10.4 Secondary prevention in patients with abdominal aortic aneurysm	161
9.10.5 Renovascular atherosclerosis	161
9.11 Other special populations at risk of atherosclerotic cardiovascular disease	161
10 Inflammation	161
11 Monitoring of lipids and enzymes in patients on lipid-lowering therapy	162
12 Cost-effectiveness of cardiovascular disease prevention by lipid modification	162
13 Strategies to encourage adoption of healthy lifestyle changes and adherence to lipid-modifying therapies	166
14 Key messages	166
15 Gaps in evidence	167
16 Evidence-based 'to do' and 'not to do' messages from the Guidelines	168
17 Supplementary data	170
18 Appendix	170
19 References	171

Tables of Recommendations

Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease	127
Recommendations for cardiovascular disease risk estimation	127
Recommendations for lipid analyses for cardiovascular disease risk estimation	131
Recommendations for treatment goals for low-density lipoprotein cholesterol	132
Recommendations for pharmacological low-density lipoprotein cholesterol lowering	145
Recommendations for drug treatment of patients with hypertriglyceridaemia	148
Recommendations for the detection and treatment of patients with heterozygous familial hypercholesterolaemia	150
Recommendations for the treatment of dyslipidaemias in older people (aged >65 years)	153
Recommendations for the treatment of dyslipidaemias in diabetes mellitus	155
Recommendations for lipid-lowering therapy in very-high-risk patients with acute coronary syndromes	157
Recommendations for lipid-lowering therapy in very-high-risk patients undergoing percutaneous coronary intervention	157
Recommendations for lipid-lowering therapy for prevention of atherosclerotic cardiovascular disease events in patients with prior ischaemic stroke	158
Recommendations for the treatment of dyslipidaemias in chronic heart failure or valvular heart diseases	159
Recommendations for lipid management in patients with moderate to severe (Kidney Disease Outcomes Quality Initiative stages 3–5) chronic kidney disease	159
Recommendations for low-density lipoprotein lowering in solid organ transplant patients	160
Recommendations for lipid-lowering drugs in patients with peripheral arterial disease (including carotid artery disease)	161

List of tables

Table 1 Classes of recommendations	117
Table 2 Levels of evidence	117
Table 3 New recommendations, and new and revised concepts	119
Table 4 Cardiovascular risk categories	125
Table 5 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein cholesterol levels	126
Table 6 Physical and chemical characteristics of human plasma lipoproteins	128
Table 7 Treatment targets and goals for cardiovascular disease prevention	133
Table 8 Impact of specific lifestyle changes on lipid levels	134
Table 9 Food choices to lower low-density lipoprotein cholesterol and improve the overall lipoprotein profile	135
Table 10 Drugs potentially interacting with statins metabolized by cytochrome P450 3A4 leading to increased risk of myopathy and rhabdomyolysis	139
Table 11 Genetic disorders of lipoprotein metabolism	149
Table 12 Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia	149
Table 13 Summary of recommendations for monitoring lipids and enzymes in patients, before and on lipid-lowering therapy	163

List of figures

Figure 1 Systematic Coronary Risk Estimation chart for European populations at high cardiovascular disease risk	122
Figure 2 Systematic Coronary Risk Estimation chart for European populations at low cardiovascular disease risk	123
Figure 3 Expected clinical benefit of low-density lipoprotein cholesterol-lowering therapies	146
Figure 4 Treatment goals and algorithm for low-density lipoprotein cholesterol-lowering according to cardiovascular disease risk	147
Figure 5 Health impact pyramid	164
Figure 6 Absolute reductions in major vascular events with statin therapy	165

List of boxes

Box 1 How to use the risk estimation charts	124
Box 2 Risk estimation charts for different countries	124
Box 3 Qualifiers	124
Box 4 Factors modifying Systematic Coronary Risk Estimation risks	124
Box 5 Risk estimation: key messages	125
Box 6 Management of dyslipidaemia in women	152
Box 7 Summary of dyslipidaemia in metabolic syndrome and type 2 diabetes mellitus	154
Box 8 Key messages	165
Box 9 Gaps in the evidence	165
Box 10 Methods for enhancing adherence to lifestyle changes	166

Abbreviations and acronyms

ABI	Ankle–brachial index
ACCELERATE	Assessment of Clinical Effects of Cholesterol Ester Transfer Protein Inhibition with

	Evacetrapib in Patients at a High-Risk for Vascular Outcomes	eGFR	Estimated glomerular filtration rate
ACCORD	Action to Control Cardiovascular Risk in Diabetes	EMA	European Medicines Agency
ACS	Acute coronary syndrome	EPA	Eicosapentaenoic acid
ALT	Alanine aminotransferase	ESC	European Society of Cardiology
ANGPTL3	Angiotensin-like protein 3	EVOLVE	EpanoVa fOr Lowering Very high triglyceridEs
Apo	Apolipoprotein	EVOPACS	EVOlocumab for early reduction of LDL-cholesterol levels in patients with Acute Coronary Syndromes
ART	Antiretroviral treatment	FCH	Familial combined hyperlipidaemia
ASCEND	A Study of Cardiovascular Events in Diabetes	FCS	Familial chylomicronaemia syndrome
ASCOT-LLA	Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm	FDA	US Food and Drug Administration
ASCVD	Atherosclerotic cardiovascular disease	FH	Familial hypercholesterolaemia
ASSIGN	CV risk estimation model from the Scottish Intercollegiate Guidelines Network	FIELD	Fenofibrate Intervention and Event Lowering in Diabetes
AURORA	A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events	FOCUS	Fixed-Dose Combination Drug for Secondary Cardiovascular Prevention
b.i.d.	Twice a day (bis in die)	FOURIER	Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk
BIOSTAT-CHF	BIology Study to Tailored Treatment in Chronic Heart Failure	GFR	Glomerular filtration rate
BIP	Bezafibrate Infarction Prevention	GI	Gastrointestinal
BMI	Body mass index	GISSI	Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico
BP	Blood pressure	HbA1c	Glycated haemoglobin
CABG	Coronary artery bypass graft surgery	HeFH	Heterozygous familial hypercholesterolaemia
CAC	Coronary artery calcium	HDL	High-density lipoprotein
CAD	Coronary artery disease	HDL-C	High-density lipoprotein cholesterol
CANTOS	Canakinumab Antiinflammatory Thrombosis Outcome Study	HF	Heart failure
CETP	Cholesteryl ester transfer protein	HHS	Helsinki Heart Study
CHD	Coronary heart disease	HIV	Human immunodeficiency virus
CI	Confidence interval	HMG-CoA	Hydroxymethylglutaryl-coenzyme A
CIID	Chronic immune-mediated inflammatory diseases	HoFH	Homozygous familial hypercholesterolaemia
CIRT	Cardiovascular Inflammation Reduction Trial	HPS2-THRIVE	Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events
CK	Creatine kinase	HR	Hazard ratio
CKD	Chronic kidney disease	HTG	Hypertriglyceridaemia
COM-B	Capability, Opportunity and Motivation	IDEAL	Incremental Decrease In End-points Through Aggressive Lipid-lowering
CORONA	Controlled Rosuvastatin Multinational Trial in Heart Failure	IDL	Intermediate-density lipoproteins
CPG	Committee for Practice Guidelines	IL	Interleukin
CT	Computed tomography	ILLUMINATE	Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events
CTT	Cholesterol Treatment Trialists	IMPROVE-IT	Improved Reduction of Outcomes: Vytorin Efficacy International Trial
CV	Cardiovascular	IPD	Individual participant data
CVD	Cardiovascular disease	JUPITER	Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
CYP	Cytochrome P450	KDIGO	Kidney Disease: Improving Global Outcomes
4D	Die Deutsche Diabetes Dialyse Studie	LCAT	Lecithin cholesterol acyltransferase
dal-OUTCOMES	Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome	LDL	Low-density lipoprotein
DASH	Dietary Approaches to Stop Hypertension	LDL-C	Low-density lipoprotein cholesterol
DGAT-2	Diacylglycerol acyltransferase-2	LDLR	Low-density lipoprotein receptor
DHA	Docosahexaenoic acid	LEAD	Lower extremity arterial disease
DM	Diabetes mellitus		
EAPC	European Association of Preventive Cardiology		
EAS	European Atherosclerosis Society		
EBBINGHAUS	Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects		

LEADER	Lower Extremity Arterial Disease Event Reduction	TC	Total cholesterol
LPL	Lipoprotein lipase	T1DM	Type 1 diabetes mellitus
Lp(a)	Lipoprotein(a)	T2DM	Type 2 diabetes mellitus
mAb	Monoclonal antibody	TGs	Triglycerides
MACE	Major adverse cardiovascular events	TIA	Transient ischaemic attack
MESA	Multi-Ethnic Study of Atherosclerosis	TIMI	Thrombolysis In Myocardial Infarction
MetS	Metabolic syndrome	TNF	Tumour necrosis factor
MI	Myocardial infarction	TNT	Treating to New Targets
mRNA	Messenger RNA	TRL	Triglyceride-rich lipoprotein
MTP	Microsomal triglyceride transfer protein	ULN	Upper limit of normal
NAFLD	Non-alcoholic fatty liver disease	VA-HIT	Veterans Affairs High Density Lipoprotein Intervention Trial
NNT	Number needed to treat	VITAL	VITamin D and Omega-3 Trial
NPC1L1	Niemann-Pick C1-like protein 1	VLDL	Very low-density lipoprotein
NSTE-ACS	Non-ST elevation acute coronary syndrome	WHO	World Health Organization
o.d.	Once a day (omni die)	WOSCOPS	West of Scotland Coronary Prevention Study
ODYSSEY Outcomes	Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab		
PAD	Peripheral arterial disease		
PCI	Percutaneous coronary intervention		
PCSK9	Proprotein convertase subtilisin/kexin type 9		
PPAR- α	Peroxisome proliferator-activated receptor- α		
PREDIMED	Prevención con Dieta Mediterránea		
PROCAM	Prospective Cardiovascular Munster Study		
PROMINENT	Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides IN PatiENts With DiabeTes		
PUFA	Polyunsaturated fatty acid		
PURE	Prospective Urban Rural Epidemiology		
RA	Rheumatoid arthritis		
RCT	Randomized controlled trial		
REDUCE-IT	Reduction of Cardiovascular Events with EPA-Intervention Trial		
REVEAL	Randomized EVAluation of the Effects of Anacetrapib Through Lipid modification		
RR	Relative risk		
RYR	Red yeast rice		
SAMS	Statin-associated muscle symptoms		
SBP	Systolic blood pressure		
SCORE	Systematic Coronary Risk Estimation		
SEAS	Simvastatin and Ezetimibe in Aortic Stenosis		
SECURE-PCI	Statins Evaluation in Coronary Procedures and Revascularization		
SFA	Saturated fatty acid		
SHARP	Study of Heart and Renal Protection		
siRNA	Small interfering RNA		
SMI	Severe mental illness		
SPARCL	Stroke Prevention by Aggressive Reduction in Cholesterol Levels		
STAREE	STAtin Therapy for Reducing Events in the Elderly		
STEMI	ST-elevation myocardial infarction		
STRENGTH	Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGH CV Risk PatienTs with Hypertriglyceridemia		

1 Preamble

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

A great number of guidelines have been issued in recent years by the European Society of Cardiology (ESC) and its partners such as European Atherosclerosis Society (EAS), as well as by other societies and organisations. Because of their impact on clinical practice, quality criteria for the development of guidelines have been established in order to make all decisions transparent to the user. The recommendations for formulating and issuing ESC Guidelines can be found on the ESC website (<http://www.escardio.org/Guidelines-&Education/Clinical-Practice-Guidelines/Guidelines-development/Writing-ESC-Guidelines>). The ESC Guidelines represent the official position of the ESC on a given topic and are regularly updated.

The ESC carries out a number of registries which are essential to assess diagnostic/therapeutic processes, use of resources and adherence to Guidelines. These registries aim at providing a better understanding of medical practice in Europe and around the world, based on data collected during routine clinical practice.

The guidelines are developed together with derivative educational material addressing the cultural and professional needs for cardiologists and allied professionals. Collecting high-quality observational data, at appropriate time interval following the release of ESC Guidelines, will help evaluate the level of implementation of the Guidelines, checking in priority the key end points defined with the ESC Guidelines and Education Committees and Task Force members in charge.

The Members of this Task Force were selected by the ESC and EAS, including representation from relevant ESC sub-specialty groups, in order to represent professionals involved with the medical care of patients with this pathology. Selected experts in the field from

both societies undertook a comprehensive review of the published evidence for management of a given condition according to ESC Committee for Practice Guidelines (CPG) policy. A critical evaluation of diagnostic and therapeutic procedures was performed, including assessment of the risk–benefit ratio. The level of evidence and the strength of the recommendation of particular management options were weighed and graded according to predefined ESC scales, as outlined in the tables below.

The experts of the writing and reviewing panels provided declaration of interest forms for all relationships that might be perceived as real or potential sources of conflicts of interest. These forms were compiled into one file and can be found on the ESC website (<http://www.escardio.org/guidelines>). Any changes in declarations of interest that arise during the writing period were notified to the ESC and EAS Chairpersons and updated. The Task Force received its entire financial support from the ESC and EAS without any involvement from the healthcare industry.

The ESC CPG supervises and coordinates the preparation of new Guidelines. The Committee is also responsible for the endorsement process of these Guidelines. The ESC Guidelines undergo extensive review by the CPG and external experts. After appropriate revisions the Guidelines are approved by all the experts involved in the Task Force. The finalized document is approved by the CPG and EAS for publication in the European Heart Journal and Atherosclerosis Journal. The Guidelines were developed after careful consideration of the scientific and medical knowledge and the evidence available at the time of their dating.

The task of developing ESC/EAS Guidelines also includes the creation of educational tools and implementation programmes for the recommendations including condensed pocket guideline versions, summary slides, booklets with essential messages, summary cards for non-specialists and an electronic version for digital applications (smartphones, etc.). These versions are abridged and thus, for more detailed information, the user should always access the full text

Table 1 Classes of recommendations

	Definition	Wording to use	
Classes of recommendations	Class I	Evidence and/or general agreement that a given treatment or procedure is beneficial, useful, effective.	Is recommended or is indicated
	Class II	Conflicting evidence and/or a divergence of opinion about the usefulness/efficacy of the given treatment or procedure.	
	Class IIa	Weight of evidence/opinion is in favour of usefulness/efficacy.	Should be considered
	Class IIb	Usefulness/efficacy is less well established by evidence/opinion.	May be considered
	Class III	Evidence or general agreement that the given treatment or procedure is not useful/effective, and in some cases may be harmful.	Is not recommended

©ESC 2019

Table 2 Levels of evidence

Level of evidence A	Data derived from multiple randomized clinical trials or meta-analyses.
Level of evidence B	Data derived from a single randomized clinical trial or large non-randomized studies.
Level of evidence C	Consensus of opinion of the experts and/or small studies, retrospective studies, registries.

©ESC 2019

version of the Guidelines, which is freely available via the ESC and EAS websites and hosted on their journals' websites (EHJ and Atherosclerosis Journal). The National Cardiac Societies of the ESC are encouraged to endorse, translate and implement all ESC Guidelines. Implementation programmes are needed because it has been shown that the outcome of disease may be favourably influenced by the thorough application of clinical recommendations.

Health professionals are encouraged to take the ESC/EAS Guidelines fully into account when exercising their clinical judgment, as well as in the determination and the implementation of preventive, diagnostic or therapeutic medical strategies. However, the ESC/EAS Guidelines do not override in any way whatsoever the individual responsibility of health professionals to make appropriate and accurate decisions in consideration of each patient's health condition and in consultation with that patient or the patient's caregiver where appropriate and/or necessary. It is also the health professional's responsibility to verify the rules and regulations applicable in each country to drugs and devices at the time of prescription.

2 Introduction

The previous ESC/EAS lipid Guidelines were published in August 2016.¹ The emergence of a substantial body of evidence over the last few years has required new, up-to-date Guidelines.

New evidence has confirmed that the key initiating event in atherogenesis is the retention of low-density lipoprotein (LDL) cholesterol (LDL-C) and other cholesterol-rich apolipoprotein (Apo) B-containing lipoproteins within the arterial wall.² Several recent placebo-controlled clinical studies have shown that the addition of either ezetimibe or anti-proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies (mAbs) to statin therapy provides a further reduction in atherosclerotic cardiovascular disease (ASCVD) risk, which is directly and positively correlated with the incrementally achieved absolute LDL-C reduction. Furthermore, these clinical trials have clearly indicated that the lower the achieved LDL-C values, the lower the risk of future cardiovascular (CV) events, with no lower limit for LDL-C values, or 'J'-curve effect. In addition, studies of the clinical safety of these very low achieved LDL-C values have proved reassuring, albeit monitoring for longer periods is required. For raising high-density lipoprotein (HDL) cholesterol (HDL-C), recent studies have indicated that the currently available therapies do not reduce the risk of ASCVD. Finally, human Mendelian randomization studies have demonstrated the critical role of LDL-C, and other cholesterol-rich ApoB-containing lipoproteins, in atherosclerotic plaque formation and related subsequent CV events. Thus, there is no longer an 'LDL-C hypothesis', but established facts that increased LDL-C values are causally related to ASCVD, and that lowering LDL particles and other ApoB-containing lipoproteins as much as possible reduces CV events.

In order to be aligned with these new findings, the ESC/EAS Task Force members who have written these Guidelines have proposed new LDL-C goals, as well as a revised CV risk stratification, which are especially relevant to high- and very-high-risk patients.

These novel ESC/EAS Guidelines on lipids provide important new advice on patient management, which should enable more clinicians to efficiently and safely reduce CV risk through lipid modification.

2.1 What is new in the 2019 Guidelines?

New recommendations, and new and revised concepts, are presented in *Table 3*.

3 What is cardiovascular disease prevention?

3.1 Definition and rationale

Cardiovascular disease (CVD), of which ASCVD is the major component, is responsible for >4 million deaths in Europe each year. It kills more women (2.2 million) than men (1.8 million), although CV deaths before the age of 65 years are more common in men (490 000 vs. 193 000).³ Prevention is defined as a co-ordinated set of actions, either at the population or individual level, aimed at eliminating or minimizing the impact of CV diseases and their related disabilities. More patients are surviving their first CVD event and are at high-risk of recurrences. In addition, the prevalence of some risk factors, notably diabetes (DM) and obesity, is increasing. The importance of ASCVD prevention remains undisputed and should be delivered at the general population level by promoting healthy lifestyle behaviour,⁴ and at the individual level by tackling unhealthy lifestyles and by reducing increased levels of causal CV risk factors, such as LDL cholesterol or blood pressure (BP) levels.

3.2 Development of the Joint Task Force Guidelines for the management of dyslipidaemias

The present Guidelines represent an evidence-based consensus of the European Task Force, including the ESC and the EAS.

By appraising the current evidence and identifying remaining knowledge gaps in the management of dyslipidaemias, the Task Force has formulated recommendations to guide action in clinical practice to prevent ASCVD by modifying plasma lipid levels.

This document has been developed for healthcare professionals to facilitate informed communication with individuals about their CV risk and the benefits of adopting and sustaining a healthy lifestyle, and of early modification of their lipid-related CV risk. In addition, the Guidelines provide tools for healthcare professionals to promote up-to-date intervention strategies, integrate these strategies into national or regional prevention frameworks, and to translate them into locally delivered healthcare services, in line with the recommendations of the World Health Organization (WHO) *Global Status Report on Noncommunicable Diseases 2014*.⁵

A lifetime approach to CV risk should be considered.¹ This implies that—apart from improving lifestyle habits and reducing risk factor levels in patients with established ASCVD, and in those at increased risk of developing ASCVD—people of all ages should be encouraged to adopt or sustain a healthy lifestyle.

4 Total cardiovascular risk

4.1 Total cardiovascular risk estimation

CV risk in the context of these Guidelines means the likelihood of a person developing an atherosclerotic CV event over a defined period

Table 3 New recommendations, and new and revised concepts

New recommendations	
Cardiovascular imaging for assessment of ASCVD risk	
Assessment of arterial (carotid and/or femoral) plaque burden on arterial ultrasonography should be considered as a risk modifier in individuals at low or moderate risk.	
Cardiovascular imaging for assessment of ASCVD risk	
CAC score assessment with CT may be considered as a risk modifier in the CV risk assessment of asymptomatic individuals at low or moderate risk.	
Lipid analyses for CVD risk estimation	
Lp(a) measurement should be considered at least once in each adult person's lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (>430 nmol/L) who may have a lifetime risk of ASCVD equivalent to the risk associated with heterozygous familial hypercholesterolaemia.	
Drug treatments of patients with hypertriglyceridaemia	
In high-risk (or above) patients with TG between 1.5 and 5.6 mmol/L (135 - 499 mg/dL) despite statin treatment, n-3 PUFAs (icosapent ethyl 2 × 2g/day) should be considered in combination with statins.	
Treatment of patients with heterozygous FH	
In primary prevention, for individuals with FH at very-high risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) should be considered.	
Treatment of dyslipidaemias in older people	
Treatment with statins is recommended for primary prevention, according to the level of risk, in older people aged ≤75.	
Treatment of dyslipidaemias in older people	
Initiation of statin treatment for primary prevention in older people aged >75 may be considered, if at high risk or above.	
Treatment of dyslipidaemias in DM	
In patients with T2DM at very-high risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.4 mmol/L (<55mg/dL) is recommended. In patients with T2DM at high risk, an LDL-C reduction of ≥50% from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) is recommended. Statin are recommended in patients with T1DM who are at high or very-high risk.	
Treatment of dyslipidaemias in DM	
Intensification of statin therapy should be considered before the introduction of combination therapy. If the goal is not reached, statin combination with ezetimibe should be considered.	
Treatment of dyslipidaemias in DM	
Statin therapy is not recommended in pre-menopausal patients with DM who are considering pregnancy or not using adequate contraception.	
Lipid-lowering therapy in patients with ACS	
For patients who present with an ACS, and whose LDL-C levels are not at goal despite already taking a maximally tolerated statin dose and ezetimibe, adding a PCSK9 inhibitor early after the event (if possible, during hospitalization for the ACS event) should be considered.	
Changes in recommendations	
Upgrades	
2016	2019
Lipid analyses for CVD risk estimation	Lipid analyses for CVD risk estimation
ApoB should be considered as an alternative risk marker whenever available, especially in individuals with high TG.	ApoB analysis is recommended for risk assessment, particularly in people with high TG, DM, obesity or metabolic syndrome, or very low LDL-C. It can be used as an alternative to LDL-C, if available, as the primary measurement for screening, diagnosis, and management, and may be preferred over non-HDL-C in people with high TG, DM, obesity, or very low LDL-C.
Pharmacological LDL-C lowering	Pharmacological LDL-C lowering
If the LDL goal is not reached, statin combination with a cholesterol absorption inhibitor should be considered.	If the goals are not achieved with the maximum tolerated dose of statin, combination with ezetimibe is recommended.
Pharmacological LDL-C lowering	Pharmacological LDL-C lowering
In patients at very-high risk, with persistent high LDL-C despite treatment with maximal tolerated statin dose, in combination with ezetimibe or in patients with statin intolerance, a PCSK9 inhibitor may be considered.	For secondary prevention, patients at very-high risk not achieving their goal on a maximum tolerated dose of statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended. For very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who do not achieve their goals on a maximum tolerated dose of statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended.

Continued

Drug treatments of hypertriglyceridaemia	Drug treatments of hypertriglyceridaemia
Statin treatment may be considered as the first drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridaemia.	Statin treatment is recommended as the first drug of choice for reducing CVD risk in high-risk individuals with hypertriglyceridaemia [TG >2.3 mmol/L (200 mg/dL)].
Treatment of patients with heterozygous FH	Treatment of patients with heterozygous FH
Treatment should be considered to aim at reaching an LDL-C <2.6 mmol/L (<100 mg/dL) or in the presence of CVD <1.8 mmol/L (<70 mg/dL). If targets cannot be reached, maximal reduction of LDL-C should be considered using appropriate drug combinations.	For FH patients with ASCVD who are at very-high risk, treatment to achieve at least a 50% reduction from baseline and an LDL-C <1.4 mmol/L (<55 mg/dL) is recommended. If goals cannot be achieved, a drug combination is recommended.
Treatment of patients with heterozygous FH	Treatment of patients with heterozygous FH
Treatment with a PCSK9 antibody should be considered in FH patients with CVD or with other factors putting them at very-high risk for CHD, such as other CV risk factors, family history, high Lp(a), or statin intolerance.	Treatment with a PCSK9 inhibitor is recommended in very-high-risk FH patients if the treatment goal is not achieved on maximal tolerated statin plus ezetimibe.
Treatment of dyslipidaemias in older adults	Treatment of dyslipidaemias in older people
Since older people often have comorbidities and have altered pharmacokinetics, lipid-lowering medication should be started at a lower dose and then titrated with caution to achieve target lipid levels that are the same as in younger people.	It is recommended that the statin is started at a low dose if there is significant renal impairment and/or the potential for drug interactions, and then titrated upwards to achieve LDL-C treatment goals.
Lipid-lowering therapy in patients with ACS	Lipid-lowering therapy in patients with ACS
If the LDL-C target is not reached with the highest tolerated statin dose and/or ezetimibe, PCSK9 inhibitors may be considered on top of lipid-lowering therapy; or alone or in combination with ezetimibe in statin-intolerant patients or in whom a statin is contraindicated.	If the LDL-C goal is not achieved after 4-6 weeks despite maximal tolerated statin therapy and ezetimibe, addition of a PCSK9 inhibitor is recommended.

Recommendation grading

Class I

Class IIa

Class IIb

Class III

New sections

- A new section is focused on the utility of non-invasive CV imaging for classification of total CVD risk, with implications for recommended lipid-modifying therapies.
- More data are provided on the biology and physiology of lipids and lipoproteins, and on their roles in pathophysiology. Emerging evidence from observational studies, RCTs, and genetic (Mendelian randomization) studies unequivocally showing a causal effect of LDL-C in the development of ASCVD is discussed, and newer evidence regarding the effects of TGs and HDL on ASCVD risk is presented.
- New sections describe novel lipid-modifying medications as well as emerging approaches for lowering LDL-C, TGs, and Lp(a).
- A new section discusses the inflammation-related risk in very high-risk patients and the potential role of inflammation as a therapeutic target to lower ASCVD risk.

• New/revised concepts

More intensive reduction of LDL-C across CV risk categories

- For secondary prevention in very-high-risk patients, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.
 - For patients with ASCVD who experience a second vascular event within 2 years (not necessarily of the same type as the first event) while taking maximally tolerated statin therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) may be considered.
- In primary prevention, for individuals at very-high risk but without FH, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended. For individuals at very-high risk (that is, with another risk factor but without ASCVD), in primary prevention the same goals for LDL-C lowering should be considered.
- For patients at high risk, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) are recommended.
- For individuals at moderate risk, an LDL-C goal of <2.6 mmol/L (<100 mg/dL) should be considered.
- For individuals at low risk, an LDL-C goal of <3.0 mmol/L (<116 mg/dL) may be considered.

The rationale for the revised, lower LDL-C goals across CV risk categories is discussed, based on a critical synthesis of available evidence from lipid-modifying interventions resulting in reductions in CV risk.

Pharmacological LDL-C-lowering strategies

The section on pharmacological strategies to lower LDL-C emphasizes the concept that the absolute LDL-C reduction (determined by pre-treatment LDL-C levels and the LDL-lowering efficacy of the medications) dictates the relative risk reduction, which in turn—depending on the baseline CV risk—defines the associated absolute CV risk reduction in individual patients.

Risk classification in patients with FH

Patients with FH and ASCVD, or another major risk factor, are classified as very-high-risk, and those without known ASCVD and without other risk factors as high-risk. Recommended treatment goals are defined accordingly.

Adverse effects of statins

The distinction between formal statin myopathy vs. so-called statin-associated muscle symptoms is emphasized, and the discordance in reported frequency of symptoms in RCTs vs. observational studies are critically discussed on the basis of new relevant evidence.

Continued

PCSK9 inhibitors

New outcome study data of PCSK9 inhibitors are presented, and updated recommendations for their clinical use are provided.

Cost-effectiveness

The issue of cost-effectiveness of lipid-modifying interventions is updated in view of changes in the availability of generic products for statins and ezetimibe, and of PCSK9 inhibitors.

ACS = acute coronary syndrome; ApoB = apolipoprotein B; ASCVD = atherosclerotic cardiovascular disease; CAC = coronary artery calcium; CHD = coronary heart disease; CT = computed tomography; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; FH = familial hypercholesterolaemia; HDL = high-density lipoprotein; LDL-C = low-density lipoproteins cholesterol; Lp(a) = lipoprotein(a); PCSK9 = proprotein convertase subtilisin/kexin type 9; PUFAs = polyunsaturated fatty acids; RCTs = randomized controlled trials; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus; TGs = triglycerides.

of time. Total CVD risk expresses the combined effect of a number of risk factors on this risk estimate. In these Guidelines, we address the lipid-related contribution to total CV risk and how to manage it at the clinical level.

4.1.1 Rationale for assessing total cardiovascular disease risk

All current guidelines on the prevention of ASCVD in clinical practice recommend the assessment of total CVD risk. Prevention of ASCVD in a given person should relate to his or her total CV risk: the higher the risk, the more intense the action should be.

Many risk assessment systems are available and have been comprehensively reviewed (*Supplementary Table 1* in the *Supplementary Data*). Most guidelines use one of these risk assessment systems.^{6–8} Ideally, risk charts should be based on country-specific cohort data. These are not available for most countries. The SCORE (Systematic Coronary Risk Estimation) system can be recalibrated for use in different populations by adjusting for secular changes in CVD mortality and risk factor prevalence. Calibrated country-specific versions are available for many European countries and can be found at <http://www.heartscore.org>. These are now being updated to provide recalibrated, contemporaneous country-specific charts for all European countries. Other risk estimation systems—using both fatal and non-fatal events—can also be recalibrated, but the process is easier and scientifically more robust for mortality than for total events. The European Guidelines on CVD prevention in clinical practice (both the 2012⁹ and 2016¹⁰ versions) recommend the use of the SCORE system because it is based on large, representative European cohort data sets and because it is relatively straightforward to recalibrate for individual countries.

Persons with documented ASCVD, type 1 or type 2 DM (T1DM and T2DM, respectively), very high levels of individual risk factors, or chronic kidney disease (CKD) are generally at very-high or high total CV risk. No risk estimation models are needed for such persons; they all need active management of all risk factors. For other, apparently healthy people, the use of a risk estimation system such as SCORE, which estimates the 10 year cumulative risk of a first fatal atherosclerotic event, is recommended to estimate total CV risk, since many people have several risk factors that, in combination, may result in high levels of total CV risk.

Risk estimates have been produced as charts for high- and low-risk regions in Europe (*Figures 1 and 2*).¹¹ All International Classification of Diseases codes that are related to deaths from vascular origin caused by atherosclerosis are included. The reasons for retaining a system that estimates fatal as opposed to total fatal + non-fatal events are that non-fatal events are dependent on definition, developments in

diagnostic tests, and methods of ascertainment, all of which can vary, resulting in very variable multipliers to convert fatal to total events. In addition, total event charts, in contrast to those based on mortality, are more difficult to recalibrate to suit different populations. That said, work is in progress to produce regional total event charts.

The SCORE data indicate that the total CVD event risk is about three times higher than the risk of fatal CVD for men, so a SCORE risk of 5% translates into a CVD risk of ~15% of total (fatal + non-fatal) CVD endpoints; the multiplier is higher in women and lower in older people.

Clinicians often ask for thresholds to trigger certain interventions. This is problematic since risk is a continuum and there is no threshold at which, for example, a drug is automatically indicated. This is true for all continuous risk factors such as plasma cholesterol or systolic BP (SBP). Therefore, the goals that are proposed in this document reflect this concept.


A particular problem relates to young people with high levels of risk factors; a low absolute risk may conceal a very high relative risk requiring at least intensive lifestyle advice. To motivate young people (i.e. aged <40 years) not to delay changing their unhealthy lifestyle, an estimate of their relative risk—illustrating that lifestyle changes can reduce relative risk substantially—may be helpful (*Supplementary Figure 1*).

Another approach to this problem is to use CV risk age. The risk age of a person with several CV risk factors is the age of a person with the same level of risk but with ideal levels of risk factors. Thus, a high-risk 40-year-old would have a risk age ≥ 65 years. Risk age can be estimated visually by looking at the SCORE chart (as illustrated in *Supplementary Figure 2*). In this chart, the risk age of a person with risk factors is defined as the age at which a person with ideal risk factor levels would reach the same risk level. Ideal risk factors are non-smoking, total cholesterol (TC) ≤ 4 mmol/L (≤ 155 mg/dL), and SBP ≤ 120 mmHg. Risk age is also automatically calculated as part of the latest revision of HeartScore (<http://www.HeartScore.org>).

Risk age has been shown to be independent of the CV endpoint used,^{6,8} can be used in any population regardless of baseline risk or secular changes in mortality, and therefore avoids the need for recalibration.

Lifetime risk is another approach to illustrate the impact of risk factors that may be useful in younger people.¹² The greater the burden of risk factors, the higher the lifetime risk. This approach produces higher risk figures for younger people because of their longer exposure times. Therefore, it is more useful as a way of illustrating risk than as a guide to treatment, because therapeutic trials have been based on a fixed follow-up period and not on lifetime risk.

Another problem relates to older people. In some age categories, the majority of people, especially males, will have estimated 10 year



Downloaded from https://academic.oup.com/eurheartj/article/41/11/1155/56353 by guest on 12 May 2021

Figure 1 Systematic Coronary Risk Estimation chart for European populations at high cardiovascular disease risk. The 10-year risk of fatal cardiovascular disease in populations at high cardiovascular disease risk based on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal cardiovascular disease to risk of total (fatal + non-fatal) cardiovascular disease, multiply by 3 in men and by 4 in women, and slightly less in older people. Note: the Systematic Coronary Risk Estimation chart is for use in people without overt cardiovascular disease, diabetes (type 1 and 2), chronic kidney disease, familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high-risk and need intensive risk factor management. Cholesterol: 1 mmol/L = 38.67 mg/dL. The SCORE risk charts presented above differ slightly from those in the 2016 European Society of Cardiology/European Atherosclerosis Society Guidelines for the management of dyslipidaemias and the 2016 European Guidelines on cardiovascular disease prevention in clinical practice, in that: (i) age has been extended from age 65 to 70; (ii) the interaction between age and each of the other risk factors has been incorporated, thus reducing the overestimation of risk in older persons in the original Systematic Coronary Risk Estimation charts; and (iii) the cholesterol band of 8 mmol/L has been removed, since such persons will qualify for further evaluation in any event. SCORE = Systematic Coronary Risk Estimation.




Figure 2 Systematic Coronary Risk Estimation chart for European populations at low cardiovascular disease risk. The 10-year risk of fatal cardiovascular disease in populations at low cardiovascular disease risk based on the following risk factors: age, gender, smoking, systolic blood pressure, and total cholesterol. To convert the risk of fatal cardiovascular disease to risk of total (fatal + non-fatal) cardiovascular disease, multiply by 3 in men and by 4 in women, and slightly less in older people. Note: the Systematic Coronary Risk Estimation chart is for use in people without overt cardiovascular disease, diabetes (type 1 and 2), chronic kidney disease, familial hypercholesterolaemia, or very high levels of individual risk factors because such people are already at high-risk and need intensive risk factor management. Cholesterol: 1 mmol/L=38.67 mg/dL. The SCORE risk charts presented above differ slightly from those in the 2016 European Society of Cardiology/European Atherosclerosis Society Guidelines for the management of dyslipidaemias and the 2016 European Guidelines on cardiovascular disease prevention in clinical practice, in that: (i) age has been extended from age 65 to 70; (ii) the interaction between age and each of the other risk factors has been incorporated, thus reducing the overestimation of risk in older persons in the original Systematic Coronary Risk Estimation charts; and (iii) the cholesterol band of 8 mmol/L has been removed since such persons will qualify for further evaluation in any event. SCORE = Systematic Coronary Risk Estimation.

cumulative CV death risks exceeding the 5–10% level, based on age only, even when other CV risk factor levels are relatively low. Therefore, before initiating treatment in the elderly, clinicians should evaluate patients carefully. The relative strengths of risk factors vary with age and SCORE overestimates risk in older people (that is, those aged >65 years).¹¹ These Guidelines include illustrative charts for older people (see *Figures 1 and 2*). While older people benefit from smoking cessation, and control of hypertension and hyperlipidaemia (see *section 9.3*), clinical judgement is required to avoid side effects from overmedication.

The additional impact of HDL-C on risk estimation is illustrated in *Supplementary Figures 3 and 4*; HDL-C can be used to increase the accuracy of the risk evaluation. In these charts, HDL-C is used categorically. The electronic version of SCORE, HeartScore (http://www.heartscore.org/en_GB/), has been modified to take HDL-C into consideration as a continuous variable. Clinicians should be aware that at extremely high values [above ~2.3 mmol/L (90 mg/dL)] of HDL-C there appears to be an increased risk of ASCVD, so at such levels HDL-C cannot be used as a risk predictor.

4.1.2 How to use the risk estimation charts

Use of the low- or the high-risk SCORE charts will depend on the CVD mortality experience in each country. While any cut-off point is arbitrary and open to debate, in these Guidelines, the cut-off point for calling a country ‘low CVD risk’ is based on WHO data derived from the Global Burden of Disease Study.

Countries are categorized as low-risk if their age-adjusted 2016 CVD mortality rate was <150/100 000 (for men and women together) (http://www.who.int/healthinfo/global_burden_disease/estimates/en/). Countries with a CVD mortality rate of ≥150/100 000 or more are considered to be at high-risk.

Boxes 1 to 5 summarize the main points regarding the risk estimation charts and their use.

Box 1 How to use the risk estimation charts

To estimate a person's 10-year risk of CVD death, find the table for his/her gender, smoking status, and age. Within the table, find the cell nearest to the person's BP and TC. Risk estimates will need to be adjusted upwards as the person approaches the next age category.

Risk is initially assessed on the level of TC and systolic BP before treatment, if known. The longer the treatment and the more effective it is, the greater the reduction in risk, but in general it will not be more than about one-third of the baseline risk. For example, for a person on antihypertensive drug treatment in whom the pre-treatment BP is not known, if the total CV SCORE risk is 6%, then the pre-treatment total CV risk may have been 9%.

Low-risk persons should be offered advice to maintain their low-risk status. While no threshold is universally applicable, the intensity of advice should increase with increasing risk.

The charts may be used to give some indication of the effects of reducing risk factors, given that there is apparently a time lag before the risk reduces. In general, people who stop smoking halve their cumulative risk over a relatively short period of time.

BP = blood pressure; CV = cardiovascular; CVD = cardiovascular disease; SCORE = Systematic Coronary Risk Estimation; TC = total cholesterol.

© ESC 2019

Box 2 Risk estimation charts for different countries

The **low-risk charts** should be considered for use in Austria, Belgium, Cyprus, Denmark, Finland, France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Netherlands, Norway, Malta, Portugal, Slovenia, Spain, Sweden, Switzerland, and the UK.

The **high-risk charts** should be considered for use in Albania, Algeria, Armenia, Bosnia and Herzegovina, Croatia, Czech Republic, Estonia, Hungary, Latvia, Lebanon, Libya, Lithuania, Montenegro, Morocco, Poland, Romania, Serbia, Slovakia, Tunisia, and Turkey.

Some countries have a cardiovascular disease mortality rate >350/100 000, and the **high-risk chart may underestimate risk**. These are Azerbaijan, Belarus, Bulgaria, Egypt, Georgia, Kazakhstan, Kyrgyzstan, North Macedonia, Republic of Moldova, Russian Federation, Syria, Tajikistan, Turkmenistan, Ukraine, and Uzbekistan.

See <http://apps.who.int/gho/data/node.home>.

© ESC 2019

Box 3 Qualifiers

The charts can assist in risk assessment and management, but must be interpreted in light of the clinician's knowledge and experience, and of the patient's pre-test likelihood of CVD.

Risk will be overestimated in countries with decreasing CVD mortality, and underestimated in countries in which mortality is increasing. This is dealt with by recalibration (http://www.heartscore.org/en_GB/).

Risk estimates are lower in women than in men. However, risk is only deferred in women; the risk of a 60-year-old woman is similar to that of a 50-year-old man. Ultimately, more women die from CVD than men.

Relative risks may be unexpectedly high in young persons, even if absolute risk levels are low. The relative risk chart (*Supplementary Figure 1*) and the estimated risk age (*Supplementary Figure 2*) may be helpful in identifying and counselling such persons.

CVD = cardiovascular disease.

© ESC 2019

Box 4 Factors modifying Systematic Coronary Risk Estimation risks

Social deprivation: the origin of many of the causes of CVD.

Obesity and central obesity as measured by the body mass index and waist circumference, respectively.

Physical inactivity.

Psychosocial stress including vital exhaustion.

Family history of premature CVD (men: <55 years and women: <60 years).

Chronic immune-mediated inflammatory disorder.

Major psychiatric disorders.

Treatment for human immunodeficiency virus infection.

Atrial fibrillation.

Left ventricular hypertrophy.

Chronic kidney disease.

Obstructive sleep apnoea syndrome.

Non-alcoholic fatty liver disease.

CVD = cardiovascular disease.

© ESC 2019

Social deprivation and psychosocial stress set the scene for increased risk.¹³ For those at moderate risk, other factors—including metabolic factors such as increased ApoB, lipoprotein(a) [Lp(a)], triglycerides (TGs), or C-reactive protein; the presence of albuminuria; the presence of atherosclerotic plaque in the carotid or femoral arteries; or the coronary artery calcium (CAC) score—may improve risk classification. Many other biomarkers are also associated with increased CVD risk, although few of these have been shown to be associated with appreciable reclassification. Total CV risk will also be higher than indicated in the SCORE charts in asymptomatic persons with abnormal markers of subclinical atherosclerotic vascular damage. Reclassification is of value in people identified as being at moderate CV risk by using markers such as CAC score >100 Agatston units, ankle–brachial index (ABI) <0.9 or >1.40, carotid–femoral pulse wave velocity >10 m/s, or the presence of plaques at carotid or femoral ultrasonography. In studies comparing these markers, CAC had the best reclassification ability.^{14–16}

Some factors such as a high HDL-C up to 2.3 mmol/L (90mg/dL)¹⁷ or a family history of longevity can also be associated with lower risk.

Box 5 Risk estimation: key messages

In apparently healthy persons, CVD risk is most frequently the result of multiple, interacting risk factors. This is the basis for total CV risk estimation and management.

Risk factor screening including the lipid profile should be considered in men >40 years old, and in women >50 years of age or post-menopausal.

A risk estimation system such as SCORE can assist in making logical management decisions, and may help to avoid both under- and overtreatment.

Certain individuals declare themselves to be at high or very high CVD risk without needing risk scoring, and all risk factors require immediate attention. This is true for patients with documented CVD, older individuals with long-standing DM, familial hypercholesterolaemia, chronic kidney disease, carotid or femoral plaques, coronary artery calcium score >100, or extreme Lp(a) elevation.

All risk estimation systems are relatively crude and require attention to qualifying statements.

Additional factors affecting risk can be accommodated in electronic risk estimation systems such as HeartScore (www.heartscore.org).

The total risk approach allows flexibility; if optimal control cannot be achieved with one risk factor, trying harder with the other factors can still reduce risk.

CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; SCORE = Systematic Coronary Risk Estimation.

4.2 Risk levels

A total CV risk estimate is part of a continuum. The cut-off points that are used to define high-risk are, in part, both arbitrary and based on the risk levels at which benefit is evident in clinical trials. In clinical practice, consideration should be given to practical issues in relation to the local healthcare systems. Not only should those at high risk be identified and managed, but those at moderate risk should also receive professional advice regarding lifestyle changes; in some cases, drug therapy will be needed to reduce atherosclerotic risk.

Low-risk people should be given advice to help them maintain this status. Thus, the intensity of preventive actions should be tailored to the patient's total CV risk. The strongest driver of total CV risk is age, which can be considered as 'exposure time' to risk factors.

For these reasons, the Task Force suggests the following categories of risk and LDL-C goals, based on the best available evidence and in an ideal setting with unlimited resources. These categories represent a counsel of perfection, but these ideals are for guidance only and practical decision-making must be based on what is appropriate to the local situation.

With these considerations, we propose the levels of total CV risk presented in Table 4.

Table 4 Cardiovascular risk categories

Very-high-risk	<p>People with any of the following:</p> <p>Documented ASCVD, either clinical or unequivocal on imaging. Documented ASCVD includes previous ACS (MI or unstable angina), stable angina, coronary revascularization (PCI, CABG, and other arterial revascularization procedures), stroke and TIA, and peripheral arterial disease. Unequivocally documented ASCVD on imaging includes those findings that are known to be predictive of clinical events, such as significant plaque on coronary angiography or CT scan (multivessel coronary disease with two major epicardial arteries having >50% stenosis), or on carotid ultrasound.</p> <p>DM with target organ damage,^a or at least three major risk factors, or early onset of T1DM of long duration (>20 years).</p> <p>Severe CKD (eGFR <30 mL/min/1.73 m²).</p> <p>A calculated SCORE ≥10% for 10-year risk of fatal CVD.</p> <p>FH with ASCVD or with another major risk factor.</p>
High-risk	<p>People with:</p> <p>Markedly elevated single risk factors, in particular TC >8 mmol/L (>310 mg/dL), LDL-C >4.9 mmol/L (>190 mg/dL), or BP ≥180/110 mmHg.</p> <p>Patients with FH without other major risk factors.</p> <p>Patients with DM without target organ damage,^a with DM duration ≥10 years or another additional risk factor.</p> <p>Moderate CKD (eGFR 30–59 mL/min/1.73 m²).</p> <p>A calculated SCORE ≥5% and <10% for 10-year risk of fatal CVD.</p>
Moderate-risk	<p>Young patients (T1DM <35 years; T2DM <50 years) with DM duration <10 years, without other risk factors. Calculated SCORE ≥1 % and <5% for 10-year risk of fatal CVD.</p>
Low-risk	<p>Calculated SCORE <1% for 10-year risk of fatal CVD.</p>

ASCVD = atherosclerotic cardiovascular disease; ACS = acute coronary syndrome; BP = blood pressure; CABG = coronary artery bypass graft surgery; CKD = chronic kidney disease; CT = computed tomography; CVD = cardiovascular disease; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; MI = myocardial infarction; PCI = percutaneous coronary intervention; SCORE = Systematic Coronary Risk Estimation; T1DM = type 1 DM; T2DM = type 2 DM; TC = total cholesterol; TIA = transient ischaemic attack.

^aTarget organ damage is defined as microalbuminuria, retinopathy, or neuropathy.

4.2.1 Role of non-invasive cardiovascular imaging techniques in the assessment of total cardiovascular disease risk

Non-invasive imaging techniques can detect the presence, estimate the extent, and evaluate the clinical consequences of atherosclerotic vascular damage. Detection of coronary artery calcification with non-contrast computed tomography (CT) gives a good estimate of the atherosclerotic burden and is strongly associated with CV events.¹⁸ A recent meta-analysis from the US Preventive Services Task Force summarized the available evidence on the value of non-traditional risk factors for risk prediction, and found that, although there are no randomized trials showing that the use of CAC reduces health outcomes, nevertheless it improves both discrimination and

reclassification.¹⁹ Assessment of carotid or femoral plaque burden with ultrasound has also been demonstrated to be predictive of CV events, comparable to CAC,^{20–23} while the measurement of the carotid intima-media thickness is inferior to CAC score and carotid plaque detection.^{16,24,25}

In asymptomatic patients at low or moderate risk who would be eligible for statin therapy (see Table 5), assessment of ASCVD with imaging may have an impact on medical treatment, both from the physician's and the patient's points of view. Data from the Multi-Ethnic Study of Atherosclerosis (MESA) showed that 41–57% of individuals who would be eligible for statin therapy had a CAC score of zero and the rate of atherosclerotic CVD events in the 10 year

Table 5 Intervention strategies as a function of total cardiovascular risk and untreated low-density lipoprotein cholesterol levels

	Total CV risk (SCORE) %	Untreated LDL-C levels					
		<1.4 mmol/L (55 mg/dL)	1.4 to <1.8 mmol/L (55 to <70 mg/dL)	1.8 to <2.6 mmol/L (70 to <100 mg/dL)	2.6 to <3.0 mmol/L (100 to <116 mg/dL)	3.0 to <4.9 mmol/L (116 to <190 mg/dL)	≥4.9 mmol/L (≥190 mg/dL)
Primary prevention	<1, low-risk	Lifestyle advice	Lifestyle advice	Lifestyle advice	Lifestyle advice	Lifestyle intervention, consider adding drug if uncontrolled	Lifestyle intervention and concomitant drug intervention
	Class ^a /Level ^b	I/C	I/C	I/C	I/C	I/a/A	I/a/A
	≥1 to <5, or moderate risk (see Table 4)	Lifestyle advice	Lifestyle advice	Lifestyle advice	Lifestyle intervention, consider adding drug if uncontrolled	Lifestyle intervention, consider adding drug if uncontrolled	Lifestyle intervention and concomitant drug intervention
	Class ^a /Level ^b	I/C	I/C	I/a/A	I/a/A	I/a/A	I/a/A
	≥5 to <10, or high-risk (see Table 4)	Lifestyle advice	Lifestyle advice	Lifestyle intervention, consider adding drug if uncontrolled	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention
	Class ^a /Level ^b	I/a/A	I/a/A	I/a/A	I/A	I/A	I/A
	≥10, or at very-high risk due to a risk condition (see Table 4)	Lifestyle advice	Lifestyle intervention, consider adding drug if uncontrolled	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention
	Class ^a /Level ^b	I/a/B	I/a/A	I/A	I/A	I/A	I/A
Secondary prevention	Very-high-risk	Lifestyle intervention, consider adding drug if uncontrolled	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention	Lifestyle intervention and concomitant drug intervention
	Class ^a /Level ^b	I/a/A	I/A	I/A	I/A	I/A	I/A

CV = cardiovascular; LDL-C = low-density lipoprotein cholesterol; SCORE = Systematic Coronary Risk Estimation.

^aClass of recommendation.

^bLevel of evidence.

follow-up period was low (1.5–4.9%).²⁶ In contrast, the rates of ASCVD and coronary heart disease (CHD) events in individuals with a CAC score >100 Agatston were 18.9 and 12.7 per 1000 person-years, respectively.¹⁸ Compared with a strategy of treating all patients, the use of CAC score to guide long-term statin therapy has been shown to be cost-effective.²⁷ Note that CAC score is often very low in patients younger than 45 years of age with severe familial hypercholesterolaemia (FH), including homozygous FH (HoFH), and has low specificity in this population.

Assessment of coronary luminal stenosis >50% and plaque composition with coronary CT angiography also provides incremental prognostic value over traditional risk stratification models.²⁸ As a result, in asymptomatic individuals with moderate risk, the presence of a CAC score >100 Agatston, and carotid or femoral plaque burden on ultrasonography, may reclassify them to a higher risk category. Therefore, the use of methods to detect these markers should be of interest in that group (see *Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease* below).^{14–16} Overall, CAC score assessment with CT may be considered in individuals at low or moderate risk in whom the respective LDL-C goal is not achieved with lifestyle intervention alone, and pharmacological therapy is an option (see *Table 5*). The use of imaging techniques to determine the presence and extent of atherosclerotic vascular damage in low-risk individuals not being considered for statin therapy is not justified due to low prognostic yield, and the associated costs and radiation hazards when measuring CAC score, particularly among low-risk women.²⁹ Of note, CAC score is increased following statin treatment; therefore, the CAC scores of statin-treated patients should be interpreted with caution.

Recommendations for cardiovascular imaging for risk assessment of atherosclerotic cardiovascular disease

Recommendations	Class ^a	Level ^b
Arterial (carotid and/or femoral) plaque burden on arterial ultrasonography should be considered as a risk modifier in individuals at low or moderate risk. ^{29,30}	IIa	B
CAC score assessment with CT may be considered as a risk modifier in the CV risk assessment of asymptomatic individuals at low or moderate risk. ^{14–16,24,26}	IIb	B

CAC = coronary artery calcium; CT = computed tomography; CV = cardiovascular.

^aClass of recommendation.

^bLevel of evidence.

4.2.2 Risk-based intervention strategies

Table 5 presents suggested intervention strategies as a function of total CV risk and LDL-C level. This graded approach is based on evidence from multiple meta-analyses and individual randomized controlled trials (RCTs), which show a consistent and graded reduction in ASCVD risk in response to reductions in TC and LDL-C levels (see *Recommendations for cardiovascular disease risk estimation* below).^{31–41} These data are consistent in showing that, since the relative risk

reduction is proportional to the absolute reduction in LDL-C and the absolute reduction in LDL-C resulting from a particular drug regimen depends only on baseline LDL-C, at any given level of baseline risk the higher the initial LDL-C level the greater the absolute reduction in risk. Advice on individual drug treatments is given in *section 8*.

Recommendations for cardiovascular disease risk estimation

Recommendations	Class ^a	Level ^b
Total risk estimation using a risk estimation system such as SCORE is recommended for asymptomatic adults >40 years of age without evidence of CVD, DM, CKD, familial hypercholesterolaemia, or LDL-C >4.9 mmol/L (>190 mg/dL).	I	C
It is recommended that high- and very-high-risk individuals are identified on the basis of documented CVD, DM, moderate-to-severe renal disease, very high levels of individual risk factors, FH, or a high SCORE risk. It is recommended that such patients are considered as a priority for advice and management of all risk factors.	I	C
Risk scores developed for the general population are not recommended for CV risk assessment in patients with DM or FH.	III	C

CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; SCORE = Systematic Coronary Risk Estimation.

^aClass of recommendation.

^bLevel of evidence.

5 Lipids and lipoproteins

5.1 Biological role of lipids and lipoproteins

Lipoproteins in plasma transport lipids to tissues for energy utilization, lipid deposition, steroid hormone production, and bile acid formation. Lipoproteins consist of esterified and unesterified cholesterol, TGs, and phospholipids and protein components named apolipoproteins that act as structural components, ligands for cellular receptor binding, and enzyme activators or inhibitors.

There are six major lipoproteins in blood: chylomicrons, very low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL), LDL; Lp(a), and HDL (*Table 6* and *Supplementary Figure 5*).

5.2 Role of lipids and lipoproteins in the pathophysiology of atherosclerosis

All ApoB-containing lipoproteins <70 nm in diameter, including smaller TG-rich lipoproteins and their remnant particles, can cross the endothelial barrier, especially in the presence of endothelial dysfunction, where they can become trapped after interaction with extracellular structures such as proteoglycans.⁴² ApoB-containing

Table 6 Physical and chemical characteristics of human plasma lipoproteins

	Density (g/mL)	Diameter (nm)	TGs (%)	Cholesteryl esters (%)	PLs (%)	Cholesterol (%)	Apolipoproteins	
							Major	Others
Chylomicrons	<0.95	80–100	90–95	2–4	2–6	1	ApoB-48	ApoA-I, A-II, A-IV, A-V
VLDL	0.95–1.006	30–80	50–65	8–14	12–16	4–7	ApoB-100	ApoA-I, C-II, C-III, E, A-V
IDL	1.006–1.019	25–30	25–40	20–35	16–24	7–11	ApoB-100	ApoC-II, C-III, E
LDL	1.019–1.063	20–25	4–6	34–35	22–26	6–15	ApoB-100	
HDL	1.063–1.210	8–13	7	10–20	55	5	ApoA-I	ApoA-II, C-III, E, M
Lp(a)	1.006–1.125	25–30	4–8	35–46	17–24	6–9	Apo(a)	ApoB-100

Apo = apolipoprotein; HDL = high-density lipoprotein; IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; Lp(a) = lipoprotein(a); PLs = phospholipids; TGs = triglycerides; VLDL = very low-density lipoprotein.

© ESC 2019

lipoproteins retained in the arterial wall provoke a complex process that leads to lipid deposition and the initiation of an atheroma.⁴³

Continued exposure to ApoB-containing lipoproteins leads to additional particles being retained over time in the artery wall, and to the growth and progression of atherosclerotic plaques. On average, people with higher concentrations of plasma ApoB-containing lipoproteins will retain more particles and accumulate lipids faster, resulting in more rapid growth and the progression of atherosclerotic plaques.

Because atherosclerotic plaques grow over time as additional ApoB-containing lipoprotein particles are retained, the size of the total atherosclerotic plaque burden is likely to be determined by both the concentration of circulating LDL-C and other ApoB-containing lipoproteins, and by the total duration of exposure to these lipoproteins. Therefore, a person's total atherosclerotic plaque burden is likely to be proportional to the cumulative exposure to these lipoproteins.⁴⁴

Eventually, the increase of the atherosclerotic plaque burden along with changes in the composition of the plaque reaches a critical point at which disruption of a plaque can result, with the formation of an overlying thrombus that acutely obstructs blood flow resulting in unstable angina, myocardial infarction (MI), or death. Therefore, the risk of experiencing an acute ASCVD event rises rapidly as more ApoB-containing lipoproteins become retained and the atherosclerotic plaque burden increases. This provides the rationale for encouraging a healthy lifestyle to maintain low levels of ApoB-containing lipoproteins throughout life to slow the progression of atherosclerosis; it also explains the motivation to recommend treatment to lower LDL-C and other ApoB-containing lipoproteins, for both the primary prevention of ASCVD and the secondary prevention of recurrent CV events.⁴⁴

5.3 Evidence for the causal effects of lipids and lipoproteins on the risk of atherosclerotic cardiovascular disease

5.3.1 Low-density lipoprotein cholesterol and risk of atherosclerosis

Plasma LDL-C is a measure of the cholesterol mass carried by LDL particles, by far the most numerous of the ApoB-containing lipoproteins, and is an estimate of the concentration of circulating LDL. Numerous epidemiological studies, Mendelian randomization studies, and RCTs have consistently demonstrated a log-linear relationship

between the absolute changes in plasma LDL-C and the risk of ASCVD.^{34,45–50} The remarkable consistency among these studies, in addition to biological and experimental evidence, provides compelling evidence that LDL-C is causally associated with the risk of ASCVD, and that lowering LDL-C reduces the risk of ASCVD proportionally to the absolute achieved reduction in LDL-C.^{2,51}

Furthermore, Mendelian randomization studies have demonstrated that long-term exposure to lower LDL-C levels is associated with a much lower risk of CV events as compared with shorter-term exposure to lower LDL-C (as achieved, for example, in randomized trials).^{48,52} These data provide strong support for the concept that LDL particles have both a causal and cumulative effect on the risk of ASCVD. Therefore, the effect of LDL-C on the risk of ASCVD appears to be determined by both the absolute magnitude and the total duration of exposure to LDL-C.²

The clinical benefit of lowering LDL-C is determined by the reduction in circulating LDL particles as estimated by ApoB, which is usually mirrored by a reduction of cholesterol carried by those particles.^{2,53} Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDL-C, because—on average—the reduction in LDL-C and LDL particles will be concordant.^{34,50,54,55} In contrast, the clinical benefit of therapies that lower LDL-C by a mechanism that may dramatically modify their composition may not be proportional to the observed absolute reduction in LDL-C, but instead would be expected to be proportional to the absolute change in LDL particle concentration as measured by a reduction in ApoB.^{2,53}

5.3.2 Triglyceride-rich lipoproteins and risk of atherosclerosis

TG-rich VLDL particles and their remnants carry most of the circulating TGs. Therefore, the plasma TG concentration reflects the concentration of circulating ApoB-containing TG-rich lipoproteins.

Elevated plasma TG levels are associated with an increasing risk of ASCVD, but this association becomes null after adjusting for non-HDL-C, an estimate of the total concentration of all ApoB-containing lipoproteins.⁴⁵ Similarly, lowering TG with fibrates reduces the risk of CV events by the same amount as LDL-C-lowering therapies when measured per unit change of non-HDL-C,⁵⁰ suggesting that the effect of plasma TGs on ASCVD is mediated by changes in the concentration of TG-rich lipoproteins as estimated by non-HDL-C.

Mendelian randomization studies also suggest that the association between plasma TGs and the risk of CHD may be causal; however, this evidence must be interpreted with caution because nearly all variants associated with TGs are also associated with HDL-C, LDL-C, or Lp(a).^{56–59} A recent Mendelian randomization study demonstrated that TG-lowering lipoprotein lipase (LPL) variants and LDL-C-lowering LDL receptor variants had the same effect on the risk of ASCVD per unit change of ApoB, suggesting that all ApoB-containing lipoproteins have the same effect on the risk of CHD.⁵³ Together, these studies strongly suggest that the causal effect of TG-rich lipoproteins and their remnants on the risk of ASCVD is determined by the circulating concentration of ApoB-containing particles, rather than by the TG content itself.

5.3.3 High-density lipoprotein cholesterol and risk of atherosclerosis

The inverse association between plasma HDL-C and the risk of ASCVD is among the most consistent and reproducible associations in observational epidemiology.^{45,60} In contrast, Mendelian randomization studies do not provide compelling evidence that HDL-C is causally associated with the risk of ASCVD.^{49,61,62} However, this evidence must be interpreted with caution because most genetic variants associated with HDL-C are also associated with directionally opposite changes in TGs, LDL-C, or both, thus making estimates of the effect of HDL-C on the risk of ASCVD very difficult using the Mendelian randomization study design. Furthermore, there is no evidence from randomized trials that therapeutically increasing plasma HDL-C reduces the risk of CV events.^{63–67} In the Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome (dal-OUTCOMES) trial, treatment with the cholesteryl ester transfer protein (CETP) inhibitor dalcetrapib increased HDL-C without any effect on LDL-C or ApoB, but did not reduce the risk of major CV events.⁶⁵ Similarly, in the Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition with Evacetrapib in Patients at a High-Risk for Vascular Outcomes (ACCELERATE) and Randomized Evaluation of the Effects of Anacetrapib Through Lipid Modification (REVEAL) trials, treatment with CETP inhibitors more than doubled HDL-C levels, but did not appear to reduce the risk of ASCVD events beyond that expected from the modest reductions in ApoB levels.^{2,63,64} Furthermore, several randomized trials have shown that directly infused HDL mimetics increase plasma HDL-C concentrations, but do not reduce the progression of atherosclerosis as measured by intravascular ultrasound.^{68,69}

Therefore, there is currently no randomized trial or genetic evidence to suggest that raising plasma HDL-C is likely to reduce the risk of ASCVD events. Whether therapies that alter the function of HDL particles will reduce the risk of ASCVD is unknown.

5.3.4 Lipoprotein(a) and risk of atherosclerosis

Lp(a) is an LDL particle with an Apo(a) moiety covalently bound to its ApoB component.⁷⁰ It is <70 nm in diameter and can freely flux across the endothelial barrier, where it can become—similarly to LDL—retained within the arterial wall and thus may increase the risk of ASCVD. Pro-atherogenic effects of Lp(a) have also been attributed to pro-coagulant effects as Lp(a) has a similar structure to

plasminogen, and it has pro-inflammatory effects most likely related to the oxidized phospholipid load carried by Lp(a).⁷¹

Higher plasma Lp(a) concentrations are associated with an increased risk of ASCVD, but it appears to be a much weaker risk factor for most people than LDL-C.^{72,73} In contrast, Mendelian randomization studies have consistently demonstrated that lifelong exposure to higher Lp(a) levels is strongly and causally associated with an increased risk of ASCVD.^{74,75} While randomized trials evaluating therapies that lower Lp(a) by 20–30% (including niacin and CETP inhibitors) have not provided evidence that lowering Lp(a) reduces the risk of ASCVD beyond that which would be expected from the observed reduction in ApoB-containing lipoproteins, recent data with PCSK9 inhibitors have suggested a possible role for Lp(a) lowering in reducing CV risk.⁷⁶

This conflicting evidence appears to have been reconciled by a recent Mendelian randomization study that showed that the causal effect of Lp(a) on the risk of ASCVD is proportional to the absolute change in plasma Lp(a) levels. Importantly, this study also suggested that people with extremely high Lp(a) levels >180 mg/dL (>430 nmol/L) may have an increased lifetime risk of ASCVD similar to that of people with heterozygous FH (HeFH). Because about 90% of a person's Lp(a) level is inherited, extremely elevated Lp(a) may represent a new inherited lipid disorder that is associated with extremely high lifetime risk of ASCVD and is two-fold more prevalent than HeFH.⁷⁷ However, this study⁷⁷ and another based on the Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial⁷⁸ have shown that large absolute changes in Lp(a) may be needed to produce a clinically meaningful reduction in the risk of ASCVD events.

5.4 Laboratory measurement of lipids and lipoproteins

Measurement of lipids and lipoproteins is used to estimate the risk of ASCVD and guide therapeutic decision-making. Quantification of plasma lipids can be performed on whole plasma and quantification of lipoproteins can be achieved by measuring their protein component. Operationally, lipoproteins are classified based on their hydrated density (see *Table 6*).

5.4.1 Lipoprotein measurement

Given the central causal role of ApoB-containing lipoproteins in the initiation and progression of atherosclerosis, direct measurement of the circulating concentration of atherogenic ApoB-containing lipoproteins to both estimate risk and guide treatment decisions would be ideal. Because all ApoB-containing lipoproteins—including VLDL, TG-rich remnant particles, and LDL—contain a single ApoB molecule, quantitation of ApoB directly estimates the number of atherogenic particles in plasma.

Standardized, automated, accurate, and inexpensive methods to measure ApoB are available. Fasting is not required because even in the post-prandial state, ApoB48-containing chylomicrons typically represent <1% of the total concentration of circulating ApoB-containing lipoproteins. Furthermore, the analytical performances of ApoB measurement methods are superior to the measurement or calculation of LDL-C and non-HDL-C.⁷⁹

5.4.2 Lipid measurements

In clinical practice, the concentration of plasma lipoproteins is not usually measured directly but is instead estimated by measuring their cholesterol content. TC in humans is distributed primarily among three major lipoprotein classes: VLDL, LDL, and HDL. Smaller amounts of cholesterol are also contained in two minor lipoprotein classes: IDL and Lp(a). A standard serum lipid profile measures the concentration of TC and HDL-C, as well as TG. With these values, the LDL-C concentration can be estimated.

Plasma LDL-C can be measured directly using enzymatic techniques or preparative ultracentrifugation, but in clinical medicine it is most often calculated using the Friedewald formula:

$$\text{LDL-C} = \text{TC} - \text{HDL-C} - (\text{TG}/2.2) \text{ in mmol/L}$$

or

$$\text{LDL-C} = \text{TC} - \text{HDL-C} - (\text{TG}/5) \text{ in mg/dL}$$

Although convenient, the Friedewald calculated value of LDL-C has several well-established limitations: (i) methodological errors may accumulate since the formula necessitates three separate analyses of TC, TGs, and HDL-C; and (ii) a constant cholesterol/TG ratio in VLDL is assumed. With high TG values (>4.5 mmol/L or >400 mg/dL) the formula cannot be used. This should especially be considered in non-fasting samples.

To overcome the problems associated with calculated LDL-C, direct enzymatic methods for the measurement of LDL-C have been developed. These methods are commercially available as ready to use tools for automatic analysis. The definition of LDL-C by the Friedewald equation and by direct measurement is the same: non-HDL-C – VLDL-C, representing the sum of the cholesterol carried by the biochemically defined LDL, IDL, and Lp(a) subfractions.

For the general population, calculated LDL-C and direct LDL-C show very strong correlations.^{80–83} However, calculated LDL-C has been found to underestimate LDL-C at concentrations of TG ≥ 2 mmol/L (177 mg/dL).^{81,82} Equally, at very low levels of LDL-C, calculated LDL-C may be misleading, especially in the presence of high TG.^{81,84–86} To avoid some of the problems with the Friedewald formula, a number of modifications for the calculation of LDL-C have been suggested, but it remains to be proved whether these modifications are superior to Friedewald's formula for the estimation of CV risk.^{81,85–87} It is important to note that direct LDL-C measurements also have limitations, including systematic bias and inaccuracy in patients with dyslipidaemia, especially for high TG levels.^{88–90}

As an alternative calculated LDL-C, non-HDL-C can be calculated as TC – HDL-C and is a measure of the TC carried by all atherogenic ApoB-containing lipoproteins, including TG-rich particles in VLDL and their remnants.¹⁰⁰

Several methods for the determination of Lp(a) are available. The complex molecular structure of Lp(a) and the variation in size of Apo(a) has been a challenge in the development of analytical methods for Lp(a). Available methods are, to a varying degree, influenced by the Apo(a) isoform.⁹¹ Furthermore, the concentration of Lp(a) is reported as either a molar concentration (nmol/L) or as a mass (mg/dL) by the various assays, and conversion between molar and mass concentrations has been found to be both size- and concentration-dependent.^{91–93} Therefore, standardization between assays is

needed to establish a reliable and reproducible method for the quantification of Lp(a) mass or particle number.⁹²

5.4.3 Fasting or non-fasting?

Traditionally, blood sampling for lipid analyses has been recommended in the fasting state. Recent systematic studies comparing fasting and non-fasting samples have suggested that the difference is small for most lipid parameters.^{85,94–100} Non-fasting sampling has been used in large population-based studies.¹⁰⁰ In most studies, non-fasting samples display a higher TG level of ~ 0.3 mmol/L (27 mg/dL).^{100,101} On average, and for most individuals, this increment will be of no clinical significance. Indeed, a number of guidelines recommend non-fasting sampling.^{100,102,103}

For general risk screening, non-fasting samples seem to have at least the same prognostic value as fasting samples.¹⁰⁴ The practical advantages of non-fasting samples, including better patient acceptability, outweigh the potential imprecision in some patients, although the determination of some key analytes, such as fasting glucose, may be compromised. Furthermore, even if non-fasting sampling can be used in most cases, in patients with metabolic syndrome (MetS), DM, or hypertriglyceridaemia (HTG), calculated LDL-C should be interpreted with caution.

5.5 Recommendations for measuring lipids and lipoproteins to estimate risk of atherosclerotic cardiovascular disease

Measurement of plasma TC is needed to calculate risk using SCORE, while the inclusion of plasma HDL-C level can improve risk estimation using the online SCORE calculator. Therefore, both TC and HDL-C should be measured to estimate a person's risk of ASCVD using SCORE, or one of the other risk calculators (almost all of which also include measurements of TC and HDL-C).

Plasma LDL-C should be measured to estimate the risk of ASCVD that can be modified with LDL-C-lowering therapies, and to identify whether markedly elevated LDL-C levels are present that may suggest a lifetime high-risk of ASCVD due to lifelong cumulative exposure to high levels of atherogenic lipoproteins, such as in FH. Plasma LDL-C can be either calculated or measured directly.

Plasma TG should be assessed to identify people who may have a greater modifiable risk of ASCVD than is reflected by LDL-C, due to the presence of an increased concentration of atherogenic ApoB-containing TG-rich lipoproteins and their remnants, and to identify people in whom calculated and directly measured LDL-C may underestimate the risk of ASCVD by underestimating either the concentration of circulating LDL particles or the cholesterol content carried by those particles, such as those with very low levels of LDL. This may be especially relevant in patients with DM or MetS.

In general, LDL-C, non-HDL-C, and ApoB concentrations are very highly correlated. As a result, under most circumstances, they provide very similar information about ASCVD risk.^{45,105–108} However, under certain circumstances—including among people with elevated TG levels, DM, obesity, or very low achieved LDL-C levels—the calculated or directly measured LDL-C level may underestimate both the total concentration of cholesterol carried by LDL and, more importantly, underestimate the total concentration of ApoB-containing lipoproteins, thus underestimating the risk of ASCVD. In around

20% of patients there may be discordance between measured LDL-C and ApoB levels.^{85,109}

Considering the potential inaccuracy of LDL-C in dyslipidaemia, among patients with DM or high TG levels, and in patients with very low LDL-C levels, measurement of both ApoB and non-HDL-C is recommended as part of routine lipid analysis for risk evaluation in patients with elevated plasma TGs. Because ApoB provides an accurate estimate of the total concentration of atherogenic particles under all circumstances, it is the preferred measurement to further refine the estimate of ASCVD risk that is modifiable by lipid-lowering therapy.

Lp(a) has a similar structure to plasminogen and binds to the plasminogen receptor, leading to increased thrombosis (pro-thrombotic factor). Measurement of Lp(a) should be considered at least once in each person's lifetime, if available, to identify people who have inherited an extremely elevated level of Lp(a) ≥ 180 mg/dL (≥ 430 nmol/L) and therefore have a very high lifetime risk of ASCVD that is approximately equivalent to the risk associated with HeFH. In addition, this strategy can identify people with less-extreme Lp(a) elevations who may be at a higher risk of ASCVD, which is not reflected by the SCORE system, or by other lipid or lipoprotein measurements. Measurement of Lp(a) has been shown to provide clinically significant improved risk reclassification under certain conditions, and therefore should be considered in patients who have an estimated 10-year risk of ASCVD that is close to the threshold between high and moderate risk.^{110–112}

Recommendations for measuring lipids and lipoproteins to estimate the risk of ASCVD are summarized below.

Recommendations for lipid analyses for cardiovascular disease risk estimation

Recommendations	Class ^a	Level ^b
TC is to be used for the estimation of total CV risk by means of the SCORE system.	I	C
HDL-C analysis is recommended to further refine risk estimation using the online SCORE system.	I	C
LDL-C analysis is recommended as the primary lipid analysis method for screening, diagnosis, and management.	I	C
TG analysis is recommended as part of the routine lipid analysis process.	I	C
Non-HDL-C evaluation is recommended for risk assessment, particularly in people with high TG levels, DM, obesity, or very low LDL-C levels.	I	C
ApoB analysis is recommended for risk assessment, particularly in people with high TG levels, DM, obesity, metabolic syndrome, or very low LDL-C levels. It can be used as an alternative to LDL-C, if available, as the primary measurement for screening, diagnosis, and management, and may be preferred over non-HDL-C in people with high TG levels, DM, obesity, or very low LDL-C levels.	I	C
Lp(a) measurement should be considered at least once in each adult person's lifetime to identify those with very high inherited Lp(a) levels >180 mg/dL (>430 nmol/L) who may have a lifetime risk of ASCVD equivalent to the risk associated with heterozygous familial hypercholesterolaemia.	IIa	C
Lp(a) should be considered in selected patients with a family history of premature CVD, and for reclassification in people who are borderline between moderate and high-risk.	IIa	C

Apo = apolipoprotein; ASCVD = atherosclerotic cardiovascular disease; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; Lp(a) = lipoprotein(a); SCORE = Systematic Coronary Risk Estimation; TC = total cholesterol; TG = triglyceride.

6 Treatment targets and goals

In previous EAS/ESC Guidelines for the management of dyslipidaemias^{1,113} and other major guidelines on the treatment of blood cholesterol to reduce atherosclerotic CV risk in adults,^{40,114} the importance of LDL-C lowering to prevent ASCVD is strongly emphasized. The European Task Force felt that limiting the current knowledge on CV prevention only to results from RCTs reduces the exploitation of the potential that is available for the prevention of ASCVD. It is the concordance of the conclusions from many different approaches (from basic science, clinical observations, genetics, epidemiology, RCTs, etc.) that contributes to the understanding of the causes of ASCVD and to the potential of prevention. The Task Force is aware of the limitations of some of the sources of evidence and accepts that RCTs have not examined different LDL-C goals systematically, but felt that it was appropriate to look at the totality of the evidence. Particular consideration was given to results from meta-analyses confirming the dose-dependent reduction in ASCVD with LDL-C-lowering agents; the greater the absolute LDL-C reduction, the greater the CV risk reduction.^{35,36,50,115} The benefits related to LDL-C reduction are not specific for statin therapy.³³ No level of LDL-C below which benefit ceases or harm occurs has been defined.

There is considerable individual variability in the LDL-C response to dietary and drug treatments,³¹ which is traditionally taken to support a tailored approach to management. Total CV risk reduction should be individualized, and this can be more specific if goals are defined. The use of goals can also aid patient–doctor communication. It is judged that a goal approach may facilitate adherence to

treatment, although this consensus opinion has not been fully tested. For all these reasons, the European Task Force retains a goal approach to lipid management and treatment goals are tailored to the total CV risk level. There is also evidence suggesting that lowering of LDL-C beyond the goals that were set in the previous EAS/ESC Guidelines is associated with fewer ASCVD events.^{34,116,117} Therefore, it seems appropriate to reduce LDL-C to as low a level as possible, at least in patients at very high CV risk, and for this reason a minimum 50% reduction is suggested for LDL reduction, together with reaching the tailored goal.

The lipid goals are part of a comprehensive CV risk reduction strategy and are summarized in *Table 7*. The rationales for the non-lipid targets are given in the 2016 ESC Joint Prevention Guidelines.¹⁰

The targeted approach to lipid management is primarily aimed at reducing atherosclerotic risk by substantially lowering LDL-C to levels that have been achieved in recent large-scale trials of PCSK-9 inhibitors. Therefore, for patients at very high CV risk, whether in secondary prevention or (rarely) in primary prevention, LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended. For patients with ASCVD who experience a second vascular event within 2 years (not necessarily of the same type as the first event) while taking maximally tolerated statin-based therapy, an LDL-C goal <1.0 mmol/L (<40 mg/dL) may be considered.^{119,120} For people at high CV risk, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal <1.8 mmol/L (<70 mg/dL) are recommended. In patients at moderate CV risk, an LDL-C goal <2.6 mmol/L (<100 mg/dL) should be considered, while for low-risk individuals a goal of <3.0 mmol/L (<116 mg/dL) may be considered (see *Recommendations for treatment goals for low-density lipoprotein cholesterol below and Supplementary Table 2*).

Secondary goals have also been defined by inference for non-HDL-C and for ApoB; they receive a moderate grading, as they have not been extensively studied in RCTs. The specific goal for non-HDL-C should be 0.8 mmol/L (30 mg/dL) higher than the corresponding LDL-C goal; the adjustment of lipid-lowering therapy in accordance with these secondary goals may be considered in patients at very high CV risk after achievement of an LDL-C goal, although the clinical advantages of this approach with respect to outcomes remain to be addressed. When secondary targets are used the recommendations are: (i) non-HDL-C <2.2 mmol/L (<85 mg/dL), <2.6 mmol/L (<100 mg/dL), and <3.4 mmol/L (<130 mg/dL) in people at very high, high, and moderate CV risk, respectively,^{121–123} and (ii) ApoB <65 mg/dL, <80 mg/dL, and <100 mg/dL in very-high, high, and moderate total CV risk, respectively.^{121,123,124}

To date, no specific goals for HDL-C or TG levels have been determined in clinical trials, although increases in HDL-C predict atherosclerosis regression, and low HDL-C is associated with excess events and mortality in coronary artery disease (CAD) patients, even at low LDL levels. Clinicians should use clinical judgment when considering further treatment intensification in patients at high or very high total CV risk.

7 Lifestyle modifications to improve the plasma lipid profile

The pivotal role of nutrition in the prevention of ASCVD has been extensively reviewed.^{125–129} Dietary factors influence the development of CVD either directly or through their action on traditional risk factors, such as plasma lipids, BP, or glucose levels.

Recommendations for treatment goals for low-density lipoprotein cholesterol

Recommendations	Class ^a	Level ^b
In secondary prevention for patients at very-high risk, ^c an LDL-C reduction of $\geq 50\%$ from baseline ^d and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended. ^{33–35,119,120}	I	A
In primary prevention for individuals at very-high risk but without FH, ^c an LDL-C reduction of $\geq 50\%$ from baseline ^d and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended. ^{34–36}	I	C
In primary prevention for individuals with FH at very-high risk, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) should be considered.	IIa	C
For patients with ASCVD who experience a second vascular event within 2 years (not necessarily of the same type as the first event) while taking maximally tolerated statin-based therapy, an LDL-C goal of <1.0 mmol/L (<40 mg/dL) may be considered. ^{119,120}	IIb	B
In patients at high risk, ^c an LDL-C reduction of $\geq 50\%$ from baseline ^d and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) are recommended. ^{34,35}	I	A
In individuals at moderate risk, ^c an LDL-C goal of <2.6 mmol/L (<100 mg/dL) should be considered. ³⁴	IIa	A
In individuals at low risk, ^c an LDL-C goal <3.0 mmol/L (<116 mg/dL) may be considered. ³⁶	IIb	A

ASCVD = atherosclerotic cardiovascular disease; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol.

^aClass of recommendation.

^bLevel of evidence.

^cFor definitions see *Table 4*.

^dThe term 'baseline' refers to the LDL-C level in a person not taking any LDL-C-lowering medication. In people who are taking LDL-C-lowering medication(s), the projected baseline (untreated) LDL-C levels should be estimated, based on the average LDL-C-lowering efficacy of the given medication or combination of medications.

Table 7 Treatment targets and goals for cardiovascular disease prevention

Smoking	No exposure to tobacco in any form.
Diet	Healthy diet low in saturated fat with a focus on wholegrain products, vegetables, fruit, and fish.
Physical activity	3.5–7 h moderately vigorous physical activity per week or 30–60 min most days.
Body weight	BMI 20–25 kg/m ² , and waist circumference <94 cm (men) and <80 cm (women).
Blood pressure	<140/90 mmHg. ^a
LDL-C	<p>Very-high risk in primary or secondary prevention: A therapeutic regimen that achieves ≥50% LDL-C reduction from baseline^b and an LDL-C goal of <1.4 mmol/L (<55 mg/dL). No current statin use: this is likely to require high-intensity LDL-lowering therapy. Current LDL-lowering treatment: an increased treatment intensity is required.</p> <p>High risk: A therapeutic regimen that achieves ≥50% LDL-C reduction from baseline^b and an LDL-C goal of <1.8 mmol/L (<70 mg/dL).</p> <p>Moderate risk: A goal of <2.6 mmol/L (<100 mg/dL).</p> <p>Low risk: A goal of <3.0 mmol/L (<116 mg/dL).</p>
Non-HDL-C	Non-HDL-C secondary goals are <2.2, 2.6, and 3.4 mmol/L (<85, 100, and 130 mg/dL) for very-high-, high-, and moderate-risk people, respectively.
ApoB	ApoB secondary goals are <65, 80, and 100 mg/dL for very-high-, high-, and moderate-risk people, respectively.
Triglycerides	No goal, but <1.7 mmol/L (<150 mg/dL) indicates lower risk and higher levels indicate a need to look for other risk factors.
Diabetes	HbA1c: <7% (<53 mmol/mol).

Apo = apolipoprotein; BMI = body mass index; HbA1c = glycated haemoglobin; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol.

^aLower treatment targets are recommended for most treated hypertensive patients, provided that the treatment is well tolerated.¹¹⁸

^bThe term 'baseline' refers to the LDL-C level in a person not taking any lipid-lowering medication, or to the extrapolated baseline value for those who are on current treatment.

©ESC 2019

Convincing evidence of the causal association between diet and ASCVD risk is, nevertheless, available indirectly from randomized 'metabolic ward' studies showing that high saturated fat intake causes increased LDL-C concentrations, and from cohort studies, genetic epidemiological studies, and randomized trials showing that higher LDL-C levels cause ASCVD.

The lack of concordance between studies is due both to methodological problems (particularly inadequate sample sizes or short study durations) and the difficulties of evaluating the impact of a single dietary factor independently of any other changes in the diet.¹³⁰ In fact, as foods are mixtures of different nutrients and other components, it is not appropriate to attribute the health effects of a food to only one of its components. Moreover, if energy intake must be kept constant, eating less of one macronutrient implies necessarily eating more of others. The quality of the replacement (for instance, unsaturated fat vs. highly refined grains) can influence the effect observed, significantly modifying the impact on health of the nutrient replaced. These limitations suggest caution in interpreting the results of RCTs or even meta-analyses of RCTs in relation to the effect of a single dietary change on ASCVD.¹³⁰

To overcome, at least in part, these problems, in recent years nutrition research has focused on the relationship between ASCVD on the one hand, and foods and dietary patterns—rather than single nutrients—on the other. Consistent evidence from epidemiological studies indicates that higher consumption of fruit, non-starchy vegetables, nuts, legumes, fish, vegetable oils, yoghurt, and wholegrains, along with a lower intake of red and processed

meats, foods higher in refined carbohydrates, and salt, is associated with a lower incidence of CV events.¹³¹ Moreover, it indicates that the replacement of animal fats, including dairy fat, with vegetable sources of fats and polyunsaturated fatty acids (PUFAs) may decrease the risk of CVD.¹³²

Dietary patterns that have been more extensively evaluated are the Dietary Approaches to Stop Hypertension (DASH) diet—particularly in relation to BP control—and the Mediterranean diet; both have proved to be effective in reducing CV risk factors and, possibly, to contribute to ASCVD prevention.¹³³ The most relevant difference between the Mediterranean and the DASH diet is the emphasis of the former on extra-virgin olive oil. The Mediterranean diet is associated with a reduced incidence of CV and other non-communicable diseases in epidemiological studies,^{134,135} and has been proved in RCTs to be effective in reducing CV events in primary and secondary prevention.¹³⁶ In particular, the Prevención con Dieta Mediterránea (PREDIMED) trial indicated that participants allocated to a Mediterranean-type diet, supplemented with extra-virgin olive oil or nuts, had a significantly lower (around 30%) incidence of major CV events compared with those who were on a low-fat diet.¹³⁷

In summary, despite the results of PREDIMED and a few other intervention studies with ASCVD endpoints that support a healthy lifestyle for ASCVD prevention, RCTs cannot represent the sole grounds on which dietary recommendations should rely. They also need to be based on the combination of large observational cohort studies and relatively short-term randomized trials having intermediate risk factors (such as blood lipids) as outcomes.

Table 8 Impact of specific lifestyle changes on lipid levels

	Magnitude of the effect	Level	Reference
Lifestyle interventions to reduce TC and LDL-C levels			
Avoid dietary trans fats	++	A	129,138
Reduce dietary saturated fats	++	A	129,139
Increase dietary fibre	++	A	140,141
Use functional foods enriched with phytosterols	++	A	142,143
Use red yeast rice nutraceuticals	++	A	144–146
Reduce excessive body weight	++	A	147,148
Reduce dietary cholesterol	+	B	149,150
Increase habitual physical activity	+	B	151
Lifestyle interventions to reduce TG-rich lipoprotein levels			
Reduce excessive body weight	+	A	147,148
Reduce alcohol intake	+++	A	152,153
Increase habitual physical activity	++	A	151,154
Reduce total amount of dietary carbohydrates	++	A	147,155
Use supplements of n-3 polyunsaturated fats	++	A	156,157
Reduce intake of mono- and disaccharides	++	B	158,159
Replace saturated fats with mono- or polyunsaturated fats	+	B	129,137
Lifestyle interventions to increase HDL-C levels			
Avoid dietary trans fats	++	A	129,160
Increase habitual physical activity	+++	A	151,161
Reduce excessive body weight	++	A	147,148
Reduce dietary carbohydrates and replace them with unsaturated fats	++	A	147,162
Modest consumption in those who take alcohol may be continued	++	B	153
Quit smoking	+	B	163

The magnitude of the effect (+++ = >10%, ++ = 5–10%, + = <5%) and the level of evidence refer to the impact of each dietary modification on plasma levels of a specific lipoprotein class.

HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TC = total cholesterol; TG = triglyceride.

Table 8 summarizes the currently available evidence on the influences of lifestyle changes and functional foods on lipoproteins, indicating the magnitudes of the effects and the levels of evidence in relation to the impacts on the specific lipoprotein class; for the reasons outlined above, the levels of evidence are not based on RCTs with ASCVD endpoints. Moreover, within the Guidelines on the management of dyslipidaemias, information on the potential to improve plasma lipoprotein profiles by dietary means is clinically relevant, even in the absence of a clear demonstration of CV benefits.

7.1 Influence of lifestyle on total cholesterol and low-density lipoprotein cholesterol levels

Saturated fatty acids (SFAs) are the dietary factor with the greatest impact on LDL-C levels (0.02–0.04 mmol/L or 0.8–1.6 mg/dL of LDL-C increase for every additional 1% energy coming from saturated fat).¹⁶⁴ Quantitatively, dietary trans fatty acids have a similar elevating effect on LDL-C to that of SFAs; however, while SFAs increase HDL-C levels, trans fats decrease them.¹³⁷ Trans unsaturated fatty acids can be found in limited amounts (usually <5% of total fat) in dairy products and in meats from ruminants. 'Partially hydrogenated fatty acids' of industrial origin represent the major source of trans fatty acids in the diet; the average consumption of trans fatty acids

ranges from 0.2–6.5% of the total energy intake in different populations.¹⁶⁵ Unsaturated fat-rich oils from safflower, sunflower, rapeseed, flaxseed, corn, olives, or soybean were shown to reduce LDL-C levels (-0.42 to -0.20 mmol/L) when used in substitution of SFA-rich foods like butter or lard.¹⁶⁶ The effects of carbohydrate consumption on LDL-C are described in section 7.4.3.

Body weight reduction also influences TC and LDL-C levels, but the magnitude of the effect is small: in obese people, a decrease in LDL-C concentration of 0.2 mmol/L (8 mg/dL) is observed for every 10 kg of weight loss.^{147,167} The reduction of LDL-C levels induced by regular physical exercise is even smaller.^{151,168} The benefits of weight reduction and physical exercise on the CV risk profile likely impact on other risk factors, especially hypertension and diabetes.

Table 9 summarizes the possible choices of foods to lower TC and LDL-C levels. Given the cultural diversity of the European populations, they should be translated into practical behaviours, considering local habits and socio-economic factors.

7.2 Influence of lifestyle on triglyceride levels

Weight reduction improves insulin sensitivity and decreases TG levels. Regular physical exercise reduces plasma TG levels over and above the effect of weight reduction.^{151,168,169} Alcohol intake has a

Table 9 Food choices to lower low-density lipoprotein cholesterol and improve the overall lipoprotein profile

	To be preferred	To be used in moderation	To be chosen occasionally in limited amounts
Cereals	Wholegrains	Refined bread, rice, and pasta, biscuits, corn flakes	Pastries, muffins, pies, croissants
Vegetables	Raw and cooked vegetables	Potatoes	Vegetables prepared in butter or cream
Legumes	Lentils, beans, fava beans, peas, chickpeas, soybean		
Fruit	Fresh or frozen fruit	Dried fruit, jelly, jam, canned fruit, sorbets, ice lollies/popsicles, fruit juice	
Sweets and sweeteners	Non-caloric sweeteners	Sucrose, honey, chocolate, sweets/candies	Cakes, ice creams, fructose, soft drinks
Meat and fish	Lean and oily fish, poultry without skin	Lean cuts of beef, lamb, pork, and veal, seafood, shellfish	Sausages, salami, bacon, spare ribs, hot dogs, organ meats
Dairy food and eggs	Skimmed milk and yoghurt	Low-fat milk, low-fat cheese and other milk products, eggs	Regular cheese, cream, whole milk and yoghurt
Cooking fat and dressings	Vinegar, mustard, fat-free dressings	Olive oil, non-tropical vegetable oils, soft margarines, salad dressing, mayonnaise, ketchup	Trans fats and hard margarines (better to avoid them), palm and coconut oils, butter, lard, bacon fat
Nuts/seeds		All, unsalted (except coconut)	Coconut
Cooking procedures	Grilling, boiling, steaming	Stir-frying, roasting	Frying

© ESC 2019

major impact on TG levels, particularly in individuals with HTG.^{153,170} The detrimental effects of a high-carbohydrate diet on TGs occur mainly when refined carbohydrate-rich foods are consumed, while they are much less prominent if the diet is based largely on fibre-rich, low-glycaemic index foods. This applies particularly to people with DM or MetS.^{171,172}

Habitual consumption of significant amounts (>10% energy) of dietary fructose contributes to TG elevation, particularly in people with HTG or abdominal obesity. These effects are dose-dependent; with a habitual fructose consumption between 15–20% of total energy intake, plasma TG increases by as much as 30–40%. Sucrose, a disaccharide containing glucose and fructose, represents an important source of fructose in the diet.^{159,173,174}

7.3 Influence of lifestyle on high-density lipoprotein cholesterol levels

Weight reduction increases HDL-C levels; a 0.01 mmol/L (0.4 mg/dL) increase is observed for every kilogram decrease in body weight when weight reduction has stabilized. Aerobic physical activity, such as 25–30 km of brisk walking per week (or any equivalent activity), may increase HDL-C levels by 0.08–0.15 mmol/L (3.1–6 mg/dL).¹⁶⁹ Smoking cessation may also contribute to HDL-C elevation, provided that weight gain is prevented.¹⁶³

7.4 Lifestyle recommendations to improve the plasma lipid profile

LDL-C lowering represents the primary target for reducing CV risk and therefore deserves special emphasis in the evaluation of lifestyle measures. The diet recommended to the general population, and

particularly to people at increased CV risk, may also be able to modify plasma TG and HDL-C levels (Table 9). This section focuses on dietary and other lifestyle factors that may be implemented to improve the overall lipoprotein profile.

7.4.1 Body weight and physical activity

Since overweight, obesity, and—in particular—abdominal adiposity often contribute to dyslipidaemia, caloric intake should be reduced and energy expenditure increased in those with excessive weight and/or abdominal adiposity.

In the case of excess weight, body weight reduction, even if modest (5–10% of basal body weight), improves lipid abnormalities and favourably affects the other CV risk factors often present in dyslipidaemic individuals.¹⁴⁸ While the beneficial effects of weight reduction on metabolic and surrogate markers have been demonstrated, the benefits of weight loss on mortality and CV outcome are less clear.¹⁷⁵

Weight reduction can be achieved by decreasing the consumption of energy-dense foods, inducing a caloric deficit of 300–500 kcal/day. The intervention should combine diet and exercise; this approach also leads to the greatest improvement in physical performance and quality of life, and mitigates reductions in muscle and bone mass, particularly in older people.¹⁷⁶ It is always appropriate to advise people with dyslipidaemia to engage in regular physical exercise of moderate intensity for ≥30 min/day, even if they are not overweight.¹⁶⁸

7.4.2 Dietary fat

Avoiding any consumption of trans fat is a key measure of the dietary prevention of CVD. The trans fatty acids produced in the partial hydrogenation of vegetable oils account for 80% of total intake. Thanks to

efforts made in different parts of the world, the intake of trans fatty acids has decreased substantially over the past 10–15 years.

As for saturated fat, its consumption should be <10% of the total caloric intake and should be further reduced (<7% of energy) in the presence of hypercholesterolaemia. For most individuals, a wide range of total fat intakes is acceptable, and will depend upon individual preferences and characteristics. However, fat intakes >35–40% of calories are generally associated with increased intakes of both saturated fat and calories. Conversely, low intakes of fats and oils increase the risk of inadequate intakes of vitamin E and of essential fatty acids, and may contribute to a reduction of HDL-C.¹⁶⁴

Fat intake should predominantly come from sources of monounsaturated fatty acids, including both n-6 and n-3 PUFAs. Not enough data are available to make a recommendation regarding the optimal n-3:n-6 fatty acid ratio.^{177,178} The cholesterol intake in the diet should be reduced (<300 mg/day), particularly in people with high plasma cholesterol levels.

7.4.3 Dietary carbohydrate and fibre

Dietary carbohydrate has a 'neutral' effect on LDL-C, although excessive consumption is represented by untoward effects on plasma TGs and HDL-C levels.¹⁶⁴ Dietary fibre (particularly of the soluble type)—which is present in legumes, fruits, vegetables, and wholegrain cereals (e.g. oats and barley)—has a hypocholesterolaemic effect and represents a good dietary substitute for saturated fat to maximize the effects of the diet on LDL-C levels, and to minimize the untoward effects of a high-carbohydrate diet on other lipoproteins.^{140,179}

Carbohydrate intake should range between 45–55% of total energy intake, since both higher and lower percentages of carbohydrate diets are associated with increased mortality.^{180,181} A fat-modified diet that provides 25–40 g per day of total dietary fibre, including ≥ 7 –13 g of soluble fibre, is well tolerated, effective, and recommended for plasma lipid control; conversely, there is no justification for the recommendation of very low-carbohydrate diets.¹⁸²

Intake of added sugar should not exceed 10% of total energy (in addition to the amount present in natural foods such as fruits and dairy products); more restrictive advice concerning sugars may be useful for those needing to lose weight or with high plasma TG values, MetS, or DM. Soft drinks should be used with moderation by the general population, and should be drastically limited in those individuals with elevated TG values or visceral adiposity.^{158,159,174} The Prospective Urban Rural Epidemiology (PURE) study was a large, epidemiological cohort study of 135 335 individuals enrolled in 18 countries with food frequency questionnaires recorded. Total fat and types of fat were not associated with CVD, MI, or CVD mortality, whereas saturated fat had an inverse association with stroke.¹⁸¹ However, a meta-analysis of epidemiological studies including the PURE study showed a U-shaped relationship between carbohydrate intake and mortality: diets associated with the highest mortality rate had carbohydrate intakes >70% and <40% of energy, with minimal risk observed when carbohydrate intake was between 45–55% of total energy intake.¹⁸⁰

7.4.4 Alcohol

Moderate alcohol consumption [≤ 10 g/day (1 unit) for men and women] is acceptable for those who drink alcoholic beverages, if TG levels are not elevated.^{183,184}

7.4.5 Smoking

Smoking cessation has clear benefits regarding overall CV risk, and specifically on HDL-C levels.¹⁶³

7.5 Dietary supplements and functional foods for the treatment of dyslipidaemias

Nutritional evaluation of functional foods includes not only the search for clinical evidence of beneficial effects relevant to improved health or the reduction of disease risk, but also the demonstration of good tolerability. Overall, the available evidence on functional foods so far identified in this field is incomplete; the major gap is an absence of diet-based intervention trials of enough duration to be relevant for the natural history of dyslipidaemia and CVD.

7.5.1 Phytosterols

The principal phytosterols are sitosterol, campesterol, and stigmasterol; they occur naturally in vegetable oils and in smaller amounts in vegetables, fresh fruits, nuts, grains, and legumes. The dietary intake of plant sterols ranges between an average of 250 mg/day in Northern Europe to ~ 500 mg/day in Mediterranean countries. Phytosterols compete with cholesterol for intestinal absorption, thereby modulating TC levels.

Daily consumption of 2 g of phytosterols can effectively lower TC and LDL-C levels by 7–10% in humans (with a certain degree of heterogeneity among individuals), while it has little or no effect on HDL-C and TG levels.¹⁴³ However, to date no studies have been performed on the subsequent effect on CVD. Based on LDL-C lowering and the absence of adverse signals, functional foods with plant sterols/stanols (≥ 2 g/day with the main meal) may be considered: (i) in individuals with high cholesterol levels at intermediate or low global CV risk who do not qualify for pharmacotherapy; (ii) as an adjunct to pharmacological therapy in high- and very-high-risk patients who fail to achieve LDL-C goals on statins or could not be treated with statins; and (iii) in adults and children (aged >6 years) with FH, in line with current guidance.¹⁴²

7.5.2 Monacolin and red yeast rice

Red yeast rice (RYR) is a source of fermented pigment that has been used in China as a food colorant and flavour enhancer for centuries. Hypocholesterolaemic effects of RYR are related to a statin-like mechanism—inhibition of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase—of monacolins, which represent the bioactive ingredient. Different commercial preparations of RYR have different concentrations of monacolins, and lower TC and LDL-C levels to variable extents, but the consumer is not able to make that distinction.^{144,185} Moreover, the long-term safety of the regular consumption of these products has not been fully documented and safety issues due to the possible presence of contaminants in some preparations have been raised. Side effects like those observed with statins have also been reported.

In the only available RCT in patients with ASCVD, a partially purified extract of RYR reduced recurrent events by 45%.¹⁴⁶ A clinically relevant hypocholesterolaemic effect (up to a 20% reduction) has been observed with RYR preparations providing an o.d. [once daily (omni die)] dose of 2.5–10 mg monacolin K.¹⁴⁵ Nutraceuticals containing purified RYR may be considered in people with elevated

plasma cholesterol concentrations who do not qualify for treatment with statins in view of their global CV risk. However, there is a clear need for better regulation of RYR supplements. Information regarding the precise composition of these products, the quantities of their components, and their purity should be implemented.¹⁸⁵

7.5.3 Dietary fibre

Available evidence consistently demonstrates a TC- and LDL-C-lowering effect of β -glucan, a viscous fibre from oat and barley. Foods enriched with these fibres or supplements are well tolerated, effective, and recommended for LDL-C lowering.¹⁸⁶ However, the dosage needed to achieve a clinically relevant reduction in levels of LDL-C of 3–5% varies from 3–10 g per day according to the specific type of fibre.¹⁸⁷

7.5.4 Soy

The cholesterol-lowering effect of soy is generally attributed to its isoflavone and phytoestrogen content, which decreases progressively with the increasing degree of soybean processing. Soy protein has also been indicated as being able to induce a modest LDL-C-lowering effect when replacing animal protein foods. However, this was not confirmed when changes in other dietary components were taken into account.^{187,188}

7.5.5 Policosanol and berberine

Policosanol is a natural mixture of long-chain aliphatic alcohols extracted primarily from sugarcane wax.¹⁸⁹ Studies show that policosanol from sugarcane, rice or wheat germ has no significant effect on LDL-C, HDL-C, TG, ApoB, Lp(a), homocysteine, high-sensitivity C-reactive protein, fibrinogen, or blood coagulation factor levels.¹⁹⁰

As for berberine, a recent meta-analysis evaluated its effects on plasma lipids in humans.¹⁹¹ The comparative evaluation of berberine and lifestyle intervention or placebo indicated that in the berberine group, LDL-C and plasma TG levels were more effectively reduced than in the control group. However, due to the lack of high-quality randomized clinical trials, the efficacy of berberine for treating dyslipidaemia needs to be further validated. Moreover, the bioavailability of the different berberine preparations is a matter of debate.¹⁸⁷

7.5.6 n-3 unsaturated fatty acids

Observational evidence indicates that consumption of fish (at least twice a week) and vegetable foods rich in n-3 fatty acids (α -linoleic acid is present in walnuts, some vegetables, and some seed oils) is associated with lower risk of CV death and stroke, but has no major effects on plasma lipoprotein metabolism.^{178,192} Pharmacological doses of long-chain n-3 fatty acids (2–3 g/day) reduce TG levels by about 30% and also reduce the post-prandial lipaemic response, but a higher dosage may increase LDL-C levels. α -Linolenic acid is less effective at altering TG levels.^{156,193} Recently, a significantly lower risk of ischaemic events, including CV death, was observed in patients with elevated TG levels despite the use of statins treated with 2 g of icosapent ethyl b.i.d. [twice a day].¹⁹⁴

Other features of a healthy diet contributing to CVD prevention are presented in the [Supplementary Data](#).

8 Drugs for treatment of dyslipidaemias

8.1 Statins

8.1.1 Mechanism of action

Statins reduce the synthesis of cholesterol in the liver by competitively inhibiting the enzyme HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis. The reduction in intracellular cholesterol promotes increased LDL receptor (LDLR) expression at the surface of the hepatocytes, which in turn results in increased uptake of LDL from the blood, and decreased plasma concentrations of LDL- and other ApoB-containing lipoproteins, including TG-rich particles.

8.1.2 Effects on lipids

8.1.2.1 Low-density lipoprotein cholesterol. The degree of LDL-C reduction is dose-dependent and varies between the different statins. A high-intensity regimen is defined as the dose of a statin that, on average, reduces LDL-C by $\geq 50\%$; moderate-intensity therapy is defined as the dose expected to reduce LDL-C by 30–50%. Notably, there is considerable interindividual variation in LDL-C reduction with the same dose of drug.³¹ Poor responses to statin treatment in clinical studies are to some extent caused by poor compliance, but may also be explained by genetic backgrounds.^{195,196} Interindividual variations in statin responses warrant monitoring of responses on initiation of therapy.

Among patients who cannot tolerate the recommended intensity of a statin because of adverse effects or those who do not reach their goal, the addition of a non-statin lipid-modifying agent to a maximally tolerated statin is recommended.^{197,198}

8.1.2.2 Triglycerides. Statins usually reduce TG levels by 10–20% from baseline values.¹⁹⁹ More potent statins (atorvastatin, rosuvastatin, and pitavastatin) demonstrate robust lowering of TG levels, especially at high doses and in patients with elevated TGs (HTG), in whom the absolute risk, and therefore the absolute risk reduction, is larger.

The mechanism of the TG-lowering effect has not been fully elucidated, but it seems to be partly independent of the LDLR pathway. It may involve the upregulation of VLDL uptake by hepatocytes, as well as a reduction of the production rate of VLDLs; these effects seem to be dependent on pre-treatment VLDL concentrations.²⁰⁰

8.1.2.3 High-density lipoprotein cholesterol. In a meta-analysis,²⁰¹ elevations in HDL-C levels varied with dose among the respective statins; such elevations ranged from 1–10%. However, given the marked statin-mediated decrement in atherogenic ApoB-containing lipoproteins, the extent to which the very modest effect on HDL-C levels might contribute to the overall observed reductions in CV risk consistently observed in statin intervention trials cannot reliably be disentangled.

8.1.2.4 Lipoprotein(a). Statins only marginally affect Lp(a) plasma levels. Previous studies have reported either no effect on or an increase of Lp(a) levels after statin treatment.^{202,203} The mechanisms by which statins raise oxidized phospholipids on Lp(a) require further investigation.

8.1.3 Other effects of statins

Although reduction of LDL-C levels is the major effect of statins, a number of other, potentially important effects have been suggested (pleiotropic effects of statins).^{204,205} Among such effects that are potentially relevant for the prevention of CVD are the anti-inflammatory and antioxidant effects of statin treatment. These effects have been shown *in vitro* and in experimental systems, but their clinical relevance remains unproven.^{18,206}

8.1.3.1 Effect on cardiovascular morbidity and mortality. A large number of meta-analyses have been performed to analyse the effects of statins in populations and in subgroups.^{34–36,38,51,207–214} In the Cholesterol Treatment Trialists (CTT) meta-analysis of individual participant data (IPD) from >170 000 participants in 26 RCTs of a statin vs. control or a more vs. less intensive statin regimen,³⁴ for each 1 mmol/L reduction in LDL-C, statin/more statin reduced major vascular events (MI, CAD death, or any stroke or coronary revascularization) by ~22%, major coronary events by 23%, CAD death by 20%, total stroke by 17%, and total mortality by 10% over 5 years. The proportional effects (per mmol/L reduction in LDL-C) on major vascular events were similar in all subgroups examined, so the absolute risk reduction was proportional to the absolute baseline risk. The relative benefits were half as large in the first year as compared with subsequent years. There was no increased risk for any non-CV cause of death, including cancer, in those allocated statins. The absolute benefit from statin treatment was lower in people in primary prevention, who are typically at lower risk.^{36,38,214,215} In the CTT meta-analysis of treatment in people with a low-risk of vascular disease,³⁶ the relative risk reduction of major vascular events per mmol/L reduction in LDL-C was at least as large in low-risk individuals (i.e. in primary prevention). In those without a history of vascular disease, statin therapy reduced the risk of all-cause mortality by 9% per mmol/L reduction in LDL cholesterol. Similar results were reported in a Cochrane review in 2013.²¹³ The West of Scotland Coronary Prevention Study (WOSCOPS) data were recently reanalysed, and demonstrated that even people without DM and a 10 year predicted ASCVD risk of <7.5% benefit from statin treatment. There was also a legacy effect with a mortality benefit of 18% in all-cause death over 20 years.²¹⁶ Statins are effective for the prevention of ASCVD in the elderly, including those aged >75 years.²¹⁷ Statins are not effective in a few specific groups, notably those with heart failure (HF) or patients receiving haemodialysis.^{214,218–222}

Current available evidence from meta-analyses suggests that the clinical benefit of statin treatment is largely a class effect, driven by the absolute LDL-C reduction; therefore, the type of statin used should reflect the treatment goals for a given patient.

The following scheme may be proposed.

- Evaluate the total CV risk of the individual.
- Determine the treatment goals (depending on current risk).
- Involve the patient in decisions on CV risk management.
- Choose a statin regimen and, where necessary, additional treatments (e.g. ezetimibe or PCSK9 inhibitors) that can meet the treatment goals (per cent and absolute value).
- Response to statin treatment is variable, therefore uptitration of the statin dose may be required before additional LDL-lowering treatments are started.

These are general criteria for the choice of drug. Factors such as the clinical condition of the patient, concomitant medications, drug tolerability, local treatment tradition, and drug cost will play major roles in determining the final choice of drug and dose.

Furthermore, the effects of statins on a number of other clinical conditions have been evaluated. For cancer, a meta-analysis of IPD from randomized trials has shown that statins do not have any significant effect on cancer, at least over a period of ~5 years.²²³ Other conditions, such as dementia,²²⁴ hepatic steatosis,²²⁵ venous thromboembolism,²²⁶ atrial fibrillation,^{227,228} and polycystic ovary syndrome²²⁹ have also been studied, and no effect of statins on these conditions has been reliably demonstrated.

The suggested effect on Alzheimer's disease was recently reviewed in a Cochrane analysis reporting no conclusive effect from statins.²³⁰ Furthermore, neurocognitive functions were extensively investigated in the Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects (EBBINGHAUS) study²³¹ and no excess risk was observed among patients on a statin regimen randomized to a PCSK9 mAb.

8.1.4 Adverse effects and interactions of statins

Statins differ in their absorption, bioavailability, plasma protein binding, excretion, and lipophilicity. Evening administration is usually recommended. Lovastatin and simvastatin are prodrugs, whereas the other available statins are administered in their active form. Their bioavailability is relatively low, owing to a first-pass effect in the liver, and many statins undergo significant hepatic metabolism via cytochrome P450 (CYP) isoenzymes, except pravastatin, rosuvastatin, and pitavastatin. These enzymes are expressed mainly in the liver and gut wall. Although statins are generally very well tolerated, they do have some specific adverse effects on muscle, glucose haemostasis, and haemorrhagic stroke. However, there is also widespread misinformation about potential adverse effects, as reviewed recently.^{232,233}

8.1.4.1 Adverse effects on muscle. Myopathy is the most clinically relevant adverse effect of statins. Among the risk factors for myopathy, it is particularly important that interaction with concomitant drug therapy is considered (see below). Rhabdomyolysis is the most severe form of statin-induced muscle damage, characterized by severe muscular pain, muscle necrosis, and myoglobinuria potentially leading to renal failure and death. In rhabdomyolysis, creatine kinase (CK) levels are elevated by ≥ 10 times, and often ≥ 40 times, the upper limit of normal (ULN).²³⁴ The frequency of rhabdomyolysis has been estimated to represent 1–3 cases/100 000 patient-years.²³⁵ Patients taking statin therapy frequently report muscle symptoms [so-called 'statin-associated muscle symptoms' (SAMS)], and in non-randomized, observational studies, statins are associated with muscular pain and tenderness (myalgia) without CK elevation or major functional loss, with the reported frequency of SAMS in such studies varying between 10–15% among statin-treated individuals.^{236–238} However, in part because individuals in observational studies are not blind to the treatment they are receiving, such studies are unreliable when used to assess the adverse effects of statins.²³³ In contrast, in blinded randomized trials of statins vs. placebo there is no, or only a

slightly, increased frequency of muscle symptoms in statin-allocated groups.^{239,240} The Anglo-Scandinavian Cardiac Outcomes Trial – Lipid-Lowering Arm (ASCOT-LLA) study addressed this issue by comparing the incidence of four different adverse events, including muscle-related symptoms, during both the blinded, placebo-controlled trial and its open-label extension study.²³⁸ They concluded that a placebo effect (i.e. one caused by negative expectations) may partly explain the higher frequency of SAMS in observational studies compared with in trials. Suggested practical management of muscular symptoms is shown in [Supplementary Figure 6](#).^{198,234,241} Several studies have shown a considerable LDL-C-lowering effect of alternative dosing, such as every other day or twice a week, with atorvastatin or rosuvastatin.²⁴² Although no clinical endpoint trials are available, this strategy should be considered in high-risk patients in whom statin treatment with daily doses is not possible.

8.1.4.2 Adverse effects on the liver. The activity of alanine aminotransferase (ALT) in plasma is commonly used to assess hepatocellular damage. Mild elevation of ALT occurs in 0.5–2.0% of patients on statin treatment, more commonly with potent statins or high doses. The common definition of clinically relevant ALT elevation has been an increase of three times the ULN on two consecutive occasions. Mild elevation of ALT has not been shown to be associated with true hepatotoxicity or changes in liver function. Progression to liver failure is exceedingly rare, therefore routine monitoring of ALT during statin treatment is no longer recommended.²⁴³ Patients with mild ALT elevation due to steatosis have been studied during statin treatment and there is no indication that statins cause any worsening of liver disease.^{244–246}

8.1.4.3 Increased risk of new-onset diabetes mellitus. Patients on statin treatment have been shown to exhibit an increased risk of dysglycaemia and development of type 2 diabetes mellitus (T2DM). Several studies have shown that this is a consistent, dose-related effect.²³² A minor, not clinically relevant elevation of glycated haemoglobin (HbA1c) has also been observed. The number needed to cause one case of diabetes has been estimated as 255 over 4 years of statin treatment.²⁴⁷ However, the risk is higher with the more potent statins at high doses,²⁴⁸ and is also higher in the elderly, and in the presence of other risk factors for diabetes such as overweight or insulin resistance.²⁴⁹ Overall, the absolute reduction in the risk of CVD in high-risk patients clearly outweighs the possible adverse effects of a small increase in the incidence of diabetes.²³³ This effect is probably related to the mechanism of action of statins, as Mendelian randomization studies have confirmed the increased risk of DM in individuals with HMG-CoA reductase polymorphisms that reduce cholesterol synthesis.²⁵⁰

8.1.4.4 Increased risk of haemorrhagic stroke. In observational studies, TC is negatively associated with haemorrhagic stroke, and in the CTT meta-analysis, there was a 21% [95% confidence interval (CI) 5–41%; $P=0.01$] relative increase per mmol/L lower LDL cholesterol in haemorrhagic stroke.^{34,251,252} However, other meta-analyses

have yielded conflicting findings and there is a need for further exploration of the risk of haemorrhagic stroke in particular types of patients. Note, however, that the overall benefit on other stroke subtypes greatly outweighs this small (and uncertain) hazard.^{34,36}

8.1.4.5 Adverse effects on kidney function. There is no clear evidence that statins have a clinically significant beneficial or adverse effect on renal function.²⁵³ An increased frequency of proteinuria has been reported for all statins, but has been analysed in more detail for rosuvastatin. With a dose of 80 mg, a frequency of 12% was reported. With the approved doses of <40 mg, the frequency is much lower and in line with the frequency for other statins. The proteinuria induced by statins is of tubular origin, usually transitory, and is believed to be due to reduced tubular reabsorption and not to glomerular dysfunction.^{254,255} In clinical trials, the frequency of proteinuria is generally low and, in most cases, is not higher than for placebo.²⁵⁶

8.1.4.6 Interactions. A number of important drug interactions with statins have been described that may increase the risk of adverse effects. Inhibitors and inducers of enzymatic pathways involved in statin metabolism are summarized in [Table 10](#). All currently available statins—except pravastatin, rosuvastatin, and pitavastatin—undergo major hepatic metabolism via the CYPs. These isoenzymes are mainly expressed in the liver and intestine. Pravastatin does not undergo metabolism through the CYP system, but is metabolized by sulfation and conjugation. CYP3A4 isoenzymes are the most abundant, but other isoenzymes such as CYP2C8, CYP2C9, CYP2C19, and CYP2D6 are frequently involved in the metabolism of statins. Thus, other pharmacological substrates of these CYPs may interfere with statin metabolism. Conversely, statin therapy may interfere with the catabolism of other drugs that are metabolized by the same enzymatic system.

Combination of statins with gemfibrozil enhances the risk of myopathy, and its association with statins must be avoided. There is no or very little increased risk for myopathy when combining statins with other fibrates, such as fenofibrate, bezafibrate, or ciprofibrate.^{259,260}

Table 10 Drugs potentially interacting with statins metabolized by cytochrome P450 3A4 leading to increased risk of myopathy and rhabdomyolysis

Anti-infective agents	Calcium antagonists	Other
Itraconazole	Verapamil	Ciclosporin
Ketoconazole	Diltiazem	Danazol
Posaconazole	Amlodipine	Amiodarone
Erythromycin		Ranolazine
Clarithromycin		Grapefruit juice
Telithromycin		Nefazodone
HIV protease inhibitors		Gemfibrozil

Adapted from Egan and Colman,²⁵⁷ and Wiklund et al.²⁵⁸
HIV = human immunodeficiency virus.

8.2 Cholesterol absorption inhibitors

8.2.1 Mechanism of action

Ezetimibe inhibits intestinal uptake of dietary and biliary cholesterol at the level of the brush border of the intestine [by interacting with the Niemann-Pick C1-like protein 1 (NPC1L1)] without affecting the absorption of fat-soluble nutrients. By inhibiting cholesterol absorption, ezetimibe reduces the amount of cholesterol delivered to the liver. In response to reduced cholesterol delivery, the liver reacts by upregulating LDLR expression, which in turn leads to increased clearance of LDL from the blood.

8.2.2 Effects on lipids

In clinical studies, ezetimibe in monotherapy at 10 mg/day reduces LDL-C in hypercholesterolaemic patients by 15–22% with relatively high interindividual variation.²⁶¹ A meta-analysis of RCTs that included over 2700 people showed an 18.5% reduction in LDL-C as compared with placebo.²⁶² In addition, there was a significant 3% increase in HDL-C, a significant 8% reduction in TGs, and a 13% reduction in TC with ezetimibe as compared with placebo.

Ezetimibe added to ongoing statin therapy reduces LDL-C levels by an additional 21–27% compared with placebo in patients with hypercholesterolaemia with or without established CHD. In statin-naïve patients, ezetimibe and statin combination therapy has resulted in around a 15% greater reduction in LDL-C when compared with the same statins and doses in monotherapy. In other studies, this combination has also significantly improved reductions in LDL-C levels when compared with doubling of the statin dose (13–20%), and after switching from statin monotherapy to ezetimibe and statin combination therapy (11–15%).²⁶³

Co-administration of ezetimibe and bile acid sequestrants (colesevelam, colestipol, or cholestyramine) has been reported to result in an additional reduction of LDL-C levels by 10–20% when compared with the stable bile acid sequestrant regimen alone.²⁶⁴ Co-administration of ezetimibe with PCSK9 inhibitors also results in an additional effect.²⁶⁵

8.2.3 Effect on cardiovascular morbidity and mortality

The efficacy of ezetimibe in association with simvastatin has been addressed in people with aortic stenosis in the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) trial,²⁶⁶ and in patients with CKD in the Study of Heart and Renal Protection (SHARP) trial.²²² In both the SEAS and SHARP trials, a reduction in CV events was demonstrated in the simvastatin–ezetimibe arm vs. placebo.^{266,267}

In the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT), ezetimibe was added to simvastatin (40 mg) in patients after acute coronary syndrome (ACS).³³ A total of 18 144 patients were randomized to statin or statin plus ezetimibe, and 5314 patients over 7 years experienced a CV event; 170 fewer events (32.7 vs. 34.7%) were recorded in the group taking simvastatin plus ezetimibe ($P=0.016$). The average LDL-C during the study was 1.8 mmol/L (70 mg/dL) in the simvastatin group and 1.4 mmol/L (55 mg/dL) in patients taking ezetimibe plus simvastatin. Also, ischaemic stroke was reduced by 21% in this trial ($P=0.008$). There was no evidence of harm caused by ezetimibe or the further LDL-C reduction. In this group of patients already treated with statins to reach goals, the absolute CV benefit from added ezetimibe was small,

although significant and in line with the CTT expectations.²⁶⁸ Therefore, the study supports the proposition that LDL-C lowering by means other than statins is beneficial and safe. The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.^{55,269,270}

Taken together with other studies,²⁷¹ IMPROVE-IT supports the proposal that ezetimibe should be used as second-line therapy in association with statins when the therapeutic goal is not achieved at the maximal tolerated statin dose, or in cases where a statin cannot be prescribed.^{272,273}

8.2.4 Adverse effects and interactions

Ezetimibe is rapidly absorbed and extensively metabolized to pharmacologically active ezetimibe glucuronide. The recommended dose of ezetimibe of 10 mg/day can be administered in the morning or evening irrespective of food intake. There are no clinically significant effects of age, sex, or race on ezetimibe pharmacokinetics, and no dosage adjustment is necessary in patients with mild hepatic impairment or mild-to-severe renal insufficiency. Life-threatening liver failure with ezetimibe as monotherapy or in combination with statins is extremely rare. The addition of ezetimibe to statin therapy does not appear to increase the incidence of elevated CK levels beyond what is noted with statin treatment alone.²⁶¹

8.3 Bile acid sequestrants

8.3.1 Mechanism of action

Bile acids are synthesized in the liver from cholesterol and are released into the intestinal lumen, but most of the bile acid is returned to the liver from the terminal ileum via active absorption. The two older bile acid sequestrants, cholestyramine and colestipol, are both bile acid-binding exchange resins. The synthetic drug colesevelam is also available in some countries. As bile acid sequestrants are not systemically absorbed or altered by digestive enzymes, the beneficial clinical effects are indirect. By binding the bile acids, the drugs prevent the reabsorption of both the drug and cholesterol into the blood, and thereby remove a large portion of the bile acids from the enterohepatic circulation. The liver, depleted of bile, synthesizes more from hepatic cholesterol, therefore increasing the hepatic demand for cholesterol and increasing LDLR expression, which results in a decrease of circulating LDL.

8.3.2 Effects on lipids

At the top daily dose of 24 g of cholestyramine, 20 g of colestipol, or 4.5 g of colesevelam, a reduction in LDL-C of 18–25% has been observed. No major effect on HDL-C has been reported, while TGs may increase in some predisposed patients.²⁷⁴ Colesevelam can also reduce glucose levels in hyperglycaemic patients.²⁷⁵

8.3.3 Effect on cardiovascular morbidity and mortality

In clinical trials, bile acid sequestrants have contributed greatly to the demonstration of the efficacy of LDL-C lowering in reducing CV events in hypercholesterolaemic people, with a benefit proportional to the degree of LDL-C lowering. Of note, these studies were

performed before many of the modern treatment options were available.^{276–278}

8.3.4 Adverse effects and interactions

Gastrointestinal (GI) adverse effects (most commonly flatulence, constipation, dyspepsia, and nausea) are often present with these drugs, even at low doses, which limits their practical use. These adverse effects can be attenuated by beginning treatment at low doses and ingesting ample fluid with the drug. The dose should be increased gradually. Reduced absorption of fat-soluble vitamins has been reported. Furthermore, these drugs may increase circulating TG levels in certain patients.

Bile acid sequestrants have major drug interactions with several commonly prescribed drugs, and must therefore be administered either 4 h before or 1 h after other drugs. Colesevelam is better tolerated and has fewer interactions with other drugs, and can be taken together with statins and several other drugs.²⁷⁹

8.4 Proprotein convertase subtilisin/kexin type 9 inhibitors

8.4.1 Mechanism of action

Recently, a new class of drugs, PCSK9 inhibitors, has become available that targets a protein (PCSK9) involved in the control of the LDLR.²⁸⁰ Elevated concentration or function of this protein in plasma reduces LDLR expression by promoting, upon binding, LDLR lysosomal catabolism and a subsequent increase in plasma LDL concentrations, while lower concentration or function of PCSK9 is related to lower plasma LDL-C levels.²⁸¹ Therapeutic strategies have been developed mainly using mAbs; the mechanism of action relates to the reduction of the plasma level of PCSK9, which in turn is not available to bind the LDLR. Since this interaction triggers the intracellular degradation of the LDLR, lower levels of circulating PCSK9 will result in increased expression of LDLRs at the cell surface and therefore in a reduction of circulating LDL-C levels.²⁸¹ Currently, the only approved PCSK9 inhibitors are two fully human mAbs, alirocumab and evolocumab. Statin treatment increases circulating PCSK9 serum levels,²⁸² and thus the best effect of these mAbs has been demonstrated in combination with statins.

8.4.2 Effects on lipids

8.4.2.1 Low-density lipoprotein cholesterol. In clinical trials, alirocumab and evolocumab—either alone or in combination with statins, and/or other lipid-lowering therapies—have been shown to significantly reduce LDL-C levels on average by 60%, depending on dose. The efficacy appears to be largely independent of any background therapy. In combination with high-intensity or maximally tolerated statins, alirocumab and evolocumab reduced LDL-C by 46–73% more than placebo, and by 30% more than ezetimibe. Among patients in whom statins cannot be prescribed, PCSK9 inhibition reduced LDL-C when administered in combination with ezetimibe.²⁸³ Both alirocumab and evolocumab have also been shown to effectively lower LDL-C levels in patients who are at high CV risk, including those with DM.²⁸⁴

Given the mechanism of action, these drugs are effective at reducing LDL-C in all patients capable of expressing LDLR in the liver. Therefore, this pharmacological approach is effective in the vast

majority of patients, including those with HeFH and, albeit to a lower level, those with HoFH with residual LDLR expression. Receptor-deficient HoFH responds poorly to the therapy.²⁸⁵

8.4.2.2 Triglycerides and high-density lipoprotein cholesterol. These highly efficacious LDL-lowering agents also lower TG levels, and increase those of HDL-C and ApoA-I as a function of the dosing regimen. In phase II trials, evolocumab lowered TG levels by 26%, and raised HDL-C and ApoA-I by 9 and 4%, respectively; similar findings have been reported for alirocumab.^{286,287} However, the TG effect must be confirmed in populations with higher starting plasma TG levels.

8.4.2.3 Lipoprotein(a). In contrast to statins, inhibiting PCSK9 with mAbs also reduces Lp(a) plasma levels. Pooled results of phase II trials have shown that treatment leads to an Lp(a) reduction of about 30–40%.^{288,289} While recent investigations have attempted to unravel the mechanism, it remains unclear. However, it appears to be distinct from that of statins, which also enhance LDLR function but do not lower circulating Lp(a) levels in humans. The relative contribution of this effect to the reduction of risk remains to be addressed in appropriately designed studies.

8.4.3 Effect on cardiovascular morbidity and mortality

Early preliminary data from phase III trials suggests a reduction of CV events in line with the LDL-C reduction achieved.^{286,290,291}

Recently, two major studies were completed: the Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk (FOURIER) and the Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab (ODYSSEY Outcomes) trials.^{119,120} The designs of the trials were similar with regard to the settings of secondary prevention and background therapy; however, the populations enrolled had either stable CHD, peripheral arterial disease (PAD), or stroke; or a recent (median 2.6 months) ACS, respectively. The relative benefit ranged from 15–20% reductions in the risk of the primary endpoints. Both studies had relatively short follow-up periods and the evidence from statin trials indicates that the clinical benefits of LDL-lowering may only emerge after about 1 year,⁵¹ so these trials may have underestimated the potential impact of longer-term treatment.^{120,290}

In the FOURIER trial,¹¹⁹ 27 564 patients with atherosclerotic CVD, and LDL-C levels of 1.8 mmol/L (70 mg/dL) or higher who were receiving statin therapy, were randomly assigned to receive evolocumab or placebo. Allocation to evolocumab reduced median LDL-C from 2.38 mmol/L (92 mg/dL) at baseline to a mean of 0.78 mmol/L (30 mg/dL) at 48 weeks. After a median follow-up of 2.2 years, evolocumab treatment significantly reduced the risk of the primary endpoint (composite of CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% [hazard ratio (HR) 0.85, 95% CI 0.79–0.92]. An analysis of the time to benefit also showed that there was a lower benefit in the first year than in subsequent years, consistent with the effects of statins observed within the CTT meta-analysis.²⁶⁸ In the FOURIER trial, allocation to evolocumab did not reduce the risk of CV mortality (HR 1.05, 95% CI 0.88–1.25) or all-cause mortality.

The ODYSSEY Outcomes trial randomized 18 924 patients after hospitalization for acute MI or unstable angina, treated with statins, and with LDL-C ≥ 1.8 mmol/L (≥ 70 mg/dL), non-HDL cholesterol ≥ 2.6 mmol/L (≥ 100 mg/dL), or ApoB ≥ 80 mg/dL, to receive injections of alirocumab or matching placebo. Allocation to alirocumab reduced the mean baseline LDL-C from 2.38 mmol/L (92 mg/dL) to 1.24 mmol/L (48 mg/dL) at 12 months. There was a 15% relative reduction in the primary outcome (composite of CHD death, non-fatal MI, ischaemic stroke, or unstable angina requiring hospitalization) (HR 0.85, 95% CI 0.78–0.93) after a median follow-up of 2.8 years.¹²⁰ Although there was a significant reduction in all-cause mortality in the ODYSSEY trial, this was an exploratory outcome and was not supported by a significant effect on CV death.

8.4.4 Adverse effects and interactions

Anti-PCSK9 mAbs are injected subcutaneously, every other week or once a month, at different doses depending on the agent used. The potential for interaction with orally absorbed drugs is absent, as they will not interfere with pharmacokinetics or pharmacodynamics. Among the most frequently reported side effects are itching at the site of injection and flu-like symptoms.²⁹² In some studies, an increase of patient-reported neurocognitive effects has been described.²⁹³ However, the EBBINGHAUS trial,²³¹ which was specifically designed to detect neurocognitive function changes, was reassuring, as were the safety reports in both the FOURIER and ODYSSEY trials. Mendelian randomization studies have also suggested that PCSK9 inhibition may increase the risk of DM with an LDL-C-related effect, as apparently occurs for statins.²⁹⁴ To date, no signal has emerged from RCTs.^{295–297} Although large long-term trials of PCSK9 inhibitors are needed to rule out these and other potential side effects of inhibition of PCSK9,²⁹⁸ 7 year data from the IMPROVE-IT study have shown that prolonged low LDL-C concentrations are not associated with any clear adverse effects.²⁹⁹

A potential problem of long-term antibody treatment is the occurrence of autoantibodies. Evolocumab and alirocumab are fully human antibodies and, therefore, theoretically less likely to induce autoantibodies. To date, only very few cases of antidrug antibodies have been reported, and no reduction of LDL-C lowering has been observed, but long-term use needs to be monitored. Indeed, the development programme for a third PCSK9 inhibitor, bococizumab, a humanized antibody, was discontinued because of an increase of neutralizing antibodies, which resulted in the attenuation of the LDL-C-lowering effect over time, as well as a higher rate of injection site reactions.³⁰⁰ However, although PCSK9 inhibitors are very effective drugs that can reduce LDL-C and CV events on top of statin and/or ezetimibe treatment, considering the costs of the treatments and the limited data on long-term safety, these drugs are likely to be considered cost-effective only in those patients at very high-risk of ASCVD, and their use may not be possible in some countries with limited healthcare resources.

8.5 Lomitapide

The microsomal TG transfer protein (MTP) transfers TGs and phospholipids from the endoplasmic reticulum to ApoB, as a necessary step in the formation of VLDL. MTP inhibition thus prevents the formation of VLDL in the liver and of chylomicrons in the intestine.

Lomitapide is an MTP inhibitor designed for o.d. oral treatment of HoFH. In an open-label, single-arm titration study evaluating lomitapide as adjunct therapy to statins, with or without apheresis and a low-fat diet,³⁰¹ LDL-C was reduced by 50% from baseline at 26 weeks and by 44% at 56 weeks. Lomitapide was also shown to decrease the frequency of apheresis in HoFH patients. It should be noted that the drug's effect on CV outcomes has not yet been determined.

As a consequence of its mechanism of action, lomitapide has been shown to be associated with increased aminotransferase levels, which most likely reflects the increased fat in the liver, as well as poor GI tolerability.^{301,302} The GI side effects were the most frequent reasons preventing a further increase in the dose of lomitapide in clinical trials.³⁰¹ However, it has been noted that the frequency and intensity of GI side effects generally decrease with time. Therefore, prescription of lomitapide requires careful patient education and liver function monitoring during therapy.

8.6 Mipomersen

Mipomersen is an antisense oligonucleotide able to bind the messenger RNA (mRNA) of ApoB-100, which triggers the selective degradation of mRNA molecules. After subcutaneous injection, the oligonucleotide is preferentially transported to the liver, where it binds to a specific mRNA preventing the translation of ApoB protein and, consequently, reducing the production of atherogenic lipids and lipoproteins, including LDL and Lp(a).³⁰³ An adjunct to lipid-lowering medications and diet, mipomersen is indicated to reduce LDL-C in patients with HoFH. Mipomersen is currently approved by the US Food and Drug Administration (FDA), but not by the European Medicines Agency (EMA).

Reactions at the injection site are the most common adverse effects observed in patients treated with mipomersen.³⁰⁴ However, the main concerns regarding mipomersen's safety are related to liver toxicity. Mipomersen may lead to the development of steatosis. Treated patients have shown a higher increase of liver fat from baseline compared with patients randomized to placebo.³⁰³ The efficacy and safety of long-term mipomersen treatment are currently under evaluation in patients with severe HeFH, and in statin-intolerant patients.

8.7 Fibrates

8.7.1 Mechanism of action

Fibrates are agonists of peroxisome proliferator-activated receptor- α (PPAR- α), acting via transcription factors regulating, among other things, various steps in lipid and lipoprotein metabolism. As a consequence, fibrates have good efficacy in lowering fasting TG levels, as well as post-prandial TGs and TG-rich lipoprotein (TRL) remnant particles.

8.7.2 Effects on lipids

Clinical impacts on lipid profiles vary among members of the fibrate class, but are estimated to reach a 50% reduction of the TG level, a $\leq 20\%$ reduction of the LDL-C level (but a paradoxical small LDL-C increase may be observed with high TG levels), and an increase of the HDL-C level of $\leq 20\%$. The magnitude of effect is highly dependent on the baseline lipid levels.³⁰⁵ Both the HDL-raising and

TG-lowering effects of fibrates have been reported to be markedly less (~5 and ~20%, respectively) in long-term intervention trials in people with T2DM but without elevated levels of TGs.^{306,307}

8.7.3 Effect on cardiovascular morbidity and mortality

The clinical effects of fibrates have been primarily illustrated by six RCTs: the Helsinki Heart Study (HHS), Veterans Affairs High Density Lipoprotein Intervention Trial (VA-HIT), Bezafibrate Infarction Prevention (BIP), Lower Extremity Arterial Disease Event Reduction (LEADER), Fenofibrate Intervention and Event Lowering in Diabetes (FIELD), and Action to Control Cardiovascular Risk in Diabetes (ACCORD) trials; in the latter trial, fenofibrate was added to statin therapy.^{306–311} In CV outcome trials of fibrates, the risk reduction appeared to be proportional to the degree of non-HDL-C lowering.⁵⁰

Although the HHS reported a significant reduction in CVD outcomes with gemfibrozil, neither the FIELD nor the ACCORD studies involving fenofibrate showed a reduction in total CVD outcomes. The LEADER trial included male participants with lower-extremity arterial disease and failed to show that bezafibrate could lead to a clinically important reduction in CVD combined endpoints. Decreases in the rates of non-fatal MI were reported, although often as a result of *post hoc* analyses. The effect was most evident in people with elevated TG/low HDL-C levels. However, the data on other outcome parameters have remained equivocal. Only one study, ACCORD, has analysed the effect of a fibrate as an add-on treatment to a statin. No overall benefit was reported in two recent meta-analyses.^{312,313} Results from other meta-analyses suggest reduced major CVD events in patients with high TGs and low HDL-C in fibrate-treated patients, but no decrease in CVD or total mortality.^{314–316} Thus, the overall efficacy of fibrates on CVD outcomes is much less robust than that of statins. Recently, a new selective PPAR- α modulator (pemafibrate) has been reported to have marked efficacy in reducing TRLs.³¹⁷ The study, Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT), is an ongoing CVD outcome trial designed to evaluate the efficacy of pemafibrate in some 10 000 high-risk diabetic patients with high TG and low HDL-C levels.³¹⁸ Overall, the potential CV benefits of fibrates require further confirmation.

8.7.4 Adverse effects and interactions

Fibrates are generally well tolerated with mild adverse effects, GI disturbances being reported in <5% of patients, and skin rashes in 2%.³¹⁹ In general, myopathy, liver enzyme elevations, and cholelithiasis represent the most well-known adverse effects associated with fibrate therapy.³¹⁹ The risk of myopathy has been reported to be 5.5-fold greater with fibrate monotherapy (mainly with gemfibrozil) compared with a statin, and it varies with different fibrates and statins used in combination. This is explained by the pharmacological interactions between the metabolism of different fibrates and pathways of glucuronidation of statins. Gemfibrozil inhibits the metabolism of statins via the glucuronidation pathway, which leads to marked increases in plasma concentrations of statins.³²⁰ As fenofibrate does not share the same pharmacokinetic pathways as gemfibrozil, the risk of myopathy is much less with this combination therapy.³¹⁹

As a class, fibrates have been reported to raise both serum creatinine and homocysteine levels in both short- and long-term studies. The increase of serum creatinine by fibrate therapy seems to be fully reversible when the drug is stopped. Data from meta-analyses suggest that a reduction of calculated glomerular filtration rate (GFR) does not reflect any adverse effects on kidney function.³¹⁵ Fibrates are associated with a slightly increased risk of pancreatitis.³²¹ The increase in homocysteine levels caused by fibrates has been considered to be relatively neutral with respect to CVD risk. However, a fibrate-induced increase in homocysteine may blunt elevation of both HDL-C and ApoA1 levels, and this effect may contribute to the smaller than estimated benefits of fenofibrate in CV outcome parameters.³²²

8.8 n-3 fatty acids

8.8.1 Mechanism of action

The n-3 (or omega-3) fatty acids [eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)] can be used at pharmacological doses to lower TGs. n-3 fatty acids (2–4 g/day) affect serum lipids and lipoproteins, in particular VLDL concentrations. The underlying mechanism is poorly understood, although it may be related, at least in part, to their ability to interact with PPARs and to decreased secretion of ApoB.

8.8.2 Effects on lipids

n-3 fatty acids reduce TGs, but their effects on other lipoproteins are trivial. More detailed data on clinical outcomes are needed to justify wide use of prescription n-3 fatty acids.³²³ The recommended doses of total EPA and DHA to lower TGs have varied between 2–4 g/day. Three recent studies in people with high TGs using EPA reported a significant reduction in serum TG levels of up to 45% in a dose-dependent manner.^{324–326} The efficacy of omega-3 fatty acids in lowering serum TGs has also been reported in meta-analyses.¹⁵⁷ Recently, the EpanoVa fOr Lowering Very high triglyceridEs II (EVOLVE II) trial confirmed the efficacy of omega-3 fatty acids in lowering serum TGs.³²⁷

8.8.3 Effect on cardiovascular morbidity and mortality

A Cochrane meta-analysis, including 112 059 people from 79 trials, reported no overall effect of omega-3 PUFAs on total mortality (relative risk 0.98, 95% CI 0.90–1.03) or CV events (relative risk 0.99, 95% CI 0.94–1.04), with only a suggestion that omega-3 fatty acids reduced CHD events (relative risk 0.93, 95% CI 0.88–0.97).³²⁸ Recently, the A Study of Cardiovascular Events in Diabetes (ASCEND) trial,³²⁹ which randomly assigned 15 480 patients with DM but without atherosclerotic CV disease to n-3 fatty acids or placebo, showed no significant difference in the risk of serious vascular events after a mean follow-up of 7.4 years (relative risk 1.00, 95% CI 0.91–1.09).

The data remain inconclusive and the clinical efficacy of omega-3 fatty acids appears to be related to non-lipid effects.^{330,331} Moreover, studies with omega-3 fatty acids have suffered from the dose used (1 g/day), which does not affect plasma lipids to a large extent, as the dose required to decrease plasma TGs is >2 g/day. The Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT)¹⁹⁵ aimed to evaluate the potential benefits of omega-3 oil (EPA) on

ASCVD outcomes in people with elevated serum TGs; the trial enrolled ~8000 patients on statin therapy, with LDL-C levels between 1.0–2.6 mmol/L (41–100 mg/dL) and various CV risk factors, including persistent elevated TGs between 1.7–5.6 mmol/L (150–499 mg/dL), and either established ASCVD or DM, and at least one other CV risk factor. Use of high doses (2 g b.i.d.) of EPA as compared with placebo (mineral oil) resulted in a ~25% relative risk reduction ($P < 0.001$) in major adverse CV events (MACE). Another randomized placebo-controlled trial, Outcomes Study to Assess STatin Residual Risk Reduction with EpaNova in HiGh CV Risk PatientS with Hypertriglyceridemia (STRENGTH),³³² which aims to determine whether reduction of TRLs and remnants in statin-treated patients will provide additional ASCVD risk reduction, is ongoing. The VITamin D and Omega-3 Trial (VITAL), which reported recently, was a 2×2 factorial design study in which healthy participants were randomized in a 1:1 fashion to either vitamin D3 (at a dose of 2000 IU per day) vs. matching placebo, and n-3 fatty acids (1 g per day as a fish-oil capsule containing 840 mg of n-3 fatty acids, including 460 mg of EPA and 380 mg of DHA) vs. matching placebo. It showed that supplementation with either n-3 fatty acids at a dose of 1 g/day, or vitamin D3 at a dose of 2000 IU/day, was not effective for primary prevention of CV or cancer events among healthy middle-aged men and women over 5 years of follow-up.³³³

8.8.4 Safety and interactions

The administration of n-3 fatty acids appears to be safe and devoid of clinically significant interactions. The most common side effect is GI disturbance. The antithrombotic effects may increase the propensity for bleeding, especially when given in addition to aspirin/clopidogrel. Recently, data from one study have associated a risk of prostate cancer with high dietary intake of n-3 PUFAs.³³⁴

8.9 Nicotinic acid

Nicotinic acid has key action sites in both the liver and adipose tissue. In the liver, nicotinic acid inhibits diacylglycerol acyltransferase-2 resulting in decreased secretion of VLDL particles, which is also reflected in reductions of plasma levels of both IDL and LDL particles.³³⁵ Nicotinic acid primarily raises HDL-C and ApoA1 by stimulating ApoA1 production in the liver.³³⁵ Two large randomized trials with nicotinic acid—one with extended-release niacin⁶⁶ and one with niacin plus laropiprant⁶⁷—have shown no beneficial effect and an increased frequency of serious adverse effects. No medication containing nicotinic acid is currently approved in Europe.

8.10 Cholesteryl ester transfer protein inhibitors

To date, the pharmacological approach that has led to the greatest elevations in HDL-C levels has been direct inhibition of CETP by small-molecule inhibitors, which may induce an increase in HDL-C by ≥100% on a dose-dependent basis. Torcetrapib was studied in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, which was stopped early due to increased mortality.³³⁶ Dalcetrapib raises HDL-C levels by 30–40% with no appreciable effect on LDL-C, offering specific insight into pure HDL-C raising. However, dalcetrapib failed to show any benefit in ACS patients in the dal-OUTCOMES trial. Evacetrapib,

which raises HDL-C levels by 130% and lowers LDL-C by 37%, was studied in the ACCELERATE trial,⁶³ which was terminated due to futility. Recently, anacetrapib, which raises HDL-C and ApoA-I levels (by 104 and 36%, respectively), and lowers LDL-C and ApoB (by 17 and 18%, respectively), was studied in the REVEAL trial. Anacetrapib reduced major coronary events by 9% over a median of 4.1 years.⁶⁴ The magnitude of the relative risk reduction appeared to be consistent with the magnitude of LDL-C- or non-HDL-C-level lowering.³³⁷ This drug has not been submitted for regulatory approval.

8.11 Future perspectives

8.11.1 New approaches to reduce low-density lipoprotein cholesterol

An alternative approach targeting PCSK9 consists of RNA interference. In a phase I and a phase II trial, the small interfering RNA (siRNA) molecule inclisiran—which inhibits the synthesis of PCSK9—reduced LDL-C by up to 50% and the reduction was dose-dependent. Reductions in PCSK9 and LDL-C levels were maintained for ≤6 months.^{338,339} No specific serious adverse events were observed. HPS4/TIMI65/ORION4, with a planned mean duration of 5 years, is currently comparing inclisiran vs. placebo among 15 000 patients with a prior MI or stroke.

Bempedoic acid is a novel, first-in-class, oral small molecule that inhibits cholesterol synthesis by inhibiting the action of ATP citrate lyase, a cytosolic enzyme upstream of 3-hydroxy-3-methylglutaryl-coenzyme A reductase.³⁴⁰ So far, it has been tested in diabetic patients, and patients with or without statin ‘intolerance’. In monotherapy, bempedoic acid reduces LDL-C levels by ~30% and by about 50% in combination with ezetimibe. Bempedoic acid is currently being tested in phase III trials and some trials have been completed.^{341,342}

8.11.2 New approaches to reduce triglyceride-rich lipoproteins and their remnants

As genetic studies indicate that angiotensin-like protein 3 (ANGPTL3) deficiency protects against atherosclerotic disease and that this relationship is causal,³⁴³ an ANGPTL3 antibody (evinacumab) is being developed. Evinacumab has been shown to decrease TGs, LDL-C, and Lp(a) levels in HoFH patients.³⁴⁴ Another approach that is currently being investigated is the inhibition of ANGPTL3 production by antisense oligonucleotides.³⁴⁵ IONIS-ANGPTL3-LRx, an antisense oligonucleotide targeting ANGPTL3, another critical protein in the clearance of TRLs, reduces plasma TGs by about 85%. Thus, the future may yield tools to improve TRL clearance that will be reflected in the atherogenic load of the remnant particles.

The rapid development of gene-silencing technology has allowed proteins (ApoC-III) that are critical in the regulation of TRL clearance processes to be targeted. A second-generation antisense oligonucleotide targeting ApoC-III mRNA has been developed.³⁴⁶ Two phase III trials have evaluated the safety and efficacy of volanesorsen in patients with elevated TG levels.^{347,348} Volanesorsen reduced plasma TGs by ~70% and ApoC-III by 80–90%.³⁴⁹ The EMA recently issued a marketing authorization for Waylivra (volanesorsen) as an adjunct to diet in adult patients with genetically confirmed familial chylomicronaemia syndrome (FCS) who are at high-risk for pancreatitis, in whom response to diet and TG-lowering therapy has been inadequate.

8.11.3 New approaches to increase high-density lipoprotein cholesterol

Although genetic studies suggest that low HDL-C levels are not a cause of ASCVD, casting doubt on the possibilities of future treatment options to raising HDL-C levels with attenuation of CVD, major developments in the search for efficacious agents to raise HDL-C and ApoA1 levels with concomitant benefits on atherosclerosis and CV events are on the horizon. On the one hand, interest is focused on ApoA1 mimetic peptides and recombinant forms of HDL possessing potential for *in vivo* HDL particle remodelling and enhanced cardioprotective activity.³⁵⁰ On the other, agents that enhance catabolism of TG-rich lipoproteins, such as the antisense oligonucleotide to ApoC-III, and which lead to a concomitant reduction in TGs (~70%) and a marked elevation in HDL-C (~40%) in hypertriglyceridemia, are under development.³⁵¹ Importantly, however, we currently lack understanding of the relationship between the modality of raising HDL/ApoA-I levels and a possible antiatherogenic function of HDL particles.

8.11.4 New approaches to reduce lipoprotein(a) levels

Another approach under study is the selective decrease of Lp(a) concentrations. RNA-based therapies are now being evaluated in clinical settings. Results from studies of an antisense oligonucleotide in patients with normal Lp(a) values as well as in patients with elevated Lp(a) concentrations have shown a reduction of >90%.³⁵² These approaches are currently being evaluated in phase II–III studies and an outcome trial is planned to study whether Lp(a) reduction translates into risk reduction.

8.12 Strategies to control plasma cholesterol

Although LDL-C goals are attained with monotherapy in many patients, a significant proportion of patients at high-risk or with very high LDL-C levels need additional treatment. In this case, combination therapy is reasonable. In patients at very-high risk and with persistent high-risk despite being treated with a maximally tolerated statin, combination with ezetimibe is recommended and, if still not at goal, the addition of a PCSK9 inhibitor is recommended (see *Figure 4* and *Recommendations for pharmacological low-density lipoprotein cholesterol lowering*). Of note, addition of a PCSK9 inhibitor directly to a statin is also feasible^{120,290} (*Figure 4*).

As shown in *Figure 3*, the expected clinical benefit of treatment to lower the LDL-C level of any person can be estimated; it depends on the intensity of therapy, the baseline LDL-C level, and the baseline estimated risk of ASCVD. This simple algorithm can be used to help clinicians select the appropriate therapy and quantify the expected benefits of LDL-C-lowering therapy to help inform discussions with patients. For ease of reference, *Supplementary Table 3* provides a summary of the absolute LDL-C reductions that can be achieved with various therapeutic approaches at particular baseline levels of LDL-C.

8.13 Strategies to control plasma triglycerides

Although CVD risk is increased when fasting TGs are >1.7 mmol/L (>150 mg/dL),⁵⁶ the use of drugs to lower TG levels may only be considered in high-risk patients when TGs are >2.3 mmol/L (>200 mg/dL) and TGs cannot be lowered by lifestyle measures. The available pharmacological interventions include statins, fibrates, PCSK9 inhibitors, and n-3 PUFAs. A meta-analysis of 10 trials included people treated with various agents that reduce serum TGs (fibrates, niacin, and n-3 PUFAs) and reported a 12% reduction in CV

Recommendations for pharmacological low-density lipoprotein cholesterol lowering

Recommendations	Class ^a	Level ^b
It is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the goals set for the specific level of risk. ^{32,34,38}	I	A
If the goals ^c are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended. ³³	I	B
For primary prevention patients at very-high risk, but without FH, if the LDL-C goal is not achieved on a maximum tolerated dose of a statin and ezetimibe, a combination with a PCSK9 inhibitor may be considered.	IIb	C
For secondary prevention, patients at very-high risk not achieving their goal ^c on a maximum tolerated dose of a statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended. ^{119,120}	I	A
For very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who do not achieve their goal ^c on a maximum tolerated dose of a statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended.	I	C
If a statin-based regimen is not tolerated at any dosage (even after rechallenge), ezetimibe should be considered. ^{197,265,353}	IIa	C
If a statin-based regimen is not tolerated at any dosage (even after rechallenge), a PCSK9 inhibitor added to ezetimibe may also be considered. ^{197,265,353}	IIb	C
If the goal ^c is not achieved, statin combination with a bile acid sequestrant may be considered.	IIb	C

ASCVD = atherosclerotic cardiovascular disease; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.

^aClass of recommendation.

^bLevel of evidence.

^cFor definitions see *Table 7*.




Figure 3 Expected clinical benefits of low-density lipoprotein cholesterol-lowering therapies. The expected clinical benefits of treatment to lower low-density lipoprotein cholesterol for any person can be estimated; it depends on the intensity of therapy, the baseline low-density lipoprotein cholesterol level, the expected absolute achieved reduction in low-density lipoprotein cholesterol, and the baseline estimated risk of atherosclerotic cardiovascular disease. The intensity of therapy should be selected to achieve the recommended proportional reduction in low-density lipoprotein cholesterol based on the person's estimated risk of atherosclerotic cardiovascular disease. Multiplying the proportional reduction in low-density lipoprotein cholesterol by a person's baseline low-density lipoprotein cholesterol level estimates the expected absolute reduction in low-density lipoprotein cholesterol that is likely to be achieved with that therapy. Because each 1.0 mmol/L absolute reduction in low-density lipoprotein cholesterol is associated with a 20% reduction in the risk of cardiovascular events, larger absolute reductions in low-density lipoprotein cholesterol lead to larger proportional reductions in risk. Multiplying the proportional reduction in risk expected for the achieved absolute reduction in low-density lipoprotein cholesterol by a person's estimated baseline risk of atherosclerotic cardiovascular disease determines the expected absolute risk reduction for that person. LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.




Figure 4 (A) Treatment algorithm for pharmacological low-density lipoprotein cholesterol lowering. (B) Treatment goals for low-density lipoprotein cholesterol across categories of total cardiovascular disease risk. ASCVD = atherosclerotic cardiovascular disease; BP = blood pressure; CKD = chronic kidney disease; CV = cardiovascular; DM = diabetes mellitus; eGFR = estimated glomerular filtration rate; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9; SCORE = Systematic Coronary Risk Estimation; T1DM = type 1 DM; T2DM = type 2 DM; TC = total cholesterol.

outcomes.³⁵⁴ Recently, the REDUCE-IT trial¹⁹⁴ demonstrated that in statin-treated patients with high CV risk with fasting TG levels between 135–499 mg/dL (1.52–1.63 mmol/L), high-dose icosapent ethyl, a highly purified and stable EPA (2 g) taken b.i.d., significantly reduced the risk of ischaemic events, including CV death, by about one-quarter over a median follow-up of 4.9 years. In addition, the VITAL trial showed that n-3 fatty acids at the lower dose of 1 g/day were not effective for primary prevention of CV or cancer events among healthy middle-aged men and women over 5 years of follow-up.³³³ Recommendations for the treatment of HTG are shown below.

Recommendations for drug treatment of patients with hypertriglyceridaemia

Recommendations	Class ^a	Level ^b
Statin treatment is recommended as the first drug of choice to reduce CVD risk in high-risk individuals with hypertriglyceridaemia [TG levels >2.3 mmol/L (>200 mg/dL)]. ³⁵⁵	I	B
In high-risk (or above) patients with TG levels between 1.5–5.6 mmol/L (135–499 mg/dL) despite statin treatment, n-3 PUFAs (icosapent ethyl 2×2 g/day) should be considered in combination with a statin. ¹⁹⁴	IIa	B
In primary prevention patients who are at LDL-C goal with TG levels >2.3 mmol/L (>200 mg/dL), fenofibrate or bezafibrate may be considered in combination with statins. ^{305–307,356}	IIb	B
In high-risk patients who are at LDL-C goal with TG levels >2.3 mmol/L (>200 mg/dL), fenofibrate or bezafibrate may be considered in combination with statins. ^{305–307,356}	IIb	C

CVD = cardiovascular disease; LDL-C = low-density lipoprotein cholesterol; PUFA = polyunsaturated fatty acids; TG = triglyceride.

^aClass of recommendation.

^bLevel of evidence.

© ESC 2019

9 Management of dyslipidaemias in different clinical settings

9.1 Familial dyslipidaemias

Plasma lipid levels are, to a very large extent, determined by genetic factors. In its more extreme forms this is manifested as familial dyslipidaemias. A number of monogenic lipid disorders have been identified;

among these, FH is the most common and is strongly related to CVD (Table 11). In general, in a patient with dyslipidaemia, the pattern of inheritance commonly does not suggest that there is a major single gene (monogenic) disorder causing the abnormality; rather, it stems from the inheritance of more than one gene variant affecting lipoprotein metabolism that, on its own, might have relatively little effect, but in combination with another or others has a greater influence on TC, TGs, or HDL-C. The pattern of inheritance is polygenic.³⁵⁷ It is common to find that high LDL-C, high TG, or low HDL-C levels affect several family members.

9.1.1 Familial combined hyperlipidaemia

Familial combined hyperlipidaemia (FCH) is a highly prevalent mixed dyslipidaemia (1:100–200) characterized by elevated levels of LDL-C, TGs, or both, and is an important cause of premature CAD. FCH is a complex disease, and the phenotype is determined by the interaction of multiple susceptibility genes and the environment. It has considerable overlap with the dyslipidaemic phenotypes of T2DM and MetS. Even within a family, the phenotype shows high inter- and intra-personal variability based on lipid values (TGs, LDL-C, HDL-C, and ApoB). FCH has no monogenic component and is not linked to a single genetic cause, but the phenotype is high LDL-C and/or high TGs.^{358,359} Therefore, the diagnosis is commonly missed in clinical practice; the combination of ApoB >120 mg/dL and TGs >1.5 mmol/L (>133 mg/dL) with a family history of premature CVD can be used to identify people who most probably have FCH.³⁶⁰

The concept of mixed dyslipidaemia is also valuable clinically in assessing CV risk. It emphasizes both the importance of considering family history in deciding how rigorously to treat dyslipidaemia and that elevated LDL-C levels portend a higher risk when HTG is also present. Statin treatment decreases CV risk by the same relative amount in people with HTG as in those without. Because the absolute risk is often greater in those with HTG, they may therefore benefit greatly from LDL-lowering therapy.

9.1.2 Familial hypercholesterolaemia

9.1.2.1 Heterozygous familial hypercholesterolaemia. FH is a common codominant monogenic dyslipidaemia causing premature CVD due to lifelong elevation of plasma levels of LDL-C. If left untreated, men and women with HeFH typically develop early CAD before the ages of 55 and 60 years respectively. The risk of CHD among individuals with definite or probable HeFH is estimated to be increased at least 10-fold. However, early diagnosis and appropriate treatment can dramatically reduce the risk for CAD.

The prevalence of HeFH in the population is estimated to be 1/200–250,³⁶¹ translating to a total number of cases between 14–34 million worldwide.^{362,363} Only a minor fraction of these cases is identified and properly treated.

Table 11 Genetic disorders of lipoprotein metabolism

Disorder	Prevalence	Gene(s)	Effect on lipoproteins
HeFH	1 in 200–250	<i>LDLR</i> <i>APO B</i> <i>PCSK9</i>	↑LDL-C
HoFH	1 in 160 000–320 000	<i>LDLR</i> <i>APO B</i> <i>PCSK9</i>	↑↑LDL-C
FCH	1 in 100/200	<i>USF1</i> + modifying genes	↑LDL-C ↑VLDL-C ↑ApoB
Familial dysbetalipoproteinaemia	1 in 5000	<i>APO E</i>	↑↑IDL and chylomicron remnants (βVLDL)
Familial lipoprotein lipase deficiency (familial chylomicron syndrome)	2 in 10 ⁶	<i>LPL</i> <i>APO C2</i> <i>ApoAV</i> , <i>GPIHBP1</i> <i>LMF1</i>	↑↑chylomicrons and VLDL-C
Tangier disease (analphalipoproteinaemia)	1 in 10 ⁶	<i>ABCA1</i>	↓↓HDL-C
Familial LCAT deficiency	1 in 10 ⁶	<i>LCAT</i>	↓HDL-C

Apo = apolipoprotein; FCH = familial combined hyperlipidaemia; HDL-C = high-density lipoprotein cholesterol; HeFH = heterozygous familial hypercholesterolaemia; HoFH = homozygous familial hypercholesterolaemia; IDL = intermediate-density lipoprotein; LCAT = lecithin cholesterol acyltransferase; LDL-C = low-density lipoprotein cholesterol; VLDL = very low-density lipoprotein cholesterol.

© ESC 2019

Downloaded from https://academic.oup.com/eurheartj/article/41/11/1155/56353 by guest on 12 May 2021

Table 12 Dutch Lipid Clinic Network diagnostic criteria for familial hypercholesterolaemia

Criteria	Points
1) Family history	
First-degree relative with known premature (men aged <55 years; women <60 years) coronary or vascular disease, or first-degree relative with known LDL-C above the 95th percentile	1
First-degree relative with tendinous xanthomata and/or arcus cornealis, or children aged <18 years with LDL-C above the 95th percentile	2
2) Clinical history	
Patient with premature (men aged <55 years; women <60 years) CAD	2
Patient with premature (men aged <55 years; women <60 years) cerebral or peripheral vascular disease	1
3) Physical examination^a	
Tendinous xanthomata	6
Arcus cornealis before age 45 years	4
4) LDL-C levels (without treatment)	
LDL-C ≥8.5 mmol/L (≥325 mg/dL)	8
LDL-C 6.5–8.4 mmol/L (251–325 mg/dL)	5
LDL-C 5.0–6.4 mmol/L (191–250 mg/dL)	3
LDL-C 4.0–4.9 mmol/L (155–190 mg/dL)	1
5) DNA analysis	
Functional mutation in the <i>LDLR</i> , <i>apoB</i> , or <i>PCSK9</i> genes	8
Choose only one score per group, the highest applicable; diagnosis is based on the total number of points obtained	
A 'definite' FH diagnosis requires >8 points	
A 'probable' FH diagnosis requires 6–8 points	
A 'possible' FH diagnosis requires 3–5 points	

CAD = coronary artery disease; FH = familial hypercholesterolaemia; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.

^aExclusive of each other (i.e. maximum 6 points if both are present).

© ESC 2019

FH is a monogenic disease caused by loss-of-function mutations in the *LDLR* or *apoB* genes, or a gain-of-function mutation in the *PCSK9* gene; around 95% of FH cases are caused by mutations in *LDLR*. More than 1000 different mutations that cause FH have been identified in *LDLR*. The different mutations cause reduced function or complete loss-of-function, the latter being associated with more severe hypercholesterolaemia and CVD.

The diagnosis of FH is usually based on clinical presentation. The commonly used criteria from the Dutch Lipid Clinic Network are shown in Table 12. Other criteria are the Simon Broome register or the WHO criteria.^{364,365}

The diagnosis can be verified by showing causative mutations in the pathogenic genes. However, in most studies, the frequency of detectable mutations in patients with a clinically definite or probable HeFH is between 60–80%. This suggests that a considerable proportion of patients with FH have either a polygenic cause of the disease or that other genes, yet to be identified, are involved.

Genetic testing and cascade screening. Proband (index cases) should be identified according to the following criteria:

- TC ≥ 8 mmol/L (≥ 310 mg/dL) without treatment in an adult or adult family member (or >95 th percentile by age and gender for country);
- Premature CHD in the patient or a family member;
- Tendon xanthomas in the patient or a family member; or
- Sudden premature cardiac death in a family member.

Cascade screening of family members of a known index case allows for the efficient identification of new cases. Cascade screening is best performed by a lipid clinic. In most families, the cases may be identified with TC or LDL-C analysis; however, genetic testing is recommended when the causative mutation is known.

Cholesterol-lowering treatment should be initiated as soon as possible after a diagnosis has been made. To improve risk assessment, the use of imaging techniques to detect asymptomatic atherosclerosis is recommended. The concept of cumulative cholesterol burden illustrates the importance of early treatment (for children, see below). Treatment should be initiated with high-intensity statin therapy, in most cases in combination with ezetimibe. In FH patients at very-high risk of ASCVD due to a prior history of ASCVD or another major risk factor, LDL-C goals are a $\geq 50\%$ reduction of LDL-C from baseline and an LDL-C < 1.4 mmol/L (< 55 mg/dL). In the absence of ASCVD or another major risk factor, patients with FH are categorized as high-risk, and LDL-C goals are a $\geq 50\%$ reduction of LDL-C from baseline and an LDL-C < 1.8 mmol/L (< 70 mg/dL).

PCSK9 inhibitors lower LDL-C levels by up to 60% on top of statins. Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH.^{119,120} PCSK9 inhibitors are recommended in very-high-risk patients with FH if the treatment goal is not achieved on maximal tolerated statin plus ezetimibe. PCSK9 inhibitors are also recommended in FH patients who cannot tolerate statins.^{366,367}

Recommendations for the detection and treatment of patients with HeFH are shown below.

Recommendations for the detection and treatment of patients with heterozygous familial hypercholesterolaemia

Recommendations	Class ^a	Level ^b
It is recommended that a diagnosis of FH is considered in patients with CHD aged < 55 years for men and < 60 years for women, in people with relatives with premature fatal or non-fatal CVD, in people with relatives who have tendon xanthomas, in people with severely elevated LDL-C [in adults > 5 mmol/L (> 190 mg/dL), in children > 4 mmol/L (> 150 mg/dL)], and in first-degree relatives of FH patients.	I	C
It is recommended that FH should be diagnosed using clinical criteria and confirmed, when possible, via DNA analysis.	I	C
Once the index case is diagnosed, family cascade screening is recommended.	I	C
It is recommended that FH patients with ASCVD or who have another major risk factor are treated as very-high-risk, and that those with no prior ASCVD or other risk factors are treated as high-risk.	I	C
For FH patients with ASCVD who are at very-high risk, treatment to achieve a $\geq 50\%$ reduction from baseline and an LDL-C < 1.4 mmol/L (< 55 mg/dL) is recommended. If goals cannot be achieved, a drug combination is recommended.	I	C
In primary prevention, for individuals with FH at very-high risk, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of < 1.4 mmol/L (< 55 mg/dL) should be considered.	IIa	C
Treatment with a PCSK9 inhibitor is recommended in very-high-risk FH patients if the treatment goal is not achieved on maximal tolerated statin plus ezetimibe.	I	C
In children, testing for FH is recommended from the age of 5 years, or earlier if HoFH is suspected.	I	C
Children with FH should be educated to adopt a proper diet and treated with a statin from 8–10 years of age. Goals for treatment should be LDL-C < 3.5 mmol/L (< 135 mg/dL) at > 10 years of age.	IIa	C

ASCVD = atherosclerotic cardiovascular disease; CHD = coronary heart disease; CVD = cardiovascular disease; FH = familial hypercholesterolaemia; HoFH = homozygous FH; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.

^aClass of recommendation.

^bLevel of evidence.

9.1.2.2 Homozygous familial hypercholesterolaemia. HoFH is a rare and life-threatening disease. The clinical picture is characterized by extensive xanthomas, marked premature and progressive CVD, and TC >13 mmol/L (>500 mg/dL). Most patients develop CAD and aortic stenosis before the age of 20 years and die before 30 years of age. The frequency of HoFH is estimated to be 1/160 000–1/320 000. The early identification of these children and prompt referral to a specialized clinic is crucial. The patients should be treated with intensive LDL-lowering drug therapy and, when available, with lipoprotein apheresis. This treatment (every 1–2 weeks) can decrease plasma LDL-C levels by 55–70%. The procedure frequency may be adjusted for each patient as lipid levels, symptoms, and other disease-related parameters change. Maximally tolerated pharmacological therapy must be maintained.³⁶⁸ For a more detailed discussion on HoFH, see the EAS consensus statements.^{366,368}

9.1.2.3 Familial hypercholesterolaemia in children. FH is diagnosed in children based on phenotypic criteria including elevated LDL-C plus a family history of elevated LDL-C, premature CAD, and/or positive genetic testing.³⁶⁹ Testing during childhood is optimal to discriminate between FH and non-FH using LDL-C. In children with a family history of high cholesterol or premature CHD, an accepted cut-off is ≥ 4.0 mmol/L (≥ 160 mg/dL). If a parent has a known genetic defect, the diagnostic level for the child is ≥ 3.5 mmol/L (≥ 130 mg/dL). If possible, genetic testing of the child is suggested.

Although there have been no placebo-controlled trials in children, observational studies have suggested that early treatment can reduce LDL-C burden, improve endothelial function, substantially attenuate the development of atherosclerosis, and improve coronary outcomes.^{369–371} Treatment of children with FH includes a healthy lifestyle and statin treatment. A heart-healthy diet should be adopted early in life and statin treatment should be considered at 6–10 years of age. Statin treatment should be started with low doses and the dose should be increased to reach goals.³⁷² The goal in children >10 years of age is an LDL-C <3.5 mmol/L (<135 mg/dL) and at younger ages a $\geq 50\%$ reduction of LDL-C.

9.1.3 Familial dysbetalipoproteinaemia

Familial dysbetalipoproteinaemia (i.e. type III hyperlipoproteinaemia; remnant removal disease) is rare and is generally inherited as an autosomal recessive disorder with variable penetrance. Familial dysbetalipoproteinaemia produces a characteristic clinical syndrome in which both TC and TGs are elevated before treatment, usually both in the range of 7–10 mmol/L. In severe cases, patients develop tuberoeruptive xanthomas, particularly over the elbows and knees, and palmar xanthomata in the skin creases of the hands and wrists. The risk of CAD is very high, and accelerated atherosclerosis of the femoral and tibial arteries is also prevalent. The syndrome is usually not expressed at a young age or in women before menopause. The majority of cases are homozygous for the E2 isoform of ApoE. ApoE is important for the hepatic clearance of chylomicron remnants and IDL. ApoE2 binds less readily than the E3 and E4 isoforms to hepatic receptors. However, without some coincidental cause of dyslipidaemia such as dyslipidaemia associated with HTG, DM, obesity, or hypothyroidism,^{373–375} ApoE2 homozygosity does not generally cause familial dysbetalipoproteinaemia.

The detection of ApoE2 homozygosity in a dyslipidaemic patient is diagnostic and analysis of ApoE isoforms is now available in most clinical laboratories. The presence of cholesterol remnants characteristic of familial dysbetalipoproteinaemia can be reliably predicted on the basis of plasma levels of cholesterol, TGs, and ApoB.³⁷⁶ If suspicion is confirmed, ApoE genotyping can be performed. In older patients with xanthomata resembling those of familial dysbetalipoproteinaemia who prove not to be homozygous for ApoE2, a paraprotein should be sought. The treatment of familial dysbetalipoproteinaemia should be undertaken in a specialist clinic. Most cases respond well to treatment with a statin or, if dominated by high TGs, a fibrate; often a combination of a statin and a fibrate may be needed.

9.1.4 Genetic causes of hypertriglyceridaemia

Although the genetic aetiology for HTG seems to be very complex, recent data have extended our genetic understanding of HTG, in particular that of chylomicronaemia.^{37,226,377} Moderate elevation of TG levels (between 2.0–10.0 mmol/L) is caused by the polygenic effect of multiple genes influencing both VLDL production and removal. Monogenic severe HTG causes chylomicronaemia, pancreatitis, and lipid deposits. Thus far, mutations in six genes (*LPL*, *apoC2*, *apoA5*, *LMF1*, *GPIHBP1*, and *GPD1*) with monogenic effects have been recognized to lead to severe elevation of serum TGs due to disruption of the chylomicron removal pathways. These mutations are inherited as autosomal recessive traits and are rare. The profound defect in the catabolism of chylomicrons and VLDL results in chylomicronaemia and TG levels >11.2 mmol/L (>1000 mg/dL), with turbid and milky serum. Severe HTG is seen in patients who are homozygous or compound heterozygous for mutations of the enzyme LPL, and in other genes linked to the catabolism of TG-rich lipoproteins. Heterozygous carriers of these same gene mutations commonly express moderate elevations of serum TG levels that expose them to increased CVD risk.³⁷⁸ Recently, gene therapy for LPL deficiency has been developed and tested in clinical trials,³⁷⁹ and the alipogene tiparvovec was approved by the EMA in 2013. However, this therapy is no longer available. A gain-of-function mutation in *apoC3* that leads to high ApoC-III levels can also cause severe HTG by inhibiting the activity of LPL, whereas loss-of-function mutations are associated with a favourable lipid profile with low TG levels.³⁸⁰ These findings have raised the possibility of ApoC-III being a novel lipid drug target.

9.1.4.1 Action to prevent acute pancreatitis in severe hypertriglyceridaemia. The risk of pancreatitis is clinically significant if TGs are >10 mmol/L (880 mg/dL), particularly when occurring in association with familial chylomicronaemia, and actions to prevent acute pancreatitis are mandatory.^{381,382} Notably, HTG is the cause of $\sim 10\%$ of all cases with pancreatitis, and patients can develop pancreatitis even when their TG concentration is 5–10 mmol/L (440–880 mg/dL). Recent data from a prospective cohort study reported that the risk of acute pancreatitis increased significantly over the quartiles of serum TGs, highlighting the fact that, as a risk factor, serum TGs may have been underestimated.³⁸³ Any factor that increases VLDL production can aggravate the risk of pancreatitis, with alcohol consumption being the most common contributing factor. Either a patient should be admitted to hospital if symptomatic, or careful and close follow-up of the patient's TG values should be

undertaken. Restriction of calories and fat content (10–15% recommended) in the diet, and alcohol abstinence are obligatory. Fibrate therapy (fenofibrate) should be initiated, with n-3 fatty acids (2–4 g/day) as adjunct therapy. Lomitapide may also be considered in severe cases.³⁷ In patients with DM, insulin therapy should be initiated to achieve good glycaemic control. In general, a sharp decrease of TG values is seen within 2–5 days. In the acute setting, plasmapheresis is able to rapidly lower TG levels.³⁸⁴ Volanesorsen has been recently approved by the EMA as an adjunct to diet in adult patients with genetically confirmed FCS who are at high-risk for pancreatitis.

9.1.5 Other genetic disorders of lipoprotein metabolism

Sometimes patients are encountered with extremely low levels of LDL-C or HDL-C. The most common form of genetic hypolipidaemia is hypobetalipoproteinaemia, which is dominantly inherited and often due to truncation of ApoB. Serum LDL-C is typically between 0.5–1.5 mmol/L (20–60 mg/dL). A more profound deficiency of ApoB occurs in abetalipoproteinaemia when steatorrhea, and neurological or other complications require specialist treatment. Almost absent levels of HDL-C occur in Tangier disease (analphalipoproteinaemia) and very low levels of HDL-C occur in lecithin cholesterol acyltransferase (LCAT) deficiency. Both these conditions are associated with distinct clinical syndromes and require specialist investigation. Very high levels of HDL-C are detected in patients with CETP deficiency. In the heterozygous form, levels of 2.0–2.3 mmol/L (80–90 mg/dL) are typically observed, and levels ≥ 5 mmol/L (≥ 200 mg/dL) are observed in homozygotes. This is not associated with atherosclerotic disease and may be associated with reduced risk.

Lysosomal acid lipase deficiency or cholesterol ester storage disease (in children with Wolman disease) is a rare cause (recessive transmission) of elevated LDL-C and low HDL-C, accompanied by hepatomegaly and microvesicular hepatosteatosis. Statin treatment does decrease LDL-C levels and could therefore prevent ASCVD in these patients, but it cannot stop the progression of liver damage. Treatment with a PCSK9 inhibitor may lead to an even greater overload of lysosomes.³⁸⁵ Enzyme replacement therapy with sebelipase alfa might offer a treatment solution in the near future.³⁸⁶

9.2 Women

Few randomized trials of statin therapy have reported independently significant CV benefits in women,^{387,389} chiefly because women have not been adequately represented in statin trials.

9.2.1 Effects of statins in primary and secondary prevention

There has previously been controversy over whether statins are effective for primary prevention in women. Using published data, a 2013 Cochrane analysis showed that statin therapy reduced all-cause mortality, vascular events, and revascularizations in primary prevention, and the proportional effects in women were similar to those in men.²¹³ The CTT collaboration has provided a more complete assessment of the evidence through a comprehensive analysis of IPD from 22 trials of statins vs. control and five trials of more- vs. less-intensive statin therapy.³⁵ Overall, 46 675 (27%) of 174 149 participants were women, and after adjustment for non-gender differences, the proportional reductions per mmol/L reduction in LDL-C in major

vascular events, major coronary events, coronary revascularization, and stroke were similar in women and men.³⁵

9.2.2 Non-statin lipid-lowering drugs

Definitive evidence of the cardioprotective effects of non-statin drugs that lower LDL-C is now available, and the beneficial effects are similar in both women and men. In the IMPROVE-IT study,³³ the relative benefit of adding ezetimibe to simvastatin was similar in women and men.³³ In the ACCORD lipid study, there was no evidence that fenofibrate added to the effects of simvastatin in patients with T2DM,³⁰⁶ but an analysis of the FIELD study showed consistent CV event reduction in both women and men.³⁸⁹ Several outcome trials assessing the effects of adding a PCSK9 inhibitor to high-intensity statin therapy have now been reported, with similar proportional reductions in major vascular events in women and men.^{120,286,290}

9.2.3 Hormone therapy

Currently prescribed third-generation, low-dose oestrogen–progestin oral contraceptives do not appear to increase adverse coronary events³⁹⁰ and can be used, after baseline lipid profile assessment, in women with acceptable TC levels. In contrast, alternative contraceptive measures should be recommended in women with hypercholesterolaemia [LDL-C >4 mmol/L (>160 mg/dL)] or with multiple risk factors, and in those at high-risk of thrombotic events.³⁹¹ Oestrogen replacement therapy, despite some favourable effects on lipid profiles, has not been demonstrated to reduce CV risk and cannot be recommended for CVD prevention in women.³⁹² No lipid-lowering drugs should be administered during pregnancy and the period of breastfeeding because data on possible adverse effects are lacking. However, bile acid sequestrants may be considered.

Box 6 lists the main measures in the management of dyslipidaemia in women.

Box 6 Management of dyslipidaemia in women

Statin treatment is recommended for primary prevention of ASCVD in high-risk women.^{34,35}

Statins are recommended for secondary prevention in women with the same indications and goals as in men.^{34,35}

Lipid-lowering drugs should not be given when pregnancy is planned, during pregnancy, or during the breastfeeding period. However, for severe FH patients, bile acid sequestrants (which are not absorbed) and/or LDL apheresis may be considered.

ASCVD = atherosclerotic cardiovascular disease; FH = familial hypercholesterolaemia; LDL = low-density lipoprotein.

9.3 Older people

The proportion of older people (defined herein as those aged >65 years) in society is increasing and, as a consequence, $>80\%$ of individuals who die from CVD are >65 years of age. The proportion of patients with MI >85 years of age has increased several-fold.³⁹³

A meta-analysis of observational studies has shown that higher TC is associated with increased CAD mortality at all ages.^{62,394} However, since the absolute risk of CAD is higher in older persons,

the associated absolute increase in risk for a given increment in TC is larger with increasing age.²¹⁷

9.3.1 Effects of statins in primary and secondary prevention

The use of statin therapy declines with increasing age, reflecting differences in both prescription and compliance.^{395,396} This trend is even more prominent among older patients who do not have evidence of occlusive vascular disease.³⁹⁶ One explanation for this pattern may be uncertainty about the effects of statins in older people due to the relatively small number of people aged >75 years who have been included in statin trials.^{233,397,398} The CTT collaboration recently provided a comprehensive assessment of the randomized evidence on the effects of statin therapy at different ages.²¹⁷ Among 186 854 participants in 28 trials, 14 483 (8%) were aged >75 years at randomization. Overall, statin therapy produced a 21% relative reduction in major vascular events (relative risk 0.79, 95% CI 0.77–0.81) per 1.0 mmol/L reduction in LDL-C, and there was direct evidence of benefit among those aged >75 years. The relative reduction in major vascular events was similar, irrespective of age, among patients with pre-existing vascular disease, but appeared smaller among older individuals not known to have vascular disease. Therefore, the available evidence from trials indicates that statin therapy produces significant reductions in major vascular events irrespective of age. However, there is less direct evidence of benefit among patients aged >75 years who do not already have evidence of occlusive vascular disease, and this limitation is currently being addressed by the STAtin therapy for Reducing Events in the Elderly (STAREE) trial in Australia.

9.3.2 Adverse effects, interactions, and adherence

The safety and adverse effects of statins are a matter of special concern in older adults because they often have comorbidities, take multiple medications, and have altered pharmacokinetics and pharmacodynamics. Statin–drug interactions are a concern, primarily because of their potential to increase muscle-related statin-associated adverse effects such as myalgia without CK elevation, myopathy with CK elevation, and the rare but serious rhabdomyolysis. It is recommended that a statin is started at a low dose if there is significant renal impairment and/or the potential for drug interactions, and then titrated upwards to achieve LDL-C treatment goals.

The recommendations for the treatment of dyslipidaemias in older people are shown below.

Recommendations for the treatment of dyslipidaemias in older people (aged >65 years)

Recommendations	Class ^a	Level ^b
Treatment with statins is recommended for older people with ASCVD in the same way as for younger patients. ²¹⁷	I	A
Treatment with statins is recommended for primary prevention, according to the level of risk, in older people aged ≤75 years. ²¹⁷	I	A
Initiation of statin treatment for primary prevention in older people aged >75 years may be considered, if at high-risk or above. ²¹⁷	IIb	B
It is recommended that the statin is started at a low dose if there is significant renal impairment and/or the potential for drug interactions, and then titrated upwards to achieve LDL-C treatment goals.	I	C

ASCVD = atherosclerotic cardiovascular disease; LDL-C = low-density lipoprotein cholesterol.

^aClass of recommendation.

^bLevel of evidence.

9.4 Diabetes and metabolic syndrome

The number of people with DM will increase from ~415 million today up to 550 million by 2030, but the situation may get even worse.³⁹⁹ Despite significant advantages in the management strategies that lessen atherosclerotic CVD risk factors, CVD has remained the leading cause of morbidity and mortality in patients with T2DM. The good news is that fatal CVD outcomes have declined significantly in both T1DM and T2DM between 1998 and 2014.⁴⁰⁰ DM itself is an independent risk factor for CVD and is associated with a higher risk of CVD, even more so in women. The difference in CVD risk between individuals with and without DM has narrowed substantially over the last few decades,⁴⁰¹ and there are strong associations between DM and vascular outcomes.^{402,403} Recent data indicate that DM *per se* increases CVD risk about two-fold on average, but the risk is subject to wide variation depending on the population and current aggressive prophylactic therapy.^{401,404} Importantly, those with DM and CAD are at substantially higher CVD risk for future events. In T2DM, the risk of ASCVD is strongly determined by the presence of target organ damage—including nephropathy (microalbuminuria), neuropathy, or retinopathy—with the risks increasing in relation to the number of conditions present.⁴⁰⁵ Hypertension, dyslipidaemia, abdominal obesity, and non-alcoholic fatty liver disease (NAFLD) commonly coexist with T2DM and further aggravate the risk, which is highest in people with T2DM and multiple cardiometabolic risk factors.^{406–408} Importantly, DM confers excess mortality risk following ACS despite modern therapies, highlighting the poor prognosis of coronary patients with T2DM and the need for intensive therapy.⁴⁰⁹

How to capture the extra risk beyond the traditional risk factors in clinical practice is a debated issue. A practical approach is that if one component is identified, a systematic search should be made for the others.⁴¹⁰

9.4.1 Specific features of dyslipidaemia in insulin resistance and type 2 diabetes mellitus

Diabetic dyslipidaemia is a cluster of plasma lipid and lipoprotein abnormalities that are metabolically interrelated. The increase in large VLDL particles in T2DM initiates a sequence of events that generates atherogenic remnants, small dense LDL, and small TG-rich dense HDL particles.⁴¹¹ These components are not isolated abnormalities but are closely linked to each other. Both LDL and HDL particles show variable compositional changes that are reflected in their functions. Notably, ApoC-III levels are increased in people with T2DM.⁴¹² High ApoC-III concentrations prevent

the clearance of both TRLs and remnants, resulting in prolonged residence times of these particles in the circulation.^{413,414} In fact, the defective catabolism of TRLs seems to be a more important contributor to the elevation of plasma TGs than the increased production rate leading to an excess of remnant particles. Together, TRL remnants, small dense LDL, and small dense HDL comprise the atherogenic lipid profile, which is also characterized by an increase in ApoB concentration due to an increased number of ApoB-containing particles. Importantly, TRLs—including chylomicrons, VLDL, and their remnants—carry a single ApoB molecule, also like LDL particles. Therefore, the malignant nature of diabetic dyslipidaemia is not always revealed by the lipid measures used in clinical practice, as LDL-C levels may remain within the normal range. It may be better revealed by non-HDL-C levels.⁴¹⁵ Elevation of TGs or low HDL-C levels in the fasting or post-prandial state is seen in about one-half of all people with T2DM,^{416,417} and is also often present in people with abdominal adiposity, insulin resistance or impaired glucose tolerance.⁴¹³

Box 7 summarizes dyslipidaemia in MetS and T2DM.

Box 7 Summary of dyslipidaemia in metabolic syndrome and type 2 diabetes mellitus

Dyslipidaemia represents a cluster of lipid and lipoprotein abnormalities, including elevation of both fasting and post-prandial TG, ApoB, and small dense LDL, and low HDL-C and ApoA1 levels.

Non-HDL-C or ApoB are good markers of TRLs and remnants, and are a secondary objective of therapy. Non-HDL-C <2.6 mmol/L (<100 mg/dL) and ApoB <80 mg/dL are desirable in those at high-risk, and non-HDL-C <2.2 mmol/L (<85 mg/dL) and ApoB <65 mg/dL in those at very high-risk. For those at very high-risk with recurrent ASCVD events, a goal of non-HDL-C <1.8 mmol/L (<70 mg/dL) and ApoB <55 mg/dL may be considered.

Atherogenic dyslipidaemia is one of the major risk factors for CVD in people with type 2 diabetes, and in people with abdominal obesity and insulin resistance or impaired glucose tolerance.

Apo = apolipoprotein; ASCVD = atherosclerotic cardiovascular disease; CVD = cardiovascular disease; HDL-C = high-density lipoprotein cholesterol; LDL-C = low-density lipoprotein cholesterol; TG = triglyceride; TRLs = triglyceride-rich lipoproteins.

9.4.2 Evidence for lipid-lowering therapy

9.4.2.1 Low-density lipoprotein cholesterol. LDL-C is the primary target of lipid-lowering therapy in patients with DM. Trials specifically performed in people with T2DM, as well as subsets of individuals with DM in major statin trials, have consistently demonstrated significant benefits of statin therapy on CVD events in people with T2DM.⁴¹⁸ Statin therapy reduces the 5 year incidence of major CVD events by 23% per 1 mmol/L reduction in LDL-C, regardless of the initial LDL-C level or other baseline characteristics based on meta-analysis.⁴¹⁸ The CTT meta-analysis further indicates that people with T2DM will have a relative risk reduction that is comparable to that seen in non-diabetic patients; however, being at higher absolute risk, the absolute benefit will be greater, resulting in a lower number needed to treat (NNT). Thus, statin therapy is the first-line treatment for LDL-C lowering and for the reduction of CVD burden.⁴¹⁹

Ezetimibe lowers LDL-C by ~24% and, when added to statin therapy, decreases the risk of major vascular events.³³ The relative risk reduction in major vascular events is proportional to the absolute degree of LDL-C lowering and consistent with the relationship seen for statins. The subset of patients with DM in IMPROVE-IT had, as expected, a higher rate of major vascular events than patients without DM (46 vs. 31% 7 year Kaplan–Meier rate in the placebo arm). Ezetimibe appeared particularly efficacious in patients with DM, with a relative risk reduction of 15% (95% CI 6–22%) and an absolute risk reduction of 5.5%.²⁹⁹

The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDL-C levels by ~60% and, when added to statin therapy, decrease the risk of major vascular events.¹¹⁹ In the FOURIER study, the relative risk reduction for major vascular events was similar in patients with and without DM; however, given the higher baseline risk in patients with DM, the absolute risk reductions tended to be greater in patients with DM (2.7% absolute decrease in major vascular events over 3 years).²⁹⁷ Of note, the achieved LDL-C in the evolocumab arm was 0.8 mmol/L. The same benefits were also recently demonstrated for diabetic patients after ACS in the ODYSSEY trial.⁴²⁰

Recent studies have suggested an increased incidence of DM in patients treated with statins.²⁴⁷ These observations have been seen in Mendelian randomization studies and in clinical trials, although the effect appears greatest in patients already at high risk for DM (e.g. those with pre-diabetes). These observations should not lessen our attention to the treatment of patients, as the overall benefits in CV event reduction remain and greatly outweigh the increased incidence of DM. In RCTs, neither ezetimibe nor the PCSK9 inhibitors have been reported to increase the risk of DM.²⁹⁷

9.4.2.2 Triglycerides and high-density lipoprotein cholesterol. Lifestyle modification provides the first option to improve atherogenic dyslipidaemia due to its multifaceted effects. Weight loss is, in most cases, the most effective measure since it is associated with very pronounced effects on plasma TG and HDL levels, together with a modest decrease in TC and LDL-C levels. Moderate-to-heavy aerobic exercise is also associated with improvement of the plasma lipid profile by reducing TG levels and increasing HDL-C concentrations. In relation to diet composition, besides the need to eliminate trans fat, the available evidence supports the reduction of saturated fat intake and its substitution with unsaturated fat, as well as the replacement of a major proportion of refined starchy foods and simple sugars with fibre-rich foods like fruits, vegetables, and wholegrains.¹⁷⁹

The clinical benefits achieved by the treatment of high TG and low HDL-C levels (frequently seen with DM) are still a matter of debate, as the effects of fenofibrate therapy on the major outcome (MACE) remained negative in both the FIELD and the ACCORD studies performed in T2DM cohorts.^{306,307} In a *post hoc* analysis of the FIELD study, fenofibrate reduced CVD events by 27% in those with elevated TGs [\sim 2.3 mmol/L (200 mg/dL)] and increased HDL-C levels (NNT = 23).⁴¹⁶ The ACCORD trial confirmed the following: patients who had both TG levels in the higher third [\sim 2.3 mmol/L (200 mg/dL)] and an HDL-C level in the lower third [\leq 0.4 mmol/L (\leq 34 mg/dL)], representing 17% of all participants, appeared to benefit from the addition of fenofibrate to simvastatin.³⁰⁶

Recently, post-trial follow-up of the ACCORD lipid trial participants reported the beneficial effect of fenofibrate in people with

HTG and low HDL-C levels at baseline.⁴²¹ Consistent with these findings, a meta-analysis of fibrates in the prevention of CVD in 11 590 people with T2DM showed that fibrates significantly reduced the risk of non-fatal MI by 21%, but had no effect on the risk of overall mortality or coronary mortality.⁴²² In CV outcome trials of fibrates, the risk reduction has appeared to simply be proportional to the degree of non-HDL-C lowering.⁵⁰

Overall, available data indicate that diabetic patients with atherogenic dyslipidaemia may derive clinical benefits from TG-lowering therapy as an add-on to statin treatment.³⁵⁴ The ongoing PROMINENT trial is exploring the efficacy of pemafibrate, a new selective PPAR- α modulator, in reducing CVD outcomes in ~10 000 diabetic patients with atherogenic dyslipidaemia on a statin.^{317,423}

There are limited data on the impacts on CVD of adding omega-3 fatty acids to statin therapy in patients with high plasma TG levels who are treated with statins. The REDUCE-IT trial examined the effects of icosapent ethyl 2 g b.i.d. on CV events in 8179 high-risk patients with HTG who were taking a statin. Over a median of 4.9 years, there was a significant ($P < 0.001$) 25% reduction in the composite primary outcome of CV death, non-fatal MI, non-fatal stroke, coronary revascularization, or unstable angina, corresponding with an absolute reduction of 4.8%, which was offset by a 1% increased absolute risk of hospitalization for atrial fibrillation or flutter.¹⁹⁴ The STRENGTH trial is investigating the effect of omega-3 fatty acids, in addition to a statin, in individuals with HTG and low HDL-C levels who are at high-risk for CVD. The ASCEND trial was a randomized 2 \times 2 factorial design study of aspirin and omega-3 fatty acid supplements for the primary prevention of CV events in people with DM, but not specifically with HTG. Among 15 480 people randomized to omega-3 fatty acid supplements vs. placebo over a mean follow-up of 7.4 years, there was no significant effect (HR 0.97, 95% CI 0.87–1.08) on serious vascular events [non-fatal MI, non-fatal stroke, transient ischaemic attack (TIA), or vascular death].^{329,424–426}

9.4.3 Type 1 diabetes mellitus

T1DM is associated with high CVD risk, in particular in patients with microalbuminuria and renal disease.⁴²⁷ Conclusive evidence supports the proposition that hyperglycaemia accelerates atherosclerosis. Emerging evidence highlights the frequent coexistence of MetS with T1DM, resulting in the so-called double diabetes increasing CVD risk.⁴²⁸

The lipid profile in T1DM patients with good glycaemic control is 'supernormal', and is characterized by subnormal TG and LDL-C levels, whereas HDL-C levels are usually within the upper normal range or slightly elevated. This is explained by subcutaneous administration of insulin that increases LPL activity in adipose tissue and skeletal muscle, and consequently the turnover rate of VLDL particles.⁴²⁹ However, there are potentially atherogenic changes in the compositions of both HDL and LDL particles.

Consistent data have demonstrated the efficacy of statins in preventing CV events and reducing CV mortality in patients with DM, with no evidence of sex differences.^{430,431} A meta-analysis including 18 686 patients with DM demonstrated that a statin-induced reduction of LDL-C yielded a 9% reduction in all-cause mortality and a 21% reduction in the incidence of major CV events per 1.0 mmol/L (40mg/dL) lower LDL cholesterol.⁴¹⁸ Similar

benefits were seen in patients with T1DM and T2DM. In diabetic patients with ACS, intensive statin treatment led to a reduction in all-cause mortality and CV death, and contributed to a reduction in atheroma progression.⁴³²

9.4.4 Management of dyslipidaemia for pregnant women with diabetes

In both T1DM and young-onset T2DM patients, there is a paucity of evidence to indicate the age at which statin therapy should be initiated. To guide an approach, statins are not indicated in pregnancy,⁴³³ and should be avoided in both T1DM and T2DM individuals who are planning pregnancy. If diabetic individuals aged ≤ 30 years have no evidence of vascular damage and, in particular, microalbuminuria, it seems reasonable to delay statin therapy in asymptomatic patients until the age of 30. Below this age, statin therapy should be managed on a case-by-case basis, taking into account the presence of microalbuminuria, end organ damage, and ambient LDL-C levels.

Recommendations for the treatment of dyslipidaemias in DM are shown in the table below.

Recommendations for the treatment of dyslipidaemias in diabetes mellitus

Recommendations	Class ^a	Level ^b
In patients with T2DM at very-high risk ^c , an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) is recommended. ^{34,418,432}	I	A
In patients with T2DM at high risk, ^c an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) is recommended. ⁴¹⁸	I	A
Statin therapy is recommended in patients with T1DM who are at high or very-high risk. ^{c 427}	I	A
Intensification of statin therapy should be considered before the introduction of combination therapy.	IIa	C
If the goal is not reached, statin combination with ezetimibe should be considered. ^{33,299}	IIa	B
Statin therapy is not recommended in premenopausal patients with diabetes who are considering pregnancy or are not using adequate contraception.	III	C
Statin therapy may be considered in both T1DM and T2DM patients aged ≤ 30 years with evidence of end organ damage and/or an LDL-C level >2.5 mmol/L, as long as pregnancy is not being planned.	IIb	C

LDL-C = low-density lipoprotein cholesterol; T1DM = type 1 diabetes mellitus; T2DM = type 2 diabetes mellitus.

^aClass of recommendation.

^bLevel of evidence.

^cSee Table 6.

9.5 Patients with acute coronary syndromes and patients undergoing percutaneous coronary intervention

Patients who present with ACS are at increased risk of experiencing recurrent CV events. For these patients, lipid management should be undertaken in the context of a comprehensive global risk reduction strategy including lifestyle adaptations, risk factor management, and the implementation of cardioprotective drug strategies. Ideally, patients should be signed up to cardiac rehabilitation programmes to enhance the control of lipid levels⁴³⁴ and improve overall survival following ACS.⁴³⁵ Despite the acknowledged clinical benefits of lowering LDL-C in patients with ACS,⁴³⁶ attainment of LDL-C target values remains suboptimal in this very high-risk setting.⁴³⁷

9.5.1 Lipid-lowering therapy in patients with acute coronary syndromes

LDL-C levels tend to decrease during the first days of ACS and therefore a lipid profile should be obtained as soon as possible after admission for ACS. Patients do not have to be fasting as this has little impact on LDL-C levels.¹⁰⁰ Lipid-lowering treatment should be initiated as early as possible to increase patient adherence after discharge. Lipid levels should be re-evaluated 4–6 weeks after ACS to determine whether treatment goals have been achieved and to check for any safety issues; the therapeutic regimen can then be adapted accordingly.

9.5.1.1 Statins. Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits.^{438–442} We recommend the initiation of high-intensity statin therapy in all statin-naïve ACS patients with no contraindication, regardless of initial LDL-C values; the treatment goal is to reach a 50% LDL-C reduction from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL). In those with recurrent events within 2 years while taking maximally tolerated statin therapy, a goal of <1.0 mmol/L (<40 mg/dL) for LDL-C should be considered. The intensity of statin therapy should be increased in those patients receiving low- or moderate-intensity statin treatment at presentation, unless there is a definite history of intolerance to high-intensity statin therapy. The use of lower-intensity statin therapy should be considered in patients at increased risk of adverse effects with high-intensity statin therapy, such as in the elderly, patients diagnosed with hepatic or renal impairment, or in the case of a potential risk of drug–drug interactions with other essential concomitant therapies.

Regarding the timing of statin treatment initiation, the Statins Evaluation in Coronary Procedures and Revascularization (SECURE-PCI) randomized, placebo-controlled trial recently assessed the impact of peri-procedural loading with atorvastatin [two loading doses of 80 mg, before and 24 h after the planned percutaneous coronary intervention (PCI)] on MACE at 30 days in 4191 patients with ACS and planned invasive management.⁴⁴³ All patients received atorvastatin 40 mg per day starting 24 h after the second loading dose. The authors found no significant treatment benefit in the overall study population. In a pre-specified analysis, a significant 28% relative risk reduction in MACE was observed among patients who underwent PCI (65% of all patients). The benefit was even more

pronounced (46% relative risk reduction) in a *post hoc* analysis including 865 ST-elevation MI (STEMI) patients undergoing reperfusion by primary PCI.⁴⁴³ Based on current evidence, we recommend the initiation of high-intensity statin therapy during the first 1–4 days of hospitalization for the index ACS.^{438–442} Moreover, pre-treatment (or loading dose for patients already on a statin) with a high-intensity statin should be considered in ACS patients with planned invasive management.⁴⁴³

9.5.1.2 Ezetimibe. In the IMPROVE-IT trial, the addition of ezetimibe to simvastatin therapy provided an additional benefit (6.4% relative risk reduction in the composite clinical endpoint) to post-ACS patients.³³ The clinical benefit of adding ezetimibe was consistent across patient subgroups^{299,444} and also led to a reduction of total CV events,⁴⁴⁵ stroke,⁴⁴⁶ and rehospitalizations.⁴⁴⁷ Patients at higher atherothrombotic risk [as assessed by the TIMI (Thrombolysis In Myocardial Infarction) risk score for secondary prevention] benefited the most from the addition of ezetimibe.⁴⁴⁸ In another randomized, open-label trial including 1734 patients with ACS, the addition of ezetimibe to moderate-intensity statin (pitavastatin 2 mg) therapy failed to improve outcomes overall, but did reduce the composite primary endpoint (death, MI, stroke, unstable angina, and ischaemia-driven revascularization) during 3.9-year follow-up in patients with increased intestinal absorption of cholesterol (as assessed by elevated levels of sitosterol)⁴⁴⁹; however, this finding requires further confirmation.

9.5.1.3 Proprotein convertase subtilisin/kexin type 9 inhibitors. In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up. Results were consistent in the subgroup of patients with a history of MI (81% of all patients).^{119,450} A subanalysis of the FOURIER trial showed that patients who achieved the lowest LDL-C values under PCSK9 treatment also had the lowest risk of future MACE.⁴⁵¹ In the ODYSSEY Outcomes trial, which included 18 924 patients with recent ACS (1–12 months prior to enrolment, median 2.6 months), alirocumab added to statin therapy (89% high-intensity therapy) also resulted in a 15% relative risk reduction in the primary composite endpoint and was associated with a 15% relative reduction in all-cause mortality throughout a 2.8 year follow-up.¹²⁰ No serious side effects or safety concerns were reported in these two large trials. The optimal timing of initiating PCSK9 inhibition after ACS and its impact on clinical outcomes remain to be determined. Regarding the timing of PCSK9 inhibitor treatment initiation, *post hoc* analyses from the FOURIER trial have shown that the closer to the event this is done, the better. Treatment initiation with PCSK9 inhibitors during the acute phase of ACS is under investigation in the EVolocumab for Early Reduction of LDL-cholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS) trial.⁴⁵² Based on current evidence, we recommend the initiation of treatment with PCSK9 inhibitors in patients with ACS who do not reach their respective LDL-C goals (as outlined in Table 7) after 4–6 weeks of maximum tolerated statin and ezetimibe therapy. In patients who present with an ACS and whose LDL-C levels are not at goal, despite already taking a

maximally tolerated statin dose and ezetimibe prior to the event, the addition of a PCSK9 inhibitor early after the event (during the hospitalization for the ACS event if possible) should be considered.

9.5.1.4 n-3 polyunsaturated fatty acids. Oral supplementation with highly purified n-3 PUFAs reduced mortality in survivors of MI in one study [Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Prevenzione (GISSI-P)] but failed to affect clinical outcomes in subsequent trials using contemporary secondary prevention therapies. A recent meta-analysis of available RCTs showed no reduction in mortality, MI, or major vascular events associated with n-3 PUFAs, including the subgroup of patients with known CAD.⁴⁵³ Therefore, routine treatment with n-3 PUFAs cannot be recommended.

9.5.1.5 Cholesteryl ester transfer protein inhibitors. In 2007, a large prospective study using the CETP inhibitor torcetrapib failed to show any clinical benefit in more than 15 000 high-risk patients, and was potentially harmful.³³⁶ The CETP inhibitors dalcetrapib (in >30 000 patients with recent ACS⁶⁵) and evacetrapib (in >12 000 high-risk patients⁶³) were investigated in 2012 and 2017, respectively. Neither clinical study was able to show any clinical benefit associated with CETP inhibitors.⁶⁵ More recently, the REVEAL study investigated anacetrapib in >30 000 patients with atherosclerotic vascular disease and resulted in a lower incidence of MACE compared with placebo after 4 years, with no safety concerns.⁶⁴ However, this compound was not filed for marketing authorization.

9.5.2 Lipid-lowering therapy in patients undergoing percutaneous coronary intervention

In a meta-analysis of 13 randomized studies including 3341 patients who were planned to undergo PCI, pre-treatment with a high-dose statin (statin-naïve patients, 11 studies) or a high-dose statin loading dose reduced the risk of MACE (death, MI, or target vessel revascularization) by 44% both for peri-procedural MI and MACE at 30 days.⁴⁵⁴ In all but one study, PCI was performed in the setting of stable angina or in a non-emergency setting in non-ST elevation ACS (NSTEMI-ACS). One of the studies that was included in the meta-analysis showed an improvement in coronary flow when primary PCI was used for the treatment of STEMI.⁴⁵⁵ A routine strategy of either short pre-treatment or loading (on the background of pre-existing therapy) with a high-dose statin before PCI should be considered in elective PCI or NSTEMI-ACS.^{454,456,457}

In addition, pre-treatment with a statin has also been shown to reduce the risk of contrast-induced acute kidney injury after coronary angiography or intervention.⁴⁵⁸

Recommendations for lipid-lowering therapy in patients with ACS and patients undergoing PCI are summarized below.

Recommendations for lipid-lowering therapy in very-high-risk patients with acute coronary syndromes

Recommendations	Class ^a	Level ^b
In all ACS patients without any contraindication or definite history of intolerance, it is recommended that high-dose statin therapy is initiated or continued as early as possible, regardless of initial LDL-C values. ^{438,440,442}	I	A
Lipid levels should be re-evaluated 4–6 weeks after ACS to determine whether a reduction of ≥50% from baseline and goal levels of LDL-C <1.4 mmol/L (<55 mg/dL) have been achieved. Safety issues need to be assessed at this time and statin treatment doses adapted accordingly.	IIa	C
If the LDL-C goal is not achieved after 4–6 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended. ³³	I	B
If the LDL-C goal is not achieved after 4–6 weeks despite maximal tolerated statin therapy and ezetimibe, the addition of a PCSK9 inhibitor is recommended. ^{119,120}	I	B
In patients with confirmed statin intolerance or in patients in whom a statin is contraindicated, ezetimibe should be considered.	IIa	C
For patients who present with an ACS and whose LDL-C levels are not at goal, despite already taking a maximally tolerated statin dose and ezetimibe, the addition of a PCSK9 inhibitor early after the event (during hospitalization for the ACS event if possible) should be considered.	IIa	C

ACS = acute coronary syndrome; LDL-C = low-density lipoprotein cholesterol; PCSK9 = proprotein convertase subtilisin/kexin type 9.

^aClass of recommendation.

^bLevel of evidence.

Recommendations for lipid-lowering therapy in very-high-risk patients undergoing percutaneous coronary intervention

Recommendations	Class ^a	Level ^b
Routine pre-treatment or loading (on a background of chronic therapy) with a high-dose statin should be considered in patients undergoing PCI for an ACS or elective PCI. ^{443,454,456}	IIa	B

ACS = acute coronary syndrome; PCI = percutaneous coronary intervention.

^aClass of recommendation.

^bLevel of evidence.

9.6 Stroke

Stroke has a heterogeneous aetiology, including cardiac thromboembolism [often associated with atrial fibrillation, but also of uncertain source (embolic stroke of undetermined source)], carotid artery and proximal aortic atherosclerosis and thromboembolism, small-vessel CVD, and intracranial haemorrhage (including intracerebral and subarachnoid haemorrhage). Dyslipidaemia may play a variable role in the pathogenesis of stroke according to the particular aetiology. The relationship between dyslipidaemia and atherothrombotic events, including ischaemic stroke and TIA, is well recognized, while the association of dyslipidaemia with other types of stroke is uncertain. Notwithstanding, concomitant control of other aetiological factors, such as hypertension, is of paramount importance.

Following ischaemic stroke or TIA, patients are at risk not only of recurrent cerebrovascular events, but also of other major CV events, including MI. Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12% per mmol/L reduction in LDL cholesterol), MI, and vascular death.^{459,460} Statin pre-treatment at TIA onset was associated with reduced recurrent early stroke risk in patients with carotid stenosis in a pooled data analysis, supporting as-early-as-possible initiation of statins after stroke.^{460–462} Statin therapy may yield a small increase in the risk of haemorrhagic stroke, but the evidence regarding this risk is uncertain.^{34,36,251,252}

Recommendations for lipid-lowering therapy for the prevention of atherosclerotic cardiovascular disease events in patients with prior ischaemic stroke

Recommendations	Class ^a	Level ^b
Patients with a history of ischaemic stroke or TIA are at very high-risk of ASCVD, particularly recurrent ischaemic stroke, so it is recommended that they receive intensive LDL-C-lowering therapy. ^{459,460}	I	A

ASCVD = atherosclerotic cardiovascular disease; LDL-C = low-density lipoprotein cholesterol; TIA = transient ischaemic attack.

^aClass of recommendation.

^bLevel of evidence.

9.7 Heart failure and valvular diseases

9.7.1 Prevention of incident heart failure in coronary artery disease patients

Cholesterol lowering with statins reduces the incidence of HF in patients with CAD (stable CAD or a history of ACS) without previous HF; this has been shown consistently in RCTs that have compared statin vs. no statin treatment^{463,464} as well as more-intensive vs. less-intensive statin therapy.^{465–468} A large-scale meta-analysis of primary and secondary prevention RCTs with statins showed a modest (10%) reduction in first non-fatal HF hospitalizations with statin treatment, with no effect on HF death within the limited RCT period.⁴⁶⁹ There is no evidence that statins can prevent HF of non-ischaemic origin.

9.7.2 Chronic heart failure

Two large RCTs^{466,470} (mainly including patients with systolic HF), as well as a meta-analysis of 24 RCTs, have shown no benefit of statin treatment on CV mortality or stroke;⁴⁷¹ a reduction in HF

hospitalizations,^{218,471} as well as a small reduction in MI, was observed in a pooled analysis of the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) and GISSI-HF trials.⁴⁷² Based on current evidence, routine administration of statins in patients with HF without other indications for their use (e.g. CAD) is not recommended. Because there is no evidence of harm in patients on statin treatment after the occurrence of HF, there is no need for statin discontinuation for patients already on treatment.

There is no evidence regarding the effect of PCSK9 inhibition in patients with chronic HF. In the recent PCSK9 clinical outcomes trials, FOURIER¹¹⁹ and ODYSSEY Outcomes,¹²⁰ PCSK9 inhibition in patients with atherosclerotic CVD or after an ACS did not reduce the risk of HF hospitalization. In the BIOlogy Study to Tailored Treatment in Chronic Heart Failure (BIOSTAT-CHF) study of 2174 patients with worsening HF, multivariable analysis revealed a positive linear association between PCSK9 levels and the risk of mortality, and the composite of mortality and unplanned HF hospitalization.⁴⁷³ Similarly, there was a negative association between LDLR levels and mortality, indicating a potential relationship between the PCSK9–LDLR axis and outcomes among patients with HF that requires further investigation.^{473,474}

Treatment with n-3 PUFAs 1 g o.d. may confer a small benefit in patients with chronic HF, as shown by a significant 9% relative risk reduction for mortality in the GISSI-HF RCT.⁴⁷⁵

9.7.3 Valvular heart diseases

Aortic stenosis increases the risk of CV events and mortality, and frequently coexists with atherosclerotic CVD. Life-long high levels of LDL-C⁴⁷⁶ and Lp(a)⁴⁷⁷ have been associated with incident aortic valve stenosis and aortic valve calcification in genetic Mendelian randomization studies. Observational studies have suggested possible beneficial effects of intensive lipid lowering in slowing the progression of native valve aortic stenosis.⁴⁷⁸ However, this has not been confirmed in RCTs,^{266,479–481} or in meta-analyses of observational and randomized trials.^{482,483} Three modestly sized trials^{479–481} and one large randomized trial (SEAS, which included 1873 patients treated with simvastatin 40 mg plus ezetimibe 10 mg or placebo)²⁶⁶ failed to show a reduction in the clinical progression of aortic stenosis in patients with mild-to-moderate native valve aortic stenosis. In a *post hoc* analysis of the SEAS trial, the efficacy of lipid-lowering therapy in impeding the progression of aortic stenosis increased with higher pre-treatment LDL-C levels and lower peak aortic jet velocity (i.e. milder stenosis at baseline).⁴⁸⁴ Similarly, a *post hoc* analysis of three RCTs, including patients without known aortic valve stenosis at baseline [Treating to New Targets (TNT), Incremental Decrease In End-points Through Aggressive Lipid-lowering (IDEAL), and Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)] showed no impact of high-dose vs. usual-dose statin therapy on the incidence of aortic valve stenosis.⁴⁸⁵ In patients who underwent transcatheter aortic valve replacement, statin therapy was associated with improved outcomes in a small observational study.⁴⁸⁶

Aortic valve sclerosis (calcification of the aortic leaflets without significant transvalvular pressure gradient) is associated with an increased risk of CAD even in the absence of increased risk profiles. Whether or not statins may be useful both for aortic valve disease and CAD progression in such patients warrants further investigation.⁴⁸⁷

Recommendations for lipid-lowering therapy in patients with HF and valvular diseases are shown below.

Recommendations for the treatment of dyslipidaemias in chronic heart failure or valvular heart diseases

Recommendations	Class ^a	Level ^b
Initiation of lipid-lowering therapy is not recommended in patients with HF in the absence of other indications for their use. ^{466,470}	III	A
Initiation of lipid-lowering treatment in patients with aortic valvular stenosis without CAD to slow progression of aortic valve stenosis in the absence of other indications for their use is not recommended. ^{266,479–481}	III	A

CAD = coronary artery disease; HF = heart failure.

^aClass of recommendation.

^bLevel of evidence.

9.8 Chronic kidney disease

CKD is defined as abnormalities of kidney structure or function, present for >3 months, with implications for health. CKD is classified on the basis of the cause, GFR category, and category of albuminuria.⁴⁸⁸ In the adult population, decreasing GFR is associated with increased CVD risk, independent of other CV risk factors.^{489–492} There is an increased risk of both atherosclerotic vascular disease and structural heart disease.⁴⁹² Patients with CKD and established CVD have a much higher mortality rate compared with patients with CVD and normal renal function.⁴⁹³ Therefore, patients with CKD are considered to be at high (stage 3 CKD) or very-high risk (stage 4–5 CKD or on dialysis) of CVD, and there is no need to use risk estimation models in these patients.

9.8.1 Lipoprotein profile in chronic kidney disease

In the initial stages of CKD, TG levels are specifically elevated and HDL-C levels are lowered. LDL subclasses display a shift to an excess of small dense LDL particles. Studies suggest that the kidney has a role in Lp(a) catabolism and that Lp(a) levels are increased in association with kidney disease. Such acquired abnormalities can be reversed by kidney transplantation or remission of nephrosis.

9.8.2 Evidence for risk reduction through statin-based therapy in patients with chronic kidney disease

In the Die Deutsche Diabetes Dialyse Studie (4D) trial, which involved 1200 patients with diabetes on haemodialysis, atorvastatin had no significant effect on risk of CVD.²²⁰ Similar results were obtained in the AURORA (A study to evaluate the Use of Rosuvastatin in subjects On Regular haemodialysis: an Assessment of survival and cardiovascular events) trial, which involved 2776 patients on haemodialysis.²²¹

In the SHARP study,²²² simvastatin and ezetimibe combination therapy reduced the risk for major atherosclerotic events (coronary death, MI, non-haemorrhagic stroke, or any revascularization) compared with placebo in persons with CKD stage 3A–5. The trial did not have sufficient power to separately assess the effects on the primary outcome in dialysis and non-dialysis patients. Although statin-based therapy is clearly effective in mild-to-moderate CKD, a major controversy that remained after the publication of the 4D, AURORA, and SHARP studies was

whether statin therapy is effective in more advanced CKD, particularly dialysis patients. By combining data from the three CKD trials with other trials in the existing database, the CTT investigators found that, even after adjusting for the smaller LDL-C reductions achieved among patients with more advanced CKD and for differences in outcome definitions between dialysis trials, there was a trend towards smaller relative reductions per mmol/L reduction in LDL-C in major atherosclerotic events as estimated GFR (eGFR) declines (with little evidence of benefit among dialysis patients).²¹⁴ This diminution in relative risk reduction as GFR declines implies that, at least in non-dialysis patients, more intensive LDL-lowering regimens are required to achieve the same benefit.

9.8.3 Safety of lipid management in patients with chronic kidney disease

Safety issues and dose adjustments are important in advanced stages of CKD (stages 3–5), as adverse events are commonly dose-related and due to increased blood concentrations of compounds. Although it has been suggested that preference should be given to regimens and doses that have been shown to be beneficial in RCTs conducted specifically in such patients,⁴⁹⁴ the CTT meta-analysis makes clear that the goal—as in patients without CKD—should be to achieve the largest possible absolute reduction in LDL-C safely. Although there were no specific safety concerns raised by the 4D, AURORA, or SHARP trials, statins metabolized via CYP3A4 may result in adverse effects due to drug–drug interactions and caution is required.

Based on the evidence for lipid management in patients with CKD, the Kidney Disease: Improving Global Outcomes (KDIGO) organization has developed an updated clinical practice guideline for lipid management in CKD.⁴⁹⁴ In line with this, but with a focus on those patients at high or very-high risk for developing CVD, recommendations are summarized below.

Recommendations for lipid management in patients with moderate-to-severe (Kidney Disease Outcomes Quality Initiative stages 3–5) chronic kidney disease

Recommendations	Class ^a	Level ^b
It is recommended that patients with Kidney Disease Outcomes Quality Initiative stage 3–5 ^c CKD are considered to be at high or very-high risk of ASCVD. ^{489–493}	I	A
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent stage 3–5 CKD. ^{214,222,495,496}	I	A
In patients already on statins, ezetimibe, or a statin/ezetimibe combination at the time of dialysis initiation, continuation of these drugs should be considered, particularly in patients with ASCVD.	IIa	C
In patients with dialysis-dependent CKD who are free of ASCVD, commencement of statin therapy is not recommended. ^{220,221}	III	A

ASCVD = atherosclerotic cardiovascular disease; CKD = chronic kidney disease; eGFR = estimated glomerular filtration rate.

^aClass of recommendation.

^bLevel of evidence.

^cDefined as eGFR < 60ml/min/1.73m² on two measurements more than 3 months apart.

9.9 Transplantation

Dyslipidaemias are very common in patients who have undergone heart, lung, liver, kidney, or allogenic haematopoietic stem cell transplantation, and predispose such patients to an increased risk of developing ASCVD and transplant arterial vasculopathy.^{497–501} In patients with CKD undergoing renal transplantation, the risk of ASCVD may be determined, at least in part, by the increased risk resulting from CKD itself.

Immunosuppressive drug regimens may have adverse effects on lipid metabolism leading to increases in TC, VLDL, and TGs, and in the size and density of LDL particles. These effects vary with different immunosuppressive drugs.^{497,498,502–506}

The management of dyslipidaemias in transplant recipients is comparable to what is recommended for patients at high or very high ASCVD risk, although more attention is needed regarding the causes of the lipid disturbances and possible side effects due to drug–drug interactions (see *Recommendations for low-density lipoprotein in solid organ transplant patients* below).

The clinical effectiveness of statins in renal transplant patients is uncertain owing to a lack of randomized trials in this population. A systematic review of the benefits and harms of statins in patients with a functioning kidney transplant included 3465 patients, free of CHD, from 22 studies. Although the authors concluded that statins may reduce CV events, they also suggested a need for additional studies.²⁵³ However, in patients with a functioning renal transplant at increased risk of CVD, it may be appropriate to extrapolate from the clear evidence of benefit from statin therapy, without safety concerns, in people with moderate reductions in GFR.²¹⁴

Several potential drug interactions must also be considered, especially with ciclosporin, which is metabolized through CYP3A4, and may increase systemic statin exposure and the risk of myopathy. Ciclosporin increases the blood levels of all statins.

Fluvastatin, pravastatin, pitavastatin, and rosuvastatin are metabolized through different CYP enzymes than the others and have less potential for interaction.⁵⁰⁷

Tacrolimus is also metabolized by CYP3A4, but appears to have less potential for harmful interaction with statins than ciclosporin. Other drugs that influence CYP3A4 activity should be avoided if possible, and used with extreme caution in patients receiving both calcineurin inhibitors and statins.

For transplant patients with dyslipidaemia, ezetimibe could be considered as an alternative for patients unable to take a statin or added to the highest tolerated statin dose.^{507–509} No outcome data are available for this drug, which should generally be reserved for second-line use. Ciclosporin can induce a 2–12-fold increase in the ezetimibe level.

Care is required with the use of fibrates, as they can decrease ciclosporin levels and have the potential to cause myopathy. Extreme caution is required if fibrate therapy is planned in combination with a statin. Cholestyramine is not effective as monotherapy in heart transplant patients and has the potential to reduce absorption of immunosuppressants; this potential is minimized by separate administration.

Recommendations for low-density lipoprotein lowering in solid organ transplant patients

Recommendations	Class ^a	Level ^b
Statins should be considered as first-line agents in transplant patients. Initiation should be at low doses with careful up-titration and with caution regarding potential drug–drug interactions, particularly for patients on ciclosporin. ⁵⁰⁷	IIa	B
In patients who are intolerant of statins or those with significant dyslipidaemia despite maximally tolerated statin treatment, alternative or additional therapy with ezetimibe may be considered.	IIb	C

^aClass of recommendation.

^bLevel of evidence.

© ESC 2019

9.10 Peripheral arterial disease

PAD encompasses all vascular sites, including carotid, vertebral, upper extremity, mesenteric, renal, and lower extremity arteries. The aorta is often included in the term.⁵¹⁰ PAD is a common manifestation of atherosclerosis and such patients are at elevated risk of coronary events, with PAD representing an independent risk factor for MI and CV death.^{510,511} Patients with PAD are at very-high risk and should be managed according to the recommendations in *Table 7*. Elevated CV risk has led to the inclusion of PAD among the list of ‘risk equivalent’ conditions, and therapeutic strategies of secondary prevention should be implemented [see *Recommendations for lipid-lowering drugs in patients with peripheral arterial disease (including carotid artery disease)* below]. Yet, despite the high CV morbidity and mortality risk, PAD patients are usually inadequately managed compared with CAD patients.⁵¹¹

9.10.1 Lower extremity arterial disease

A low ABI (0.90) is diagnostic for lower extremity arterial disease (LEAD). Either a low (0.90) or high (1.40, related to stiffened arteries) ABI is predictive of CV morbidity and mortality. Lowering LDL-C levels reduces the risk of ischaemic CV events and worsening of claudication, while it also improves walking performance. As for cardiac events, a systematic review of 18 trials including 10 000 patients, with cholesterol levels ranging from normal to elevated, reported that lipid-lowering therapy in people affected by atherosclerosis of the lower limbs was associated with a 20% reduction in total CV events, together with a non-significant 14% reduction of all-cause mortality.⁵¹² In the Heart Protection Study, the need for non-coronary revascularization was reduced by 16% with statin therapy.⁵¹³

In addition to statins, PCSK9 inhibitors have also been shown to reduce CV events in PAD patients. In a pre-specified subgroup analysis of the FOURIER trial, evolocumab significantly reduced the primary endpoint in patients with PAD.⁵¹⁴ PAD had larger absolute risk reductions for the primary endpoint (3.5% with PAD and 1.6% without PAD). Evolocumab also reduced the risk of major adverse limb events by 42% in patients, with consistent effects in those with and without known PAD. In the FIELD trial, fenofibrate reduced the risk of amputations, particularly minor amputations without known large-vessel disease, probably through non-lipid mechanisms.⁵¹⁵

9.10.2 Carotid artery disease

While there are currently no randomized studies that have assessed whether lipid-lowering treatments reduce the incidence of CV events in patients enrolled on the basis of carotid atherosclerotic disease and without previous CV events, lipid-lowering therapy had reduced stroke in numerous studies. In a meta-analysis of RCTs enrolling >90 000 patients, statin therapy did lead to a 21% reduction in the incidence of all strokes in different populations; this effect was mainly driven by the extent of LDL-C reduction.⁴⁶⁰

9.10.3 Retinal vascular disease

Atherosclerotic changes of retinal arteries correlate with TC, LDL-C, TG, and apoB levels and also with CAD.⁵¹⁶ Fenofibrate reduces the progression of diabetic retinopathy.^{517,518}

9.10.4 Secondary prevention in patients with abdominal aortic aneurysm

The presence of an abdominal aortic aneurysm represents a risk-equivalent condition for CAD and is associated with age, male gender, personal history of atherosclerotic CVD, smoking, hypertension, and dyslipidaemia;⁵¹⁹ in contrast, diabetic patients are at decreased risk.

There are currently no available clinical trials on the reduction of CV risk with lipid-lowering therapy in patients affected by this condition. Systematic reviews,⁵²⁰ mostly based on retrospective non-randomized studies, have reported that there is still inconclusive evidence that statin therapy reduces peri-operative CV morbidity and mortality. In an RCT comparing atorvastatin 20 mg with placebo, the composite endpoint of cardiac death, MI, stroke, and unstable angina was significantly reduced in 100 patients undergoing vascular non-cardiac surgery, including abdominal aortic aneurysm repair.⁵²¹ In another double-blind, placebo-controlled trial in 497 patients undergoing vascular surgery, peri-operative fluvastatin therapy (80 mg/day) was associated with an improvement in post-operative cardiac outcome.⁵²²

9.10.5 Renovascular atherosclerosis

Lipid-lowering therapy has never been tested in an RCT in patients affected by renovascular atherosclerosis; however, a recent non-randomized population-based study showed that in patients older than 65 years of age with atherosclerotic renovascular disease raised the hypothesis that such treatment may yield cardiorenal benefits; the risk of a major cardiorenal composite endpoint (MI, stroke, HF, acute renal failure, dialysis, and death) was significantly lower in statin users than in non-users.⁵²³

Recommendations for lipid-lowering drugs in patients with peripheral arterial disease (including carotid artery disease)

Recommendations	Class ^a	Level ^b
In patients with PAD, lipid-lowering therapy, including a maximum tolerated dose of statin, plus ezetimibe or a combination with a PCSK9 inhibitor if needed, is recommended to reduce the risk of ASCVD events. ^{512,524}	I	A

ASCVD = atherosclerotic cardiovascular disease; PAD = peripheral arterial disease; PCSK9 = proprotein convertase subtilisin/kexin type 9.

^aClass of recommendation.

^bLevel of evidence.

9.11 Other special populations at risk of atherosclerotic cardiovascular disease

In general, the effects of lowering LDL-C are determined by the absolute risk of ASCVD and the achieved reduction in LDL-C, so it is important to identify and treat all those at increased risk of ASCVD. There are a few specific groups of patients in whom an underlying disease confers such increased risk, and in addition in whom the standard treatments may themselves cause dyslipidaemia that may contribute to the risk of ASCVD. These include: (i) chronic immune-mediated inflammatory disease, (ii) patients with human immunodeficiency virus (HIV), and (iii) patients with severe mental illness. The management principles are the same in these patient groups, but their management may need to address specific issues related to individual dyslipidaemias and drug safety. Details are provided in the [Supplementary Data](#) document.

10 Inflammation

Recent advances in basic science have established a fundamental role for low-degree chronic inflammation in mediating all stages of atherosclerosis, from initiation through progression and, ultimately, to the rupture of plaque and ensuing thrombotic complications of atherosclerosis. The cellular and molecular interactions involved during atherogenesis are fundamentally not different from those in chronic inflammatory–fibroproliferative diseases, such as rheumatoid arthritis (RA), glomerulosclerosis, or pulmonary fibrosis.⁵²⁵ Almost all cell types of the immuno-inflammatory system, such as macrophages, and T- and B-cells, as well as many pro- and anti-inflammatory cytokines and chemokines, have been identified during the process of atherosclerosis.⁵²⁶

Interestingly, cholesterol accumulation in cells triggers the inflammasome response and results in the production of inflammatory mediators such as interleukin (IL)-1 β . Numerous animal studies, using the knockout model, have demonstrated that inflammation and the immune system both play crucial roles during atherogenesis.⁵²⁷

During inflammatory processes, large numbers of acute-phase proteins have been identified, and several clinical studies have reported C-reactive protein⁵²⁸ to be the most useful serum marker of inflammation, even though it has poor specificity for any particular inflammation process, including atherosclerosis. The high-sensitivity C-reactive protein diagnostic test was developed to detect very low levels of C-reactive protein, and thereby enable a more accurate and precise measure of chronic inflammation compared with standard C-reactive protein.⁵²⁹ This diagnostic tool differs only in the range of C-reactive protein levels that it can detect. Several studies have found that elevated levels of high-sensitivity C-reactive protein in the blood are associated with an increased risk of CV events and could be used to predict clinical outcomes independently of cholesterol levels.^{530,531} Other studies have not been able to show any relationship between low-grade chronic inflammation, as indicated by high-sensitivity C-reactive protein levels, and increased risk of CV.^{532–535} Finally, genetic studies of large population cohorts have not demonstrated that chronic elevated high-sensitivity C-reactive protein increases the risk of atherosclerotic events.⁵³⁶ Nevertheless, in some guidelines, high-sensitivity C-reactive protein has been added to traditional risk factors for prognostic information, especially for patients at intermediate risk.^{537,538}

Statins have been shown to reduce C-reactive protein secretion by hepatocytes,⁵³⁹ and a series of clinical trials and *post hoc* analyses have found that beneficial outcomes after statin therapy relate both to a reduction in cholesterol levels and reduced inflammation.^{540–544} The Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial⁵⁴² demonstrated that in primary prevention for individuals with chronically elevated C-reactive protein (>2 mg/L), statin treatment markedly reduced CV events.⁵⁴⁵ It is of note that other lipid-lowering agents, such as ezetimibe and more recently the anti-PCSK9 mAbs, do not influence high-sensitivity C-reactive protein levels,^{546,547} but lead to further significant reductions in CV events when added to statin therapy.

Specific anti-inflammatory treatment was tested in the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) trial.⁵⁴⁸ In patients with previous MI and chronic elevated high-sensitivity C-reactive protein levels, all on optimal medical treatment, including statins, the anti-IL-1 β mAb canakinumab dose-dependently reduced high-sensitivity C-reactive protein and significantly lowered the rate of recurrent CV events compared with placebo, independently of the level of lipid lowering. Not surprisingly, there was a slight increase in the risk of severe and fatal infections associated with canakinumab. This study was the first to highlight the positive correlation between high-sensitivity C-reactive protein and CV events, where lower achieved high-sensitivity C-reactive protein values were directly correlated with a lower risk of future CV events.⁵⁴⁸ Nevertheless, the FDA declined to approve canakinumab for CV risk reduction on the strength of data from the CANTOS study. As canakinumab treatment has not been tested against anti-PCSK9 mAb and/or ezetimibe added to statin therapy, the question of residual risk remains for patients with elevated high-sensitivity C-reactive protein despite achieving very low (below goal) LDL-C values, and whether patients with very low LDL-C would benefit from anti-IL-1 β treatment or other anti-inflammatory agents. In addition, all currently recommended lipid-lowering drugs, including anti-PCSK9 mAbs, have demonstrated beneficial effects on atherosclerotic plaque composition as well as plaque volume regression; such results are still missing for anti-inflammatory treatment. Another anti-inflammatory approach using methotrexate was tested in the Cardiovascular Inflammation Reduction Trial (CIRT).⁵⁴⁹ Very low-dose methotrexate (10 mg weekly), a proven anti-inflammatory regimen that reduces tumour necrosis factor (TNF), IL-6, and C-reactive protein levels and is widely used in the treatment of RA, was allocated vs. placebo to 7000 stable CAD patients. This study was stopped prematurely due to futility. Interestingly, this regimen of methotrexate had no effect on either IL-6 or high-sensitivity C-reactive protein blood levels in this population, which could explain the neutral results of this trial.⁵⁵⁰ Based on the current level of evidence, no further recommendations on the use of anti-inflammatory agents can be made.⁵⁵¹

11 Monitoring of lipids and enzymes in patients on lipid-lowering therapy

Evidence concerning which tests should be carried out to monitor lipids in patients on treatment is limited. Similar limited evidence

applies to tests of possible toxicity, such as ALT and CK. Recommendations stem from consensus rather than evidence-based medicine.

Response to therapy can be assessed at 6–8 weeks from initiation of therapy, but response to lifestyle may take longer. Standard practice for subsequent follow-up monitoring is 6–12 months, but such monitoring intervals are arbitrary. As a minimum, LDL-C should be assessed whenever available, but better management decisions will probably occur if a full lipid profile is performed, including HDL-C and TGs. Non-HDL-C or ApoB should also be analysed, and used as a secondary treatment target. A separate issue is the impact of regular lipid monitoring in promoting patient adherence to lifestyle changes or drug regimens that impact positively on their health, as found in a range of studies. It is unclear whether only the process of monitoring is critical in achieving this or whether a combination of education, regular contact, and adherence assessment is required.

Where pharmacological lipid-lowering therapy is implemented, safety blood tests are advised, including ALT and CK at baseline, to identify the limited number of patients where treatment is contraindicated. CK should be checked in patients at high-risk for myopathy, such as the very elderly with comorbidities, patients with antecedents of muscle symptoms, or patients receiving interacting drugs. A mild and typically transient elevation of ALT is seen in about 2% of patients and normalization is seen with continuing therapy.^{240,244,552} Recent reviews are encouraging regarding the safety of long-term statin therapy and statin-induced liver injury is reported to be very uncommon.^{243,244,553–555} ALT is recommended before the start of statin therapy; routine control of ALT during treatment is not recommended but should be performed, if indicated, based on clinical observations. During fibrate therapy, regular ALT control is still recommended. In patients whose liver function tests increase to above three times the ULN, explanations such as alcohol ingestion or NAFLD should be sought, and the levels monitored. If levels remain elevated then lipid-lowering therapy should be stopped, but may be cautiously reintroduced under monitoring after levels have returned to normal.

There is no predictive value of routine repeat CK testing for rhabdomyolysis since the level can increase for many reasons, including muscle injury or excess muscular exercise. However, CK must be assessed immediately in patients who present with muscle pain and weakness, and especially in the elderly, and treatment stopped if CK rises to >10 times the ULN. Strategies to handle CK elevations are given in *Table 13*.

Due to the increased frequency of DM during statin treatment,^{247,249,556,557} regular checks of HbA1c should be considered in patients at high-risk of developing DM and under high-dose statin treatment. Groups to be considered for glucose control are the elderly or those with MetS, obesity, or signs of insulin resistance.

12 Cost-effectiveness of cardiovascular disease prevention by lipid modification

In 2015, there were >85 million people in Europe living with CVD.⁵⁵⁸ Aging populations,⁵⁵⁹ unhealthy diets, smoking, sedentary lifestyles,

Table 13 Summary of recommendations for monitoring lipids and enzymes in patients, before and on lipid-lowering therapy

Testing lipids
<p>How often should lipids be tested?</p> <ul style="list-style-type: none"> ● Before starting lipid-lowering drug treatment, at least two measurements should be made, with an interval of 1–12 weeks, with the exception of conditions where prompt drug treatment is suggested, such as ACS and very high-risk patients.
<p>How often should a patient's lipids be tested after starting lipid-lowering treatment?</p> <ul style="list-style-type: none"> ● After starting treatment: 8 (\pm4) weeks. ● After adjustment of treatment: 8 (\pm4) weeks until the goal is achieved.
<p>How often should lipids be tested once a patient has achieved the target or optimal lipid level?</p> <ul style="list-style-type: none"> ● Annually (unless there are adherence problems or other specific reasons for more frequent reviews).
Monitoring liver and muscle enzymes
<p>How often should liver enzymes (ALT) be routinely measured in patients on lipid-lowering drugs?</p> <ul style="list-style-type: none"> ● Before treatment. ● Once, 8–12 weeks after starting a drug treatment or after dose increase. ● Routine control of ALT thereafter is not recommended during statin treatment, unless symptoms suggesting liver disease evolve. During treatment with fibrates, control of ALT is still recommended.
<p>What if liver enzymes become elevated in a person taking lipid-lowering drugs?</p> <p>If ALT $<3 \times$ ULN:</p> <ul style="list-style-type: none"> ● Continue therapy. ● Recheck liver enzymes in 4–6 weeks. <p>If ALT rises to $\geq 3 \times$ ULN</p> <ul style="list-style-type: none"> ● Stop lipid-lowering therapy or reduce dose and recheck liver enzymes within 4–6 weeks. ● Cautious reintroduction of therapy may be considered after ALT has returned to normal. ● If ALT remains elevated check for the other reasons.
<p>How often should CK be measured in patients taking lipid-lowering drugs?</p> <p><i>Pre-treatment</i></p> <ul style="list-style-type: none"> ● Before starting therapy. ● If baseline CK is $>4 \times$ ULN, do not start drug therapy; recheck. <p><i>Monitoring:</i></p> <ul style="list-style-type: none"> ● Routine monitoring of CK is not necessary. ● Check CK if patient develops myalgia. <p>Be alert regarding myopathy and CK elevation in patients at risk, such as: elderly patients, those on concomitant interfering therapy, multiple medications, liver or renal disease, or athletes.</p>
<p>What if CK becomes elevated in a person taking lipid-lowering drugs?</p> <p>Re-evaluate indication for statin treatment.</p> <p>If $\geq 4 \times$ ULN:</p> <ul style="list-style-type: none"> ● If CK $>10 \times$ ULN: stop treatment, check renal function, and monitor CK every 2 weeks. ● If CK $<10 \times$ ULN: if no symptoms, continue lipid-lowering therapy while monitoring CK between 2 and 6 weeks. ● If CK $<10 \times$ ULN: if symptoms present, stop statin and monitor normalization of CK, before rechallenge with a lower statin dose. ● Consider the possibility of transient CK elevation for other reasons such as exertion. ● Consider myopathy if CK remains elevated. ● Consider combination therapy or an alternative drug. <p>If $<4 \times$ ULN:</p> <ul style="list-style-type: none"> ● If no muscle symptoms, continue statin (patient should be alerted to report symptoms; check CK). ● If muscle symptoms, monitor symptoms and CK regularly. ● If symptoms persist, stop statin and re-evaluate symptoms after 6 weeks; re-evaluate indication for statin treatment. ● Consider rechallenge with the same or another statin. ● Consider low-dose statin, alternate day or once/twice weekly dosing regimen, or combination therapy. <p>For details on CK elevation and treatment of muscular symptoms during statin treatment see algorithm in Supplementary Figure 4.</p>
<p>In which patients should HbA1c or blood glucose be checked?</p> <ul style="list-style-type: none"> ● Regular checks of HbA1c or glucose should be considered in patients at high-risk of developing diabetes, and on high-dose statin treatment. ● Groups to be considered for glucose control are the elderly and patients with metabolic syndrome, obesity, or other signs of insulin resistance.

ACS = acute coronary syndrome; ALT = alanine aminotransferase; CK = creatine kinase; ULN = upper limit of normal.

increasing obesity, and diabetes^{560–563} are the main contributors. CVD cost the European Union about €210 billion in 2015, one-half of which was in healthcare costs (~8% of total healthcare expenditure), and the other half in productivity losses and informal care.⁵⁵⁸

In these Guidelines, the Joint Task Force recommends a range of actions to reduce CVD by targeting plasma lipids, ranging from population-wide initiatives to promote healthy lifestyles to individual-level interventions to reduce CVD risk factors, such as unhealthy diets and high lipid levels. Cost-effectiveness analysis can help target resources for interventions where the net health gain is greatest in relation to the net resources, and is increasingly required across Europe.⁵⁶⁴ However, cost-effectiveness depends on available resources, the costs of services, and disease risk in the population, and results obtained in one country might not be valid in another.⁵⁶⁵ In addition, to fully capture the long-term effects of interventions, cost-effectiveness studies combining evidence from RCTs with modelling and limitations in both could affect the reliability of findings. Here, the evidence for the cost-effectiveness of ASCVD preventive interventions with respect to lipid modification is summarized; further scrutiny in view of local circumstances is recommended.

The health impact pyramid summarizes the evidence on the relative effort in relation to health impact (Figure 5), with interventions with the broadest impact on populations at the base and interventions requiring considerable individual effort at the top.⁵⁶⁶ There is consensus that all the levels of the pyramid should be targeted but that emphasis should be placed on the lower levels. This would address the persistent socio-economic divide in CV health despite major improvements in ASCVD treatment.⁵⁵⁸

More than one-half of the reduction in CV mortality over the last three decades has been attributed to population-level changes




Figure 5 Health impact pyramid.

in CV risk factors, primarily reductions in plasma cholesterol, BP levels, and smoking.^{560–563,567} Lifestyle changes at the population level may be more cost-effective than lifestyle and drug interventions at the individual level, particularly when targeted to populations at increased risk. Awareness and knowledge of how lifestyle risk factors lead to CVD has increased in recent decades. Moreover, legislation promoting a healthy lifestyle, such as reduced salt intake and smoking bans, has been reported to be cost-effective in preventing CVD,^{568–573} and initiatives to improve infrastructure and promote physical activity have shown promise.^{574,575} A number of structural strategies at international, national, and regional levels combined can substantially reduce CVD morbidity and mortality.^{576,577} Individual-level interventions to improve diet,^{578,579} increase physical activity,⁵⁸⁰ and stop smoking⁵⁸¹ could also be cost-effective.⁵⁸² However, suboptimal adherence limits benefits,^{583,584} and interventions to improve adherence, such as electronic device reminders to reinforce favourable health behaviours, are increasingly being investigated.⁵⁸⁵

All statin regimens and ezetimibe are now generically available across Europe. There is strong evidence that lowering blood cholesterol levels using low-cost statins is widely cost-effective^{586–590} in many categories of patients. For secondary prevention of CVD, the evidence suggests that statin treatments are highly cost-effective,^{586,590,591} and adding low-cost ezetimibe to high-intensity statin therapy further reduces LDL-C and CVD risk cost-effectively.⁵⁹² In primary ASCVD prevention, the evidence indicates that generic statin-based treatments are cost-effective for people at least down to 1% annual total CVD risk and could be cost-effective at even lower risk,⁵⁸⁹ with the highest tolerated statin dose likely the most cost-effective.^{591,593,594} Importantly, many patients on statin treatment fail to take their medications adequately and/or to reach their therapeutic goals,⁵⁹⁵ with clinical and economic consequences.^{596,597} Reinforcing measures aimed at improving adherence to treatment is cost-effective.^{598–600}

Studies have shown that at mid-2018 prices PCSK9 inhibitors were largely not cost-effective.^{601–604} Their cost-effectiveness is improved in selected high-risk patients, such as those with clinical CVD or FH, other comorbidities, and high LDL-C levels.^{605,606} However, at lower prices, PCSK9 inhibitors would become cost-effective in a wider range of high-risk patients; recent price reductions may therefore lead to increased use.⁶⁰⁷ Cost-effectiveness evidence for other lipid-modifying therapies is lacking.

Effective interventions to prevent ASCVD, including statins, typically exhibit similar relative risk reductions across categories of patients, including by ASCVD risk; therefore, health benefits and cost-effectiveness are greater among people at higher ASCVD risk (Figure 6).^{36,233} Consequently, increased efforts and higher-intensity interventions should be aimed at individuals and populations at higher ASCVD risk.




Figure 6 Absolute reductions in major vascular events with statin therapy.²³³ LDL = low-density lipoprotein. Reproduced from *The Lancet*, 388/10059, Collins et al., 'Interpretation of the evidence for the efficacy and safety of statin therapy', 2532-2561, 2016, with permission from Elsevier.

Box 8 lists the key messages regarding the cost-effectiveness of CVD prevention by lipid modification, and Box 9 highlights gaps in the evidence.

Box 8 Key messages

Prevention of CVD by lifestyle changes, medication, or both is cost-effective in many scenarios, including population-based approaches and actions directed at individuals at increased CVD risk.

Cost-effectiveness depends on several factors, including baseline CVD risk and LDL levels, cost of treatment, and uptake of preventive strategies.

Interventions to prevent CVD are more cost-effective among individuals and populations at higher CVD risk.

Cost-effectiveness analyses are importantly informed by assumptions about long-term disease prognosis and treatment effects. Strengthening of the evidence to inform these assumptions is encouraged.

CVD = cardiovascular disease; LDL = low-density lipoprotein.

Box 9 Gaps in the evidence

Cost-effectiveness requires evidence for effects of interventions on health and healthcare over a long time period; modelling techniques fill gaps. More data are needed from RCTs and observational studies.

Direct evidence of effects of lipid-modifying treatments on overall mortality, particularly among people at low-to-moderate CVD risk, older people, and for newer interventions, is lacking. Long-term post-trial follow-up in RCTs should be encouraged.

The cost-effectiveness of using lifetime CVD risk and more precise CVD risk scores to target interventions needs further investigation.

CVD = cardiovascular disease; RCT = randomized controlled trial.

13 Strategies to encourage adoption of healthy lifestyle changes and adherence to lipid-modifying therapies

Helping patients to change to healthier lifestyle habits is most effectively achieved through formal programmes of preventive care, possibly because of the intensive follow-up and multidisciplinary expertise they provide.⁶⁰⁸ However, in everyday care, adherence to both healthy lifestyle changes and medication regimens is a challenge to patients and professionals.

A comprehensive patient- and family-centred approach located in one healthcare setting is recommended rather than addressing single risk factors with more than one intervention in different locations. Box 10 includes some useful techniques when counselling patients for behavioural change.

Box 10 Methods for enhancing adherence to lifestyle changes

1. Explore motivation and identify ambivalence. Weigh pros and cons for change, assess and build self-efficacy and confidence, and avoid circular discussion.
2. Offer support, and establish an alliance with the patient and his/her family.
3. Involve the partner, other household members, or caregiver who may be influential in the lifestyle of the patient.
4. Use the **OARS** method (**O**pen-ended questions, **A**ffirmation, **R**eflective listening, **S**ummarising when discussing behaviour changes (www.smartrecovery.org/wp-content/uploads/2017/03/UsingMlinSR.pdf).
5. Tailor advice to an individual patient's culture, habits, and situation.
6. Use **SMART** goal setting (negotiate goals for change that are **S**pecific, **M**easurable, **A**chievable, **R**ealistic, and **T**imely). Follow-up on goals and record progress on a shared record.

© ESC 2019

A comprehensive approach to improving adherence to medication is described in the [Supplementary Data](#) document.

14 Key messages

- (3) **Use of cardiac imaging for risk stratification.** CAC score assessment with CT may be helpful in reaching decisions about treatment in people who are at moderate risk of ASCVD. Obtaining such a score may assist in discussions about treatment strategies in patients where the LDL-C goal is not achieved with lifestyle intervention alone and there is a question of whether to institute LDL-C-lowering treatment. Assessment of arterial (carotid or femoral) plaque burden on ultrasonography may also be informative in these circumstances.
- (4) **Use of ApoB in risk stratification.** ApoB may be a better measure of an individual's exposure to pro atherogenic lipoproteins, and hence its use may be particularly helpful for risk assessment in people where measurement of LDL-C underestimates this burden, such as those with high TG, DM, obesity, or very low LDL-C.
- (5) **Use of Lp(a) in risk stratification.** A one-off measurement of Lp(a) may help to identify people with very high inherited Lp(a) levels who may have a substantial lifetime risk of ASCVD. A high Lp(a) plasma level may also be helpful in further risk stratification of patients at high risk of ASCVD, in patients with a family history of premature CVD, and to determine treatment strategies in people whose estimated risk is on the border of risk categories.
- (6) **Intensification of treatment goals.** It is important to ensure that treatment of the highest-risk patients achieves the largest LDL-C reduction possible. These Guidelines aim to support this by setting both a minimum percentage LDL-C reduction (50%) and an absolute LDL-C treatment goal of <1.4 mmol/L (<55 mg/dL) for very-high-risk patients, and <1.8 mmol/L (<70 mg/dL) for high-risk patients. It is recommended that FH patients with ASCVD or who have another major risk factor are treated as very-high-risk, and those with no prior ASCVD or other risk factors as high-risk.
- (7) **Treatment of patients with recent ACS.** New randomized trials support a strategy of intensification of LDL-C-lowering therapy in very-high-risk patients with ACS (MI or unstable angina). If the specified LDL-C treatment goal is not achieved after 4–6 weeks with the highest tolerated statin dose and ezetimibe, it is appropriate to add a PCSK9 inhibitor.
- (8) **Safety of low LDL cholesterol concentrations.** To date there are no known adverse effects of very low LDL-C concentrations [e.g. <1 mmol/L (40 mg/dL)].
- (9) **Management of statin 'intolerance'.** While statins rarely cause serious muscle damage (myopathy, or rhabdomyolysis in the most severe cases), there is much public concern that statins may commonly cause less serious muscle symptoms. Such statin 'intolerance' is frequently encountered by practitioners and may be difficult to manage. However, placebo-controlled randomized trials have shown very clearly that true statin intolerance is rare, and that it is generally possible to institute some form of statin therapy (e.g. by changing the statin or reducing the dose) in the overwhelming majority of patients at risk of ASCVD.
- (10) **Statin treatment for older people.** A meta-analysis of randomized trials has shown that the effects of statin therapy are determined by the absolute reduction in LDL-C as well as the baseline ASCVD risk, and are independent of all known risk factors, including age. Statin therapy in older people should therefore be considered according to the estimated level of risk and baseline

- (1) **Cholesterol and risk.** Prospective studies, randomized trials, and Mendelian randomization studies have all shown that raised LDL-C is a cause of ASCVD. Throughout the range of LDL-C levels, 'lower is better' with no lower threshold, at least down to ~1 mmol/L. Lowering LDL-C may yield worthwhile benefits in patients with average or below average LDL-C who are already receiving LDL-C-lowering treatment. The proportional reduction in ASCVD risk achieved by lowering LDL-C (e.g. with a statin, ezetimibe, or PCSK9-inhibitor) depends on the absolute reduction in LDL-C, with each 1 mmol/L reduction corresponding to a reduction of about one-fifth in ASCVD.
- (2) **PCSK-9 inhibitors.** Large trials have shown that PCSK9 inhibitors further reduce ASCVD risk when given on top of statin-based therapy and their use may need to be restricted to those at the highest risk for ASCVD.

LDL-C, albeit with due regard to an individual's underlying health status and the risk of drug interactions. There is less certainty about the effects of statins in individuals aged >75 years, particularly in primary prevention. Statin therapy should be started at a

low dose if there is significant renal impairment and/or the potential for drug interactions, and then titrated upwards to achieve LDL-C treatment goals.

15 Gaps in the evidence

- Prospective studies are needed to investigate the incremental value of reclassifying total CV risk and defining eligibility for lipid-lowering therapy based on CAC scores in individuals at moderate or high-risk.
- Outcome-based comparisons of CAC scores vs. assessment of arterial (carotid or femoral) plaque burden by ultrasonography for CV risk reclassification in people at moderate or high-risk are needed.
- Although calibrated country-specific versions of the SCORE system are available for many European countries, risk charts based on country-specific cohort data are missing for most countries. Regional total event charts (vs. mortality-only charts) are needed.
- Total CV risk estimation by means of the SCORE system and, accordingly, recommendations on eligibility for statins as well as treatment goals are based on TC, whereas LDL-C is the primary lipid analysis method for screening, diagnosis, and management.
- There are no outcome-based comparisons of LDL-C vs. ApoB as primary measurement methods for screening, diagnosis, and management.
- Against a background of genetic and randomized clinical trial evidence showing no significant effect of increasing HDL levels on the risk of CVD events, the clinical impact of therapies altering the function of HDL particles is unknown. More evidence is needed regarding the apparently adverse association of extremely high levels of HDL-C with clinical outcomes.
- Dedicated studies assessing outcomes with specific Lp(a)-lowering therapies are warranted.
- More evidence is needed for PCSK9 inhibitors in specific populations, including patients with severe CKD and on dialysis, patients with HIV infection, in children and adolescents with FH, after heart transplantation, and during pregnancy.
- The effects of PCSK9 inhibition on specific body compartments (as with siRNA or antisense) or only within plasma (as with monoclonal antibodies) remain to be established.
- How early should a PCSK9 inhibitor be initiated in patients with ACS or stroke? In view of evidence of sustained clinical benefit associated with the early initiation of statin treatment in the acute phase of ACS or stroke, the optimal timing of PCSK9 inhibitor treatment in ACS and stroke patients remains to be addressed in outcome studies.
- Whether very low LDL-C levels achieved with the combination of statin, ezetimibe, and PCSK9 inhibitor reduce the need for further PCI remains to be addressed in outcome studies.
- In patients with chronic HF, a small benefit of n-3 PUFAs has been shown in one RCT and merits further investigation.
- What is the optimal screening programme for detecting FH?
- In view of limited access to genetic testing in several environments, more evidence is needed regarding outcomes with only clinical vs. genetic screening and diagnosis of FH.
- More RCT evidence is required to support the use of statin-based treatment in older people (aged ≥ 75 years, but particularly in those aged ≥ 80 years).
- More RCT evidence is needed for statin treatment in kidney transplant recipients.
- There are no data on the effects of statins, ezetimibe, or fibrates on CV events in dyslipidaemic HIV-infected patients.
- More evidence is needed regarding attainment of recommended LDL goals among very high-risk patients in real-world practice in the era of increasingly prescribed combination therapies for LDL lowering.

16 'What to do' and 'what not to do' messages from the Guidelines

Recommendations	Class ^a	Level ^b
CVD risk estimation		
Total risk estimation using a risk estimation system such as SCORE is recommended for asymptomatic adults aged >40 years without evidence of CVD, DMCKD, FH, or LDL > 4.9 mmol/L (>190 mg/dL).	I	C
High- and very-high-risk individuals may be identified on the basis of documented CVD, DM, moderate-to-severe renal disease, very high levels of individual risk factors, FH, or a high SCORE risk, and are a priority for advice and management of all risk factors.	I	C
Risk scores developed for the general population are not recommended for CV risk assessment in patients with DM or FH.	III	C
Lipid analyses for CVD risk estimation		
TC is to be used for the estimation of total CV risk by means of the SCORE system.	I	C
HDL-C analysis is recommended to further refine risk estimation using the online SCORE system.	I	C
LDL-C analysis is recommended as the primary lipid analysis method for screening, diagnosis, and management.	I	C
TG analysis is recommended as a part of the routine lipid analysis approach.	I	C
Non-HDL-C evaluation is recommended for risk assessment, particularly in people with high TG levels, DM, obesity, or very low LDL-C levels.	I	C
ApoB analysis is recommended for risk assessment, particularly in people with high TG levels, DM, obesity, or MetS, or very low LDL-C levels. It can be used as an alternative to LDL-C, if available, as the primary measurement for screening, diagnosis, and management, and may be preferred over non-HDL-C in people with high TG levels, DM, obesity, or very low LDL-C levels.	I	C
Treatment goals for LDL-C		
In secondary prevention for patients at very-high risk, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.	I	A
In primary prevention for individuals at very-high risk, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.4 mmol/L (<55 mg/dL) are recommended.	I	C
In patients at high risk, an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of <1.8 mmol/L (<70 mg/dL) are recommended.	I	A
Pharmacological LDL-C lowering		
It is recommended that a high-intensity statin is prescribed up to the highest tolerated dose to reach the goals set for the specific level of risk.	I	A
If the goals are not achieved with the maximum tolerated dose of a statin, combination with ezetimibe is recommended.	I	B
For secondary prevention in patients at very-high risk not achieving their goal on a maximum tolerated dose of a statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended.	I	A
For very-high-risk FH patients (that is, with ASCVD or with another major risk factor) who do not achieve their goal on a maximum tolerated dose of a statin and ezetimibe, a combination with a PCSK9 inhibitor is recommended.	I	C
Drug treatment of patients with HTG		
Statin treatment is recommended as the first drug of choice for reducing CVD risk in high-risk individuals with HTG [TGs >2.3 mmol/L (>200 mg/dL)].	I	B
Management of patients with HeFH		
It is recommended that a diagnosis of FH is considered in patients with CHD aged <55 years for men and <60 years for women, in people with relatives with premature fatal or non-fatal CVD, in people with relatives having tendon xanthomas, in people with severely elevated LDL-C levels [in adults >5 mmol/L (>190 mg/dL), in children >4 mmol/L (>150 mg/dL)], and in first-degree relatives of FH patients.	I	C
It is recommended that FH is diagnosed using clinical criteria and confirmed, when possible, with DNA analysis.	I	C
Once the index case is diagnosed, family cascade screening is recommended.	I	C
It is recommended that FH patients with ASCVD or who have another major risk factor are treated as very-high-risk, and those with no prior ASCVD or other risk factors as high-risk.	I	C

Continued

For FH patients with ASCVD who are at very-high risk, treatment to achieve a $\geq 50\%$ reduction from baseline and an LDL-C < 1.4 mmol/L (< 55 mg/dL) is recommended. If goals cannot be achieved, a drug combination is recommended.	I	C
Treatment with a PCSK9 inhibitor is recommended in very-high risk FH patients if the treatment goal is not achieved on a maximal tolerated statin plus ezetimibe.	I	C
In children, testing for FH is recommended from the age of 5 years, or earlier if HoFH is suspected.	I	C
Treatment of dyslipidaemias in older people		
Treatment with statins is recommended for older people with ASCVD in the same way as for younger patients.	I	A
Treatment with statins is recommended for primary prevention, according to the level of risk, in older people aged ≤ 75 years.	I	A
It is recommended that the statin is started at a low dose if there is significant renal impairment and/or the potential for drug interactions, and then titrated upwards to achieve LDL-C treatment goals.	I	C
Treatment of dyslipidaemias in DM		
In patients with T2DM at very-high risk, ^c an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of < 1.4 mmol/L (< 55 mg/dL) is recommended.	I	A
In patients with T2DM at high risk, ^c an LDL-C reduction of $\geq 50\%$ from baseline and an LDL-C goal of < 1.8 mmol/L (< 70 mg/dL) is recommended.	I	A
Statins are recommended in patients with T1DM who are at high or very-high risk. ^c	I	A
Statin therapy is not recommended in pre-menopausal patients with or without DM who are considering pregnancy, or not using adequate contraception.	III	C
Management of patients with ACS		
In all ACS patients without any contraindication or definite history of intolerance, it is recommended that high-dose statin therapy is initiated or continued as early as possible, regardless of initial LDL-C values.	I	A
If the LDL-C goal is not achieved after 4–6 weeks with the maximally tolerated statin dose, combination with ezetimibe is recommended.	I	B
If the LDL-C goal is not achieved after 4–6 weeks despite maximal tolerated statin therapy and ezetimibe, adding a PCSK9 inhibitor is recommended.	I	B
Lipid-lowering therapy for prevention of ASCVD events in patients with prior ischaemic stroke		
Patients with a history of ischaemic stroke or TIA are at very-high risk of ASCVD, particularly recurrent ischaemic stroke, so it is recommended that they receive intensive LDL-C-lowering therapy.	I	A
Treatment of dyslipidaemias in chronic HF or valvular heart diseases		
Initiation of lipid-lowering therapy is not recommended in patients with HF in the absence of other indications for their use.	III	A
Initiation of lipid-lowering treatment is not recommended in patients with aortic valvular stenosis without CAD to slow progression of aortic valve stenosis in the absence of other indications for their use.	III	A
Lipid management in patients with moderate-to-severe (Kidney Disease Outcomes Quality Initiative stages 3–5) CKD		
It is recommended that patients with stage 3–5 CKD are considered to be at high or very-high risk of ASCVD.	I	A
The use of statins or statin/ezetimibe combination is recommended in patients with non-dialysis-dependent stage 3–5 CKD.	I	A
In patients with dialysis-dependent CKD who are free of ASCVD, commencement of statin therapy is not recommended.	III	A
Lipid-lowering drugs in patients with PAD (including carotid artery disease)		
In patients with PAD, lipid-lowering therapy—including a maximum tolerated dose of a statin, plus ezetimibe, or a combination with a PCSK9 inhibitor if needed—is recommended to reduce the risk of ASCVD events.	I	A
Lipid-lowering drugs in patients with CIID		
The use of lipid-lowering drugs only on the basis of the presence of CIID is not recommended.	III	C
Lipid-lowering drugs in patients with SMI		
It is recommended that SMIs are used as modifiers for estimating total ASCVD risk.	I	C
It is recommended that the same guidelines for the management of total ASCVD risk are used in patients with SMI as are used in patients without such disease.	I	C
It is recommended that in patients with SMI, intensified attention is paid to adherence to lifestyle changes and to compliance with drug treatment.	I	C

ACS = acute coronary syndrome(s); Apo = apolipoprotein; ASCVD = atherosclerotic cardiovascular disease; CAD = coronary artery disease; CHD = coronary heart disease; CIID = chronic immune-mediated inflammatory diseases; CKD = chronic kidney disease; CV = cardiovascular; CVD = cardiovascular disease; DM = diabetes mellitus; FH = familial hypercholesterolaemia; HDL-C = high-density lipoprotein cholesterol; HeFH = heterozygous FH; HF = heart failure; HoFH = homozygous FH; HTG = hypertriglyceridaemia; LDL-C = low-density lipoprotein cholesterol; MetS = metabolic syndrome; PAD = peripheral arterial disease; PCSK9 = proprotein convertase subtilisin/kexin type 9; SCORE = Systematic Coronary Risk Estimation; SMI = severe mental illness; TC = total cholesterol; TG = triglycerides; TIA = transient ischaemic event; T1DM = type 1 DM; T2DM = type 2 DM.

^aClass of recommendation.

^bLevel of evidence.

17 Supplementary data

Supplementary Data with additional **Supplementary Tables**, Boxes, and text complementing the full text—as well as sections on other features of a healthy diet contributing to cardiovascular disease prevention, chronic immune-mediated inflammatory diseases, HIV patients, severe mental illness, and adhering to medications along with the related references—are available on the *European Heart Journal* website and via the ESC website at www.escardio.org/guidelines.

18 Appendix

Author/Task Force Member Affiliations:

Konstantinos C. Koskinas, Cardiology, Bern University Hospital (Inselspital), Bern, Switzerland; **Manuela Casula**, Epidemiology and Preventive Pharmacology Service (SEFAP), Department of Pharmacological and Biomolecular Sciences (DiSFeB), University of Milan, Milan, Italy and IRCCS MultiMedica, Sesto S. Giovanni (Milan), Italy; **Lina Badimon**, Cardiovascular Program-ICCC and CiberCV, IR-Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; **M. John Chapman**, National Institute for Health and Medical Research (INSERM), Paris, France; Sorbonne University, Paris, France; and Division of Endocrinology- Metabolism, Pitie-Salpetriere University Hospital, Paris, France; **Guy G. De Backer**, Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, Ghent, Belgium; **Victoria Delgado**, Cardiology, Leiden University Medical Center, Leiden, Netherlands; **Brian A. Ference**, Centre for Naturally Randomized Trials, Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom; **Ian M. Graham**, Cardiology, Trinity College, Dublin, Ireland; **Alison Halliday**, Nuffield Department of Surgery, University of Oxford, Oxford, United Kingdom and NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom; **Ulf Landmesser**, Department of Cardiology, Charite Universitätsmedizin Berlin, Berlin, Germany; Berlin Institute of Health (BIH), Berlin, Germany; and German Center of Cardiovascular Research (DZHK), Berlin, Germany; **Borislava Mihaylova**, Nuffield Department of Population Health and NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom and Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom; **Terje R. Pedersen**, Preventive Cardiology, Oslo University Hospital, Aker, Oslo, Norway; **Gabriele Riccardi**, Clinical Medicine and Surgery, Federico II University, Naples, Italy; **Dimitrios J. Richter**, Cardiac Department, Euroclinic, Athens, Greece; **Marc S. Sabatine**, TIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States of America; **Marja-Riitta Taskinen**, Research Program for Clinical and Molecular Metabolism, University of Helsinki, Helsinki, Finland; **Lale Tokgozoglu**, Cardiology, Hacettepe University, Ankara, Turkey; **Olov Wiklund**, Institute of Medicine, The Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden.

ESC Committee for Practice Guidelines (CPG): Stephan Windecker (Chairperson) (Switzerland), Victor Aboyans (France),

Colin Baigent (United Kingdom), Jean-Philippe Collet (France), Veronica Dean (France), Victoria Delgado (Netherlands), Donna Fitzsimons (United Kingdom), Chris P. Gale (United Kingdom), Diederick E. Grobbee (Netherlands), Sigrun Halvorsen (Norway), Gerhard Hindricks (Germany), Bernard Jung (France), Peter Juni (Canada), Hugo A. Katus (Germany), Ulf Landmesser (Germany), Christophe Leclercq (France), Maddalena Lettino (Italy), Basil S. Lewis (Israel), Bela Merkely (Hungary), Christian Mueller (Switzerland), Steffen Petersen (United Kingdom), Anna Sonia Petronio (Italy), Dimitrios J. Richter (Greece), Marco Roffi (Switzerland), Evgeny Shlyakhto (Russian Federation), Iain A. Simpson (United Kingdom), Miguel Sousa-Uva (Portugal), Rhian M. Touyz (United Kingdom).

ESC National Cardiac Societies actively involved in the review process of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Algeria: Algerian Society of Cardiology, Djamaledine Nibouche; **Armenia:** Armenian Cardiologists Association, Parounak H. Zelveian; **Austria:** Austrian Society of Cardiology, Peter Siostrzonek; **Azerbaijan:** Azerbaijan Society of Cardiology, Ruslan Najafov; **Belgium:** Belgian Society of Cardiology, Philippe van de Borne; **Bosnia and Herzegovina:** Association of Cardiologists of Bosnia and Herzegovina, Belma Pojskic; **Bulgaria:** Bulgarian Society of Cardiology, Arman Postadzhiyan; **Cyprus:** Cyprus Society of Cardiology, Lambros Kypris; **Czech Republic:** Czech Society of Cardiology, Jindřich Špinar; **Denmark:** Danish Society of Cardiology, Mogens Lytken Larsen; **Egypt:** Egyptian Society of Cardiology, Hesham Salah Eldin; **Estonia:** Estonian Society of Cardiology, Margus Viigimaa; **Finland:** Finnish Cardiac Society, Timo E. Strandberg; **France:** French Society of Cardiology, Jean Ferrières; **Georgia:** Georgian Society of Cardiology, Rusudan Agladze; **Germany:** German Cardiac Society, Ulrich Laufs; **Greece:** Hellenic Society of Cardiology, Loukianos Rallidis; **Hungary:** Hungarian Society of Cardiology, László Bajnok; **Iceland:** Icelandic Society of Cardiology, Thorbjörn Gudjónsson; **Ireland:** Irish Cardiac Society, Vincent Maher; **Israel:** Israel Heart Society, Yaakov Henkin; **Italy:** Italian Federation of Cardiology, Michele Massimo Gulizia; **Kazakhstan:** Association of Cardiologists of Kazakhstan, Aisulu Mussagaliyeva; **Kosovo (Republic of):** Kosovo Society of Cardiology, Gani Bajraktari; **Kyrgyzstan:** Kyrgyz Society of Cardiology, Alina Kerimkulova; **Latvia:** Latvian Society of Cardiology, Gustavs Latkovskis; **Lebanon:** Lebanese Society of Cardiology, Omar Hamoui; **Lithuania:** Lithuanian Society of Cardiology, Rimvydas Slapikas; **Luxembourg:** Luxembourg Society of Cardiology, Laurent Visser; **Malta:** Maltese Cardiac Society, Philip Dingli; **Moldova (Republic of):** Moldavian Society of Cardiology, Victoria Ivanov; **Montenegro:** Montenegro Society of Cardiology, Aneta Boskovic; **Morocco:** Moroccan Society of Cardiology, Mbarek Nazzi; **Netherlands:** Netherlands Society of Cardiology, Frank Visseren; **North Macedonia:** North Macedonian Society of Cardiology, Irena Mitevka; **Norway:** Norwegian Society of Cardiology, Kjetil Retterstøl; **Poland:** Polish Cardiac Society, Piotr Jankowski; **Portugal:** Portuguese Society of Cardiology, Ricardo Fontes-Carvalho; **Romania:** Romanian Society of Cardiology, Dan Gaita; **Russian Federation:** Russian Society of Cardiology, Marat

Ezhov; **San Marino:** San Marino Society of Cardiology, Marina Foscoli; **Serbia:** Cardiology Society of Serbia, Vojislav Giga; **Slovakia:** Slovak Society of Cardiology, Daniel Pella; **Slovenia:** Slovenian Society of Cardiology, Zlatko Fras; **Spain:** Spanish Society of Cardiology, Leopoldo Perez de Isla; **Sweden:** Swedish Society of Cardiology, Emil Hagström; **Switzerland:** Swiss Society of Cardiology, Roger Lehmann; **Tunisia:** Tunisian Society of Cardiology and Cardio-Vascular Surgery, Leila Abid; **Turkey:** Turkish Society of Cardiology, Oner Ozdogan; **Ukraine:** Ukrainian Association of Cardiology, Olena Mitchenko; **United Kingdom of Great Britain and Northern Ireland:** British Cardiovascular Society, Riyaz S. Patel.

19 References

- Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, Pedersen TR, Reiner Z, Riccardi G, Taskinen MR, Tokgozoglu L, Verschuren WMM, Vlachopoulos C, Wood DA, Zamorano JL, Cooney MT; ESC Scientific Document Group. 2016 ESC/EAS Guidelines for the management of dyslipidaemias. *Eur Heart J* 2016;**37**:2999–3058.
- Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Boren J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen MR, Tokgozoglu L, Landmesser U, Laufs U, Wiklund O, Stock JK, Chapman MJ, Catapano AL. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. *Eur Heart J* 2017;**38**:2459–2472.
- Townsend N, Nichols M, Scarborough P, Rayner M. Cardiovascular disease in Europe—epidemiological update 2015. *Eur Heart J* 2015;**36**:2696–2705.
- Cooney MT, Dudina A, Whincup P, Capewell S, Menotti A, Jousilahti P, Njolstad I, Oganov R, Thomsen T, Tverdal A, Wedel H, Wilhelmsen L, Graham I; SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. *Eur J Cardiovasc Prev Rehabil* 2009;**16**:541–549.
- World Health Organization. *Global Status Report on Noncommunicable Diseases 2014*. Geneva, Switzerland: World Health Organization; 2014. <https://www.who.int/nmh/publications/ncd-status-report-2014/en/> (17 July 2019).
- Cooney MT, Dudina AL, Graham IM. Value and limitations of existing scores for the assessment of cardiovascular risk: a review for clinicians. *J Am Coll Cardiol* 2009;**54**:1209–1227.
- Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA, Azizi F, Cifkova R, Di Cesare M, Eriksen L, Farzadfar F, Ikeda N, Khalili D, Khang YH, Lanska V, Leon-Munoz L, Magliano D, Msymboza KP, Oh K, Rodriguez-Artalejo F, Rojas-Martinez R, Shaw JE, Stevens GA, Tolstrup J, Zhou B, Salomon JA, Ezzati M, Danaei G. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): a pooled analysis of prospective cohorts and health examination surveys. *Lancet Diabet Endocrinol* 2015;**3**:339–355.
- Cooney MT, Dudina A, D'Agostino R, Graham IM. Cardiovascular risk-estimation systems in primary prevention: do they differ? Do they make a difference? Can we see the future? *Circulation* 2010;**122**:300–310.
- Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, Zannad F; European Association for Cardiovascular Prevention & Rehabilitation; ESC Committee for Practice Guidelines (CPG). European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). *Eur Heart J* 2012;**33**:1635–1701.
- Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, Cooney MT, Corra U, Cosyns B, Deaton C, Graham I, Hall MS, Hobbs FD, Lochen ML, Lollgen H, Marques-Vidal P, Perk J, Prescott E, Redon J, Richter DJ, Sattar N, Smulders Y, Tiberi M, van der Worp HB, van Dis I, Verschuren WM, Authors/Task Force M. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;**37**:2315–2381.
- Cooney MT, Selmer R, Lindman A, Tverdal A, Menotti A, Thomsen T, DeBacker G, De Bacquer D, Tell GS, Njolstad I, Graham IM; SCORE and CONOR investigators. Cardiovascular risk estimation in older persons: SCORE O.P. *Eur J Prev Cardiol* 2016;**23**:1093–1103.
- Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM. Lifetime risks of cardiovascular disease. *N Engl J Med* 2012;**366**:321–329.
- Foster HME, Celis-Morales CA, Nicholl BI, Petermann-Rocha F, Pell JP, Gill JMR, O'Donnell CA, Mair FS. The effect of socioeconomic deprivation on the association between an extended measurement of unhealthy lifestyle factors and health outcomes: a prospective analysis of the UK Biobank cohort. *Lancet Public Health* 2018;**3**:e576–e585.
- Kavousi M, Elias-Smale S, Rutten JH, Leening MJ, Vliegelandt R, Verwoert GC, Krestin GP, Oudkerk M, de Maat MP, Leebeek FW, Mattace-Raso FU, Lindemans J, Hofman A, Steyerberg EW, van der Lugt A, van den Meiracker AH, Witteman JC. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. *Ann Intern Med* 2012;**156**:438–444.
- Vlachopoulos C, Xaplanteris P, Aboyans V, Brodmann M, Cifkova R, Cosentino F, De Carlo M, Gallino A, Landmesser U, Laurent S, Lekakis J, Mikhailidis DP, Naka KK, Protogerou AD, Rizzoni D, Schmidt-Trucksass A, Van Bortel L, Weber T, Yamashina A, Zimlichman R, Boutouyrie P, Cockcroft J, O'Rourke M, Park JB, Schillaci G, Sillesen H, Townsend RR. The role of vascular biomarkers for primary and secondary prevention. A position paper from the European Society of Cardiology Working Group on peripheral circulation: endorsed by the Association for Research into Arterial Structure and Physiology (ARTERY) Society. *Atherosclerosis* 2015;**241**:507–532.
- Yeboah J, McClelland RL, Polonsky TS, Burke GL, Sibley CT, O'Leary D, Carr JJ, Goff DC, Greenland P, Herrington DM. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. *JAMA* 2012;**308**:788–795.
- Madsen CM, Varbo A, Nordestgaard BG. Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies. *Eur Heart J* 2017;**38**:2478–2486.
- Mortensen MB, Falk E, Li D, Nasir K, Blaha MJ, Sandfort V, Rodriguez CJ, Ouyang P, Budoff M. Statin trials, cardiovascular events, and coronary artery calcification: implications for a trial-based approach to statin therapy in MESA. *JACC Cardiovasc Imaging* 2018;**11**:221–230.
- Lin JS, Evans CV, Johnson E, Redmond N, Coppola EL, Smith N. Nontraditional risk factors in cardiovascular disease risk assessment: updated evidence report and systematic review for the US Preventive Services Task Force. *JAMA* 2018;**320**:281–297.
- Baber U, Mehran R, Sartori S, Schoos MM, Sillesen H, Muntendam P, Garcia MJ, Gregson J, Pocock S, Falk E, Fuster V. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults: the Biolmage study. *J Am Coll Cardiol* 2015;**65**:1065–1074.
- McDermott MM, Kramer CM, Tian L, Carr J, Guralnik JM, Polonsky T, Carroll T, Kibbe M, Criqui MH, Ferrucci L, Zhao L, Hippe DS, Wilkins J, Xu D, Liao Y, McCarthy W, Yuan C. Plaque composition in the proximal superficial femoral artery and peripheral artery disease events. *JACC Cardiovasc Imaging* 2017;**10**:1003–1012.
- Sillesen H, Sartori S, Sandholt B, Baber U, Mehran R, Fuster V. Carotid plaque thickness and carotid plaque burden predict future cardiovascular events in asymptomatic adult Americans. *Eur Heart J Cardiovasc Imaging* 2018;**19**:1042–1050.
- Perrone-Filardi P, Achenbach S, Mohlenkamp S, Reiner Z, Sambucetti G, Schuijff JD, Van der Wall E, Kaufmann PA, Knuuti J, Schroeder S, Zellweger MJ. Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology. *Eur Heart J* 2011;**32**:1986–1993, 1993a, 1993b.
- Den Ruijter HM, Peters SA, Anderson TJ, Britton AR, Dekker JM, Eijkemans MJ, Engstrom G, Evans GVV, de Graaf J, Grobbee DE, Hedblad B, Hofman A, Holewijn S, Ikeda A, Kavousi M, Kitagawa K, Kitamura A, Koffijberg H, Lonn EM, Lorenz MW, Mathiesen EB, Nijpels G, Okazaki S, O'Leary DH, Polak JF, Price JF, Robertson C, Rembold CM, Rosvall M, Rundek T, Salonen JT, Sitzer M, Stehouwer CD, Witteman JC, Moons KG, Bots ML. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. *JAMA* 2012;**308**:796–803.
- Lorenz MW, Schaefer C, Steinmetz H, Sitzer M. Is carotid intima media thickness useful for individual prediction of cardiovascular risk? Ten-year results from the Carotid Atherosclerosis Progression Study (CAPS). *Eur Heart J* 2010;**31**:2041–2048.
- Garg PK, Jorgensen NW, McClelland RL, Leigh JA, Greenland P, Blaha MJ, Yoon AJ, Wong ND, Yeboah J, Budoff MJ. Use of coronary artery calcium testing to improve coronary heart disease risk assessment in a lung cancer screening population: the Multi-Ethnic Study of Atherosclerosis (MESA). *J Cardiovasc Comput Tomogr* 2018;**12**:493–499.

27. Hong JC, Blankstein R, Shaw LJ, Padula WV, Arrieta A, Fialkow JA, Blumenthal RS, Blaha MJ, Krumholz HM, Nasir K. Implications of coronary artery calcium testing for treatment decisions among statin candidates according to the ACC/AHA cholesterol management guidelines: a cost-effectiveness analysis. *JACC Cardiovasc Imaging* 2017;**10**:938–952.
28. Cho I, Al'Aref SJ, Berger AB OH, Gransar H, Valenti V, Lin FY, Achenbach S, Berman DS, Budoff MJ, Callister TQ, Al-Mallah MH, Cademartiri F, Chinnaiyan K, Chow BJW, DeLago A, Villines TC, Hadamitzky M, Hausleiter J, Leipsic J, Shaw LJ, Kaufmann PA, Feuchtner G, Kim YJ, Maffei E, Raff G, Pontone G, Andreini D, Marques H, Rubinshtein R, Chang HJ, Min JK. Prognostic value of coronary computed tomographic angiography findings in asymptomatic individuals: a 6-year follow-up from the prospective multicentre international CONFIRM study. *Eur Heart J* 2018;**39**:934–941.
29. Kavousi M, Desai CS, Ayers C, Blumenthal RS, Budoff MJ, Mahabadi AA, Ikram MA, van der Lugt A, Hofman A, Erbel R, Khera A, Geisel MH, Jockel KH, Lehmann N, Hoffmann U, O'Donnell CJ, Massaro JM, Liu K, Mohlenkamp S, Ning H, Franco OH, Greenland P. Prevalence and prognostic implications of coronary artery calcification in low-risk women: a meta-analysis. *JAMA* 2016;**316**:2126–2134.
30. Lorenz MW, Polak JF, Kavousi M, Mathiesen EB, Volzke H, Tuomainen TP, Sander D, Plichart M, Catapano AL, Robertson CM, Kiechl S, Rundek T, Desvarieux M, Lind L, Schmid C, DasMahapatra P, Gao L, Ziegelbauer K, Bots ML, Thompson SG; PROG-IMT Study Group. Carotid intima-media thickness progression to predict cardiovascular events in the general population (the PROG-IMT collaborative project): a meta-analysis of individual participant data. *Lancet* 2012;**379**:2053–2062.
31. Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarencu P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM Jr, Ridker PM, Grundy SM, Kastelein JJ. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *J Am Coll Cardiol* 2014;**64**:485–494.
32. Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ* 2009;**338**:b2376.
33. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, Darius H, Lewis BS, Ophuis TO, Jukema JW, De Ferrari GM, Ruzyllo W, De Lucca P, Im K, Bohula EA, Reist C, Wiviott SD, Tereshakovec AM, Musliner TA, Braunwald E, Califf RM; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. *N Engl J Med* 2015;**372**:2387–2397.
34. Cholesterol Treatment Trialists Collaboration, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhalra N, Peto R, Barnes EH, Keech A, Simes J, Collins R. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;**376**:1670–1681.
35. Cholesterol Treatment Trialists Collaboration, Fulcher J, O'Connell R, Voysey M, Emberson J, Blackwell L, Mihaylova B, Simes J, Collins R, Kirby A, Colhoun H, Braunwald E, La Rosa J, Pedersen TR, Tonkin A, Davis B, Sleight P, Franzosi MG, Baigent C, Keech A. Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. *Lancet* 2015;**385**:1397–1405.
36. Cholesterol Treatment Trialists Collaboration, Mihaylova B, Emberson J, Blackwell L, Keech A, Simes J, Barnes EH, Voysey M, Gray A, Collins R, Baigent C. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. *Lancet* 2012;**380**:581–590.
37. Hegele RA, Ginsberg HN, Chapman MJ, Nordestgaard BG, Kuivenhoven JA, Averna M, Boren J, Bruckert E, Catapano AL, Descamps OS, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Stroes E, Taskiran MR, Tybjaerg-Hansen A, Watts GF, Wiklund O; European Atherosclerosis Society Consensus Panel. The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *Lancet Diabetes Endocrinol* 2014;**2**:655–666.
38. Mills EJ, Rachlis B, Wu P, Devereaux PJ, Arora P, Perri D. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. *J Am Coll Cardiol* 2008;**52**:1769–1781.
39. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendixsen FS, Lindahl C, Szarek M, Tsai J; Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. *JAMA* 2005;**294**:2437–2445.
40. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, Goldberg AC, Gordon D, Levy D, Lloyd-Jones DM, McBride P, Schwartz JS, Shero ST, Smith SC Jr, Watson K, Wilson PW, Eddleman KM, Jarrett NM, LaBresh K, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;**129**:S1–S45.
41. Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK. Low-density lipoprotein cholesterol lowering for the primary prevention of cardiovascular disease among men with primary elevations of low-density lipoprotein cholesterol levels of 190 mg/dL or above: analyses from the WOSCOPS (West of Scotland Coronary Prevention Study) 5-year randomized trial and 20-year observational follow-up. *Circulation* 2017;**136**:1878–1891.
42. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein retention as the initiating process in atherosclerosis: update and therapeutic implications. *Circulation* 2007;**116**:1832–1844.
43. Boren J, Williams KJ. The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis: a triumph of simplicity. *Curr Opin Lipidol* 2016;**27**:473–483.
44. Ference BA, Graham I, Tokgozoglul L, Catapano AL. Impact of lipids on cardiovascular health: JACC Health Promotion Series. *J Am Coll Cardiol* 2018;**72**:1141–1156.
45. Emerging Risk Factors Collaboration, Di Angelantonio E, Gao P, Pennells L, Kaptoge S, Caslake M, Thompson A, Butterworth AS, Sarwar N, Wormser D, Saleheen D, Ballantyne CM, Psaty BM, Sundstrom J, Ridker PM, Nagel D, Gillum RF, Ford I, Ducimetiere P, Kiechl S, Koenig W, Dullaart RP, Assmann G, D'Agostino RB Sr, Dagenais GR, Cooper JA, Kromhout D, Onat A, Tipping RW, Gomez-de-la-Camara A, Rosengren A, Sutherland SE, Gallacher J, Fowkes FG, Casiglia E, Hofman A, Salomaa V, Barrett-Connor E, Clarke R, Brunner E, Jukema JW, Simons LA, Sandhu M, Wareham NJ, Khaw KT, Kauhanen J, Salonen JT, Howard VJ, Nordestgaard BG, Wood AM, Thompson SG, Boekholdt SM, Sattar N, Packard C, Gudnason V, Danesh J. Lipid-related markers and cardiovascular disease prediction. *JAMA* 2012;**307**:2499–2506.
46. Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Do R, Donnelly LA, Ehret GB, Esko T, Feitosa MF, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkila K, Hypponen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luan J, Lyttikainen LP, Magnusson PKE, Mangino M, Mihailov E, Montasser ME, Muller-Nurasyid M, Nolte IM, O'Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney ASF, Doring A, Elliott P, Epstein SE, Ingi Eyjolfsson G, Gigante B, Goodarzi MO, Grallert H, Gravito ML, Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kaleebu P, Kastelein JJP, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimaki T, Lin SY, Lindstrom J, Loos RFJ, Mach F, McArdle WL, Meisinger C, Mitchell BD, Muller G, Nagaraja R, Narisu N, Nieminen TVM, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruokonen A, Samani N, Scharnagl H, Seeley J, Silander K, Stancakova A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemsen G, Wilsaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YJ, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrieres J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gyllenstein U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE, Hunt SC, Hveem K, Iribarren C, Jarvelin MR, Jula A, Kahonen M, Kaprio J, Kesaniemi A, Kivimaki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG, Marz W, McCarthy ML, McKenzie CA, Meneton P, Metspalu A, Moilanen L, Morris AD, Munroe PB, Njolstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PEH, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wollert L, Wareham NJ, Whitfield JB, Wolfenbutter BHR, Ordovas JM, Boerwinkle E, Palmer CNA, Thorsteinsdottir U, Chasman DI, Rotter JI, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, Ingelsson E, Abecasis

- GR; Global Lipids Genetics Consortium. Discovery and refinement of loci associated with lipid levels. *Nat Genet* 2013;**45**:1274–1283.
47. Nikpay M, Goel A, Won HH, Hall LM, Willenborg C, Kanoni S, Saleheen D, Kyriakou T, Nelson CP, Hopewell JC, Webb TR, Zeng L, Dehghan A, Alver M, Armasu SM, Auro K, Bjorndal A, Chasman DI, Chen S, Ford I, Franceschini N, Gieger C, Grace C, Gustafsson S, Huang J, Hwang SJ, Kim YK, Kleber ME, Lau KW, Lu X, Lu Y, Lyytikäinen LP, Mihailov E, Morrison AC, Perjakova N, Qu L, Rose LM, Salfati E, Saxena R, Scholz M, Smith AV, Tikkanen E, Uitterlinden A, Yang X, Zhang W, Zhao W, de Andrade M, de Vries PS, van Zuydam NR, Anand SS, Bertram L, Beutner F, Dedoussis G, Frossard P, Gauguier D, Goodall AH, Gottesman O, Haber M, Han BG, Huang J, Jalilzadeh S, Kessler T, König IR, Lannfelt L, Lieb W, Lind L, Lindgren CM, Lokki ML, Magnusson PK, Mallick NH, Mehra N, Meitinger T, Memon FU, Morris AP, Nieminen MS, Pedersen NL, Peters A, Rallidis LS, Rasheed A, Samuel M, Shah SH, Sinisalo J, Stirrups KE, Trompet S, Wang L, Zaman KS, Ardisino D, Boerwinkle E, Borecki IB, Bottinger EP, Buring JE, Chambers JC, Collins R, Cupples LA, Danesh J, Demuth I, Elosua R, Epstein SE, Esko T, Feitosa MF, Franco OH, Franzosi MG, Granger CB, Gu D, Gudnason V, Hall AS, Hamsten A, Harris TB, Hazen SL, Hengstenberg C, Hofman A, Ingelsson E, Iribarren C, Jukema JW, Karhunen PJ, Kim BJ, Kooner JS, Kullo IJ, Lehtimäki T, Loos RJF, Melander O, Metspalu A, Marz W, Palmer CN, Perola M, Quertermous T, Rader DJ, Ridker PM, Ripatti S, Roberts R, Salomaa V, Sanghera DK, Schwartz SM, Seedorf U, Stewart AJ, Stott DJ, Thiery J, Zalloua PA, O'Donnell CJ, Reilly MP, Assimes TL, Thompson JR, Erdmann J, Clarke R, Watkins H, Kathiresan S, McPherson R, Deloukas P, Schunkert H, Samani NJ, Farrall M. A comprehensive 1,000 Genomes-based genome-wide association meta-analysis of coronary artery disease. *Nat Genet* 2015;**47**:1121–1130.
 48. Ference BA, Yoo W, Alesh I, Mahajan N, Mirowska KK, Mewada A, Kahn J, Alfonso L, Williams KA Sr, Flack JM. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. *J Am Coll Cardiol* 2012;**60**:2631–2639.
 49. Holmes MV, Asselbergs FW, Palmer TM, Drenos F, Lanktree MB, Nelson CP, Dale CE, Padmanabhan S, Finan C, Swerdlow DI, Tragante V, van Iperen EP, Sivapalaratnam S, Shah S, Elbers CC, Shah T, Engmann J, Giambartolomei C, White J, Zabaneh D, Sofat R, McLachlan S, consortium U, Doevendans PA, Balmforth AJ, Hall AS, North KE, Almqvister B, Hoogeveen RC, Cushman M, Fornage M, Patel SR, Redline S, Siscovick DS, Tsai MY, Karczewski KJ, Hofker MH, Verschuren WM, Bots ML, van der Schouw YT, Melander O, Dominiczak AF, Morris R, Ben-Shlomo Y, Price J, Kumari M, Baumert J, Peters A, Thorand B, Koenig W, Gaunt TR, Humphries SE, Clarke R, Watkins H, Farrall M, Wilson JG, Rich SS, de Bakker PI, Lange LA, Davey Smith G, Reiner AP, Talmud PJ, Kivimäki M, Lawlor DA, Dudbridge F, Samani NJ, Keating BJ, Hingorani AD, Casas JP. Mendelian randomization of blood lipids for coronary heart disease. *Eur Heart J* 2015;**36**:539–550.
 50. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, Braunwald E, Sabatine MS. Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. *JAMA* 2016;**316**:1289–1297.
 51. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;**366**:1267–1278.
 52. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med* 2006;**354**:1264–1272.
 53. Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL. Association of triglyceride-lowering LPL variants and LDL-C-lowering LDLR variants with risk of coronary heart disease. *JAMA* 2019;**321**:364–373.
 54. Ference BA, Majeed F, Penumetcha R, Flack JM, Brook RD. Effect of naturally random allocation to lower low-density lipoprotein cholesterol on the risk of coronary heart disease mediated by polymorphisms in NPC1L1, HMGCR, or both: a 2 x 2 factorial Mendelian randomization study. *J Am Coll Cardiol* 2015;**65**:1552–1561.
 55. Ference BA, Robinson JG, Brook RD, Catapano AL, Chapman MJ, Neff DR, Voros S, Giugliano RP, Davey Smith G, Fazio S, Sabatine MS. Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. *N Engl J Med* 2016;**375**:2144–2153.
 56. Triglyceride Coronary Disease Genetics Consortium, Emerging Risk Factors Collaboration, Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J. Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. *Lancet* 2010;**375**:1634–1639.
 57. Varbo A, Benn M, Tybjaerg-Hansen A, Jorgensen AB, Frikke-Schmidt R, Nordestgaard BG. Remnant cholesterol as a causal risk factor for ischemic heart disease. *J Am Coll Cardiol* 2013;**61**:427–436.
 58. Lewis GF, Xiao C, Hegele RA. Hypertriglyceridemia in the genomic era: a new paradigm. *Endocr Rev* 2015;**36**:131–147.
 59. Dron JS, Hegele RA. Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants. *Curr Opin Lipidol* 2017;**28**:161–169.
 60. Prospective Studies Collaboration, Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J, Qizilbash N, Peto R, Collins R. Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. *Lancet* 2007;**370**:1829–1839.
 61. Frikke-Schmidt R, Nordestgaard BG, Stene MC, Sethi AA, Remaley AT, Schnohr P, Grande P, Tybjaerg-Hansen A. Association of loss-of-function mutations in the ABCA1 gene with high-density lipoprotein cholesterol levels and risk of ischemic heart disease. *JAMA* 2008;**299**:2524–2532.
 62. Voight BF, Peloso GM, Orho-Melander M, Frikke-Schmidt R, Barbalic M, Jensen MK, Hindy G, Holm H, Ding EL, Johnson T, Schunkert H, Samani NJ, Clarke R, Hopewell JC, Thompson JF, Li M, Thorleifsson G, Newton-Cheh C, Musunuru K, Pirruccello JP, Saleheen D, Chen L, Stewart A, Schillert A, Thorsteinsdottir U, Thorgeirsson G, Anand S, Engert JC, Morgan T, Spertus J, Stoll M, Berger K, Martinelli N, Girelli D, McKeown PP, Patterson CC, Epstein SE, Devaney J, Burnett MS, Mooser V, Ripatti S, Surakka I, Nieminen MS, Sinisalo J, Lokki ML, Perola M, Havulinna A, de Faire U, Gigante B, Ingelsson E, Zeller T, Wild P, de Bakker PI, Klungel OH, Maitland-van der Zee AH, Peters BJ, de Boer A, Grobbee DE, Kamphuisen PW, Deneer VH, Elbers CC, Onland-Moret NC, Hofker MH, Wijmenga C, Verschuren WM, Boer JM, van der Schouw YT, Rasheed A, Frossard P, Demissie S, Willer C, Do R, Ordoñez JM, Abecasis GR, Boehnke M, Mohlke KL, Daly MJ, Guiducci C, Burt NP, Surti A, Gonzalez E, Purcell S, Gabriel S, Marrugat J, Peden J, Erdmann J, Diemert P, Willenborg C, König IR, Fischer M, Hengstenberg C, Ziegler A, Buyschaert I, Lambrechts D, Van de Werf F, Fox KA, El Mokhtari NE, Rubin D, Schrezenmeier J, Schreiber S, Schafer A, Danesh J, Blankenberg S, Roberts R, McPherson R, Watkins H, Hall AS, Overvad K, Rimm E, Boerwinkle E, Tybjaerg-Hansen A, Cupples LA, Reilly MP, Melander O, Mannucci PM, Ardisino D, Siscovick D, Elosua R, Stefansson K, O'Donnell CJ, Salomaa V, Rader DJ, Peltonen L, Schwartz SM, Altschuler D, Kathiresan S. Plasma HDL cholesterol and risk of myocardial infarction: a Mendelian randomisation study. *Lancet* 2012;**380**:572–580.
 63. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, Fox KAA, Gibson CM, Granger C, Menon V, Montalescot G, Rader D, Tall AR, McEneaney E, Woloski K, Ruotolo G, Vangerow B, Weerakkody G, Goodman SG, Conde D, McGuire DK, Nicolau JC, Leiva-Pons JL, Pesant Y, Li W, Kandath D, Kouz S, Tahrkheili N, Mason D, Nissen SE; ACCELERATE Investigators. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. *N Engl J Med* 2017;**376**:1933–1942.
 64. HPS/TIMI/REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, Stevens W, Collins R, Wiviott SD, Cannon CP, Braunwald E, Sammons E, Landray MJ. Effects of anacetrapib in patients with atherosclerotic vascular disease. *N Engl J Med* 2017;**377**:1217–1227.
 65. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, Brumm J, Chaitman BR, Holme IM, Kallend D, Leiter LA, Leitersdorf E, McMurray JJ, Mundt H, Nicholls SJ, Shah PK, Tardif JC, Wright RS; dal-OUTCOMES Investigators. Effects of dalcetrapib in patients with a recent acute coronary syndrome. *N Engl J Med* 2012;**367**:2089–2099.
 66. Aim-High Investigators, Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. *N Engl J Med* 2011;**365**:2255–2267.
 67. Group HTC, Landray MJ, Haynes R, Hopewell JC, Parish S, Aung T, Tomson J, Wallendszus K, Craig M, Jiang L, Collins R, Armitage J. Effects of extended-release niacin with laropiprant in high-risk patients. *N Engl J Med* 2014;**371**:203–212.
 68. Andrews J, Jansan A, Nguyen T, Pisanelli AD, Scherer DJ, Kastelein JJ, Merkely B, Nissen SE, Ray K, Schwartz GG, Worthley SG, Keyserling C, Dasseux JL, Butters J, Girardi J, Miller R, Nicholls SJ. Effect of serial infusions of reconstituted high-density lipoprotein (CER-001) on coronary atherosclerosis: rationale and design of the CARAT study. *Cardiovasc Diagn Ther* 2017;**7**:45–51.
 69. Tardif JC, Ballantyne CM, Barter P, Dasseux JL, Fayad ZA, Guertin MC, Kastelein JJ, Keyserling C, Klepp H, Koenig W, L'Allier PL, Lesperance J, Luscher TF, Paolini JF, Tawakol A, Waters DD; Can HDL Infusions Significantly Quick Atherosclerosis Regression (CHI-SQUARE) Investigators. Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. *Eur Heart J* 2014;**35**:3277–3286.
 70. Nordestgaard BG, Langsted A. Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology. *J Lipid Res* 2016;**57**:1953–1975.

71. van der Valk FM, Bekkering S, Kroon J, Yeang C, Van den Bossche J, van Buul JD, Ravandi A, Nederveen AJ, Verberne HJ, Scipione C, Nieuwdorp M, Joosten LA, Netea MG, Koschinsky ML, Witztum JL, Tsimikas S, Riksen NP, Stroes ES. Oxidized phospholipids on lipoprotein(a) elicit arterial wall inflammation and an inflammatory monocyte response in humans. *Circulation* 2016;**134**:611–624.
72. Nordestgaard BG, Chapman MJ, Ray K, Borén J, Andreotti F, Watts GF, Ginsberg H, Amarenco P, Catapano A, Descamps OS, Fisher E, Kovane PT, Kuivenhoven JA, Lesnik P, Masana L, Reiner Z, Taskinen MR, Tokgözoğlu L, Tybjaerg-Hansen A; European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. *Eur Heart J* 2010;**31**:2844–2853.
73. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, Marcovina SM, Collins R, Thompson SG, Danesh J. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. *JAMA* 2009;**302**:412–423.
74. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, Heath SC, Parish S, Barlera S, Franzosi MG, Rust S, Bennett D, Silveira A, Malarstig A, Green FR, Lathrop M, Gigante B, Leander K, de Faire U, Seedorf U, Hamsten A, Collins R, Watkins H, Farrall M; PROCARDIS Consortium. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. *N Engl J Med* 2009;**361**:2518–2528.
75. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. *JAMA* 2009;**301**:2331–2339.
76. O'Donoghue ML, Fazio S, Giugliano RP, Stroes ESG, Kanevsky E, Gouni-Berthold I, Im K, Lira Pineda A, Wasserman SM, Ceska R, Ezhov MV, Jukema JW, Jensen HK, Tokgozoglou SL, Mach F, Huber K, Sever PS, Keech AC, Pedersen TR, Sabatine MS. Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. *Circulation* 2019;**139**:1483–1492.
77. Burgess S, Ference BA, Staley JR, Freitag DF, Mason AM, Nielsen SF, Willeit P, Young R, Surendran P, Karthikeyan S, Bolton TR, Peters JE, Kamstrup PR, Tybjaerg-Hansen A, Benn M, Langsted A, Schnohr P, Vedel-Krogh S, Kobylecki CJ, Ford I, Packard C, Trompet S, Jukema JW, Sattar N, Di Angelantonio E, Saleheen D, Howson JMM, Nordestgaard BG, Butterworth AS, Danesh J; European Prospective Investigation Into Cancer and Nutrition–Cardiovascular Disease (EPIC-CVD) Consortium. Association of LPA variants with risk of coronary disease and the implications for lipoprotein(a)-lowering therapies: a Mendelian randomization analysis. *JAMA Cardiol* 2018;**3**:619–627.
78. Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J; HPS2-THRIVE Collaborative Group. Impact of apolipoprotein(a) isoform size on lipoprotein(a) lowering in the HPS2-THRIVE Study. *Circ Genom Precis Med* 2018;**11**:e001696.
79. Langlois MR, Chapman MJ, Cobbaert C, Mora S, Remaley AT, Ros E, Watts GF, Borén J, Baum H, Bruckert E, Catapano A, Descamps OS, von Eckardstein A, Kamstrup PR, Kolovou G, Kronenberg F, Langsted A, Pulkki K, Rifai N, Sypniewska G, Wiklund O, Nordestgaard BG; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) Joint Consensus Initiative. Quantifying atherogenic lipoproteins: current and future challenges in the era of personalized medicine and very low concentrations of LDL cholesterol. A consensus statement from EAS and EFLM. *Clin Chem* 2018;**64**:1006–1033.
80. Jialal I, Inn M, Siegel D, Devaraj S. Underestimation of low density lipoprotein-cholesterol with the Friedewald equation versus a direct homogeneous low density lipoprotein-cholesterol assay. *Lab Med* 2017;**48**:220–224.
81. Martin SS, Blaha MJ, Elshazly MB, Brinton EA, Toth PP, McEvoy JW, Joshi PH, Kulkarni KR, Mize PD, Kwiterovich PO, Defilippis AP, Blumenthal RS, Jones SR. Friedewald-estimated versus directly measured low-density lipoprotein cholesterol and treatment implications. *J Am Coll Cardiol* 2013;**62**:732–739.
82. Nauck M, Warnick GR, Rifai N. Methods for measurement of LDL-cholesterol: a critical assessment of direct measurement by homogeneous assays versus calculation. *Clin Chem* 2002;**48**:236–254.
83. Razi F, Forouzanfar K, Bandarian F, Nasli-Esfahani E. LDL-cholesterol measurement in diabetic type 2 patients: a comparison between direct assay and popular equations. *J Diabetes Metab Disord* 2017;**16**:43.
84. Robinson JG, Rosenson RS, Farnier M, Chaudhari U, Sasiela WJ, Merlet L, Miller K, Kastelein JJ. Safety of very low low-density lipoprotein cholesterol levels with alirocumab: pooled data from randomized trials. *J Am Coll Cardiol* 2017;**69**:471–482.
85. Sathiyakumar V, Park J, Golozar A, Lazo M, Quispe R, Guallar E, Blumenthal RS, Jones SR, Martin SS. Fasting versus nonfasting and low-density lipoprotein cholesterol accuracy. *Circulation* 2018;**137**:10–19.
86. Whelton SP, Meeusen JW, Donato LJ, Jaffe AS, Saenger A, Sokoll LJ, Blumenthal RS, Jones SR, Martin SS. Evaluating the atherogenic burden of individuals with a Friedewald-estimated low-density lipoprotein cholesterol <70 mg/dL compared with a novel low-density lipoprotein estimation method. *J Clin Lipidol* 2017;**11**:1065–1072.
87. Meeusen JW, Lueke AJ, Jaffe AS, Saenger AK. Validation of a proposed novel equation for estimating LDL cholesterol. *Clin Chem* 2014;**60**:1519–1523.
88. Langlois MR, Descamps OS, van der Laarse A, Weykamp C, Baum H, Pulkki K, von Eckardstein A, De Bacquer D, Borén J, Wiklund O, Laitinen P, Oosterhuis WP, Cobbaert C; EAS-EFLM Collaborative Project. Clinical impact of direct HDLc and LDLc method bias in hypertriglyceridemia. A simulation study of the EAS-EFLM Collaborative Project Group. *Atherosclerosis* 2014;**233**:83–90.
89. Miida T, Nishimura K, Okamura T, Hirayama S, Ohmura H, Yoshida H, Miyashita Y, Ai M, Tanaka A, Sumino H, Murakami M, Inoue I, Kayamori Y, Nakamura M, Nobori T, Miyazawa Y, Teramoto T, Yokoyama S. A multicenter study on the precision and accuracy of homogeneous assays for LDL-cholesterol: comparison with a beta-quantification method using fresh serum obtained from non-diseased and diseased subjects. *Atherosclerosis* 2012;**225**:208–215.
90. Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Nilsson G, Shamburek RD, Vetrovec GW, Warnick GR, Remaley AT. Seven direct methods for measuring HDL and LDL cholesterol compared with ultracentrifugation reference measurement procedures. *Clin Chem* 2010;**56**:977–986.
91. Marcovina SM, Albers JJ. Lipoprotein (a) measurements for clinical application. *J Lipid Res* 2016;**57**:526–537.
92. Marcovina SM, Koschinsky ML, Albers JJ, Skarlatos S. Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: recent advances and future directions. *Clin Chem* 2003;**49**:1785–1796.
93. Tsimikas S, Fazio S, Viney NJ, Xia S, Witztum JL, Marcovina SM. Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. *J Clin Lipidol* 2018;**12**:1313–1323.
94. Mora S, Rifai N, Buring JE, Ridker PM. Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events. *Circulation* 2008;**118**:993–1001.
95. Jorgensen AB, Frikke-Schmidt R, West AS, Grande P, Nordestgaard BG, Tybjaerg-Hansen A. Genetically elevated non-fasting triglycerides and calculated remnant cholesterol as causal risk factors for myocardial infarction. *Eur Heart J* 2013;**34**:1826–1833.
96. Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Assessment and clinical relevance of non-fasting and postprandial triglycerides: an expert panel statement. *Curr Vasc Pharmacol* 2011;**9**:258–270.
97. Mihalas C, Kolovou GD, Mikhailidis DP, Kovar J, Lairon D, Nordestgaard BG, Ooi TC, Perez-Martinez P, Bilianou H, Anagnostopoulou K, Panotopoulos G. Diagnostic value of postprandial triglyceride testing in healthy subjects: a meta-analysis. *Curr Vasc Pharmacol* 2011;**9**:271–280.
98. Nordestgaard BG, Varbo A. Triglycerides and cardiovascular disease. *Lancet* 2014;**384**:626–635.
99. Baca AM, Warnick GR. Estimation of LDL-associated apolipoprotein B from measurements of triglycerides and total apolipoprotein B. *Clin Chem* 2008;**54**:907–910.
100. Chapman MJ, Ginsberg HN, Amarenco P, Andreotti F, Borén J, Catapano AL, Descamps OS, Fisher E, Kovane PT, Kuivenhoven JA, Lesnik P, Masana L, Nordestgaard BG, Ray KK, Reiner Z, Taskinen MR, Tokgözoğlu L, Tybjaerg-Hansen A, Watts GF; European Atherosclerosis Society Consensus Panel. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. *Eur Heart J* 2011;**32**:1345–1361.
101. Cartier LJ, Collins C, Lagace M, Douville P. Comparison of fasting and non-fasting lipid profiles in a large cohort of patients presenting at a community hospital. *Clin Biochem* 2018;**52**:61–66.
102. National Clinical Guideline Centre (UK). *Lipid Modification: Cardiovascular Risk Assessment and the Modification of Blood Lipids for the Primary and Secondary Prevention of Cardiovascular Disease*. London: National Institute for Health and Care Excellence (UK); 2014.
103. Joint British Societies Board. Joint British Societies' consensus recommendations for the prevention of cardiovascular disease (JBS3). *Heart* 2014;**100**:ii1–ii67.
104. Doran B, Guo Y, Xu J, Weintraub H, Mora S, Maron DJ, Bangalore S. Prognostic value of fasting versus nonfasting low-density lipoprotein cholesterol levels on long-term mortality: insight from the National Health and Nutrition Examination Survey III (NHANES-III). *Circulation* 2014;**130**:546–553.
105. Harari G, Green MS, Magid A, Zelber-Sagi S. Usefulness of non-high-density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men in 22-year follow-up. *Am J Cardiol* 2017;**119**:1193–1198.
106. Gu X, Yang X, Li Y, Cao J, Li J, Liu X, Chen J, Shen C, Yu L, Huang J, Gu D. Usefulness of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol as predictors of cardiovascular disease in Chinese. *Am J Cardiol* 2015;**116**:1063–1070.
107. van den Berg MJ, van der Graaf Y, de Borst GJ, Kappelle LJ, Nathoe HM, Vissers FLJ; SMART Study Group. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and

- cardiovascular risk in patients with manifest arterial disease. *Am J Cardiol* 2016;**118**:804–810.
108. van Deventer HE, Miller WG, Myers GL, Sakurabayashi I, Bachmann LM, Caudill SP, Dziekonski A, Edwards S, Kimberly MM, Korzun WJ, Leary ET, Nakajima K, Nakamura M, Shamburek RD, Vetovec GW, Warnick GR, Remaley AT. Non-HDL cholesterol shows improved accuracy for cardiovascular risk score classification compared to direct or calculated LDL cholesterol in a dyslipidemic population. *Clin Chem* 2011;**57**:490–501.
 109. Sniderman AD, Islam S, Yusuf S, McQueen MJ. Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. *Atherosclerosis* 2012;**225**:444–449.
 110. Cook NR, Mora S, Ridker PM. Lipoprotein(a) and cardiovascular risk prediction among women. *J Am Coll Cardiol* 2018;**72**:287–296.
 111. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Extreme lipoprotein(a) levels and improved cardiovascular risk prediction. *J Am Coll Cardiol* 2013;**61**:1146–1156.
 112. Willeit P, Kiechl S, Kronenberg F, Witztum JL, Santer P, Mayr M, Xu Q, Mayr A, Willeit J, Tsimikas S. Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): prospective 15-year outcomes in the Bruneck Study. *J Am Coll Cardiol* 2014;**64**:851–860.
 113. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, Graham I, Taskinen MR, Wiklund O, Agewall S, Alegria E, Chapman MJ, Durrington P, Erdine S, Halcox J, Hobbs R, Kjekshus J, Filardi PP, Riccardi G, Storey RF, Wood D; ESC Committee for Practice Guidelines Committees (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). *Eur Heart J* 2011;**32**:1769–1818.
 114. Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. *J Am Coll Cardiol* 2017;**70**:1785–1822.
 115. Navarese EP, Robinson JG, Kowalewski M, Kolodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. *JAMA* 2018;**319**:1566–1579.
 116. Hsia J, MacFadyen JG, Monyak J, Ridker PM. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *J Am Coll Cardiol* 2011;**57**:1666–1675.
 117. McCormack T, Dent R, Blagden M. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. *Int J Clin Pract* 2016;**70**:886–897.
 118. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier F, Clement DL, Coca A, de Simone G, Dominiczak A, Kahan T, Mahfoud F, Redon J, Ruilope L, Zanchetti A, Kerins M, Kjeldsen SE, Kreutz R, Laurent S, Lip GYH, McManus R, Narkiewicz K, Ruschitzka F, Schmieder RE, Shlyakhto E, Tsioufis C, Aboyans V, Desormais I; Authors/Task Force Members. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens* 2018;**36**:1953–2041.
 119. Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;**376**:1713–1722.
 120. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, Edelberg JM, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Lecroq G, Mahaffey KW, Moryusef A, Pordy R, Quintero K, Roe MT, Sasiela WJ, Tamby JF, Tricoci P, White HD, Zeiher AM; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and cardiovascular outcomes after acute coronary syndrome. *N Engl J Med* 2018;**379**:2097–2107.
 121. Charlton-Menys V, Betteridge DJ, Colhoun H, Fuller J, France M, Hitman GA, Livingstone SJ, Neil HA, Newman CB, Szarek M, DeMicco DA, Durrington PN. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). *Clin Chem* 2009;**55**:473–480.
 122. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. *J Intern Med* 2006;**259**:481–492.
 123. Thanassoulis G, Williams K, Ye K, Brook R, Couture P, Lawler PR, de Graaf J, Furberg CD, Sniderman A. Relations of change in plasma levels of LDL-C, non-HDL-C and apoB with risk reduction from statin therapy: a meta-analysis of randomized trials. *J Am Heart Assoc* 2014;**3**:e000759.
 124. Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk. *J Am Coll Cardiol* 2009;**53**:316–322.
 125. Dalen JE, Devries S. Diets to prevent coronary heart disease 1957-2013: what have we learned? *Am J Med* 2014;**127**:364–369.
 126. Eckel RH, Jakicic JM, Ard JD, de Jesus JM, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Houston Miller N, Hubbard VS, Lee IM, Lichtenstein AH, Loria CM, Millen BE, Houston Miller N, Hubbard VS, Lee IM, Svetkey LP, Wadden TA, Yanovski SZ, Kendall KA, Morgan LC, Trisolini MG, Velasco G, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation* 2014;**129**:S76–S99.
 127. Mente A, de Koning L, Shannon HS, Anand SS. A systematic review of the evidence supporting a causal link between dietary factors and coronary heart disease. *Arch Intern Med* 2009;**169**:659–669.
 128. Chowdhury R, Warnakula S, Kunutsor S, Crowe F, Ward HA, Johnson L, Franco OH, Butterworth AS, Forouhi NG, Thompson SG, Khaw KT, Mozaffarian D, Danesh J, Di Angelantonio E. Association of dietary, circulating, and supplement fatty acids with coronary risk: a systematic review and meta-analysis. *Ann Intern Med* 2014;**160**:398–406.
 129. Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. *PLoS Med* 2010;**7**:e1000252.
 130. Forouhi NG, Krauss RM, Taubes G, Willett W. Dietary fat and cardiometabolic health: evidence, controversies, and consensus for guidance. *BMJ* 2018;**361**:k2139.
 131. Mozaffarian D. Natural trans fat, dairy fat, partially hydrogenated oils, and cardiometabolic health: the Ludwigshafen Risk and Cardiovascular Health Study. *Eur Heart J* 2016;**37**:1079–1081.
 132. Chen M, Li Y, Sun Q, Pan A, Manson JE, Rexrode KM, Willett WC, Rimm EB, Hu FB. Dairy fat and risk of cardiovascular disease in 3 cohorts of US adults. *Am J Clin Nutr* 2016;**104**:1209–1217.
 133. Moore TJ, Vollmer WM, Appel LJ, Sacks FM, Svetkey LP, Vogt TM, Conlin PR, Simmons-Morton DG, Carter-Edwards L, Harsha DW. Effect of dietary patterns on ambulatory blood pressure: results from the Dietary Approaches to Stop Hypertension (DASH) Trial. DASH Collaborative Research Group. *Hypertension* 1999;**34**:472–477.
 134. Sofi F, Macchi C, Abbate R, Gensini GF, Casini A. Mediterranean diet and health status: an updated meta-analysis and a proposal for a literature-based adherence score. *Public Health Nutr* 2014;**17**:2769–2782.
 135. Grosso G, Marventano S, Yang J, Micek A, Pajak A, Scalfi L, Galvano F, Kales SN. A comprehensive meta-analysis on evidence of Mediterranean diet and cardiovascular disease: are individual components equal? *Crit Rev Food Sci Nutr* 2017;**57**:3218–3232.
 136. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon Diet Heart Study. *Circulation* 1999;**99**:779–785.
 137. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz-Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventós RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA. Retraction and republication: primary prevention of cardiovascular disease with a Mediterranean diet. *N Engl J Med* 2018;**378**:2441–2442.
 138. Mozaffarian D, Aro A, Willett WC. Health effects of trans-fatty acids: experimental and observational evidence. *Eur J Clin Nutr* 2009;**63**:S5–S21.
 139. Clifton PM, Keogh JB. A systematic review of the effect of dietary saturated and polyunsaturated fat on heart disease. *Nutr Metab Cardiovasc Dis* 2017;**27**:1060–1080.
 140. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. *Am J Clin Nutr* 1999;**69**:30–42.
 141. Hollaender PL, Ross AB, Kristensen M. Whole-grain and blood lipid changes in apparently healthy adults: a systematic review and meta-analysis of randomized controlled studies. *Am J Clin Nutr* 2015;**102**:556–572.
 142. Gylling H, Plat J, Turley S, Ginsberg HN, Ellegård L, Jessup W, Jones PJ, Lütjohann D, Maerz W, Masana L, Silbernagel G, Staels B, Borén J, Catapano AL, De Backer G, Deafield J, Descamps OS, Kovanen PT, Riccardi G, Tokgözoğlu L, Chapman MJ; European Atherosclerosis Society Consensus Panel on Phytosterols. Plant

- sterols and plant stanols in the management of dyslipidaemia and prevention of cardiovascular disease. *Atherosclerosis* 2014;**232**:346–360.
143. Musa-Veloso K, Poon TH, Elliot JA, Chung C. A comparison of the LDL-cholesterol lowering efficacy of plant stanols and plant sterols over a continuous dose range: results of a meta-analysis of randomized, placebo-controlled trials. *Prostaglandins Leukot Essent Fatty Acids* 2011;**85**:9–28.
 144. Poli A, Barbagallo CM, Cicero AFG, Corsini A, Manzato E, Trimarco B, Bernini F, Visioli F, Bianchi A, Canzone G, Crescini C, de Kreutzenberg S, Ferrara N, Gambacciani M, Ghiselli A, Lubrano C, Marelli G, Marrocco W, Montemurro V, Parretti D, Pedretti R, Perticone F, Stella R, Marangoni F. Nutraceuticals and functional foods for the control of plasma cholesterol levels. An intersociety position paper. *Pharmacol Res* 2018;**134**:51–60.
 145. Li Y, Jiang L, Jia Z, Xin W, Yang S, Yang Q, Wang L. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. *PLoS One* 2014;**9**:e98611.
 146. Lu Z, Kou W, Du B, Wu Y, Zhao S, Brusco OA, Morgan JM, Capuzzi DM; Chinese Coronary Secondary Prevention Study Group, Li S. Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction. *Am J Cardiol* 2008;**101**:1689–1693.
 147. Nordmann AJ, Nordmann A, Briel M, Keller U, Yancy WS Jr, Brehm BJ, Bucher HC. Effects of low-carbohydrate vs low-fat diets on weight loss and cardiovascular risk factors: a meta-analysis of randomized controlled trials. *Arch Intern Med* 2006;**166**:285–293.
 148. Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, James WP, Finer N. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. *Obes Rev* 2016;**17**:1001–1011.
 149. Berger S, Raman G, Vishwanathan R, Jacques PF, Johnson EJ. Dietary cholesterol and cardiovascular disease: a systematic review and meta-analysis. *Am J Clin Nutr* 2015;**102**:276–294.
 150. Griffin JD, Lichtenstein AH. Dietary cholesterol and plasma lipoprotein profiles: randomized-controlled trials. *Curr Nutr Rep* 2013;**2**:274–282.
 151. Shaw K, Gennat H, O'Rourke P, Del Mar C. Exercise for overweight or obesity. *Cochrane Database Syst Rev* 2006;**4**:CD003817.
 152. Droste DW, Iliescu C, Vaillant M, Gantenbein M, De Bremaeker N, Lieunard C, Velez T, Meyer M, Guth T, Kuemmerle A, Gilson G, Chioti A. A daily glass of red wine associated with lifestyle changes independently improves blood lipids in patients with carotid arteriosclerosis: results from a randomized controlled trial. *Nutr J* 2013;**12**:147.
 153. Rimm EB, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. *BMJ* 1999;**319**:1523–1528.
 154. Yu-Poth S, Zhao G, Etherton T, Naglak M, Jonnalagadda S, Kris-Etherton PM. Effects of the National Cholesterol Education Program's Step I and Step II dietary intervention programs on cardiovascular disease risk factors: a meta-analysis. *Am J Clin Nutr* 1999;**69**:632–646.
 155. Santos FL, Esteves SS, da Costa Pereira A, Yancy WS Jr, Nunes JP. Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. *Obes Rev* 2012;**13**:1048–1066.
 156. Rivellese AA, Maffettone A, Vessby B, Uusitupa M, Hermansen K, Berglund L, Louheranta A, Meyer BJ, Riccardi G. Effects of dietary saturated, monounsaturated and n-3 fatty acids on fasting lipoproteins, LDL size and post-prandial lipid metabolism in healthy subjects. *Atherosclerosis* 2003;**167**:149–158.
 157. Wei MY, Jacobson TA. Effects of eicosapentaenoic acid versus docosahexaenoic acid on serum lipids: a systematic review and meta-analysis. *Curr Atheroscler Rep* 2011;**13**:474–483.
 158. Kelishadi R, Mansourian M, Heidari-Beni M. Association of fructose consumption and components of metabolic syndrome in human studies: a systematic review and meta-analysis. *Nutrition* 2014;**30**:503–510.
 159. Stanhope KL, Schwarz JM, Keim NL, Griffen SC, Bremer AA, Graham JL, Hatcher B, Cox CL, Dyachenko A, Zhang W, McGahan JP, Seibert A, Krauss RM, Chiu S, Schaefer EJ, Ai M, Otokozawa S, Nakajima K, Nakano T, Beysen C, Hellerstein MK, Berglund L, Havel PJ. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. *J Clin Invest* 2009;**119**:1322–1334.
 160. Gayet-Boyer C, Tenenhaus-Aziza F, Prunet C, Marmonier C, Malpuech-Brugere C, Lamarche B, Chardigny JM. Is there a linear relationship between the dose of ruminant trans-fatty acids and cardiovascular risk markers in healthy subjects: results from a systematic review and meta-regression of randomised clinical trials. *Br J Nutr* 2014;**112**:1914–1922.
 161. Kelley GA, Kelley KS. Impact of progressive resistance training on lipids and lipoproteins in adults: a meta-analysis of randomized controlled trials. *Prev Med* 2009;**48**:9–19.
 162. Kastorini CM, Milionis HJ, Esposito K, Giugliano D, Goudevenos JA, Panagiotakos DB. The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals. *J Am Coll Cardiol* 2011;**57**:1299–1313.
 163. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a meta-analysis. *Prev Med* 2003;**37**:283–290.
 164. Mensink RP, Zock PL, Kester AD, Katan MB. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials. *Am J Clin Nutr* 2003;**77**:1146–1155.
 165. Micha R, Khatibzadeh S, Shi P, Fahimi S, Lim S, Andrews KG, Engell RE, Powles J, Ezzati M, Mozaffarian D; Global Burden of Diseases Nutrition and Chronic Diseases Expert Group NutriCoDE. Global, regional, and national consumption levels of dietary fats and oils in 1990 and 2010: a systematic analysis including 266 country-specific nutrition surveys. *BMJ* 2014;**348**:g2272.
 166. Schwingshackl L, Bogensberger B, Bencic A, Knuppel S, Boeing H, Hoffmann G. Effects of oils and solid fats on blood lipids: a systematic review and network meta-analysis. *J Lipid Res* 2018;**59**:1771–1782.
 167. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis. *Am J Clin Nutr* 1992;**56**:320–328.
 168. Huffman KM, Hawk VH, Henes ST, Ocampo CI, Orenduff MC, Slentz CA, Johnson JL, Houmard JA, Samsa GP, Kraus WE, Bales CW. Exercise effects on lipids in persons with varying dietary patterns—does diet matter if they exercise? Responses in studies of a targeted risk reduction intervention through defined exercise I. *Am Heart J* 2012;**164**:117–124.
 169. Kraus WE, Houmard JA, Duscha BD, Knetzger KJ, Wharton MB, McCartney JS, Bales CW, Henes S, Samsa GP, Otvos JD, Kulkarni KR, Slentz CA. Effects of the amount and intensity of exercise on plasma lipoproteins. *N Engl J Med* 2002;**347**:1483–1492.
 170. Brien SE, Ronksley PE, Turner BJ, Mukamal KJ, Ghali WA. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. *BMJ* 2011;**342**:d636.
 171. De Natale C, Annuzzi G, Bozzetto L, Mazzarella R, Costabile G, Ciano O, Riccardi G, Rivellese AA. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. *Diabetes Care* 2009;**32**:2168–2173.
 172. Liu S, Manson JE, Stampfer MJ, Holmes MD, Hu FB, Hankinson SE, Willett WC. Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women. *Am J Clin Nutr* 2001;**73**:560–566.
 173. Stanhope KL, Medici V, Bremer AA, Lee V, Lam HD, Nunez MV, Chen GX, Keim NL, Havel PJ. A dose-response study of consuming high-fructose corn syrup-sweetened beverages on lipid/lipoprotein risk factors for cardiovascular disease in young adults. *Am J Clin Nutr* 2015;**101**:1144–1154.
 174. Taskinen MR, Soderlund S, Bogl LH, Hakkarainen A, Matikainen N, Pietilainen KH, Rasanen S, Lundbom N, Bjornson E, Eliasson B, Mancina RM, Romeo S, Almeras N, Pepa GD, Vetrani C, Prinster A, Annuzzi G, Rivellese A, Despres JP, Boren J. Adverse effects of fructose on cardiometabolic risk factors and hepatic lipid metabolism in subjects with abdominal obesity. *J Intern Med* 2017;**282**:187–201.
 175. Look Ahead Research Group, Wing RR, Bolin P, Brancati FL, Bray GA, Clark JM, Coday M, Crow RS, Curtis JM, Egan CM, Espeland MA, Evans M, Foreyt JP, Gazarian S, Gregg EV, Harrison B, Hazuda HP, Hill JO, Horton ES, Hubbard VS, Jakicic JM, Jeffery RW, Johnson KC, Kahn SE, Kitabchi AE, Knowler WC, Lewis CE, Maschak-Carey BJ, Montez MG, Murillo A, Nathan DM, Patricia J, Peters A, Pi-Sunyer X, Pownall H, Reboussin D, Regensteiner JG, Rickman AD, Ryan DH, Safford M, Wadden TA, Wagenknecht LE, West DS, Williamson DF, Yanovski SZ. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. *N Engl J Med* 2013;**369**:145–154.
 176. Batsis JA, Gill LE, Masutani RK, Adachi-Mejia AM, Blunt HB, Bagley PJ, Lopez-Jimenez F, Bartels SJ. Weight loss interventions in older adults with obesity: a systematic review of randomized controlled trials since 2005. *J Am Geriatr Soc* 2017;**65**:257–268.
 177. Harris WS, Mozaffarian D, Rimm E, Kris-Etherton P, Rudel LL, Appel LJ, Engler MM, Engler MB, Sacks F. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. *Circulation* 2009;**119**:902–907.
 178. Mozaffarian D, Lemaitre RN, King IB, Song X, Huang H, Sacks FM, Rimm EB, Wang M, Siscovick DS. Plasma phospholipid long-chain omega-3 fatty acids and total and cause-specific mortality in older adults: a cohort study. *Ann Intern Med* 2013;**158**:515–525.
 179. Riccardi G, Vaccaro O, Costabile G, Rivellese AA. How well can we control dyslipidemias through lifestyle modifications? *Curr Cardiol Rep* 2016;**18**:66.
 180. Seidelmann SB, Claggett B, Cheng S, Henglin M, Shah A, Steffen LM, Folsom AR, Rimm EB, Willett WC, Solomon SD. Dietary carbohydrate intake and

- mortality: a prospective cohort study and meta-analysis. *Lancet Public Health* 2018;**3**:e419–e428.
181. Dehghan M, Mente A, Rangarajan S, Sheridan P, Mohan V, Iqbal R, Gupta R, Lear S, Wentzel-Viljoen E, Avezum A, Lopez-Jaramillo P, Mony P, Varma RP, Kumar R, Chifamba J, Alhabib KF, Mohammadifard N, Ogunz O, Lanus F, Rozanska D, Bostrom KB, Yusuf K, Tsolkile LP, Dans A, Yusufali A, Orlandini A, Poirier P, Khatib R, Hu B, Wei L, Yin L, Deerali A, Yeates K, Yusuf R, Ismail N, Mozaffarian D, Teo K, Anand SS, Yusuf S; Prospective Urban Rural Epidemiology study investigators. Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. *Lancet* 2018;**392**:2288–2297.
 182. Poli A, Marangoni F, Paoletti R, Mannarino E, Lupattelli G, Notarbartolo A, Aureli P, Bernini F, Cicero A, Gaddi A, Catapano A, Ricelli C, Gattone M, Marrocco W, Porrini M, Stella R, Vanotti A, Volpe M, Volpe R, Cannella C, Pinto A, Del Toma E, La Vecchia C, Tavani A, Manzato E, Riccardi G, Sirtori C, Zamboni A; Nutrition Foundation of Italy. Non-pharmacological control of plasma cholesterol levels. *Nutr Metab Cardiovasc Dis* 2008;**18**:S1–S16.
 183. Global Burden of Disease 2016 Alcohol Collaborators. Alcohol use and burden for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 2018;**392**:1015–1035.
 184. Wood AM, Kaptoge S, Butterworth AS, Willeit P, Warnakula S, Bolton T, Paige E, Paul DS, Sweeting M, Burgess S, Bell S, Astle W, Stevens D, Koulman A, Selmer RM, Verschuren WMM, Sato S, Njolstad I, Woodward M, Salomaa V, Nordestgaard BG, Yeap BB, Fletcher A, Melander O, Kuller LH, Balkau B, Marmot M, Koenig W, Casiglia E, Cooper C, Arndt V, Franco OH, Wennberg P, Gallacher J, de la Camara AG, Volzke H, Dahm CC, Dale CE, Bergmann MM, Crespo CJ, van der Schouw YT, Kaaks R, Simons LA, Lagiou P, Schoufour JD, Boer JMA, Key TJ, Rodriguez B, Moreno-Iribas C, Davidson KW, Taylor JO, Sacerdote C, Wallace RB, Quiros JR, Trichopoulos A, Kuhn T, Grobbee DE, Barrett-Connor E, van Schoor N, Boeing H, Overvad K, Kahonen J, Wareham N, Langenberg C, Forouhi N, Wennberg M, Despres JP, Cushman M, Cooper JA, Rodriguez CJ, Sakurai M, Shaw JE, Knuiam M, Voortman T, Meisinger C, Tjonneland A, Brenner H, Palmieri L, Dallongeville J, Brunner EJ, Assmann G, Trevisan M, Gillum RF, Ford I, Sattar N, Lazo M, Thompson SG, Ferrari P, Leon DA, Smith GD, Peto R, Jackson R, Banks E, Di Angelantonio E, Danesh J; Emerging Risk Factors Collaboration/EPIC-CVD/UK Biobank Alcohol Study Group. Risk thresholds for alcohol consumption: combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet* 2018;**391**:1513–1523.
 185. De Backer GG. Food supplements with red yeast rice: more regulations are needed. *Eur J Prev Cardiol* 2017;**24**:1429–1430.
 186. Hartley L, May MD, Loveman E, Colquitt JL, Rees K. Dietary fibre for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2016;**1**:CD011472.
 187. Pirro M, Vetrani C, Bianchi C, Mannarino MR, Bernini F, Rivellese AA. Joint position statement on "Nutraceuticals for the treatment of hypercholesterolemia" of the Italian Society of Diabetology (SID) and of the Italian Society for the Study of Arteriosclerosis (SISA). *Nutr Metab Cardiovasc Dis* 2017;**27**:2–17.
 188. Dewell A, Hollenbeck PL, Hollenbeck CB. Clinical review: a critical evaluation of the role of soy protein and isoflavone supplementation in the control of plasma cholesterol concentrations. *J Clin Endocrinol Metab* 2006;**91**:772–780.
 189. Mas R, Castano G, Illnait J, Fernandez L, Fernandez J, Aleman C, Pontigas V, Lescay M. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. *Clin Pharmacol Ther* 1999;**65**:439–447.
 190. Reiner Z, Tedeschi-Reiner E, Romic Z. Effects of rice policosanol on serum lipoproteins, homocysteine, fibrinogen and C-reactive protein in hypercholesterolaemic patients. *Clin Drug Investig* 2005;**25**:701–707.
 191. Lan J, Zhao Y, Dong F, Yan Z, Zheng W, Fan J, Sun G. Meta-analysis of the effect and safety of berberine in the treatment of type 2 diabetes mellitus, hyperlipemia and hypertension. *J Ethnopharmacol* 2015;**161**:69–81.
 192. Sacks FM, Lichtenstein AH, Wu JHY, Appel LJ, Creager MA, Kris-Etherton PM, Miller M, Rimm EB, Rudel LL, Robinson JG, Stone NJ, Van Horn LV; American Heart Association. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. *Circulation* 2017;**136**:e1–e23.
 193. Jacobson TA, Glickstein SB, Rowe JD, Soni PN. Effects of eicosapentaenoic acid and docosahexaenoic acid on low-density lipoprotein cholesterol and other lipids: a review. *J Clin Lipidol* 2012;**6**:5–18.
 194. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med* 2019;**380**:11–22.
 195. Chasman DI, Giulianini F, MacFadyen J, Barratt BJ, Nyberg F, Ridker PM. Genetic determinants of statin-induced low-density lipoprotein cholesterol reduction: the Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) trial. *Circ Cardiovasc Genet* 2012;**5**:257–264.
 196. Reiner Z. Resistance and intolerance to statins. *Nutr Metab Cardiovasc Dis* 2014;**24**:1057–1066.
 197. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, Bruckert E, Jacobson TA, Kopecky SL, Baccara-Dinet MT, Du Y, Porfy R, Gipe DA; ODYSSEY ALTERNATIVE Investigators. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial. *J Clin Lipidol* 2015;**9**:758–769.
 198. Stroes E, Colquhoun D, Sullivan D, Civeira F, Rosenson RS, Watts GF, Bruckert E, Cho L, Dent R, Knusel B, Xue A, Scott R, Wasserman SM, Rocca M; GAUSS-2 Investigators. Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab. *J Am Coll Cardiol* 2014;**63**:2541–2548.
 199. Reiner Z. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update. *Nutr Metab Cardiovasc Dis* 2013;**23**:799–807.
 200. Sharma A, Joshi PH, Rinehart S, Thakker KM, Lele A, Voros S. Baseline very low-density lipoprotein cholesterol is associated with the magnitude of triglyceride lowering on statins, fenofibrate, or their combination in patients with mixed dyslipidemia. *J Cardiovasc Transl Res* 2014;**7**:465–474.
 201. Barter PJ, Brandrup-Wognsen G, Palmer MK, Nicholls SJ. Effect of statins on HDL-C: a complex process unrelated to changes in LDL-C: analysis of the VOYAGER Database. *J Lipid Res* 2010;**51**:1546–1553.
 202. Tsimikas S, Witztum JL, Miller ER, Sasiela WJ, Szarek M, Olsson AG, Schwartz GG; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. *Circulation* 2004;**110**:1406–1412.
 203. Khera AV, Everett BM, Caulfield MP, Hantash FM, Wohlgemuth J, Ridker PM, Mora S. Lipoprotein(a) concentrations, rosuvastatin therapy, and residual vascular risk: an analysis from the JUPITER Trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). *Circulation* 2014;**129**:635–642.
 204. Davignon J. Beneficial cardiovascular pleiotropic effects of statins. *Circulation* 2004;**109**:III39–III43.
 205. Oesterle A, Laufs U, Liao JK. Pleiotropic effects of statins on the cardiovascular system. *Circ Res* 2017;**120**:229–243.
 206. Pedersen TR. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering. *Am J Cardiovasc Drugs* 2010;**10**:10–17.
 207. Genser B, Marz W. Low density lipoprotein cholesterol, statins and cardiovascular events: a meta-analysis. *Clin Res Cardiol* 2006;**95**:393–404.
 208. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. *Circulation* 1995;**91**:2274–2282.
 209. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. *Circulation* 1998;**97**:946–952.
 210. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. *JAMA* 1999;**282**:2340–2346.
 211. Mills EJ, Wu P, Chong G, Ghement I, Singh S, Akl EA, Eyawo O, Guyatt G, Bravanger O, Briel M. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170,255 patients from 76 randomized trials. *QJM* 2011;**104**:109–124.
 212. Ray KK, Seshasai SR, Erqou S, Sever P, Jukema JW, Ford I, Sattar N. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65,229 participants. *Arch Intern Med* 2010;**170**:1024–1031.
 213. Taylor F, Huffman MD, Macedo AF, Moore TH, Burke M, Davey Smith G, Ward K, Ebrahim S. Statins for the primary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2013;**1**:CD004816.
 214. Cholesterol Treatment Trialists Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellstrom B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. *Lancet Diabetes Endocrinol* 2016;**4**:829–839.
 215. Naci H, Bruggs JJ, Fleurence R, Tsoi B, Toor H, Ades AE. Comparative benefits of statins in the primary and secondary prevention of major coronary events and all-cause mortality: a network meta-analysis of placebo-controlled and active-comparator trials. *Eur J Prev Cardiol* 2013;**20**:641–657.
 216. Ford I, Murray H, McCowan C, Packard CJ. Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study. *Circulation* 2016;**133**:1073–1080.

217. Cholesterol Treatment Trialists C. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. *Lancet* 2019;**393**:407–415.
218. Rogers JK, Jhund PS, Perez AC, Bohm M, Cleland JG, Gullestad L, Kjekshus J, van Veldhuisen DJ, Wikstrand J, Wedel H, McMurray JJ, Pocock SJ. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). *JACC Heart Fail* 2014;**2**:289–297.
219. Tavazzi L, Maggioni AP, Marchioli R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G, Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;**372**:1231–1239.
220. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, Ritz E; German Diabetes and Dialysis Study Investigators. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. *N Engl J Med* 2005;**353**:238–248.
221. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, Chae DW, Chevaile A, Cobbe G, Gissi-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;**372**:1231–1239.
222. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, Wanner C, Krane V, Cass A, Craig J, Neal B, Jiang L, Hooi LS, Levin A, Agodoa L, Gaziano M, Kasiske B, Walker R, Massy ZA, Feldt-Rasmussen B, Krairitichai U, Ophascharoensuk V, Fellstrom B, Holdaas H, Tesar V, Wiecek A, Grobbee D, de Zeeuw D, Gronhagen-Riska C, Dasgupta T, Lewis D, Herrington W, Mafham M, Majoni W, Wallendzus K, Grimm R, Pedersen T, Tobert J, Armitage J, Baxter A, Bray C, Chen Y, Chen Z, Hill M, Knott C, Parish S, Simpson D, Sleight P, Young A, Collins R; SHARP Investigators. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. *Lancet* 2011;**377**:2181–2192.
223. Cholesterol Treatment Trialists Collaboration, Emberson JR, Kearney PM, Blackwell L, Newman C, Reith C, Bhalal N, Holland L, Peto R, Keech A, Collins R, Simes J, Baigent C. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. *PLoS One* 2012;**7**:e29849.
224. McGuinness B, Craig D, Bullock R, Malouf R, Passmore P. Statins for the treatment of dementia. *Cochrane Database Syst Rev* 2014;**7**:CD007514.
225. Eslami L, Merat S, Malekzadeh R, Nasser-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. *Cochrane Database Syst Rev* 2013;**12**:CD008623.
226. Rahimi K, Bhalal N, Kamphuisen P, Emberson J, Biere-Rafi S, Krane V, Robertson M, Wikstrand J, McMurray J. Effect of statins on venous thromboembolic events: a meta-analysis of published and unpublished evidence from randomised controlled trials. *PLoS Med* 2012;**9**:e1001310. doi: 10.1371/journal.pmed.1001310. Epub 18 September 2012.
227. Rahimi K, Emberson J, McGale P, Majoni W, Merhi A, Asselbergs FW, Krane V, Macfarlane PW; PROSPER Executive. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials. *BMJ* 2011;**342**:d1250.
228. Zheng Z, Jayaram R, Jiang L, Emberson J, Zhao Y, Li Q, Du J, Guarguagli S, Hill M, Chen Z, Collins R, Casadei B. Perioperative rosuvastatin in cardiac surgery. *N Engl J Med* 2016;**374**:1744–1753.
229. Raval AD, Hunter T, Stuckey B, Hart RJ. Statins for women with polycystic ovary syndrome not actively trying to conceive. *Cochrane Database Syst Rev* 2011;**10**:CD008565.
230. McGuinness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. *Cochrane Database Syst Rev* 2016;**1**:CD003160.
231. Giugliano RP, Mach F, Zavitz K, Kurtz C, Im K, Kanevsky E, Schneider J, Wang H, Keech A, Pedersen TR, Sabatine MS, Sever PS, Robinson JG, Honarpour N, Wasserman SM, Ott BR; EBBINGHAUS Investigators. Cognitive function in a randomized trial of evolocumab. *N Engl J Med* 2017;**377**:633–643.
232. Mach F, Ray KK, Wiklund O, Corsini A, Catapano AL, Bruckert E, De Backer G, Hegele RA, Hovingh GK, Jacobson TA, Krauss RM, Laufs U, Leiter LA, Marz W, Nordestgaard BG, Raal FJ, Roden M, Santos RD, Stein EA, Stroes ES, Thompson PD, Tokgozoglu L, Vladutiu GD, Gencer B, Stock JK, Ginsberg HN, Chapman MJ; European Atherosclerosis Society Consensus Panel. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *Eur Heart J* 2018;**39**:2526–2539.
233. Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R. Interpretation of the evidence for the efficacy and safety of statin therapy. *Lancet* 2016;**388**:2532–2561.
234. Stroes ES, Thompson PD, Corsini A, Vladutiu GD, Raal FJ, Ray KK, Roden M, Stein E, Tokgozoglu L, Nordestgaard BG, Bruckert E, De Backer G, Krauss RM, Laufs U, Santos RD, Hegele RA, Hovingh GK, Leiter LA, Mach F, Marz W, Newman CB, Wiklund O, Jacobson TA, Catapano AL, Chapman MJ, Ginsberg HN; European Atherosclerosis Society Consensus Panel. Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *Eur Heart J* 2015;**36**:1012–1022.
235. Law M, Rudnicka AR. Statin safety: a systematic review. *Am J Cardiol* 2006;**97**:52C–60C.
236. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients—the PRIMO study. *Cardiovasc Drugs Ther* 2005;**19**:403–414.
237. Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. *Am J Cardiol* 2006;**97**:32C–43C.
238. Gupta A, Thompson D, Whitehouse A, Collier T, Dahlof B, Poulter N, Collins R, Sever P; ASCOT Investigators. Adverse events associated with unblinded, but not with blinded, statin therapy in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA): a randomised double-blind placebo-controlled trial and its non-randomised non-blind extension phase. *Lancet* 2017;**389**:2473–2481.
239. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. *Eur J Prev Cardiol* 2014;**21**:464–474.
240. Naci H, Bruggs J, Ades T. Comparative tolerability and harms of individual statins: a study-level network meta-analysis of 246 955 participants from 135 randomized, controlled trials. *Circ Cardiovasc Qual Outcomes* 2013;**6**:390–399.
241. Moriarty PM, Jacobson TA, Bruckert E, Thompson PD, Guyton JR, Baccara-Dinet MT, Gipe D. Efficacy and safety of alirocumab, a monoclonal antibody to PCSK9, in statin-intolerant patients: design and rationale of ODYSSEY ALTERNATIVE, a randomized phase 3 trial. *J Clin Lipidol* 2014;**8**:554–561.
242. Keating AJ, Campbell KB, Guyton JR. Intermittent nondaily dosing strategies in patients with previous statin-induced myopathy. *Ann Pharmacother* 2013;**47**:398–404.
243. Marcum ZA, Vande Griend JP, Linnebur SA. FDA drug safety communications: a narrative review and clinical considerations for older adults. *Am J Geriatr Pharmacother* 2012;**10**:264–271.
244. Chalasani N, Aljadhey H, Kesterson J, Murray MD, Hall SD. Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity. *Gastroenterology* 2004;**126**:1287–1292.
245. Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, Maggioni M, Kakela P, Wiklund O, Mozzi E, Grimaudo S, Kaminska D, Rametta R, Craxi A, Fargion S, Nobili V, Romeo S, Pihlajamaki J, Valenti L. Statin use and non-alcoholic steatohepatitis in at risk individuals. *J Hepatol* 2015;**63**:705–712.
246. Vuppalanchi R, Teal E, Chalasani N. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes. *Am J Med Sci* 2005;**329**:62–65.
247. Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. *Lancet* 2010;**375**:735–742.
248. Preiss D, Seshasai SR, Welsh P, Murphy SA, Ho JE, Waters DD, DeMicco DA, Barter P, Cannon CP, Sabatine MS, Braunwald E, Kastelein JJ, de Lemos JA, Blazing MA, Pedersen TR, Tikkanen MJ, Sattar N, Ray KK. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. *JAMA* 2011;**305**:2556–2564.
249. Waters DD, Ho JE, Boekholdt SM, DeMicco DA, Kastelein JJ, Messig M, Breazna A, Pedersen TR. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. *J Am Coll Cardiol* 2013;**61**:148–152.
250. Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JE, Shah T, Sofat R, Stender S, Johnson PC, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmén J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MC, Tzoulaki I, Buxbaum SG, van der AD, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Bacevicevic M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RG, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, Consortium D,

- Consortium M, InterAct C, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJ, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SR, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WM, Redline S, Patel SR, Whittaker JC, Hamsten A, Delaney JA, Dale C, Gaunt TR, Wong A, Kuh D, Hardy R, Kathiresan S, Castillo BA, van der Harst P, Brunner EJ, Tybjaerg-Hansen A, Marmot MG, Krauss RM, Tsai M, Coresh J, Hoogetveen RC, Psaty BM, Lange LA, Hakonarson H, Dudbridge F, Humphries SE, Talmud PJ, Kivimaki M, Timpson NJ, Langenberg C, Asselbergs FW, Voevoda M, Bobak M, Pikhart H, Wilson JG, Reiner AP, Keating BJ, Hingorani AD, Sattar N. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. *Lancet* 2015;**385**:351–361.
251. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. *Stroke* 2012;**43**:2149–2156.
252. Hackam DG, Woodward M, Newby LK, Bhatt DL, Shao M, Smith EE, Donner A, Mamdani M, Douketis JD, Arima H, Chalmers J, MacMahon S, Tirschwell DL, Psaty BM, Bushnell CD, Aguilar MI, Capampangan DJ, Werring DJ, De Rango P, Viswanathan A, Danchin N, Cheng CL, Yang YH, Verdell BM, Lai MS, Kennedy J, Uchiyama S, Yamaguchi T, Ikeda Y, Mrkobrada M. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. *Circulation* 2011;**124**:2233–2242.
253. Palmer SC, Navaneethan SD, Craig JC, Perkovic V, Johnson DW, Nigwekar SU, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for kidney transplant recipients. *Cochrane Database Syst Rev* 2014;**1**:CD005019.
254. Agarwal R. Effects of statins on renal function. *Am J Cardiol* 2006;**97**:748–755.
255. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ. Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. *J Am Soc Nephrol* 2004;**15**:2258–2265.
256. Davidson MH. Rosuvastatin safety: lessons from the FDA review and post-approval surveillance. *Expert Opin Drug Saf* 2004;**3**:547–557.
257. Egan A, Colman E. Weighing the benefits of high-dose simvastatin against the risk of myopathy. *N Engl J Med* 2011;**365**:285–287.
258. Wiklund O, Pirazzi C, Romeo S. Monitoring of lipids, enzymes, and creatine kinase in patients on lipid-lowering drug therapy. *Curr Cardiol Rep* 2013;**15**:397.
259. Franssen R, Vergeer M, Stroes ES, Kastelein JJ. Combination statin-fibrate therapy: safety aspects. *Diabetes Obes Metab* 2009;**11**:89–94.
260. Holoshitz N, Alsheikh-Ali AA, Karas RH. Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use. *Am J Cardiol* 2008;**101**:95–97.
261. Phan BA, Dayspring TD, Toth PP. Ezetimibe therapy: mechanism of action and clinical update. *Vasc Health Risk Manag* 2012;**8**:415–427.
262. Pandor A, Ara RM, Tumor I, Wilkinson AJ, Paisley S, Duenas A, Durrington PN, Chilcott J. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta-analysis of randomized controlled trials. *J Intern Med* 2009;**265**:568–580.
263. Morrone D, Weintraub VS, Toth PP, Hanson ME, Lowe RS, Lin J, Shah AK, Tershakovec AM. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials. *Atherosclerosis* 2012;**223**:251–261.
264. Jones MR, Nwose OM. Role of colessevelam in combination lipid-lowering therapy. *Am J Cardiovasc Drugs* 2013;**13**:315–323.
265. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceska R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA; Gauss-3 Investigators. Efficacy and tolerability of evolocumab vs ezetimibe in patients with muscle-related statin intolerance: the GAUSS-3 randomized clinical trial. *JAMA* 2016;**315**:1580–1590.
266. Rossebø AB, Pedersen TR, Boman K, Brudi P, Chambers JB, Egstrup K, Gerds E, Gohlke-Bärwolf C, Holme I, Kesäniemi YA, Malbecq WV, Nienaber CA, Ray S, Skjaerpe T, Wachtell K, Willenheimer R; SEAS Investigators. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. *N Engl J Med* 2008;**359**:1343–1356.
267. Sharp Collaborative Group. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease. *Am Heart J* 2010;**160**:785–794.e10.
268. Ference BA, Cannon CP, Landmesser U, Luscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration. *Eur Heart J* 2018;**39**:2540–2545.
269. Myocardial Infarction Genetics Consortium Investigators, Stitzel NO, Won HH, Morrison AC, Peloso GM, Do R, Lange LA, Fontanillas P, Gupta N, Duga S, Goel A, Farrall M, Saleheen D, Ferrario P, König I, Asselta R, Merlini PA, Marziliano N, Notarangelo MF, Schick U, Auer P, Assimes TL, Reilly M, Wilensky R, Rader DJ, Hovingh GK, Meitinger T, Kessler T, Kastrati A, Laugwitz KL, Siscovick D, Rotter JJ, Hazen SL, Tracy R, Cresci S, Spertus J, Jackson R, Schwartz SM, Natarajan P, Crosby J, Muzny D, Ballantyne C, Rich SS, O'Donnell CJ, Abecasis G, Sunyaev S, Nickerson DA, Buring JE, Ridker PM, Chasman DI, Austin E, Ye Z, Kullo IJ, Weeke PE, Shaffer CM, Bastarache LA, Denny JC, Roden DM, Palmer C, Deloukas P, Lin DY, Tang ZZ, Erdmann J, Schunkert H, Danesh J, Marrugat J, Elosua R, Ardissino D, McPherson R, Watkins H, Reiner AP, Wilson JG, Altshuler D, Gibbs RA, Lander ES, Boerwinkle E, Gabriel S, Kathiresan S. Inactivating mutations in NPC1L1 and protection from coronary heart disease. *N Engl J Med* 2014;**371**:2072–2082.
270. Pirillo A, Catapano AL, Norata GD. Niemann-Pick C1-Like 1 (NPC1L1) inhibition and cardiovascular diseases. *Curr Med Chem* 2016;**23**:983–999.
271. Tsujita K, Sugiyama S, Sumida H, Shimomura H, Yamashita T, Yamanaga K, Komura N, Sakamoto K, Oka H, Nakao K, Nakamura S, Ishihara M, Matsui K, Sakaino N, Nakamura N, Yamamoto N, Koide S, Matsumura T, Fujimoto K, Tsunoda R, Morikami Y, Matsuyama K, Oshima S, Kaikita K, Hokimoto S, Ogawa H; PRECISE-IVUS Investigators. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. *J Am Coll Cardiol* 2015;**66**:495–507.
272. Khan SU, Talluri S, Riaz H, Rahman H, Nasir F, Bin Riaz I, Sattar S, Ahmed H, Kaluski E, Krasuski R. A Bayesian network meta-analysis of PCSK9 inhibitors, statins and ezetimibe with or without statins for cardiovascular outcomes. *Eur J Prev Cardiol* 2018;**25**:844–853.
273. Koskinas KC, Siontis GCM, Piccolo R, Mavridis D, Raber L, Mach F, Windecker S. Effect of statins and non-statin LDL-lowering medications on cardiovascular outcomes in secondary prevention: a meta-analysis of randomized trials. *Eur Heart J* 2018;**39**:1172–1180.
274. Mazidi M, Rezaie P, Karimi E, Kengne AP. The effects of bile acid sequestrants on lipid profile and blood glucose concentrations: a systematic review and meta-analysis of randomized controlled trials. *Int J Cardiol* 2017;**227**:850–857.
275. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus: an abridged Cochrane review. *Diabet Med* 2014;**31**:2–14.
276. The Lipid Research Clinics Program. Pre-entry characteristics of participants in the Lipid Research Clinics' Coronary Primary Prevention Trial. *J Chronic Dis* 1983;**36**:467–479.
277. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. *JAMA* 1984;**251**(3):351–64.
278. The Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial. Results of 6 years of post-trial follow-up. The Lipid Research Clinics Investigators. *Arch Intern Med* 1992;**152**:1399–1410.
279. He L, Wickremasingha P, Lee J, Tao B, Mendell-Harary J, Walker J, Wight D. Lack of effect of colessevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. *Diabetes Res Clin Pract* 2014;**104**:401–409.
280. Abifadel M, Varret M, Rabes JP, Allard D, Ouguerram K, Devillers M, Cruaud C, Benjannet S, Wickham L, Erlich D, Derré A, Villegier L, Farnier M, Beucler I, Bruckert E, Chambaz J, Chanu B, Lecerf JM, Luc G, Moulin P, Weissenbach J, Prat A, Krempf M, Junien C, Seidah NG, Boileau C. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. *Nat Genet* 2003;**34**:154–156.
281. Norata GD, Tibolla G, Catapano AL. Targeting PCSK9 for hypercholesterolemia. *Annu Rev Pharmacol Toxicol* 2014;**54**:273–293.
282. Nozue T. Lipid lowering therapy and circulating PCSK9 concentration. *J Atheroscler Thromb* 2017;**24**:895–907.
283. Cho L, Rocco M, Colquhoun D, Sullivan D, Rosenson RS, Dent R, Xue A, Scott R, Wasserman SM, Stroes E. Clinical profile of statin intolerance in the phase 3 GAUSS-2 Study. *Cardiovasc Drugs Ther* 2016;**30**:297–304.
284. Schmidt AF, Pearce LS, Wilkins JT, Overington JP, Hingorani AD, Casas JP. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2017;**4**:CD011748.
285. Thedrez A, Blom DJ, Ramin-Mangata S, Blanchard V, Croyal M, Chemello K, Nativel B, Pichelin M, Cariou B, Bourane S, Tang L, Farnier M, Raal FJ, Lambert G. Homozygous familial hypercholesterolemia patients with identical mutations variably express the LDLR (low-density lipoprotein receptor): implications for the efficacy of evolocumab. *Arterioscler Thromb Vasc Biol* 2018;**38**:592–598.
286. Robinson JG, Farnier M, Krempf M, Bergeron J, Luc G, Averna M, Stroes ES, Langslet G, Raal FJ, El Shahawy M, Koren MJ, Lepor NE, Lorenzato C, Pordy R, Chaudhari U, Kastelein JJ; ODYSSEY LONG TERM Investigators. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. *N Engl J Med* 2015;**372**:1489–1499.

287. Stein EA, Turner TA. Are the PCSK9 inhibitors the panacea of atherosclerosis treatment? *Expert Rev Cardiovasc Ther* 2017;**15**:491–494.
288. Gaudet D, Kereiakes DJ, McKenney JM, Roth EM, Hanotin C, Gipe D, Du Y, Ferrand AC, Ginsberg HN, Stein EA. Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). *Am J Cardiol* 2014;**114**:711–715.
289. Raal FJ, Giugliano RP, Sabatine MS, Koren MJ, Langset G, Bays H, Blom D, Eriksson M, Dent R, Wasserman SM, Huang F, Xue A, Albizem M, Scott R, Stein EA. Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. *J Am Coll Cardiol* 2014;**63**:1278–1288.
290. Sabatine MS, Giugliano RP, Wiviott SD, Raal FJ, Blom DJ, Robinson J, Ballantyne CM, Somaratne R, Legg J, Wasserman SM, Scott R, Koren MJ, Stein EA: Open-Label Study of Long-Term Evaluation against LDL Cholesterol (OSLER) Investigators. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. *N Engl J Med* 2015;**372**:1500–1509.
291. Navarese EP, Kolodziejczak M, Kereiakes DJ, Tantry US, O'Connor C, Gurbel PA. Proprotein convertase subtilisin/kexin type 9 monoclonal antibodies for acute coronary syndrome: a narrative review. *Ann Intern Med* 2016;**164**:600–607.
292. Cicero AF, Tartagni E, Ertek S. Safety and tolerability of injectable lipid-lowering drugs: a review of available clinical data. *Expert Opin Drug Saf* 2014;**13**:1023–1030.
293. Lipinski MJ, Benedetto U, Escarcega RO, Biondi-Zoccai G, Lhermusier T, Baker NC, Torguson R, Brewer HB Jr, Waksman R. The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis. *Eur Heart J* 2016;**37**:536–545.
294. Schmidt AF, Swerdlow DI, Holmes MV, Patel RS, Fairhurst-Hunter Z, Lyall DM, Hartwig FP, Horta BL, Hypponen E, Power C, Moldovan M, van Iperen E, Hovingh GK, Demuth I, Norman K, Steinhagen-Thiessen E, Demuth J, Bertram L, Liu T, Coassin S, Willeit J, Kiechl S, Willeit K, Mason D, Wright J, Morris R, Wanamethee G, Whincup P, Ben-Shlomo Y, McLachlan S, Price JF, Kivimaki M, Welch C, Sanchez-Galvez A, Marques-Vidal P, Nicolaidis A, Panayiotou AG, Onland-Moret NC, van der Schouw YT, Matullo G, Fiorito G, Guarrera S, Sacerdote C, Wareham NJ, Langenberg C, Scott R, Luan J, Bobak M, Malyutina S, Pajak A, Kubinova R, Tamosiunas A, Pikhart H, Husemoen LL, Garup N, Pedersen O, Hansen T, Linneberg A, Simonsen KS, Cooper J, Humphries SE, Brilliant M, Kitchner T, Hakonarson H, Carrell DS, McCarty CA, Kirchner HL, Larson EB, Crosslin DR, de Andrade M, Roden DM, Denny JC, Carty C, Hancock S, Attia J, Holliday E, O'Donnell M, Yusuf S, Chong M, Pare G, van der Harst P, Said MA, Eppinga RN, Verweij N, Snieder H, LifeLines Cohort study g, Christen T, Mook-Kanamori DO, Gustafsson S, Lind L, Ingelsson E, Pazoki R, Franco O, Hofman A, Uitterlinden A, Dehghan A, Teumer A, Baumeister S, Dorr M, Lerch MM, Volker U, Volzke H, Ward J, Pell JP, Smith DJ, Meade T, Maitland-van der Zee AH, Baranova EV, Young R, Ford I, Campbell A, Padmanabhan S, Bots ML, Grobbee DE, Froguel P, Thuillier D, Balkau B, Bonnefond A, Cariou B, Smart M, Bao Y, Kumari M, Mahajan A, Ridker PM, Chasman DI, Reiner AP, Lange LA, Ritchie MD, Asselbergs FW, Casas JP, Keating BJ, Preiss D, Hingorani AD, UCLEB consortium, Sattar N. PCSK9 genetic variants and risk of type 2 diabetes: a Mendelian randomisation study. *Lancet Diabetes Endocrinol* 2017;**5**:97–105.
295. Cao YX, Liu HH, Dong QT, Li S, Li JJ. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: a systematic review and meta-analysis. *Diabetes Obes Metab* 2018;**20**:1391–1398.
296. de Carvalho LSF, Campos AM, Sposito AC. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and incident type 2 diabetes: a systematic review and meta-analysis with over 96,000 patient-years. *Diabetes Care* 2018;**41**:364–367.
297. Sabatine MS, Leiter LA, Wiviott SD, Giugliano RP, Deedwania P, De Ferrari GM, Murphy SA, Kuder JF, Gouni-Berthold I, Lewis BS, Handelsman Y, Pineda AL, Honarpour N, Keech AC, Sever PS, Pedersen TR. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. *Lancet Diabetes Endocrinol* 2017;**5**:941–950.
298. Zhang XL, Zhu L, Wei ZH, Zhu QQ, Qiao JZ, Dai Q, Huang W, Li XH, Xie J, Kang LN, Wang L, Xu B. Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents: a systematic review and meta-analysis. *Ann Intern Med* 2016;**164**:752–763.
299. Giugliano RP, Cannon CP, Blazing MA, Nicolau JC, Corbalan R, Spinar J, Park JG, White JA, Bohula EA, Braunwald E; IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) Investigators. Benefit of adding ezetimibe to statin therapy on cardiovascular outcomes and safety in patients with versus without diabetes mellitus: results from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). *Circulation* 2018;**137**:1571–1582.
300. Ridker PM, Tardif JC, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C; SPIRE Investigators. Lipid-reduction variability and antidrug-antibody formation with bococizumab. *N Engl J Med* 2017;**376**:1517–1526.
301. Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Probert KJ, Sasiela WJ, Bloedon LT, Rader DJ; Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. *Lancet* 2013;**381**:40–46.
302. Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. *N Engl J Med* 2007;**356**:148–156.
303. Agarwala A, Jones P, Nambi V. The role of antisense oligonucleotide therapy in patients with familial hypercholesterolemia: risks, benefits, and management recommendations. *Curr Atheroscler Rep* 2015;**17**:467.
304. Li N, Li Q, Tian XQ, Qian HY, Yang YJ. Mipomersen is a promising therapy in the management of hypercholesterolemia: a meta-analysis of randomized controlled trials. *Am J Cardiovasc Drugs* 2014;**14**:367–376.
305. Chapman MJ, Redfern JS, McGovern ME, Giral P. Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk. *Pharmacol Ther* 2010;**126**:314–345.
306. Accord Study Group, Ginsberg HN, Elam MB, Lovato LC, Crouse JR III, Leiter LA, Linz P, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm RH, Ismail-Beigi F, Bigger JT, Goff DC Jr, Cushman WC, Simons-Morton DG, Byington RP. Effects of combination lipid therapy in type 2 diabetes mellitus. *N Engl J Med* 2010;**362**:1563–1574.
307. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forde P, Pillai A, Davis T, Glasziou P, Drury P, Kesaniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. *Lancet* 2005;**366**:1849–1861.
308. Frick MH, Elo O, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Manninen V, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. *N Engl J Med* 1987;**317**:1237–1245.
309. Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schemtman G, Wilt TJ, Wittes J. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. *N Engl J Med* 1999;**341**:410–418.
310. Lipids and lipoproteins in symptomatic coronary heart disease. Distribution, intercorrelations, and significance for risk classification in 6,700 men and 1,500 women. The Bezafibrate Infarction Prevention (BIP) Study Group, Israel. *Circulation* 1992;**86**:839–848.
311. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. *BMJ* 2002;**325**:1139.
312. Ip CK, Jin DM, Gao JJ, Meng Z, Meng J, Tan Z, Wang JF, Geng DF. Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials. *Int J Cardiol* 2015;**191**:138–148.
313. Keene D, Price C, Shun-Shin MJ, Francis DP. Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients. *BMJ* 2014;**349**:g4379.
314. Bruckert E, Labreuche J, Deplanque D, Touboul PJ, Amarenco P. Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis. *J Cardiovasc Pharmacol* 2011;**57**:267–272.
315. Jun M, Zhu B, Tonelli M, Jardine MJ, Patel A, Neal B, Liyanage T, Keech A, Cass A, Perkovic V. Effects of fibrates in kidney disease: a systematic review and meta-analysis. *J Am Coll Cardiol* 2012;**60**:2061–2071.
316. Lee M, Saver JL, Towfighi A, Chow J, Ovbiagele B. Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis. *Atherosclerosis* 2011;**217**:492–498.
317. Fruchart JC. Pemafibrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia. *Cardiovasc Diabetol* 2017;**16**:124.
318. Pradhan AD, Paynter NP, Everett BM, Glynn RJ, Amarenco P, Elam M, Ginsberg H, Hiatt WR, Ishibashi S, Koenig W, Nordestgaard BG, Fruchart JC, Libby P, Ridker PM. Rationale and design of the Pemafibrate to Reduce Cardiovascular

- Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. *Am Heart J* 2018;**206**:80–93.
319. Davidson MH, Armani A, McKenney JM, Jacobson TA. Safety considerations with fibrates therapy. *Am J Cardiol* 2007;**99**:3C–18C.
 320. Graham DJ, Staffa JA, Shatin D, Andrade SE, Schech SD, La Grenade L, Gurwitz JH, Chan KA, Goodman MJ, Platt R. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. *JAMA* 2004;**292**:2585–2590.
 321. Preiss D, Tikkanen MJ, Welsh P, Ford I, Lovato LC, Elam MB, LaRosa JC, DeMicco DA, Colhoun HM, Goldenberg I, Murphy MJ, MacDonald TM, Pedersen TR, Keech AC, Ridker PM, Kjekshus J, Sattar N, McMurray JJ. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. *JAMA* 2012;**308**:804–811.
 322. Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; FIELD study investigators. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. *Arterioscler Thromb Vasc Biol* 2009;**29**:950–955.
 323. Balk EM, Lichtenstein AH, Chung M, Kupelnick B, Chew P, Lau J. Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review. *Atherosclerosis* 2006;**189**:19–30.
 324. Ballantyne CM, Bays HE, Kastelein JJ, Stein E, Isaacsohn JL, Braeckman RA, Soni PN. Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study). *Am J Cardiol* 2012;**110**:984–992.
 325. Bays HE, Ballantyne CM, Kastelein JJ, Isaacsohn JL, Braeckman RA, Soni PN. Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, placebo-controlled, Randomized, double-blind, 12-week study with an open-label Extension [MARINE] trial). *Am J Cardiol* 2011;**108**:682–690.
 326. Kastelein JJ, Maki KC, Susekov A, Ezhov M, Nordestgaard BG, Machielse BN, Kling D, Davidson MH. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial. *J Clin Lipidol* 2014;**8**:94–106.
 327. Stroes ESG, Susekov AV, de Bruin TWA, Kvarnstrom M, Yang H, Davidson MH. Omega-3 carboxylic acids in patients with severe hypertriglyceridemia: EVOLVE II, a randomized, placebo-controlled trial. *J Clin Lipidol* 2018;**12**:321–330.
 328. Abdelhamid AS, Brown TJ, Brainard JS, Biswas P, Thorpe GC, Moore HJ, Deane KH, AlAbdulghafoor FK, Summerbell CD, Worthington HV, Song F, Hooper L. Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2018;**7**:CD003177.
 329. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J. Effects of n-3 fatty acid supplements in diabetes mellitus. *N Engl J Med* 2018;**379**:1540–1550.
 330. Hooper L, Thompson RL, Harrison RA, Summerbell CD, Ness AR, Moore HJ, Worthington HV, Durrington PN, Higgins JP, Capps NE, Riemersma RA, Ebrahim SB, Davey Smith G. Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review. *BMJ* 2006;**332**:752–760.
 331. Marchioli R, Barzi F, Bomba E, Chieffo C, Di Gregorio D, Di Mascio R, Franzosi MG, Geraci E, Levantesi G, Maggioni AP, Mantini L, Marfisi RM, Mastrogiuseppe G, Mininni N, Nicolosi GL, Santini M, Schweiger C, Tavazzi L, Tognoni G, Tucci C, Valagussa F; GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. *Circulation* 2002;**105**:1897–1903.
 332. Nicholls SJ, Lincoff AM, Bash D, Ballantyne CM, Barter PJ, Davidson MH, Kastelein JJP, Koenig W, McGuire DK, Mozaffarian D, Pedersen TR, Ridker PM, Ray K, Karlson BW, Lundstrom T, Wolksi K, Nissen SE. Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial. *Clin Cardiol* 2018;**41**:1281–1288.
 333. Manson JE, Cook NR, Lee IM, Christen W, Bassus SS, Mora S, Gibson H, Albert CM, Gordon D, Copeland T, D'Agostino D, Friedenberg G, Ridge C, Bubes V, Giovannucci EL, Willett WC, Buring JE; VITAL Research Group. Marine n-3 fatty acids and prevention of cardiovascular disease and cancer. *N Engl J Med* 2019;**380**:23–32.
 334. Brasky TM, Darke AK, Song X, Tangen CM, Goodman PJ, Thompson IM, Meyskens FL Jr, Goodman GE, Minasian LM, Parnes HL, Klein EA, Kristal AR. Plasma phospholipid fatty acids and prostate cancer risk in the SELECT trial. *J Natl Cancer Inst* 2013;**105**:1132–41.
 335. Kamanna VS, Kashyap ML. Mechanism of action of niacin. *Am J Cardiol* 2008;**101**:20B–26B.
 336. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, Komajda M, Lopez-Sendon J, Mosca L, Tardif JC, Waters DD, Shear CL, Revkin JH, Buhr KA, Fisher MR, Tall AR, Brewer B; ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. *N Engl J Med* 2007;**357**:2109–2122.
 337. Ference BA, Kastelein JJP, Ginsberg HN, Chapman MJ, Nicholls SJ, Ray KK, Packard CJ, Laufs U, Brook RD, Oliver-Williams C, Butterworth AS, Danesh J, Smith GD, Catapano AL, Sabatine MS. Association of genetic variants related to CETP inhibitors and statins with lipoprotein levels and cardiovascular risk. *JAMA* 2017;**318**:947–956.
 338. Fitzgerald K, White S, Borodovsky A, Bettencourt BR, Strahs A, Clausen V, Wijngaard P, Horton JD, Tubel J, Brooks A, Fernando C, Kauffman RS, Kallend D, Vaishnav A, Simon A. A highly durable RNAi therapeutic inhibitor of PCSK9. *N Engl J Med* 2017;**376**:41–51.
 339. Ray KK, Landmesser U, Leiter LA, Kallend D, Dufour R, Karakas M, Hall T, Troquay RP, Turner T, Visseren FL, Wijngaard P, Wright RS, Kastelein JJ. Inclisiran in patients at high cardiovascular risk with elevated LDL cholesterol. *N Engl J Med* 2017;**376**:1430–1440.
 340. Saeed A, Ballantyne CM. Bempedoic acid (ETC-1002): a current review. *Cardiol Clin* 2018;**36**:257–264.
 341. Ballantyne CM, Banach M, Mancini GBJ, Lepor NE, Hanselman JC, Zhao X, Leiter LA. Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study. *Atherosclerosis* 2018;**277**:195–203.
 342. Ray KK, Bays HE, Catapano AL, Lalwani ND, Bloedon LT, Sterling LR, Robinson PL, Ballantyne CM; CLEAR Harmony Trial. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. *N Engl J Med* 2019;**380**:1022–1032.
 343. Stitzel NO, Khera AV, Wang X, Bierhals AJ, Vourakis AC, Sperry AE, Natarajan P, Klarin D, Emdin CA, Zekavat SM, Nomura A, Erdmann J, Schunkert H, Samani NJ, Kraus WE, Shah SH, Yu B, Boerwinkle E, Rader DJ, Gupta N, Frossard PM, Rasheed A, Danesh J, Lander ES, Gabriel S, Saleheen D, Musunuru K, Kathiresan S; PROMIS and Myocardial Infarction Genetics Consortium Investigators. ANGPTL3 deficiency and protection against coronary artery disease. *J Am Coll Cardiol* 2017;**69**:2054–2063.
 344. Gaudet D, Gipe DA, Pordy R, Ahmad Z, Cuchel M, Shah PK, Chyu KY, Sasiela WJ, Chan KC, Brisson D, Khoury E, Banerjee P, Gusarova V, Gromada J, Stahl N, Yancopoulos GD, Hovingh GK. ANGPTL3 inhibition in homozygous familial hypercholesterolemia. *N Engl J Med* 2017;**377**:296–297.
 345. Graham MJ, Lee RG, Brandt TA, Tai LJ, Fu W, Peralta R, Yu R, Hurh E, Paz E, McEvoy BW, Baker BF, Pham NC, Digenio A, Hughes SG, Geary RS, Witztum JL, Crooke RM, Tsimikas S. Cardiovascular and metabolic effects of ANGPTL3 antisense oligonucleotides. *N Engl J Med* 2017;**377**:222–232.
 346. Graham MJ, Lee RG, Bell TA III, Fu W, Mullick AE, Alexander VJ, Singleton W, Viney N, Geary R, Su J, Baker BF, Burke J, Crooke ST, Crooke RM. Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans. *Circ Res* 2013;**112**:1479–1490.
 347. Gouni-Berthold I, Alexander V, Digenio A, DuFour R, Steinhagen-Thiessen E, Martin S, Moriarty P, Hughes S, Jones R, Witztum JL, Gaudet D. Apolipoprotein C-III inhibition with volanesorsen in patients with hypertriglyceridemia (COMPASS): a randomized, double-blind, placebo-controlled trial. *Atherosclerosis Supp* 2017;**28**:e1–e2.
 348. Gaudet D, Digenio A, Alexander V, Arca M, Jones A, Stroes E, Bergeron J, Civeira F, Hemphill L, Blom D, Flaim J, Hughes S, Geary R, Tsimikas S, Witztum J, Bruckert E. The approach study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). *Atherosclerosis* 2017;**263**:e10.
 349. Rocha NA, East C, Zhang J, McCullough PA. ApoCIII as a cardiovascular risk factor and modulation by the novel lipid-lowering agent volanesorsen. *Curr Atheroscler Rep* 2017;**19**:62.
 350. Didichenko SA, Navdaev AV, Cukier AM, Gille A, Schuetz P, Spycher MO, Therond P, Chapman MJ, Kontush A, Wright SD. Enhanced HDL functionality in small HDL species produced upon remodeling of HDL by reconstituted HDL, CSL112: effects on cholesterol efflux, anti-inflammatory and antioxidative activity. *Circ Res* 2016;**119**:751–763.
 351. Digenio A, Dunbar RL, Alexander VJ, Hompesch M, Morrow L, Lee RG, Graham MJ, Hughes SG, Yu R, Singleton W, Baker BF, Bhanot S, Crooke RM. Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes. *Diabetes Care* 2016;**39**:1408–1415.
 352. Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. *Lancet* 2016;**388**:2239–2253.
 353. Schreml J, Gouni-Berthold I. Role of anti-PCSK9 antibodies in the treatment of patients with statin intolerance. *Curr Med Chem* 2018;**25**:1538–1548.

354. Maki KC, Guyton JR, Orringer CE, Hamilton-Craig I, Alexander DD, Davidson MH. Triglyceride-lowering therapies reduce cardiovascular disease event risk in subjects with hypertriglyceridemia. *J Clin Lipidol* 2016;**10**:905–914.
355. Vallejo-Vaz AJ, Fayyad R, Boekholdt SM, Hovingh GK, Kastelein JJ, Melamed S, Barter P, Waters DD, Ray KK. Triglyceride-rich lipoprotein cholesterol and risk of cardiovascular events among patients receiving statin therapy in the TNT trial. *Circulation* 2018;**138**:770–781.
356. Catapano AL, Farnier M, Foody JM, Toth PP, Tomassini JE, Brudi P, Tereshakovec AM. Combination therapy in dyslipidemia: where are we now? *Atherosclerosis* 2014;**237**:319–335.
357. Global Lipids Genetics Consortium, Willer CJ, Schmidt EM, Sengupta S, Peloso GM, Gustafsson S, Kanoni S, Ganna A, Chen J, Buchkovich ML, Mora S, Beckmann JS, Bragg-Gresham JL, Chang HY, Demirkan A, Den Hertog HM, Do R, Donnelly LA, Ehret GB, Esko T, Feitosa DM, Ferreira T, Fischer K, Fontanillas P, Fraser RM, Freitag DF, Gurdasani D, Heikkila K, Hypponen E, Isaacs A, Jackson AU, Johansson A, Johnson T, Kaakinen M, Kettunen J, Kleber ME, Li X, Luan J, Lyytikainen LP, Magnusson PK, Mangino M, Mihailov E, Montasser ME, Muller-Nurasyid M, Nolte IM, O'Connell JR, Palmer CD, Perola M, Petersen AK, Sanna S, Saxena R, Service SK, Shah S, Shungin D, Sidore C, Song C, Strawbridge RJ, Surakka I, Tanaka T, Teslovich TM, Thorleifsson G, Van den Herik EG, Voight BF, Volcik KA, Waite LL, Wong A, Wu Y, Zhang W, Absher D, Asiki G, Barroso I, Been LF, Bolton JL, Bonnycastle LL, Brambilla P, Burnett MS, Cesana G, Dimitriou M, Doney AS, Doring A, Elliott P, Epstein SE, Eyjolfsson GI, Gigante G, Goodarzi MO, Grallert H, Gravitto ML, Groves CJ, Hallmans G, Hartikainen AL, Hayward C, Hernandez D, Hicks AA, Holm H, Hung YJ, Illig T, Jones MR, Kaleebu P, Kastelein JJ, Khaw KT, Kim E, Klopp N, Komulainen P, Kumari M, Langenberg C, Lehtimäki T, Lin SY, Lindstrom J, Loos RJ, Mach F, McArdle WL, Meisinger C, Mitchell BD, Muller G, Nagaraja R, Narisu N, Nieminen TV, Nsubuga RN, Olafsson I, Ong KK, Palotie A, Papamarkou T, Pomilla C, Pouta A, Rader DJ, Reilly MP, Ridker PM, Rivadeneira F, Rudan I, Ruukonen A, Samani N, Schramm H, Seeley J, Silander K, Stancakova A, Stirrups K, Swift AJ, Tiret L, Uitterlinden AG, van Pelt LJ, Vedantam S, Wainwright N, Wijmenga C, Wild SH, Willemssen G, Wilsgaard T, Wilson JF, Young EH, Zhao JH, Adair LS, Arveiler D, Assimes TL, Bandinelli S, Bennett F, Bochud M, Boehm BO, Boomsma DI, Borecki IB, Bornstein SR, Bovet P, Burnier M, Campbell H, Chakravarti A, Chambers JC, Chen YD, Collins FS, Cooper RS, Danesh J, Dedoussis G, de Faire U, Feranil AB, Ferrières J, Ferrucci L, Freimer NB, Gieger C, Groop LC, Gudnason V, Gillensten U, Hamsten A, Harris TB, Hingorani A, Hirschhorn JN, Hofman A, Hovingh GK, Hsiung CA, Humphries SE, Hunt SC, Hveem K, Iribarren C, Jarvelin MR, Jula A, Kahonen M, Kaprio J, Kesaniemi A, Kivimäki M, Kooner JS, Koudstaal PJ, Krauss RM, Kuh D, Kuusisto J, Kyvik KO, Laakso M, Lakka TA, Lind L, Lindgren CM, Martin NG, Mauss W, McCarthy MI, McKenzie CA, Meneton P, Metspalu A, Moilanen L, Morris AD, Munroe PB, Njolstad I, Pedersen NL, Power C, Pramstaller PP, Price JF, Psaty BM, Quertermous T, Rauramaa R, Saleheen D, Salomaa V, Sanghera DK, Saramies J, Schwarz PE, Sheu WH, Shuldiner AR, Siegbahn A, Spector TD, Stefansson K, Strachan DP, Tayo BO, Tremoli E, Tuomilehto J, Uusitupa M, van Duijn CM, Vollenweider P, Wallentin L, Wareham NJ, Whitfield JB, Woffenbuttel BH, Ordovas JM, Boerwinkle E, Palmer CN, Thorsteinsdottir U, Chasman DI, Rotter JJ, Franks PW, Ripatti S, Cupples LA, Sandhu MS, Rich SS, Boehnke M, Deloukas P, Kathiresan S, Mohlke KL, Ingelsson E, Abecasis GR. Discovery and refinement of loci associated with lipid levels. *Nat Genet* 2013;**45**:1274–1283.
358. Brahm AJ, Hegele RA. Combined hyperlipidemia: familial but not (usually) monogenic. *Curr Opin Lipidol* 2016;**27**:131–140.
359. Ripatti P, Ramo JT, Soderlund S, Surakka I, Matikainen N, Pirinen M, Pajukanta P, Sarin AP, Service SK, Laurila PP, Ehnholm C, Salomaa V, Wilson RK, Palotie A, Freimer NB, Taskinen MR, Ripatti S. The contribution of GWAS loci in familial dyslipidemias. *PLoS Genet* 2016;**12**:e1006078.
360. Veerkamp MJ, de Graaf J, Bredie SJ, Hendriks JC, Demacker PN, Stalenhoef AF. Diagnosis of familial combined hyperlipidemia based on lipid phenotype expression in 32 families: results of a 5-year follow-up study. *Arterioscler Thromb Vasc Biol* 2002;**22**:274–282.
361. Akioyamen LE, Genest J, Shan SD, Reel RL, Albaum JM, Chu A, Tu JV. Estimating the prevalence of heterozygous familial hypercholesterolemia: a systematic review and meta-analysis. *BMJ Open* 2017;**7**:e016461.
362. de Ferranti SD, Rodday AM, Mendelson MM, Wong JB, Leslie LK, Sheldrick RC. Prevalence of familial hypercholesterolemia in the 1999 to 2012 United States National Health and Nutrition Examination Surveys (NHANES). *Circulation* 2016;**133**:1067–1072.
363. Nordestgaard BG, Chapman MJ, Humphries SE, Ginsberg HN, Masana L, Descamps OS, Wiklund O, Hegele RA, Raal FJ, Defesche JC, Wiegman A, Santos RD, Watts GF, Parhofer KG, Hovingh GK, Kovanen PT, Boileau C, Averna M, Borén J, Bruckert E, Catapano AL, Kuivenhoven JA, Pajukanta P, Ray K, Stalenhoef AF, Stroes E, Taskinen MR, Tybjaerg-Hansen A; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. *Eur Heart J* 2013;**34**:3478–3490a.
364. Risk of fatal coronary heart disease in familial hypercholesterolemia. Scientific Steering Committee on behalf of the Simon Broome Register Group. *BMJ* 1991;**303**:893–896.
365. World Health Organization. Human Genetics Programme. Familial hypercholesterolemia: Report of a second WHO consultation. WHO/HGN/FH/Cons/99.2. Geneva: World Health Organization; 1999. <https://apps.who.int/iris/handle/10665/66346> (17 July 2019).
366. Landmesser U, Chapman MJ, Farnier M, Gencer B, Gielen S, Hovingh GK, Luscher TF, Sinning D, Tokgozoglul L, Wiklund O, Zamorano JL, Pinto FJ, Catapano AL; European Society of Cardiology (ESC); European Atherosclerosis Society (EAS). European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. *Eur Heart J* 2017;**38**:2245–2255.
367. Ridker PM, Reekin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif JC; SPIRE Cardiovascular Outcome Investigators. Cardiovascular efficacy and safety of bococizumab in high-risk patients. *N Engl J Med* 2017;**376**:1527–1539.
368. Cuchel M, Bruckert E, Ginsberg HN, Raal FJ, Santos RD, Hegele RA, Kuivenhoven JA, Nordestgaard BG, Descamps OS, Steinhagen-Thiessen E, Tybjaerg-Hansen A, Watts GF, Averna M, Boileau C, Boren J, Catapano AL, Defesche JC, Hovingh GK, Humphries SE, Kovanen PT, Masana L, Pajukanta P, Parhofer KG, Ray KK, Stalenhoef AF, Stroes E, Taskinen MR, Wiegman A, Wiklund O, Chapman MJ; European Atherosclerosis Society Consensus Panel on Familial Hypercholesterolemia. Homozygous familial hypercholesterolemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolemia of the European Atherosclerosis Society. *Eur Heart J* 2014;**35**:2146–2157.
369. Wiegman A, Gidding SS, Watts GF, Chapman MJ, Ginsberg HN, Cuchel M, Ose L, Averna M, Boileau C, Boren J, Bruckert E, Catapano AL, Defesche JC, Descamps OS, Hegele RA, Hovingh GK, Humphries SE, Kovanen PT, Kuivenhoven JA, Masana L, Nordestgaard BG, Pajukanta P, Parhofer KG, Raal FJ, Ray KK, Santos RD, Stalenhoef AF, Steinhagen-Thiessen E, Stroes ES, Taskinen MR, Tybjaerg-Hansen A, Wiklund O; European Atherosclerosis Society Consensus Panel. Familial hypercholesterolemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *Eur Heart J* 2015;**36**:2425–2437.
370. Braamskamp M, Langstet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study (Hypercholesterolemia in Children and Adolescents Taking Rosuvastatin Open Label). *Circulation* 2017;**136**:359–366.
371. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Tonstad S, Wiegman A, Drogari E, U Ramaswami. Statins for children with familial hypercholesterolemia. *Cochrane Database Syst Rev* 2017;**7**:CD006401.
372. Reiner Z. Treatment of children with homozygous familial hypercholesterolemia. *Eur J Prev Cardiol* 2018;**25**:1095–1097.
373. Koopal C, Marais AD, Visseren FL. Familial dysbetalipoproteinemia: an underdiagnosed lipid disorder. *Curr Opin Endocrinol Diabetes Obes* 2017;**24**:133–139.
374. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. *J Lipid Res* 2009;**50**:S183–S188.
375. Marais D. Dysbetalipoproteinemia: an extreme disorder of remnant metabolism. *Curr Opin Lipidol* 2015;**26**:292–297.
376. Sniderman A, Couture P, de Graaf J. Diagnosis and treatment of apolipoprotein B dyslipoproteinemias. *Nat Rev Endocrinol* 2010;**6**:335–346.
377. Brahm AJ, Hegele RA. Chylomicronaemia—current diagnosis and future therapies. *Nat Rev Endocrinol* 2015;**11**:352–362.
378. Bauer RC, Khetarpal SA, Hand NJ, Rader DJ. Therapeutic targets of triglyceride metabolism as informed by human genetics. *Trends Mol Med* 2016;**22**:328–340.
379. Gaudet D, Methot J, Dery S, Brisson D, Essiembre C, Tremblay G, Tremblay K, de Wal J, Twisk J, van den Bulk N, Sier-Ferreira V, van Deventer S. Efficacy and long-term safety of alipogene tiparovec (AAV1-LPL5447X) gene therapy for lipoprotein lipase deficiency: an open-label trial. *Gene Ther* 2013;**20**:361–369.
380. Huff MW, Hegele RA. Apolipoprotein C-III: going back to the future for a lipid drug target. *Circ Res* 2013;**112**:1405–1408.
381. Moulin P, Dufour R, Averna M, Arca M, Cefalu AB, Noto D, D'Erasmo L, Di Costanzo A, Marçais C, Alvarez-Sala Walthers LA, Banach M, Boren J, Cramb R, Gouni-Berthold I, Hughes E, Johnson C, Pinto X, Reiner Z, van Lennep JR, Soran H, Stefanutti C, Stroes E, Bruckert E. Identification and diagnosis of

- patients with familial chylomicronaemia syndrome (FCS): expert panel recommendations and proposal of an "FCS score". *Atherosclerosis* 2018;**275**:265–272.
382. Meyers CD, Tremblay K, Amer A, Chen J, Jiang L, Gaudet D. Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome. *Lipids Health Dis* 2015;**14**:8.
 383. Lindkvist B, Appelros S, Regner S, Manjer J. A prospective cohort study on risk of acute pancreatitis related to serum triglycerides, cholesterol and fasting glucose. *Pancreatology* 2012;**12**:317–324.
 384. Ewald N, Hardt PD, Kloer HU. Severe hypertriglyceridemia and pancreatitis: presentation and management. *Curr Opin Lipidol* 2009;**20**:497–504.
 385. Chora JR, Alves AC, Medeiros AM, Mariano C, Lobarinhas G, Guerra A, Mansilha H, Cortez-Pinto H, Bourbon M. Lysosomal acid lipase deficiency: a hidden disease among cohorts of familial hypercholesterolemia? *J Clin Lipidol* 2017;**11**:477–484.e2.
 386. Burton BK, Balwani M, Feillet F, Baric I, Burrow TA, Camarena Grande C, Coker M, Consuelo-Sanchez A, Deegan P, Di Rocco M, Enns GM, Erbe R, Ezgu F, Ficcioglu C, Furuya KN, Kane J, Laukaitis C, Mengel E, Neilan EG, Nightingale S, Peters H, Scarpa M, Schwab KO, Smolka V, Valayannopoulos V, Wood M, Goodman Z, Yang Y, Eckert S, Rojas-Caro S, Quinn AG. A phase 3 trial of sebelipase alfa in lysosomal acid lipase deficiency. *N Engl J Med* 2015;**373**:1010–1020.
 387. Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. *Am Heart J* 2003;**145**:643–651.
 388. Miettinen TA, Pyorala K, Olsson AG, Musliner TA, Cook TJ, Faergeman O, Berg K, Pedersen T, Kjekshus J. Cholesterol-lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). *Circulation* 1997;**96**:4211–4218.
 389. d'Emden MC, Jenkins AJ, Li L, Zannino D, Mann KP, Best JD, Stuckey BG, Park K, Saltevo J, Keech AC; FIELD Study Investigators. Favourable effects of fenofibrate on lipids and cardiovascular disease in women with type 2 diabetes: results from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetologia* 2014;**57**:2296–2303.
 390. Spitzer WO, Faith JM, MacRae KD. Myocardial infarction and third generation oral contraceptives: aggregation of recent studies. *Hum Reprod* 2002;**17**:2307–2314.
 391. Shufelt CL, Bairey Merz CN. Contraceptive hormone use and cardiovascular disease. *J Am Coll Cardiol* 2009;**53**:221–231.
 392. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M; Women's Health Initiative Investigators. Estrogen plus progestin and the risk of coronary heart disease. *N Engl J Med* 2002;**349**:523–534.
 393. Rosengren A. Better treatment and improved prognosis in elderly patients with AMI: but do registers tell the whole truth? *Eur Heart J* 2012;**33**:562–563.
 394. Second Joint Task Force of European and other Societies. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. *Eur Heart J* 1998;**19**:1434–1503.
 395. Koopman C, Vaartjes I, Heintjes EM, Spiering W, van Dis I, Herings RM, Bots ML. Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998–2010. *Eur Heart J* 2013;**34**:3198–3205.
 396. Salami JA, Warraich H, Valero-Elizondo J, Spatz ES, Desai NR, Rana JS, Virani SS, Blankstein R, Khera A, Blaha MJ, Blumenthal RS, Lloyd-Jones D, Nasir K. National trends in statin use and expenditures in the US adult population from 2002 to 2013: insights from the medical expenditure panel survey. *JAMA Cardiol* 2017;**2**:56–65.
 397. Strandberg TE, Kolehmainen L, Vuorio A. Evaluation and treatment of older patients with hypercholesterolemia: a clinical review. *JAMA* 2014;**312**:1136–1144.
 398. Mangin D, Sweeney K, Heath I. Preventive health care in elderly people needs rethinking. *BMJ* 2007;**335**:285–287.
 399. Zimmet PZ. Diabetes and its drivers: the largest epidemic in human history? *Clin Diabetes Endocrinol* 2017;**3**:1.
 400. Rawshani A, Rawshani A, Franzen S, Eliasson B, Svensson AM, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjornsdottir S. Mortality and cardiovascular disease in type 1 and type 2 diabetes. *N Engl J Med* 2017;**376**:1407–1418.
 401. Olesen KKW, Madsen M, Egholm G, Thim T, Jensen LO, Raungaard B, Botker HE, Sorensen HT, Maeng M. Patients with diabetes without significant angiographic coronary artery disease have the same risk of myocardial infarction as patients without diabetes in a real-world population receiving appropriate prophylactic treatment. *Diabetes Care* 2017;**40**:1103–1110.
 402. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M, Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR, Ray KK, Danesh J. Diabetes mellitus, fasting blood glucose concentration, and risk of cardiovascular disease: a collaborative meta-analysis of 102 prospective studies. *Lancet* 2010;**375**:2215–2222.
 403. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990–2010. *N Engl J Med* 2014;**370**:1514–1523.
 404. Sattar N. Revisiting the links between glycaemia, diabetes and cardiovascular disease. *Diabetologia* 2013;**56**:686–695.
 405. Brownrigg JR, Hughes CO, Burtleigh D, Karthikesalingam A, Patterson BO, Holt PJ, Thompson MM, de Lusignan S, Ray KK, Hinchliffe RJ. Microvascular disease and risk of cardiovascular events among individuals with type 2 diabetes: a population-level cohort study. *Lancet Diabetes Endocrinol* 2016;**4**:588–597.
 406. Despres JP. Body fat distribution and risk of cardiovascular disease: an update. *Circulation* 2012;**126**:1301–1313.
 407. Targher G. Non-alcoholic fatty liver disease as driving force in coronary heart disease? *Gut* 2017;**66**:213–214.
 408. Targher G, Lonardo A, Byrne CD. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus. *Nat Rev Endocrinol* 2018;**14**:99–114.
 409. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. *JAMA* 2007;**298**:765–775.
 410. Levesque V, Poirier P, Despres JP, Almeras N. Relation between a simple life-style risk score and established biological risk factors for cardiovascular disease. *Am J Cardiol* 2017;**120**:1939–1946.
 411. Taskinen MR, Boren J. New insights into the pathophysiology of dyslipidemia in type 2 diabetes. *Atherosclerosis* 2015;**239**:483–495.
 412. Taskinen MR, Boren J. Why is apolipoprotein CIII emerging as a novel therapeutic target to reduce the burden of cardiovascular disease? *Curr Atheroscler Rep* 2016;**18**:59.
 413. Boren J, Watts GF, Adiels M, Soderlund S, Chan DC, Hakkarainen A, Lundbom N, Matikainen N, Kahri J, Verges B, Barrett PH, Taskinen MR. Kinetic and related determinants of plasma triglyceride concentration in abdominal obesity: multicenter tracer kinetic study. *Arterioscler Thromb Vasc Biol* 2015;**35**:2218–2224.
 414. Gordts PL, Nock R, Son NH, Rammes B, Lew I, Gonzales JC, Thacker BE, Basu D, Lee RG, Mullick AE, Graham MJ, Goldberg IJ, Crooke RM, Witztum JL, Esko JD. ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. *J Clin Invest* 2016;**126**:2855–2866.
 415. Mark L, Vallejo-Vaz AJ, Reiber I, Paragh G, Kondapally Seshasai SR, Ray KK. Non-HDL cholesterol goal attainment and its relationship with triglyceride concentrations among diabetic subjects with cardiovascular disease: a nationwide survey of 2674 individuals in Hungary. *Atherosclerosis* 2015;**241**:62–68.
 416. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A; Fenofibrate Intervention Event Lowering in Diabetes (FIELD) Study Investigators. Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. *Diabetes Care* 2009;**32**:493–498.
 417. Annuzzi G, Giacco R, Patti L, Di Marino L, De Natale C, Costabile G, Marra M, Santangelo C, Masella R, Rivellese AA. Postprandial chylomicrons and adipose tissue lipoprotein lipase are altered in type 2 diabetes independently of obesity and whole-body insulin resistance. *Nutr Metab Cardiovasc Dis* 2008;**18**:531–538.
 418. Cholesterol Treatment Trialists Collaboration, Kearney PM, Blackwell L, Collins R, Keech A, Simes J, Peto R, Armitage J, Baigent C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet* 2008;**371**:117–125.
 419. American Diabetes Association. Cardiovascular disease and risk management: standards of medical care in diabetes-2018. *Diabetes Care* 2018;**41**:S86–S104.
 420. Ray KK, Colhoun HM, Szarek M, Baccara-Dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Loizeau V, Lopes RD, Moryusef A, Murin J, Pordy R, Ristic AD, Roe MT, Tuñón J, White HD, Zeiher AM, Schwartz GG, Steg G; ODYSSEY OUTCOMES Committees and Investigators. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. *Lancet Diabetes Endocrinol* 2019; pii: S2213-8587(19)30158-5. doi: 10.1016/S2213-8587(19)30158-5. [Epub ahead of print] Erratum in: *Lancet Diabetes Endocrinol*. 2019 July 8.
 421. Elam MB, Ginsberg HN, Lovato LC, Corson M, Largay J, Leiter LA, Lopez C, O'Connor PJ, Sweeney ME, Weiss D, Friedewald WT, Buse JB, Gerstein HC, Probstfield J, Grimm R, Ismail-Beigi F, Goff DC Jr, Fleg JL, Rosenberg Y, Byington RP; ACCORDION Study Investigators. Association of fenofibrate therapy with long-term cardiovascular risk in statin-treated patients with type 2 diabetes. *JAMA Cardiol* 2017;**2**:370–380.
 422. Saha SA, Arora RR. Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus—a pooled meta-analysis of randomized placebo-controlled clinical trials. *Int J Cardiol* 2010;**141**:157–166.
 423. Araki E, Yamashita S, Arai H, Yokote K, Satoh J, Inoguchi T, Nakamura J, Maegawa H, Yoshioka N, Tanizawa Y, Watada H, Suganami H, Ishibashi S.

- Effects of pemafibrate, a novel selective PPAR α modulator, on lipid and glucose metabolism in patients with type 2 diabetes and hypertriglyceridemia: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care* 2018;**41**:538–546.
424. Arca M, Borghi C, Pontremoli R, De Ferrari GM, Colivicchi F, Desideri G, Temporelli PL. Hypertriglyceridemia and omega-3 fatty acids: their often overlooked role in cardiovascular disease prevention. *Nutr Metab Cardiovasc Dis* 2018;**28**:197–205.
425. Bhatt DL, Steg PG, Brinton EA, Jacobson TA, Miller M, Tardif JC, Ketchum SB, Doyle RT Jr, Murphy SA, Soni PN, Braeckman RA, Juliano RA, Ballantyne CM; REDUCE-IT Investigators. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial. *Clin Cardiol* 2017;**40**:138–148.
426. ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J. Effects of aspirin for primary prevention in persons with diabetes mellitus. *N Engl J Med* 2018;**379**:1529–1539.
427. Laing SP, Swerdlow AJ, Slater SD, Burden AC, Morris A, Waugh NR, Gatling W, Bingley PJ, Patterson CC. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. *Diabetologia* 2003;**46**:760–765.
428. Chillaron JJ, Flores Le-Roux JA, Benaiges D, Pedro-Botet J. Type 1 diabetes, metabolic syndrome and cardiovascular risk. *Metabolism* 2014;**63**:181–187.
429. Annuzzi G, Iovine C, Mandarino B, Patti L, Di Marino L, Riccardi G, Rivellese AA. Effect of acute exogenous hyperinsulinaemia on very low density lipoprotein subfraction composition in normal subjects. *Eur J Clin Invest* 2001;**31**:118–124.
430. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. *J Am Coll Cardiol* 2006;**48**:438–445.
431. Mills EJ, O'Regan C, Eyawo O, Wu P, Mills F, Berwanger O, Briel M. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. *Eur Heart J* 2011;**32**:1409–1415.
432. Nicholls SJ, Tuzcu EM, Kalidindi S, Wolski K, Moon KW, Sipahi I, Schoenhagen P, Nissen SE. Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. *J Am Coll Cardiol* 2008;**52**:255–262.
433. Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: a systematic review. *J Clin Lipidol* 2016;**10**:1081–1090.
434. Gencer B, Koskinas KC, Räber L, Karagiannis A, Nanchen D, Auer R, Carballo D, Carballo S, Klingenberg R, Heg D, Matter CM, Lüscher TF, Rodondi N, Mach F, Windecker S. Eligibility for PCSK9 inhibitors according to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) guidelines after acute coronary syndromes. *J Am Heart Assoc* 2017;**6**:e006537.
435. Kureshi F, Kennedy KF, Jones PG, Thomas RJ, Arnold SV, Sharma P, Fendler T, Buchanan DM, Qintar M, Ho PM, Nallamothu BK, Oldridge NB, Spertus JA. Association between cardiac rehabilitation participation and health status outcomes after acute myocardial infarction. *JAMA Cardiol* 2016;**1**:980–988.
436. Szummer K, Wallentin L, Lindhagen L, Alfredsson J, Erlinge D, Held C, James S, Kellerth T, Lindahl B, Ravn-Fischer A, Rydberg E, Yndegegn T, Jernberg T. Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995-2014. *Eur Heart J* 2017;**38**:3056–3065.
437. Gitt AK, Lautsch D, Ferrieres J, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Ashton V, Horack M, Almahmeed W, Chiang FT, Poh KK, Brudi P, Ambegaonkar B. Cholesterol target value attainment and lipid-lowering therapy in patients with stable or acute coronary heart disease: results from the Dyslipidemia International Study II. *Atherosclerosis* 2017;**266**:158–166.
438. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, for the A to Z Investigators. Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. *JAMA* 2004;**292**:1307–1316.
439. Navarese EP, Kowalewski M, Andreotti F, van Wely M, Camaro C, Kolodziejczak M, Gorny B, Wirianta J, Kubica J, Kelm M, de Boer MJ, Suryapranata H. Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. *Am J Cardiol* 2014;**113**:1753–1764.
440. Ray KK, Cannon CP, McCabe CH, Cairns R, Tonkin AM, Sacks FM, Jackson G, Braunwald E; PROVE IT-TIMI 22 Investigators. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. *J Am Coll Cardiol* 2005;**46**:1405–1410.
441. Schwartz GG, Fayyad R, Szarek M, DeMicco D, Olsson AG. Early, intensive statin treatment reduces 'hard' cardiovascular outcomes after acute coronary syndrome. *Eur J Prev Cardiol* 2017;**24**:1294–1296.
442. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. *JAMA* 2001;**285**:1711–1718.
443. Berwanger O, Santucci EV, de Barros ESPGM, Jesuino IA, Damiani LP, Barbosa LM, Santos RHN, Laranjeira LN, Egydio FM, Borges de Oliveira JA, Dall Orto FTC, Beraldo de Andrade P, Bienert IRC, Bosso CE, Mangione JA, Polanczyk CA, Sousa A, Kalil RAK, Santos LM, Sposito AC, Rech RL, Sousa ACS, Baldissera F, Nascimento BR, Giraldez R, Cavalcanti AB, Pereira SB, Mattos LA, Armaganjian LV, Guimaraes HP, Sousa J, Alexander JH, Granger CB, Lopes RD; SECURE-PCI Investigators. Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial. *JAMA* 2018;**319**:1331–1340.
444. Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, Murphy SA, Park JG, Braunwald E, Giugliano RP. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). *J Am Heart Assoc* 2017;**6**:e006901.
445. Murphy SA, Cannon CP, Blazing MA, Giugliano RP, White JA, Likhnygina Y, Reist C, Im K, Bohula EA, Isaza D, Lopez-Sendon J, Dellborg M, Kher U, Tershakovec AM, Braunwald E. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. *J Am Coll Cardiol* 2016;**67**:353–361.
446. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, Murphy SA, White JA, Mach F, Van de Werf F, Dalby AJ, White HD, Tershakovec AM, Cannon CP, Braunwald E. Prevention of stroke with the addition of ezetimibe to statin therapy in patients with acute coronary syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). *Circulation* 2017;**136**:2440–2450.
447. Pokharel Y, Chinnakondepalli K, Vilain K, Wang K, Mark DB, Davies G, Blazing MA, Giugliano RP, Braunwald E, Cannon CP, Cohen DJ, Magnuson EA. Impact of ezetimibe on the rate of cardiovascular-related hospitalizations and associated costs among patients with a recent acute coronary syndrome: results from the IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). *Circ Cardiovasc Qual Outcomes* 2017;**10**:e003201.
448. Bohula EA, Morrow DA, Giugliano RP, Blazing MA, He P, Park JG, Murphy SA, White JA, Kesaniemi YA, Pedersen TR, Brady AJ, Mitchel Y, Cannon CP, Braunwald E. Atherothrombotic risk stratification and ezetimibe for secondary prevention. *J Am Coll Cardiol* 2017;**69**:911–921.
449. Hagiwara N, Kawada-Watanabe E, Koyanagi R, Arashi H, Yamaguchi J, Nakao K, Tobaru T, Tanaka H, Oka T, Endoh Y, Saito K, Uchida T, Matsui K, Ogawa H. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. *Eur Heart J* 2017;**38**:2264–2276.
450. Sabatine MS, De Ferrari GM, Giugliano RP, Huber K, Lewis BS, Ferreira J, Kuder JF, Murphy SA, Wiviott SD, Kurtz CE, Honarpour N, Keech AC, Sever PS, Pedersen TR. Clinical benefit of evolocumab by severity and extent of coronary artery disease. *Circulation* 2018;**138**:756–766.
451. Giugliano RP, Pedersen TR, Park JG, De Ferrari GM, Gaciong ZA, Ceska R, Toth K, Gouni-Berthold I, Lopez-Miranda J, Schiele F, Mach F, Ott BR, Kanevsky E, Pineda AL, Somaratne R, Wasserman SM, Keech AC, Sever PS, Sabatine MS; FOURIER Investigators. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet* 2017;**390**:1962–1971.
452. Koskinas KC, Windecker S, Buhayer A, Gencer B, Pedrazzini G, Mueller C, Cook S, Muller O, Matter CM, Raber L, Heg D, Mach F; EVOPACS Investigators. Design of the randomized, placebo-controlled evolocumab for early reduction of LDL-cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. *Clin Cardiol* 2018;**41**:1513–1520.
453. Aung T, Halsey J, Kromhout D, Gerstein HC, Marchioli R, Tavazzi L, Geleijnse JM, Rauch B, Ness A, Galan P, Chew EY, Bosch J, Collins R, Lewington S, Armitage J, Clarke R; Omega-3 Treatment Trialists' Collaboration. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. *JAMA Cardiol* 2018;**3**:225–234.
454. Patti G, Cannon CP, Murphy SA, Mega S, Pasceri V, Briguori C, Colombo A, Yun KH, Jeong MH, Kim JS, Choi D, Bozbas H, Kinoshita M, Fukuda K, Jia XW, Hara H, Cay S, Di Sciascio G. Clinical benefit of statin pretreatment in patients undergoing percutaneous coronary intervention: a collaborative patient-level meta-analysis of 13 randomized studies. *Circulation* 2011;**123**:1622–1632.
455. Kim JS, Kim J, Choi D, Lee CJ, Lee SH, Ko YG, Hong MK, Kim BK, Oh SJ, Jeon DW, Yang JY, Cho JR, Lee NH, Cho YH, Cho DK, Jang Y. Efficacy of high-dose atorvastatin loading before primary percutaneous coronary intervention in ST-

- segment elevation myocardial infarction: the STATIN STEMI trial. *JACC Cardiovasc Interv* 2010;**3**:332–339.
456. Brigugori C, Visconti G, Focaccio A, Golia B, Chieffo A, Castelli A, Mussardo M, Montorfano M, Ricciardelli B, Colombo A. Novel approaches for preventing or limiting events (Naples) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. *J Am Coll Cardiol* 2009;**54**:2157–2163.
 457. Di Sciascio G, Patti G, Pasceri V, Gaspardone A, Colonna G, Montinaro A. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) randomized trial. *J Am Coll Cardiol* 2009;**54**:558–565.
 458. Navarese EP, Gurbel PA, Andreotti F, Kolodziejczak MM, Palmer SC, Dias S, Buffon A, Kubica J, Kowalewski M, Jadczyk T, Laskiewicz M, Jędrzejek M, Brockmeyer M, Airolidi F, Ruospo M, De Servi S, Wojakowski W, O'Connor C, Strippoli GF. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures—a systematic review and network meta-analysis. *PLoS One* 2017;**12**:e0168726.
 459. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillensen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;**355**:549–559.
 460. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *Lancet Neurol* 2009;**8**:453–463.
 461. Merwick A, Albers GW, Arsava EM, Ay H, Calvet D, Coutts SB, Cucchiara BL, Demchuk AM, Giles MF, Mas JL, Olivot JM, Purroy F, Rothwell PM, Saver JL, Sharma VK, Tsivgoulis G, Kelly PJ. Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. *Stroke* 2013;**44**:2814–2820.
 462. Flint AC, Conell C, Ren X, Kamel H, Chan SL, Rao VA, Johnston SC. Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. *Stroke* 2017;**48**:1788–1794.
 463. The Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. *N Engl J Med* 1998;**339**:1349–1357.
 464. Kjekshus J, Pedersen TR, Olsson AG, Faergeman O, Pyorala K. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. *J Card Fail* 1997;**3**:249–254.
 465. Khush KK, Waters DD, Bittner V, Deedwania PC, Kastelein JJ, Lewis SJ, Wenger NK. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. *Circulation* 2007;**115**:576–583.
 466. Kjekshus J, Apetrei E, Barrios V, Böhm M, Cleland JG, Cornel JH, Dunselman P, Fonseca C, Goudev A, Grande P, Gullestad L, Hjalmarson A, Hradec J, Jánosi A, Kamenský G, Komajda M, Korewicki J, Kuusi T, Mach F, Mareev V, McMurray JJ, Ranjith N, Schaufelberger M, Vanhaecke J, van Veldhuisen DJ, Waagstein F, Wedel H, Wikstrand J; CORONA Group. Rosuvastatin in older patients with systolic heart failure. *N Engl J Med* 2007;**357**:2248–2261.
 467. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, Brown L, Warnica JW, Arnold JM, Wun CC, Davis BR, Braunwald E. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. *N Engl J Med* 1996;**335**:1001–1009.
 468. Scirica BM, Morrow DA, Cannon CP, Ray KK, Sabatine MS, Jarolim P, Shui A, McCabe CH, Braunwald E; PROVE IT-TIMI 22 Investigators. Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 study. *J Am Coll Cardiol* 2006;**47**:2326–2331.
 469. Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioni R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. *Eur Heart J* 2015;**36**:1536–1546.
 470. Tavazzi L, Maggioni AP, Marchioni R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; GISSI-HF Investigators. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;**372**:1231–1239.
 471. Al-Gobari M, Le HH, Fall M, Gueyffier F, Burnand B. No benefits of statins for sudden cardiac death prevention in patients with heart failure and reduced ejection fraction: a meta-analysis of randomized controlled trials. *PLoS One* 2017;**12**:e0171168.
 472. Feinstein MJ, Jhund P, Kang J, Ning H, Maggioni A, Wikstrand J, Kjekshus J, Tavazzi L, McMurray J, Lloyd-Jones DM. Do statins reduce the risk of myocardial infarction in patients with heart failure? A pooled individual-level reanalysis of CORONA and GISSI-HF. *Eur J Heart Fail* 2015;**17**:434–441.
 473. Bayes-Genis A, Nunez J, Zannad F, Ferreira JP, Anker SD, Cleland JG, Dickstein K, Filippatos G, Lang CC, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwiderman AH, Metra M, Lupon J, Voors AA. The PCSK9-LDL receptor axis and outcomes in heart failure: BIostat-CHF subanalysis. *J Am Coll Cardiol* 2017;**70**:2128–2136.
 474. Francis GS. Cholesterol and heart failure: is there an important connection? *J Am Coll Cardiol* 2017;**70**:2137–2138.
 475. Tavazzi L, Maggioni AP, Marchioni R, Barlera S, Franzosi MG, Latini R, Lucci D, Nicolosi GL, Porcu M, Tognoni G; GISSI-HF Investigators. Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. *Lancet* 2008;**372**:1223–1230.
 476. Smith JG, Luk K, Schulz CA, Engert JC, Do R, Hindy G, Rukh G, Dufresne L, Almgren P, Owens DS, Harris TB, Peloso GM, Kerr KF, Wong Q, Smith AV, Budoff MJ, Rotter JJ, Cupples LA, Rich S, Kathiresan S, Orho-Melander M, Gudnason V, O'Donnell CJ, Post WS, Thanassoulis G; Cohorts for Heart and Aging Research in Genetic Epidemiology (CGARG) Extracoronary Calcium Working Group. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. *JAMA* 2014;**312**:1764–1771.
 477. Tsimikas S. A test in context: lipoprotein(a): diagnosis, prognosis, controversies, and emerging therapies. *J Am Coll Cardiol* 2017;**69**:692–711.
 478. Novaro GM, Tiong IY, Pearce GL, Lauer MS, Sprecher DL, Griffin BP. Effect of hydroxymethylglutaryl coenzyme a reductase inhibitors on the progression of calcific aortic stenosis. *Circulation* 2001;**104**:2205–2209.
 479. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J; ASTRONOMER Investigators. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. *Circulation* 2010;**121**:306–314.
 480. Cowell SJ, Newby DE, Prescott RJ, Bloomfield P, Reid J, Northridge DB, Boon NA; Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression (SALTIRE) Investigators. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. *N Engl J Med* 2005;**352**:2389–2397.
 481. Dichtl W, Alber HF, Feuchtnner GM, Hintringer F, Reinthaler M, Bartel T, Sussenbacher A, Grander W, Ulmer H, Pachinger O, Muller S. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). *Am J Cardiol* 2008;**102**:743–748.
 482. Thiago L, Tsuji SR, Nyong J, Puga ME, Gois AF, Macedo CR, Valente O, Atallah AN. Statins for aortic valve stenosis. *Cochrane Database Syst Rev* 2016;**9**:CD009571.
 483. Zhao Y, Nicoll R, He YH, Henein MY. The effect of statins on valve function and calcification in aortic stenosis: a meta-analysis. *Atherosclerosis* 2016;**246**:318–324.
 484. Greve AM, Bang CN, Boman K, Egstrup K, Forman JL, Kesaniemi YA, Ray S, Pedersen TR, Best P, Rajamannan NM, Wachtell K. Effect modifications of lipid-lowering therapy on progression of aortic stenosis (from the Simvastatin and Ezetimibe in Aortic Stenosis [SEAS] Study). *Am J Cardiol* 2018;**121**:739–745.
 485. Arsenault BJ, Boekholdt SM, Mora S, DeMico DA, Bao W, Tardif JC, Amarenco P, Pedersen T, Barter P, Waters DD. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). *Am J Cardiol* 2014;**113**:1378–1382.
 486. Huded CP, Benck LR, Stone NJ, Sweis RN, Ricciardi MJ, Malaisrie SC, Davidson CJ, Flaherty JD. Relation of intensity of statin therapy and outcomes after transcatheter aortic valve replacement. *Am J Cardiol* 2017;**119**:1832–1838.
 487. Milin AC, Vorobiof G, Aksoy O, Ardehali R. Insights into aortic sclerosis and its relationship with coronary artery disease. *J Am Heart Assoc* 2014;**3**:e001111.
 488. Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. *Ann Intern Med* 2013;**158**:825–830.
 489. Franczyk-Skora B, Gluba A, Banach M, Rozentryt P, Polonski L, Rysz J. Acute coronary syndromes in patients with chronic kidney disease. *Curr Vasc Pharmacol* 2013;**11**:758–767.
 490. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, Jafar TH, Heerspink HJ, Mann JF, Matsushita K, Wen CP. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. *Lancet* 2013;**382**:339–352.
 491. Olechnowicz-Tietz S, Gluba A, Paradowska A, Banach M, Rysz J. The risk of atherosclerosis in patients with chronic kidney disease. *Int Urol Nephrol* 2013;**45**:1605–1612.

492. Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. *Lancet* 2010;**375**:2073–2081.
493. Loncar G, Barthelemy O, Berman E, Kerneis M, Petroni T, Payot L, Choussat R, Silvain J, Collet JP, Helft G, Montalescot G, Le Feuvre C. Impact of renal failure on all-cause mortality and other outcomes in patients treated by percutaneous coronary intervention. *Arch Cardiovasc Dis* 2015;**108**:554–562.
494. Tonelli M, Wanner C; Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. Lipid management in chronic kidney disease: synopsis of the Kidney Disease: Improving Global Outcomes 2013 clinical practice guideline. *Ann Intern Med* 2014;**160**:182.
495. Barylski M, Nikfar S, Mikhailidis DP, Toth PP, Salari P, Ray KK, Pencina MJ, Rizzo M, Rysz J, Abdollahi M, Nicholls SJ, Banach M; Lipid and Blood Pressure Meta-Analysis Collaboration Group. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy—a meta-analysis of 11 randomized controlled trials involving 21,295 participants. *Pharmacol Res* 2013;**72**:35–44.
496. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Hegbrant J, Strippoli GF. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. *Cochrane Database Syst Rev* 2014;**5**:CD007784.
497. Agarwal A, Prasad GV. Post-transplant dyslipidemia: mechanisms, diagnosis and management. *World J Transplant* 2016;**6**:125–134.
498. Bamgbola O. Metabolic consequences of modern immunosuppressive agents in solid organ transplantation. *The Adv Endocrinol Metab* 2016;**7**:110–127.
499. Numakura K, Kagaya H, Yamamoto R, Komine N, Saito M, Hiroshi T, Akihama S, Inoue T, Narita S, Tsuchiya N, Habuchi T, Niioka T, Miura M, Satoh S. Characterization of clinical and genetic risk factors associated with dyslipidemia after kidney transplantation. *Dis Markers* 2015;2015:179434.
500. Pinto AS, Chedid MF, Guerra LT, Cabeleira DD, Krueel CD. Dietary management for dyslipidemia in liver transplant recipients. *Arq Bras Cir Dig* 2016;**29**:246–251.
501. Riella LV, Gabardi S, Chandraker A. Dyslipidemia and its therapeutic challenges in renal transplantation. *Am J Transplant* 2012;**12**:1975–1982.
502. Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study. *Nephrol Dial Transplant* 2012;**27**:850–857.
503. Deleuze S, Garrigue V, Delmas S, Chong G, Swarcz I, Cristol JP, Mourad G. New onset dyslipidemia after renal transplantation: is there a difference between tacrolimus and cyclosporine? *Transplant Proc* 2006;**38**:2311–2313.
504. Kasiske BL, de Mattos A, Flechner SM, Gallon L, Meier-Kriesche HU, Weir MR, Wilkinson A. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. *Am J Transplant* 2008;**8**:1384–1392.
505. Li HY, Li B, Wei YG, Yan LN, Wen TF, Zhao JC, Xu MQ, Wang WT, Ma YK, Yang JY. Higher tacrolimus blood concentration is related to hyperlipidemia in living donor liver transplantation recipients. *Dig Dis Sci* 2012;**57**:204–209.
506. Morrisett JD, Abdel-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD. Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. *J Lipid Res* 2002;**43**:1170–1180.
507. Page RL II, Miller GG, Lindenfeld J. Drug therapy in the heart transplant recipient: part IV: drug-drug interactions. *Circulation* 2005;**111**:230–239.
508. Almutairi F, Peterson TC, Molinari M, Walsh MJ, Alwayn I, Peltekian KM. Safety and effectiveness of ezetimibe in liver transplant recipients with hypercholesterolemia. *Liver Transpl* 2009;**15**:504–508.
509. Shaw SM, Chaggar P, Ritchie J, Shah MK, Baynes AC, O'Neill N, Fildes JE, Yonan N, Williams SG. The efficacy and tolerability of ezetimibe in cardiac transplant recipients taking cyclosporin. *Transplantation* 2009;**87**:771–775.
510. European Stroke Organisation/Tendera M, Aboyans V, Bartelink ML, Baumgartner I, Clement D, Collet JP, Cremonesi A, De Carlo M, Erbel R, Fowkes FG, Heras M, Kownator S, Minar E, Ostergren J, Poldermans D, Rimbau V, Roffi M, Rother J, Sievert H, van Sambeek M, Zeller T; ESC Committee for Practice Guidelines. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). *Eur Heart J* 2011;**32**:2851–2906.
511. McDermott MM, Mandapat AL, Moates A, Albay M, Chiou E, Celic L, Greenland P. Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease. *Arch Intern Med* 2003;**163**:2157–2162.
512. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. *Cochrane Database Syst Rev* 2007;**4**:CD000123.
513. Collins R, Armitage J, Parish S, Sleight P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. *Lancet* 2003;**361**:2005–2016.
514. Bonaca MP, Nault P, Giugliano RP, Keech AC, Pineda AL, Kanevsky E, Kuder J, Murphy SA, Jukema JW, Lewis BS, Tokgozoglu L, Somaratne R, Sever PS, Pedersen TR, Sabatine MS. Low-density lipoprotein cholesterol lowering with evolocumab and outcomes in patients with peripheral artery disease: insights from the FOURIER trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk). *Circulation* 2018;**137**:338–350.
515. Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. *Lancet* 2009;**373**:1780–1788.
516. Tedeschi-Reiner E, Strozzi M, Skoric B, Reiner Z. Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease. *Am J Cardiol* 2006;**96**:1107–1109.
517. Accord Study Group, Accord Eye Study Group, Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. Effects of medical therapies on retinopathy progression in type 2 diabetes. *N Engl J Med* 2010;**363**:233–244.
518. Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet* 2007;**370**:1687–1697.
519. Golledge J, Muller J, Daugherty A, Norman P. Abdominal aortic aneurysm: pathogenesis and implications for management. *Arterioscler Thromb Vasc Biol* 2006;**26**:2605–2613.
520. Paraskevas KI, Liapis CD, Hamilton G, Mikhailidis DP. Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery? *Eur J Vasc Endovasc Surg* 2006;**32**:286–293.
521. Durazzo AE, Machado FS, Ikeoka DT, De Bernoche C, Monachini MC, Puech-Leao P, Caramelli B. Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial. *J Vasc Surg* 2004;**39**:967–975; discussion 975–976.
522. Schouten O, Boersma E, Hoeks SE, Benner R, van Urk H, van Sambeek MR, Verhagen HJ, Khan NA, Dunkelgrun M, Bax JJ, Poldermans D; Dutch Echocardiographic Cardiac Risk Evaluation Applying Stress Echocardiography Study Group. Fluvastatin and perioperative events in patients undergoing vascular surgery. *N Engl J Med* 2009;**361**:980–989.
523. Hackam DG, Wu F, Li P, Austin PC, Tobe SW, Mamdani MM, Garg AX. Statins and renovascular disease in the elderly: a population-based cohort study. *Eur Heart J* 2011;**32**:598–610.
524. Subherwal S, Patel MR, Kober L, Peterson ED, Bhatt DL, Gislason GH, Olsen AM, Jones WS, Torp-Pedersen C, Fosbol EL. Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. *Eur J Prev Cardiol* 2015;**22**:317–325.
525. Ross R. Atherosclerosis—an inflammatory disease. *N Engl J Med* 1999;**340**:115–126.
526. Tabas I, Lichtman AH. Monocyte-macrophages and T cells in atherosclerosis. *Immunity* 2017;**47**:621–634.
527. Emini Veseli B, Perrotta P, De Meyer GRA, Roth L, Van der Donck C, Martinet W, De Meyer GRY. Animal models of atherosclerosis. *Eur J Pharmacol* 2017;**816**:3–13.
528. Tillett WS, Francis T. Serological reactions in pneumonia with a non-protein somatic fraction of *Pneumococcus*. *J Exp Med* 1930;**52**:561–571.
529. Sabatine MS, Morrow DA, Jablonski KA, Rice MM, Warnica JW, Domanski MJ, Hsia J, Gersh BJ, Rifai N, Ridker PM, Pfeffer MA, Braunwald E; PEACE Investigators. Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease. *Circulation* 2007;**115**:1528–1536.
530. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. *N Engl J Med* 1997;**336**:973–979.
531. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med* 2000;**342**:836–843.
532. Danesh J, Wheeler JG, Hirschfeld GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. *N Engl J Med* 2004;**350**:1387–1397.
533. Elliott P, Chambers JC, Zhang W, Clarke R, Hopewell JC, Peden JF, Erdmann J, Braund P, Engert JC, Bennett D, Coin L, Ashby D, Tzoulaki I, Brown JJ, Mt-Isa S, McCarthy MI, Peltonen L, Freimer NB, Farrall M, Ruokonen A, Hamsten A, Lim

- N, Froguel P, Waterworth DM, Vollenweider P, Waeber G, Jarvelin MR, Moser V, Scott J, Hall AS, Schunkert H, Anand SS, Collins R, Samani NJ, Watkins H, Kooner JS. Genetic loci associated with C-reactive protein levels and risk of coronary heart disease. *JAMA* 2009;**302**:37–48.
534. Emerging Risk Factors Collaboration, Kaptoge S, Di Angelantonio E, Pennells L, Wood AM, White IR, Gao P, Walker M, Thompson A, Sarwar N, Caslake M, Butterworth AS, Amouyel P, Assmann G, Bakker SJ, Barr EL, Barrett-Connor E, Benjamin EJ, Bjorkelund C, Brenner H, Brunner E, Clarke R, Cooper JA, Cremer P, Cushman M, Dagenais GR, D'Agostino RB Sr, Dankner R, Davey-Smith G, Deeg D, Decker JM, Engstrom G, Folsom AR, Fowkes FG, Gallacher J, Gaziano JM, Giampaoli S, Gillum RF, Hofman A, Howard BV, Ingelsson E, Iso H, Jorgensen T, Kiechl S, Kitamura A, Kiyohara Y, Koenig W, Kromhout D, Kuller LH, Lawlor DA, Meade TW, Nissinen A, Nordestgaard BG, Onat A, Panagiotakos DB, Psaty BM, Rodriguez B, Rosengren A, Salomaa V, Kaulanen J, Salonen JT, Shaffer JA, Shea S, Ford I, Stehouwer CD, Strandberg TE, Tipping RW, Tosoletto A, Wassertheil-Smoller S, Wennberg P, Westendorp RG, Whincup PH, Wilhelmsen L, Woodward M, Lowe GD, Wareham NJ, Khaw KT, Sattar N, Packard CJ, Gudnason V, Ridker PM, Pepsy MB, Thompson SG, Danesh J. C-reactive protein, fibrinogen, and cardiovascular disease prediction. *N Engl J Med* 2012;**367**:1310–1320.
535. Zacho J, Tybjaerg-Hansen A, Jensen JS, Grande P, Sillesen H, Nordestgaard BG. Genetically elevated C-reactive protein and ischemic vascular disease. *N Engl J Med* 2008;**359**:1897–1908.
536. Miller DT, Zee RY, Suk Danik J, Kozlowski P, Chasman DI, Lazarus R, Cook NR, Ridker PM, Kwiatkowski DJ. Association of common CRP gene variants with CRP levels and cardiovascular events. *Ann Hum Genet* 2005;**69**:623–638.
537. Koenig W. High-sensitivity C-reactive protein and atherosclerotic disease: from improved risk prediction to risk-guided therapy. *Int J Cardiol* 2013;**168**:5126–5134.
538. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman, DE, Goldberg, R, Heidenreich, PA, Hlatky, MA, Jones, DW, Lloyd-Jones, D, Lopez-Pajares, N, Ndumele, CE, Orringer, CE, Peralta, CA, Saseen, JJ, Smith, SC Jr, Sperling, L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *J Am Coll Cardiol* 2018;**S0735–1097:39033–39038**.
539. Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins. *Arterioscler Thromb Vasc Biol* 2005;**25**:1231–1236.
540. Bohula EA, Giugliano RP, Cannon CP, Zhou J, Murphy SA, White JA, Tereshkovec AM, Blazing MA, Braunwald E. Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT. *Circulation* 2015;**132**:1224–1233.
541. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer MA, Braunwald E; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22) Investigators. C-reactive protein levels and outcomes after statin therapy. *N Engl J Med* 2005;**352**:20–28.
542. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. *N Engl J Med* 2008;**359**:2195–2207.
543. Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS, Gotto AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study Investigators. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. *N Engl J Med* 2001;**344**:1959–1965.
544. Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, Flaker GC, Braunwald E. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. *Circulation* 1998;**98**:839–844.
545. Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. *Lancet* 2009;**373**:1175–1182.
546. Barbosa SP, Lins LC, Fonseca FA, Matos LN, Aguirre AC, Bianco HT, Amaral JB, Franca CN, Santana JM, Izar MC. Effects of ezetimibe on markers of synthesis and absorption of cholesterol in high-risk patients with elevated C-reactive protein. *Life Sci* 2013;**92**:845–851.
547. Sahebkar A, Di Giosia P, Stamerra CA, Grassi D, Pedone C, Ferretti G, Bacchetti T, Ferri C, Giorgini P. Effect of monoclonal antibodies to PCSK9 on high-sensitivity C-reactive protein levels: a meta-analysis of 16 randomized controlled treatment arms. *Br J Clin Pharmacol* 2016;**81**:1175–1190.
548. Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD, Kastelein JJP, Cornel JH, Pais P, Pella D, Genest J, Cifkova R, Lorenzatti A, Forster T, Kobalava Z, Vida-Simiti L, Flather M, Shimokawa H, Ogawa H, Dellborg M, Rossi PRF, Troquay RPT, Libby P, Glynn RJ; CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. *N Engl J Med* 2017;**377**:1119–1131.
549. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). *J Thromb Haemost* 2009;**7**:332–339.
550. Ridker PM, Everett BM, Pradhan A, MacFadyen JG, Solomon DH, Zaharris E, Mam V, Hasan A, Rosenberg Y, Iturriga E, Gupta M, Tsigoulis M, Verma S, Clearfield M, Libby P, Goldhaber SZ, Seagle R, Ofori C, Saklayen M, Butman S, Singh N, Le May M, Bertrand O, Johnston J, Paynter NP, Glynn RJ; CIRT Investigators. Low-dose methotrexate for the prevention of atherosclerotic events. *N Engl J Med* 2019;**380**:752–762.
551. Weber C, Badimon L, Mach F, van der Vorst EPC. Therapeutic strategies for atherosclerosis and atherothrombosis: past, present and future. *Thromb Haemost* 2017;**117**:1258–1264.
552. Newman C, Tsai J, Szarek M, Luo D, Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. *Am J Cardiol* 2006;**97**:61–67.
553. Bays H, Cohen DE, Chalasani N, Harrison SA, The National Lipid Association's Statin Safety Task Force. An assessment by the Statin Liver Safety Task Force: 2014 update. *J Clin Lipidol* 2014;**8**:S47–S57.
554. Bjornsson E, Jacobsen EI, Kalitzaakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. *J Hepatol* 2012;**56**:374–380.
555. Clarke AT, Johnson PC, Hall GC, Ford I, Mills PR. High dose atorvastatin associated with increased risk of significant hepatotoxicity in comparison to simvastatin in UK GPRD cohort. *PLoS One* 2016;**11**:e0151587.
556. Cederberg H, Stancakova A, Yaluri N, Modi S, Kuusisto J, Laakso M. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. *Diabetologia* 2015;**58**:1109–1117.
557. Mora S, Glynn RJ, Hsia J, MacFadyen JG, Genest J, Ridker PM. Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials. *Circulation* 2010;**121**:1069–1077.
558. Atlas Writing Group, Timmis A, Townsend N, Gale C, Grobbee R, Maniadakis N, Flather M, Wilkins E, Wright L, Vos R, Bax J, Blum M, Pinto F, Vardas P. European Society of Cardiology: cardiovascular disease statistics 2017. *Eur Heart J* 2018;**39**:508–579.
559. Roth GA, Forouzanfar MH, Moran AE, Barber R, Nguyen G, Feigin VL, Naghavi M, Mensah GA, Murray CJ. Demographic and epidemiologic drivers of global cardiovascular mortality. *N Engl J Med* 2015;**372**:1333–1341.
560. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, Steingrimsdottir L, Critchley J, Bennett K, O'Flaherty M, Capewell S. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25–74 between the years 1981 and 2006. *PLoS One* 2010;**5**:e13957.
561. Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. *Eur Heart J* 2009;**30**:1046–1056.
562. Pereira M, Azevedo A, Lunet N, Carreira H, O'Flaherty M, Capewell S, Bennett K. Explaining the decline in coronary heart disease mortality in Portugal between 1995 and 2008. *Circ Cardiovasc Qual Outcomes* 2013;**6**:634–642.
563. Unal B, Sozmen K, Arik H, Gercelkloglu G, Altun DU, Simsek H, Doganay S, Demiral Y, Aslan O, Bennett K, O'Flaherty M, Capewell S, Critchley J. Explaining the decline in coronary heart disease mortality in Turkey between 1995 and 2008. *BMC Public Health* 2013;**13**:1135.
564. EunetHTa Joint Action 2, Work Package 7, Subgroup 3; Heintz E, Gerber-Grote A, Ghabri S, Hamers FF, Rupel VP, Slabe-Erker R, Davidson T. Is there a European view on health economic evaluations? Results from a synopsis of methodological guidelines used in the EunetHTa partner countries. *Pharmacoeconomics* 2016;**34**:59–76.
565. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, Reed SD, Rutten F, Sculpher M, Severens J. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. *Value Health* 2009;**12**:409–418.
566. Frieden TR. A framework for public health action: the health impact pyramid. *Am J Public Health* 2010;**100**:590–595.
567. Hotchkiss JW, Davies CA, Dundas R, Hawkins N, Jhund PS, Scholes S, Bajekal M, O'Flaherty M, Critchley J, Leyland AH, Capewell S. Explaining trends in Scottish

- coronary heart disease mortality between 2000 and 2010 using IMPACTSEC model: retrospective analysis using routine data. *BMJ* 2014;**348**:g1088.
568. Cobiaci LJ, Magnus A, Lim S, Barendregt JJ, Carter R, Vos T. Which interventions offer best value for money in primary prevention of cardiovascular disease? *PLoS One* 2012;**7**:e41842.
569. Collins M, Mason H, O'Flaherty M, Guzman-Castillo M, Critchley J, Capewell S. An economic evaluation of salt reduction policies to reduce coronary heart disease in England: a policy modeling study. *Value Health* 2014;**17**:517–524.
570. Mason H, Shoaibi A, Ghandour R, O'Flaherty M, Capewell S, Khatib R, Jabr S, Unal B, Sozmen K, Arfa C, Aissi W, Ben Romdhane H, Fouad F, Al-Ali R, Hussein A; MedCHAMPS project team. A cost effectiveness analysis of salt reduction policies to reduce coronary heart disease in four Eastern Mediterranean countries. *PLoS One* 2014;**9**:e84445.
571. Moreira PV, Baraldi LG, Moubarac JC, Monteiro CA, Newton A, Capewell S, O'Flaherty M. Comparing different policy scenarios to reduce the consumption of ultra-processed foods in UK: impact on cardiovascular disease mortality using a modelling approach. *PLoS One* 2015;**10**:e0118353.
572. O'Keefe C, Kabir Z, O'Flaherty M, Walton J, Capewell S, Perry IJ. Modelling the impact of specific food policy options on coronary heart disease and stroke deaths in Ireland. *BMJ Open* 2013;**3**:e002837.
573. Barton P, Andronis L, Briggs A, McPherson K, Capewell S. Effectiveness and cost effectiveness of cardiovascular disease prevention in whole populations: modelling study. *BMJ* 2011;**343**:d4044.
574. Muennig PA, Epstein M, Li G, DiMaggio C. The cost-effectiveness of New York City's Safe Routes to School Program. *Am J Public Health* 2014;**104**:1294–1299.
575. Roux L, Pratt M, Tengs TO, Yore MM, Yanagawa TL, Van Den Bos J, Rutt C, Brownson RC, Powell KE, Heath G, Kohl HW III, Teutsch S, Cawley J, Lee IM, West L, Buchner DM. Cost effectiveness of community-based physical activity interventions. *Am J Prev Med* 2008;**35**:578–588.
576. Jørgensen T, Capewell S, Prescott E, Allender S, Sans S, Zdrojewski T, De Bacquer D, de Sutter J, Franco OH, Løgstrop S, Volpe M, Maluytina S, Marques-Vidal P, Reiner Z, Tell GS, Verschuren WM, Vanuzzo D; PEP section of EACPR. Population-level changes to promote cardiovascular health. *Eur J Prev Cardiol* 2013;**20**:409–421.
577. Mozaffarian D, Appel LJ, Van Horn L. Components of a cardioprotective diet: new insights. *Circulation* 2011;**123**:2870–2891.
578. Dalziel K, Segal L. Time to give nutrition interventions a higher profile: cost-effectiveness of 10 nutrition interventions. *Health Promot Int* 2007;**22**:271–283.
579. Ahern AL, Wheeler GM, Aveyard P, Boyland EJ, Halford JCG, Mander AP, Woolston J, Thomson AM, Tsiountsioura M, Cole D, Mead BR, Irvine L, Turner D, Suhrcke M, Pimpin L, Retat L, Jaccard A, Webber L, Cohn SR, Jebb SA. Extended and standard duration weight-loss programme referrals for adults in primary care (WRAP): a randomised controlled trial. *Lancet* 2017;**389**:2214–2225.
580. Neumann A, Lindholm L, Norberg M, Schoffer O, Klug SJ, Norstrom F. The cost-effectiveness of interventions targeting lifestyle change for the prevention of diabetes in a Swedish primary care and community based prevention program. *Eur J Health Econ* 2017;**18**:905–919.
581. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness of smoking cessation interventions in patients with COPD. *Thorax* 2010;**65**:711–718.
582. Forster M, Veerman JL, Barendregt JJ, Vos T. Cost-effectiveness of diet and exercise interventions to reduce overweight and obesity. *Int J Obes (Lond)* 2011;**35**:1071–1078.
583. Chow CK, Jolly S, Rao-Melacini P, Fox KA, Anand SS, Yusuf S. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. *Circulation* 2010;**121**:750–758.
584. Loveman E, Frampton GK, Shepherd J, Picot J, Cooper K, Bryant J, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of long-term weight management schemes for adults: a systematic review. *Health Technol Assess* 2011;**15**:1–182.
585. Guerriero C, Cairns J, Roberts I, Rodgers A, Whittaker R, Free C. The cost-effectiveness of smoking cessation support delivered by mobile phone text messaging: Txt2stop. *Eur J Health Econ* 2013;**14**:789–797.
586. McConnachie A, Walker A, Robertson M, Marchbank L, Peacock J, Packard CJ, Cobbe SM, Ford I. Long-term impact on healthcare resource utilization of statin treatment, and its cost effectiveness in the primary prevention of cardiovascular disease: a record linkage study. *Eur Heart J* 2014;**35**:290–298.
587. Peura P, Martikainen J, Soini E, Hallinen T, Niskanen L. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men. *Curr Med Res Opin* 2008;**24**:1823–1832.
588. Heller DJ, Coxson PG, Penko J, Pletcher MJ, Goldman L, Odden MC, Kazi DS, Bibbins-Domingo K. Evaluating the impact and cost-effectiveness of statin use guidelines for primary prevention of coronary heart disease and stroke. *Circulation* 2017;**136**:1087–1098.
589. Pandya A, Sy S, Cho S, Weinstein MC, Gaziano TA. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. *JAMA* 2015;**314**:142–150.
590. Heart Protection Study C, Mihaylova B, Briggs A, Armitage J, Parish S, Gray A, Collins R. Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people. *BMJ* 2006;**333**:1145.
591. Ward S, Lloyd Jones M, Pandor A, Holmes M, Ara R, Ryan A, Yeo W, Payne N. A systematic review and economic evaluation of statins for the prevention of coronary events. *Health Technol Assess* 2007;**11**:1–160, iii–iv.
592. Davies GM, Vyas A, Baxter CA. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States. *J Med Econ* 2017;**20**:723–731.
593. Lindgren P, Graff J, Olsson AG, Pedersen TJ, Jonsson B; IDEAL Trial Investigators. Cost-effectiveness of high-dose atorvastatin compared with regular dose simvastatin. *Eur Heart J* 2007;**28**:1448–1453.
594. Stam-Slob MC, van der Graaf Y, Greving JP, Dorresteyn JA, Visseren FL. Cost-effectiveness of intensifying lipid-lowering therapy with statins based on individual absolute benefit in coronary artery disease patients. *J Am Heart Assoc* 2017;**6**:e004648.
595. Koteva K, De Bacquer D, De Backer G, Ryden L, Jennings C, Gyberg V, Abreu A, Aguiar C, Conde AC, Davletov K, Dilic M, Dolzhenko M, Gaita D, Georgiev B, Gotcheva N, Lalic N, Laucevicius A, Lovic D, Mancas S, Milicic D, Oganov R, Pajak A, Pogoseva N, Reiner Z, Vulic D, Wood D, On Behalf Of The Euroaspire Investigators. Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions. *Eur J Prev Cardiol* 2016;**23**:2007–2018.
596. Cherry SB, Benner JS, Hussein MA, Tang SS, Nichol MB. The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. *Value Health* 2009;**12**:489–497.
597. Vonbank A, Agewall S, Kjeldsen KP, Lewis BS, Torp-Pedersen C, Ceconi C, Funck-Brentano C, Kaski JC, Niessner A, Tamargo J, Walther T, Wassmann S, Rosano G, Schmidt H, Saely CH, Drexel H. Comprehensive efforts to increase adherence to statin therapy. *Eur Heart J* 2017;**38**:2473–2479.
598. Corrao G, Scotti L, Zambon A, Baio G, Nicotra F, Conti V, Capri S, Tragni E, Merlino L, Catapano AL, Mancina G. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. *Atherosclerosis* 2011;**217**:479–485.
599. Chapman RH, Kowal SL, Cherry SB, Ferrufino CP, Roberts CS, Chen L. The modeled lifetime cost-effectiveness of published adherence-improving interventions for antihypertensive and lipid-lowering medications. *Value Health* 2010;**13**:685–694.
600. Brown MT, Bussell JK. Medication adherence: WHO cares? *Mayo Clin Proc* 2011;**86**:304–314.
601. Bonow RO, Harrington RA, Yancy CW. Cost-effectiveness of PCSK9 inhibitors: proof in the modeling. *JAMA Cardiol* 2017;**2**:1298–1299.
602. Arrieta A, Hong JC, Khera R, Virani SS, Krumholz HM, Nasir K. Updated cost-effectiveness assessments of PCSK9 inhibitors from the perspectives of the health system and private payers: insights derived from the FOURIER trial. *JAMA Cardiol* 2017;**2**:1369–1374.
603. Fonarow GC, Keech AC, Pedersen TR, Giugliano RP, Sever PS, Lindgren P, van Hout B, Villa G, Qian Y, Somaratne R, Sabatine MS. Cost-effectiveness of evolocumab therapy for reducing cardiovascular events in patients with atherosclerotic cardiovascular disease. *JAMA Cardiol* 2017;**2**:1069–1078.
604. Korman M, Wisloff T. Modelling the cost-effectiveness of PCSK9 inhibitors vs. ezetimibe through LDL-C reductions in a Norwegian setting. *Eur Heart J Cardiovasc Pharmacother* 2018;**4**:15–22.
605. Annemans L, Packard CJ, Briggs A, Ray KK. 'Highest risk-highest benefit' strategy: a pragmatic, cost-effective approach to targeting use of PCSK9 inhibitor therapies. *Eur Heart J* 2018;**39**:2546–2550.
606. Robinson JG, Huijgen R, Ray K, Persons J, Kastelein JJ, Pencina MJ. Determining when to add nonstatin therapy: a quantitative approach. *J Am Coll Cardiol* 2016;**68**:2412–2421.
607. Kazi DS, Penko J, Coxson PG, Moran AE, Ollendorf DA, Tice JA, Bibbins-Domingo K. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. *JAMA* 2017;**318**:748–750.
608. Wood DA, Koteva K, Connolly S, Jennings C, Mead A, Jones J, Holden A, De Bacquer D, Collier T, De Backer G, Faergeman O; EUROACTION Study Group. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. *Lancet* 2008;**371**:1999–2012.